Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
33400.0 | 2017-11-21 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Johnson & Johnson | ABT | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-johnson-johnson-2017-11-21 | nan | nan | They're partners. And they're rivals. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. However, the two big drugmakers compete against each other in the autoimmune disease market.
Johnson & Johnson has been a longtime favorite among investors. AbbVie has arguably been the best big pharma stock in recent years. But which is the better pick for investors now? Here's how AbbVie and J&J compare in the key categories of growth prospects, dividends, and valuation.
The case for AbbVie
There are several kinds of growth, but they're all intertwined. Revenue growth typically leads to earnings growth, and both tend to drive stock price growth. AbbVie appears to be in good shape on all three counts in the coming years.
The company recently increased its 2020 sales estimate for Humira from $18 billion to $21 billion. With Humira generating nearly two-thirds of AbbVie's total revenue, that's huge for the drugmaker's growth prospects. Other current products should also contribute to AbbVie's growth. Imbruvica is on track to become the fourth-best-selling cancer drug in the world by 2022 . Recently launched hepatitis C drug Mavyret should also be a big winner. Venclexta isn't making much money yet, but additional cancer indications could greatly expand the market for the drug.
AbbVie's pipeline also ranks as one of the best among big pharma companies. Potential blockbuster candidates include elagolix, which targets treatment of endometriosis and uterine fibroids, autoimmune disease drugs upadacitinib and risankizumab, and cancer drug Rova-T.
Although AbbVie is experiencing sales declines for some of its older hepatitis C and HIV drugs, those products combined make up for only a small percentage of total revenue. Overall, Wall Street analysts project average annual earnings growth for AbbVie of nearly 16% over the next five years.
The impressive cash flow produced by Humira and (to a lesser extent) AbbVie's other drugs has allowed the company to reward shareholders with one of the best dividends in healthcare. AbbVie's dividend currently yields a little over 3%. The company has increased its dividend nearly 78% since being spun off by Abbott Labs in 2013.
Despite its year-to-date gains of close to 50%, AbbVie shares trade at only 14.4 times expected earnings. With its strong growth prospects, the stock appears to be a bargain at the current price.
The case for Johnson & Johnson
Johnson & Johnson stands as the largest healthcare company in the world, with three multibillion-dollar business segments. J&J's consumer business, which includes well-known brands such as Band-Aids and Listerine, is growing sales, but only by low single-digit percentages. Its medical device segment is enjoying stronger growth in higher single-digit percentages, thanks primarily to acquisitions.
The most important growth engine for Johnson & Johnson is its largest business: the pharmaceutical segment. Several products are largely responsible for driving that growth, especially Imbruvica (for which J&J receives a smaller percentage of sales than AbbVie, though), blood cancer drug Darzalex, and Stelara, which treats psoriasis and psoriatic arthritis. In addition, J&J's acquisition earlier this year of Actelion gave the company a growing pulmonary hypertension franchise.
What about J&J's pipeline? Market research firm EvaluatePharma ranked the company's apalutamide as the third-most-promising cancer drug in late-stage development . Other promising candidates include antidepressant esketamine, acute myeloid leukemia treatment talacotuzumab, and cancer drug erdafitinib.
The challenge for Johnson & Johnson, though, is overcoming headwinds for several existing drugs. J&J's current top-selling drug, Remicade, faces competition from biosimilars. Several of its top drugs experienced year-over-year sales declines of 10% or more in the last quarter, including neuroscience drugs Concerta and Risperdal Consta, cancer drug Velcade, diabetes drug Invokana, and anemia drug Procrit. Because of some of these issues, Wall Street analysts project that J&J will grow average earnings by only 7% over the next five years despite its promising pipeline.
J&J's dividend is solid, with a yield of 2.37%. The company's track record of 55 consecutive years of dividend hikes is even more impressive.
As for valuation, J&J stock trades at nearly 17.6 times expected earnings. That's not cheap, but it's a little lower than the S&P 500 's forward earnings multiple.
Better buy
AbbVie clearly has better growth prospects than J&J does. Its dividend yield is higher. I don't see that advantage going away any time soon, either, with AbbVie continuing to make double-digit percentage dividend increases each year. And the stock is even a better value than J&J.
Johnson & Johnson is a great long-term pick for investors. However, in my view, AbbVie is the better stock right now.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 6, 2017
Keith Speights owns shares of AbbVie. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although AbbVie is experiencing sales declines for some of its older hepatitis C and HIV drugs, those products combined make up for only a small percentage of total revenue. The impressive cash flow produced by Humira and (to a lesser extent) AbbVie's other drugs has allowed the company to reward shareholders with one of the best dividends in healthcare. Several products are largely responsible for driving that growth, especially Imbruvica (for which J&J receives a smaller percentage of sales than AbbVie, though), blood cancer drug Darzalex, and Stelara, which treats psoriasis and psoriatic arthritis. | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. Overall, Wall Street analysts project average annual earnings growth for AbbVie of nearly 16% over the next five years. The case for Johnson & Johnson Johnson & Johnson stands as the largest healthcare company in the world, with three multibillion-dollar business segments. | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. The case for Johnson & Johnson Johnson & Johnson stands as the largest healthcare company in the world, with three multibillion-dollar business segments. Several of its top drugs experienced year-over-year sales declines of 10% or more in the last quarter, including neuroscience drugs Concerta and Risperdal Consta, cancer drug Velcade, diabetes drug Invokana, and anemia drug Procrit. | With its strong growth prospects, the stock appears to be a bargain at the current price. However, in my view, AbbVie is the better stock right now. The Motley Fool owns shares of and recommends Johnson & Johnson. |
33401.0 | 2017-11-21 00:00:00 UTC | Health Care Sector Update for 11/21/2017: JNJ, PFE, ABT, MRK, AMGN, ARDX, MDT, NVO | ABT | https://www.nasdaq.com/articles/health-care-sector-update-11212017-jnj-pfe-abt-mrk-amgn-ardx-mdt-nvo-2017-11-21 | nan | nan | Top Health Care Stocks:
JNJ: -0.3%
PFE: +0.1%
ABT: flat
MRK: flat
AMGN: +0.1%
Health care shares were mixed in pre-market trading Tuesday.
In sector news, Ardelyx ( ARDX ) shares rose 21% after the company said that it has decided to discontinue development of RDX7675 after it observed an unexpected side effect of decreased serum bicarbonate in an onset-of-action study of the treatment for hyperkalemia. The company said the change will result in a cash savings of approximately $40 million over the next two years, extending the company's operating runway into 2019. Ardelyx said it believes this side-effect of RDX7675 will limit its commercial potential. Meanwhile, the company said its second registration study for tenapanor for the treatment of hyperphosphatemia will begin enrolling shortly, after having received feedback from the United States Food and Drug Administration on the trial design.
In other sector news,
(+) MDT(+1.4%) Posts fiscal Q2 EPS beat, revenue in line; maintains growth guidance for FY18
(-) NVO (-0.04%) Provides update on research & development, commercial strategies, and market dynamics
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat In sector news, Ardelyx ( ARDX ) shares rose 21% after the company said that it has decided to discontinue development of RDX7675 after it observed an unexpected side effect of decreased serum bicarbonate in an onset-of-action study of the treatment for hyperkalemia. Meanwhile, the company said its second registration study for tenapanor for the treatment of hyperphosphatemia will begin enrolling shortly, after having received feedback from the United States Food and Drug Administration on the trial design. | ABT: flat MRK: flat Health care shares were mixed in pre-market trading Tuesday. In other sector news, (+) MDT(+1.4%) Posts fiscal Q2 EPS beat, revenue in line; maintains growth guidance for FY18 (-) NVO (-0.04%) Provides update on research & development, commercial strategies, and market dynamics The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat In sector news, Ardelyx ( ARDX ) shares rose 21% after the company said that it has decided to discontinue development of RDX7675 after it observed an unexpected side effect of decreased serum bicarbonate in an onset-of-action study of the treatment for hyperkalemia. In other sector news, (+) MDT(+1.4%) Posts fiscal Q2 EPS beat, revenue in line; maintains growth guidance for FY18 (-) NVO (-0.04%) Provides update on research & development, commercial strategies, and market dynamics The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat Top Health Care Stocks: Health care shares were mixed in pre-market trading Tuesday. |
33402.0 | 2017-11-20 00:00:00 UTC | Trade of the Day: Abbott Laboratories (ABT) | ABT | https://www.nasdaq.com/articles/trade-of-the-day%3A-abbott-laboratories-abt-2017-11-20 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
To receive further updates on this Abbott Laboratories (NYSE: ABT )trade as well as an alert when it's time to take profits, sign up for a risk-free trial of SlingShot Trader today.
After experiencing some profit-taking in the aftermath of the company's most recent earnings announcement on Oct. 18, Abbott Laboratories (NYSE: ABT ) has stabilized and completed a bullish "wedge" continuation pattern on Thursday by breaking above the down-trending resistance level that started in mid-October. We expect the stock to climb back up to its recent high of $56.68 and then continue on to set new highs.
Medical-device companies like ABT have done well this year, but some have been concerned the industry could struggle if Congress fails to extend the two-year moratorium on the medical-device excise tax it put in place at the end of 2015 with the Consolidated Appropriations Act. However, even though Congress is dealing with multiple legislative concerns, we fully expect it will extend the moratorium.
'Buy to open' the ABT December 55 Call (ABT171215C00055000) for a maximum price of $1.30.
Follow our Facebook pageto receive each Trade of the Day direct to your News Feed - and join the conversation.
You can learn more about identifying price patterns and using them to project how far you think a stock is going to move in our Advanced Technical Analysis Program.
InvestorPlace advisers John Jagerson and S. Wade Hansen, both Chartered Market Technician (CMT) designees, are co-founders of LearningMarkets.com, as well as the co-editors of SlingShot Trader, a trading service designed to help you make options profits by trading the news. Get in on the next SlingShot Trader trade and get 1 free month today by clicking here.
The post Trade of the Day: Abbott Laboratories (ABT) appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | After experiencing some profit-taking in the aftermath of the company's most recent earnings announcement on Oct. 18, Abbott Laboratories (NYSE: ABT ) has stabilized and completed a bullish "wedge" continuation pattern on Thursday by breaking above the down-trending resistance level that started in mid-October. InvestorPlace - Stock Market News, Stock Advice & Trading Tips To receive further updates on this Abbott Laboratories (NYSE: ABT )trade as well as an alert when it's time to take profits, sign up for a risk-free trial of SlingShot Trader today. Medical-device companies like ABT have done well this year, but some have been concerned the industry could struggle if Congress fails to extend the two-year moratorium on the medical-device excise tax it put in place at the end of 2015 with the Consolidated Appropriations Act. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips To receive further updates on this Abbott Laboratories (NYSE: ABT )trade as well as an alert when it's time to take profits, sign up for a risk-free trial of SlingShot Trader today. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. After experiencing some profit-taking in the aftermath of the company's most recent earnings announcement on Oct. 18, Abbott Laboratories (NYSE: ABT ) has stabilized and completed a bullish "wedge" continuation pattern on Thursday by breaking above the down-trending resistance level that started in mid-October. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips To receive further updates on this Abbott Laboratories (NYSE: ABT )trade as well as an alert when it's time to take profits, sign up for a risk-free trial of SlingShot Trader today. After experiencing some profit-taking in the aftermath of the company's most recent earnings announcement on Oct. 18, Abbott Laboratories (NYSE: ABT ) has stabilized and completed a bullish "wedge" continuation pattern on Thursday by breaking above the down-trending resistance level that started in mid-October. Medical-device companies like ABT have done well this year, but some have been concerned the industry could struggle if Congress fails to extend the two-year moratorium on the medical-device excise tax it put in place at the end of 2015 with the Consolidated Appropriations Act. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips To receive further updates on this Abbott Laboratories (NYSE: ABT )trade as well as an alert when it's time to take profits, sign up for a risk-free trial of SlingShot Trader today. The post Trade of the Day: Abbott Laboratories (ABT) appeared first on InvestorPlace . After experiencing some profit-taking in the aftermath of the company's most recent earnings announcement on Oct. 18, Abbott Laboratories (NYSE: ABT ) has stabilized and completed a bullish "wedge" continuation pattern on Thursday by breaking above the down-trending resistance level that started in mid-October. |
33403.0 | 2017-11-20 00:00:00 UTC | Health Care Sector Update for 11/20/2017: JNJ, PFE, ABT, MRK, AMGN, DBVT, EGLT, ACOR | ABT | https://www.nasdaq.com/articles/health-care-sector-update-11202017-jnj-pfe-abt-mrk-amgn-dbvt-eglt-acor-2017-11-20 | nan | nan | Top Health Care Stocks:
JNJ: +0.01%
PFE: -0.6%
ABT: -0.2%
MRK: -2.1%
AMGN: flat
Health care shares were mostly lower in pre-market trading Monday.
In sector news, DBV Technologies ( DBVT ) shares were up more than 6% after the company said a phase 3 study of its Viaskin treatment for peanut allergies met its primary objective, showing it was well-tolerated with no new adverse events. The phase 3 trial compared the safety of Viaskin Peanut to placebo in children between four and 11 years of age for six months. The most commonly reported adverse events were local application site reactions, the company said, most of which were mild and moderate. The discontinuation rate was 2.5%, with a 1% dropout related to adverse events. Patients who completed the blinded portion of the study will continue to receive treatment for up to 36 months.
In other sector news,
(+) EGLT (+9.5%) Wins grant from the Danish Growth Fund's InnoBooster to develop Guardian technology outside of pain management
(-) ACOR (-8.7%) Discontinues Tozadenant development program over safety issue.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In sector news, DBV Technologies ( DBVT ) shares were up more than 6% after the company said a phase 3 study of its Viaskin treatment for peanut allergies met its primary objective, showing it was well-tolerated with no new adverse events. The phase 3 trial compared the safety of Viaskin Peanut to placebo in children between four and 11 years of age for six months. The most commonly reported adverse events were local application site reactions, the company said, most of which were mild and moderate. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In sector news, DBV Technologies ( DBVT ) shares were up more than 6% after the company said a phase 3 study of its Viaskin treatment for peanut allergies met its primary objective, showing it was well-tolerated with no new adverse events. | AMGN: flat Health care shares were mostly lower in pre-market trading Monday. In sector news, DBV Technologies ( DBVT ) shares were up more than 6% after the company said a phase 3 study of its Viaskin treatment for peanut allergies met its primary objective, showing it was well-tolerated with no new adverse events. In other sector news, (+) EGLT (+9.5%) Wins grant from the Danish Growth Fund's InnoBooster to develop Guardian technology outside of pain management (-) ACOR (-8.7%) Discontinues Tozadenant development program over safety issue. | Top Health Care Stocks: In sector news, DBV Technologies ( DBVT ) shares were up more than 6% after the company said a phase 3 study of its Viaskin treatment for peanut allergies met its primary objective, showing it was well-tolerated with no new adverse events. The most commonly reported adverse events were local application site reactions, the company said, most of which were mild and moderate. |
33404.0 | 2017-11-16 00:00:00 UTC | How These Rivals Could Take A Chunk Of Medtronic's Heart-Unit Sales | ABT | https://www.nasdaq.com/articles/how-these-rivals-could-take-chunk-medtronics-heart-unit-sales-2017-11-16 | nan | nan | Medtronic ( MDT ) will overcome Hurricane Maria's impact in fiscal 2018, but the maker of medical devices is expected to face growing competition from Abbott Laboratories ( ABT ) and Boston Scientific ( BSX ) in heart implants, an analyst said Thursday.
[ibd-display-video id=2665856 width=50 float=left autostart=true]In September, Abbott caught up to Medtronic and Boston, gaining approval for an implantable cardioverter defibrillator, or ICD, that allows a patient to undergo an MRI scan if needed. These devices are implanted to help control abnormal heart rhythm .
Still, RBC analyst Glenn Novarro says the lower end of Medtronic's full-year forecast in August for 4%-5% sales growth on a constant basis remains realistic. He increased his view for fiscal 2018 to $29.55 billion in sales and adjusted income of $4.74 per share.
"The impact of MR-compliant ICDs from Abbott and Boston is another topic of interest as it relates to the second half of fiscal 2018 and fiscal 2019," he said. For Medtronic's fiscal 2019, Novarro forecasts the firm as managing 3% constant-currency growth.
Competitive concerns also extend to heart-valve replacements, Novarro said. In early 2018, he sees Boston re-entering the European market with its Lotus Edge product. Boston recalled the device, not approved in the U.S., due to problems with its locking mechanism.
IBD'S TAKE:Medtronic has an IBD Composite Rating of 57, meaning it performs in the top half of all stocks in terms of key growth metrics. But it still falls to No. 54 in the Medical-Products industry group in terms of rankings. Head to IBD Stock Checkup for a look at better-rated medtech players.
Despite the mounting competition for its cardiac and vascular group, Novarro sees Medtronic as capable of pulling off its full-year guidance.
"We expect management to reaffirm guidance for constant-currency revenue growth and refine guidance further on the (fiscal third-quarter) call," he said. "The only possible change in fiscal 2018 earnings per share guidance will be the impact from Hurricane Maria."
On Tuesday, Medtronic is slated to report its fiscal second-quarter earnings. The consensus expects Medtronic to report adjusted income of 99 cents per share on $6.93 billion in sales. The sales view is below the Medtronic pre-announcement on Nov. 8 for $7.05 billion.
Hurricane Maria, which battered Puerto Rico in September, is expected to have a $55 million to $65 million impact on Medtronic's second-quarter sales and to trim adjusted profit by 3 cents. The majority of the impact was on the company's minimally-invasive and restorative-therapies groups.
For that reason, Novarro shifted his segment views for Medtronic's second quarter. In the U.S., he sees the diabetes group diving 12% and minimally-invasive therapies losing 1%. He expects flat sales in restorative therapies, partly offset by 4% growth in cardiac and vascular.
Internationally, Novarro expects the cardiac and vascular and diabetes groups to grow 8% apiece. He sees the minimally-invasive and restorative-therapies groups growing a respective 6% and 5%. Only the pain-therapies group is expected to decline, by 5%.
Medtronic's diabetes group has been plagued recently by a shortage in glucose sensors. Growth in the latter half of fiscal 2018 will come on the backs of new products, Medtronic has said.
By the closing bell on the stock market today , Medtronic gained 0.7% to close at 79.26.
RELATED:
How Electricity Could Replace Opioids In Treating Chronic Pain
Edwards Lifesciences Crashes After Heart Valve Sales Miss Lofty Views
Dow Component J&J Pops After Topping Views On Pharma Strength
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medtronic ( MDT ) will overcome Hurricane Maria's impact in fiscal 2018, but the maker of medical devices is expected to face growing competition from Abbott Laboratories ( ABT ) and Boston Scientific ( BSX ) in heart implants, an analyst said Thursday. [ibd-display-video id=2665856 width=50 float=left autostart=true]In September, Abbott caught up to Medtronic and Boston, gaining approval for an implantable cardioverter defibrillator, or ICD, that allows a patient to undergo an MRI scan if needed. Still, RBC analyst Glenn Novarro says the lower end of Medtronic's full-year forecast in August for 4%-5% sales growth on a constant basis remains realistic. | Medtronic ( MDT ) will overcome Hurricane Maria's impact in fiscal 2018, but the maker of medical devices is expected to face growing competition from Abbott Laboratories ( ABT ) and Boston Scientific ( BSX ) in heart implants, an analyst said Thursday. For Medtronic's fiscal 2019, Novarro forecasts the firm as managing 3% constant-currency growth. Despite the mounting competition for its cardiac and vascular group, Novarro sees Medtronic as capable of pulling off its full-year guidance. | Medtronic ( MDT ) will overcome Hurricane Maria's impact in fiscal 2018, but the maker of medical devices is expected to face growing competition from Abbott Laboratories ( ABT ) and Boston Scientific ( BSX ) in heart implants, an analyst said Thursday. Despite the mounting competition for its cardiac and vascular group, Novarro sees Medtronic as capable of pulling off its full-year guidance. How Electricity Could Replace Opioids In Treating Chronic Pain Edwards Lifesciences Crashes After Heart Valve Sales Miss Lofty Views Dow Component J&J Pops After Topping Views On Pharma Strength The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medtronic ( MDT ) will overcome Hurricane Maria's impact in fiscal 2018, but the maker of medical devices is expected to face growing competition from Abbott Laboratories ( ABT ) and Boston Scientific ( BSX ) in heart implants, an analyst said Thursday. Despite the mounting competition for its cardiac and vascular group, Novarro sees Medtronic as capable of pulling off its full-year guidance. In the U.S., he sees the diabetes group diving 12% and minimally-invasive therapies losing 1%. |
33405.0 | 2017-11-15 00:00:00 UTC | Noteworthy ETF Inflows: IVE, MDT, ABT, GS | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows-ive-mdt-abt-gs-2017-11-15 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $59.8 million dollar inflow -- that's a 0.4% increase week over week in outstanding units (from 130,850,000.0 to 131,400,000.0). Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is off about 0.6%, and Goldman Sachs Group Incorporated (Symbol: GS) is lower by about 0.7%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average:
Looking at the chart above, IVE's low point in its 52 week range is $97.18 per share, with $110.30 as the 52 week high point - that compares with a last trade of $108.25. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is off about 0.6%, and Goldman Sachs Group Incorporated (Symbol: GS) is lower by about 0.7%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $97.18 per share, with $110.30 as the 52 week high point - that compares with a last trade of $108.25. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is off about 0.6%, and Goldman Sachs Group Incorporated (Symbol: GS) is lower by about 0.7%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $97.18 per share, with $110.30 as the 52 week high point - that compares with a last trade of $108.25. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is off about 0.6%, and Goldman Sachs Group Incorporated (Symbol: GS) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $59.8 million dollar inflow -- that's a 0.4% increase week over week in outstanding units (from 130,850,000.0 to 131,400,000.0). For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $97.18 per share, with $110.30 as the 52 week high point - that compares with a last trade of $108.25. | Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is off about 0.6%, and Goldman Sachs Group Incorporated (Symbol: GS) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $59.8 million dollar inflow -- that's a 0.4% increase week over week in outstanding units (from 130,850,000.0 to 131,400,000.0). For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $97.18 per share, with $110.30 as the 52 week high point - that compares with a last trade of $108.25. |
33406.0 | 2017-11-15 00:00:00 UTC | 3 Stocks for Retirees to Grow Their Nest Eggs | ABT | https://www.nasdaq.com/articles/3-stocks-retirees-grow-their-nest-eggs-2017-11-15 | nan | nan | Retired investors have somewhat different priorities than younger ones. Instead of focusing on growth, retirees' investments need to preserve their capital and also generate reliable income. However, that doesn't mean avoiding stocks -- in fact, there are some stocks that make excellent investments for retirees. Here's why our contributors think Welltower (NYSE: HCN) , Nucor (NYSE: NUE) , and AbbVie (NYSE: ABBV) are worth a look, even after retirement.
A 5% dividend yield and lots of room to grow
Matt Frankel (Welltower): Leading healthcare REIT Welltower is an excellent choice for retirees, with an excellent combination of reliable dividends and long-term growth potential. As far as income is concerned, Welltower yields 5.1% based on its current stock price, and is about to make its 186th consecutive quarterly dividend payment.
On the subject of growth, Welltower makes the bulk of its money from senior-housing properties, which make up about 70% of its property portfolio. Many of them are structured as operating partnerships, as opposed to standard lease deals, allowing Welltower to benefit from the income generated by the services its properties provide. In fact, about two-thirds of Welltower's total revenue comes from resident fees and services as of 2017's third quarter.
The ongoing retirement of baby boomers is expected to cause a spike in senior-housing demand over the next several decades. In fact, the 85-and-over population is expected to double in just 20 years, and by 2030, senior-housing demand will be growing by 96,000 units per year. This should especially benefit urban senior living, where Welltower concentrates its efforts, as most aging baby boomers in cities intend to stay.
This translates into an amazing long-tailed market opportunity, which should translate into a steadily growing income stream for investors, as well as significant upside potential, as the value of Welltower's property portfolio climbs over the years.
No rust growing on Nucor
Rich Smith ( Nucor ): Three months ago, I suggested retirees could " build their nest egg out of steel " by investing in steel minimill operator Nucor. Three months later, I'm of a mind to recommend Nucor again.
Why? As I hoped when I first recommended it, Nucor stock has "gone up" over the past three months. But the thing is, it's only gone up about $0.50 -- and I think there's a whole lot more growth to be had. Earnings may have slipped in Q3, but they were superb earlier in the year. As a result, Nucor stock at just 15.7 times earnings today is arguably cheaper than when I first mentioned it in August, when the price-to-earnings (P/E) ratio was 16.8.
Now as then, Wall Street is predicting that strong growth lies ahead for Nucor. Analysts, on average, estimate the company will grow its profits at better than 20% annually over the next five years -- well into many investors' retirement years. Combined with a still-respectable dividend yield of 2.5%, Nucor's total returns on its stock should be in the neighborhood of 23% annually -- more than enough to justify the stock's mid-teens P/E.
The big unknown with Nucor stock is when -- or if -- it will begin benefiting from President Trump's long-awaited trillion-dollar infrastructure plan. Presumably, that's next on the President's agenda following tax reform. If and when the spending to rebuild America's crumbling roads, bridges, airports (and so on) arrives, it could turbocharge Nucor's results. In the meantime, though, I think Nucor stock looks cheap enough to buy.
A blue-chip biotech
Keith Speights (AbbVie) : Buying a biotech stock might not seem like a good idea for retirees, but I think there's one biotech that's a great choice -- AbbVie. This isn't your stereotypical biotech stock with super-high volatility, though.
Retirees will like AbbVie's dividend, which currently yields north of 3%. Probably even better than that attractive yield, though, is the company's track record of dividend hikes. Counting the years it was part of Abbott Labs (NYSE: ABT) , AbbVie has raised its dividend for 45 years in a row. Since being spun off from Abbott in 2013, AbbVie's dividend has increased 77%.
What about growing your retirement nest egg? AbbVie is expected to increase earnings by 14% annually over the next few years. That kind of growth is definitely attainable, in my view, with continued momentum for the world's top-selling drug, Humira, and cancer drug Imbruvica, plus one of the best pipelines in the biopharmaceutical industry. Among the top candidates in that strong pipeline are several drugs with megablockbuster potential, including cancer drugs Rova-T and Venclexta.
As impressive as AbbVie's current product lineup and pipeline are, the biotech is likely to add even more drugs in the coming years. AbbVie CEO Richard Gonzalez recently stated that the company is interested in beefing up its portfolio through acquisitions and licensing deals, with a special focus in immunology and oncology. Further acquisitions could make this blue chip biotech even more attractive for retirees.
10 stocks we like better than Nucor
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Nucor wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 6, 2017
Keith Speights owns shares of AbbVie. Matthew Frankel has no position in any of the stocks mentioned. Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Nucor and Welltower. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Counting the years it was part of Abbott Labs (NYSE: ABT) , AbbVie has raised its dividend for 45 years in a row. Many of them are structured as operating partnerships, as opposed to standard lease deals, allowing Welltower to benefit from the income generated by the services its properties provide. This should especially benefit urban senior living, where Welltower concentrates its efforts, as most aging baby boomers in cities intend to stay. | Counting the years it was part of Abbott Labs (NYSE: ABT) , AbbVie has raised its dividend for 45 years in a row. A 5% dividend yield and lots of room to grow Matt Frankel (Welltower): Leading healthcare REIT Welltower is an excellent choice for retirees, with an excellent combination of reliable dividends and long-term growth potential. No rust growing on Nucor Rich Smith ( Nucor ): Three months ago, I suggested retirees could " build their nest egg out of steel " by investing in steel minimill operator Nucor. | Counting the years it was part of Abbott Labs (NYSE: ABT) , AbbVie has raised its dividend for 45 years in a row. A 5% dividend yield and lots of room to grow Matt Frankel (Welltower): Leading healthcare REIT Welltower is an excellent choice for retirees, with an excellent combination of reliable dividends and long-term growth potential. No rust growing on Nucor Rich Smith ( Nucor ): Three months ago, I suggested retirees could " build their nest egg out of steel " by investing in steel minimill operator Nucor. | Counting the years it was part of Abbott Labs (NYSE: ABT) , AbbVie has raised its dividend for 45 years in a row. However, that doesn't mean avoiding stocks -- in fact, there are some stocks that make excellent investments for retirees. AbbVie is expected to increase earnings by 14% annually over the next few years. |
33407.0 | 2017-11-12 00:00:00 UTC | 3 Dividend Stocks I'd Buy Right Now | ABT | https://www.nasdaq.com/articles/3-dividend-stocks-id-buy-right-now-2017-11-12 | nan | nan | Thousands of stocks pay dividends. Some of those dividends aren't all that attractive, though. And sometimes the dividend looks great, but the stock doesn't. It could be there's a fundamental weakness for the business or simply that the stock's valuation is too pricey.
But there are a select group of stocks with terrific dividends that are worthy of serious consideration by investors. I think AbbVie (NYSE: ABBV) , Iron Mountain (NYSE: IRM) , and Medical Properties Trust (NYSE: MPW) definitely qualify. Here's why these are three dividend stocks I'd buy right now.
AbbVie
I've been bullish about AbbVie for quite a while. The biotech has a lot going for it, with its dividend, currently yielding north of 3%, being high on the list. The company has raised its dividend for 45 consecutive years, including the period when it was part of Abbott Labs . And since being spun off from Abbott in 2013, AbbVie's dividend has increased a whopping 77%.
AbbVie's business has never been better. The company recently reported solid third-quarter results , with its top drugs Humira and Imbruvica posting impressive year-over-year sales growth. It just launched a new hepatitis C virus drug, Mavyret, that has significant potential. AbbVie also claims a deep pipeline and expects to have more than 20 new drug or indication approvals by 2020.
Even with its attractive dividend, solid business fundamentals, and tremendous growth prospects, AbbVie stock is still relatively inexpensive. Shares currently trade at less than 15 times expected earnings. With earnings projected to grow by 14% annually over the next few years, the stock should have plenty of room to run.
Iron Mountain
My colleague Matthew Frankel wrote in August that Iron Mountain is a "dividend investor's dream." I think he's right. The records and data storage company's dividend yield currently stands at 5.8%. As a real estate investment trust (REIT), Iron Mountain must distribute at least 90% of its taxable income to shareholders in the form of dividends. That means the dividends will keep coming as long as Iron Mountain remains profitable -- which shouldn't be a problem.
Iron Mountain has over 230,000 customers, including 95% of the Fortune 1,000. These customers typically sign three-year leases, but the vast majority of them renew those leases and don't leave. It's a lot easier to keep doing business with Iron Mountain, a stable company that's been around almost 70 years, than to go through the hassle of moving items to another storage provider.
At first glance, though, Iron Mountain stock might appear to be pricey. Its shares trade at 29 times expected earnings. But the company should be on track to grow earnings by more than 30% per year, thanks in part to rising demand for data storage. These growth prospects makes Iron Mountain's valuation look much more reasonable.
Medical Properties Trust
Another REIT that I really like is Medical Properties Trust. The company's name pretty much gives away what it does -- owning medical properties, primarily hospitals. Medical Properties Trust's dividend yields a little over 7%.
The company focuses on long-term leases to healthcare providers, usually for terms of 15 years or more. This gives Medical Properties Trust a reliable stream of revenue coming in the door. Thanks to acquisitions in recent years, it's now the second-largest owner of hospital beds in the U.S. but also owns properties in Europe. Aging demographic trends should drive demand for healthcare services, which should in turn give Medical Properties Trust long-term stability.
Medical Properties Trust stock trades at less than 13 times expected earnings, a valuation that's more attractive than several of its peers. Wall Street analysts think the company can grow earnings by close to 8% annually over the next few years. That's not a growth rate that would cause anyone to do cartwheels, but this respectable growth combined with a really high yield could at least make me do a few somersaults.
Top pick?
Selecting the best of these three dividend stocks is tough. I already own AbbVie and plan to hold on to it for a long time to come. But Iron Mountain deserves the nod as the top pick.
It's hard to argue against Iron Mountain's business model. The company has low maintenance and operating costs. It has a moat. And with increasingly more data and records being generated, Iron Mountain has great growth prospects.
Those growth prospects give it an advantage over Medical Properties Trust, in my view. Iron Mountain's exceptional yield gives it an edge over AbbVie. I'd buy all three of these dividend stocks right now, but if I could only choose one, it would be Iron Mountain.
10 stocks we like better than Iron Mountain
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Iron Mountain wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 6, 2017
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company recently reported solid third-quarter results , with its top drugs Humira and Imbruvica posting impressive year-over-year sales growth. As a real estate investment trust (REIT), Iron Mountain must distribute at least 90% of its taxable income to shareholders in the form of dividends. Aging demographic trends should drive demand for healthcare services, which should in turn give Medical Properties Trust long-term stability. | I think AbbVie (NYSE: ABBV) , Iron Mountain (NYSE: IRM) , and Medical Properties Trust (NYSE: MPW) definitely qualify. Even with its attractive dividend, solid business fundamentals, and tremendous growth prospects, AbbVie stock is still relatively inexpensive. Medical Properties Trust stock trades at less than 13 times expected earnings, a valuation that's more attractive than several of its peers. | I think AbbVie (NYSE: ABBV) , Iron Mountain (NYSE: IRM) , and Medical Properties Trust (NYSE: MPW) definitely qualify. Iron Mountain My colleague Matthew Frankel wrote in August that Iron Mountain is a "dividend investor's dream." I'd buy all three of these dividend stocks right now, but if I could only choose one, it would be Iron Mountain. | Medical Properties Trust's dividend yields a little over 7%. Those growth prospects give it an advantage over Medical Properties Trust, in my view. I'd buy all three of these dividend stocks right now, but if I could only choose one, it would be Iron Mountain. |
33408.0 | 2017-11-10 00:00:00 UTC | 7 Things AbbVie's Top Executives Just Said That You'll Want to Know | ABT | https://www.nasdaq.com/articles/7-things-abbvies-top-executives-just-said-youll-want-know-2017-11-10 | nan | nan | It's a good time to be AbbVie (NYSE: ABBV) . And with the biotech's share price up more than 50% year to date, it's a good time to be an AbbVie shareholder. The company reported a strong third-quarter performance a couple of weeks ago. AbbVie also increased its dividend for the 45th year in a row (including the years it was part of Abbott Labs (NYSE: ABT) ).
But can the good times continue to roll? AbbVie's top executives indirectly answered that question in different ways at the Credit Suisse healthcare conference in Arizona on Wednesday. Here are seven things management said that you'll want to know.
1. Humira
When asked about Humira, AbbVie CEO Richard Gonzalez was able to essentially respond with "see, we told you so." Gonzalez said that the company is seeing the strategy that AbbVie developed in 2013 "play out the way we anticipated." Actually, it's going even better than expected.
AbbVie updated its strategy in 2015, projecting 2020 sales for Humira of $18 billion. That estimate was too pessimistic. The company now thinks Humira will generate revenue of nearly $21 billion by 2020. Gonzalez acknowledged that the drug would see some erosion in international markets from biosimilar competition, but said the U.S. market would continue to drive overall growth, thanks to Humira remaining "the gold standard."
2. Beyond Humira
While AbbVie believes Humira will remain a big moneymaker for years to come, it's looking beyond Humira to the next generation of autoimmune-disease drugs. The two candidates at the top of the list are upadacitinib and risankizumab.
Michael Severino, AbbVie's chief scientific officer, said the company is "very pleased" with the profile seen for upadacitinib so far. The JAK1 selective inhibitor is in late-stage studies targeting treatment of rheumatoid arthritis and psoriatic arthritis, with additional late-stage studies planned for Crohn's disease and ulcerative colitis. Severino also was enthusiastic about the potential for risankizumab, citing its durable efficacy as a key differentiator for the anti-IL-23 antibody.
3. Cancer drugs' market potential
AbbVie has also become a leader in oncology. The biotech projects that Imbruvica will generate roughly $11.5 billion in U.S. sales by 2025. ( Johnson & Johnson markets Imbruvica outside the U.S.) It also anticipates around $6 billion in revenue by 2025 for Venclexta.
Severino said there are two keys for Imbruvica to achieve AbbVie's goals. Moving into front-line treatment areas in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is one important pathway for sales growth. The other is expanding into new indications. For Venclextra, Severino said that "transitioning to a broader relapsed and refractory population [in treating CLL] will be an inflection point."
4. Operating margins
The company doesn't just expect to grow its top line -- it also projects impressive improvement in operating margins, from 42% of sales now to 50% by 2020. AbbVie CFO Bill Chase pointed to two ways the company will be able to hit this projection.
First, Chase said that AbbVie won't have to pay royalties on Humira beginning in 2018. Second, a combination of rapidly growing overall revenue and controlled spending that doesn't increase as fast will improve margins. Even with this spending discipline, though, Chase said that no one should interpret that as meaning AbbVie won't invest in new products.
5. Amazon
Amazon 's (NASDAQ: AMZN) hints at moving into the retail pharmacy business have stirred up much speculation in the industry. How might Amazon impact AbbVie? Not much, according to Gonzalez.
He noted that AbbVie is primarily focused on specialty drugs. Most of its products are distributed through specialty pharmacy channels rather than retail channels. Gonzalez said that potential disruptions by Amazon will "primarily impact the retail environment" and won't significantly affect AbbVie's business.
6. Tax reform
Bill Chase said that AbbVie is "pleased we're seeing positive progress" on U.S. tax reform. However, he acknowledged that a lot of uncertainties remain. Chase stated that "the No. 1 benefit for the company and the country" relates to repatriation of cash parked overseas.
Gonzalez added, though, that tax reform won't change AbbVie's priorities with capital allocation. He said that the company will continue to invest back into its business first in order to drive growth. AbbVie's second priority, according to Gonzalez, is to return cash to shareholders through dividends and stock buybacks.
7. Potential deals
AbbVie's primary areas of focus for potential deals -- either acquisitions of companies or licensing assets -- are in immunology and oncology. Gonzalez said that lupus and early psoriasis are two areas of high interest for the company. He also stated that AbbVie will invest in early-stage oncology assets.
Will AbbVie make a big acquisition anytime soon? Gonzalez said the company will begin looking at a long-term growth strategy that extends out more than 10 years in the future within the next year or two. He added that AbbVie will make decisions in the 2019 or 2020 time frame that could lead to "something of a more significant size."
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 6, 2017
John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Keith Speights owns shares of AbbVie. The Motley Fool owns shares of and recommends Amazon and Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie also increased its dividend for the 45th year in a row (including the years it was part of Abbott Labs (NYSE: ABT) ). Moving into front-line treatment areas in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is one important pathway for sales growth. Gonzalez said that potential disruptions by Amazon will "primarily impact the retail environment" and won't significantly affect AbbVie's business. | AbbVie also increased its dividend for the 45th year in a row (including the years it was part of Abbott Labs (NYSE: ABT) ). Operating margins The company doesn't just expect to grow its top line -- it also projects impressive improvement in operating margins, from 42% of sales now to 50% by 2020. Gonzalez said that potential disruptions by Amazon will "primarily impact the retail environment" and won't significantly affect AbbVie's business. | AbbVie also increased its dividend for the 45th year in a row (including the years it was part of Abbott Labs (NYSE: ABT) ). Beyond Humira While AbbVie believes Humira will remain a big moneymaker for years to come, it's looking beyond Humira to the next generation of autoimmune-disease drugs. Gonzalez said that potential disruptions by Amazon will "primarily impact the retail environment" and won't significantly affect AbbVie's business. | AbbVie also increased its dividend for the 45th year in a row (including the years it was part of Abbott Labs (NYSE: ABT) ). AbbVie CFO Bill Chase pointed to two ways the company will be able to hit this projection. AbbVie's second priority, according to Gonzalez, is to return cash to shareholders through dividends and stock buybacks. |
33409.0 | 2017-11-07 00:00:00 UTC | Noteworthy ETF Outflows: IVE, MDT, ABT, COST | ABT | https://www.nasdaq.com/articles/noteworthy-etf-outflows-ive-mdt-abt-cost-2017-11-07 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $109.5 million dollar outflow -- that's a 0.8% decrease week over week (from 131,850,000.0 to 130,850,000.0). Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Costco Wholesale Corp (Symbol: COST) is up by about 0.5%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average:
Looking at the chart above, IVE's low point in its 52 week range is $92.04 per share, with $110.30 as the 52 week high point - that compares with a last trade of $109.61. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Costco Wholesale Corp (Symbol: COST) is up by about 0.5%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $92.04 per share, with $110.30 as the 52 week high point - that compares with a last trade of $109.61. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Costco Wholesale Corp (Symbol: COST) is up by about 0.5%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $92.04 per share, with $110.30 as the 52 week high point - that compares with a last trade of $109.61. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Costco Wholesale Corp (Symbol: COST) is up by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $109.5 million dollar outflow -- that's a 0.8% decrease week over week (from 131,850,000.0 to 130,850,000.0). For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $92.04 per share, with $110.30 as the 52 week high point - that compares with a last trade of $109.61. | Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Costco Wholesale Corp (Symbol: COST) is up by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $109.5 million dollar outflow -- that's a 0.8% decrease week over week (from 131,850,000.0 to 130,850,000.0). For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $92.04 per share, with $110.30 as the 52 week high point - that compares with a last trade of $109.61. |
33410.0 | 2017-11-01 00:00:00 UTC | If I Could Buy Only 1 Stock, This Would Be It | ABT | https://www.nasdaq.com/articles/if-i-could-buy-only-1-stock-would-be-it-2017-11-01 | nan | nan | What are the top three things you like in a stock? For me, the answer is pretty easy: I like growth most of all. Everyone wants their stocks to appreciate in value.
Second, I like dividends. The total return of a given stock includes both share-price appreciation and dividend reinvestment. When you have both, it's a wonderful thing. Finally, like most investors, I like getting a bargain.
The problem is that all three of these attributes can be hard to find in one stock. But it's not an impossible task. There's at least one alternative on the market that is a growth stock, a dividend stock, and a value stock all rolled into one. If I could buy only one stock right now, AbbVie (NYSE: ABBV) would be it.
Growth
We can only look back over the past five years to see how well AbbVie stock has performed. That's because the biotech wasn't traded as an independent entity until 2013, after being spun off from parent Abbott Labs (NYSE: ABT) . But during those five years, AbbVie stock has nearly doubled the gains posted by the S&P 500 Index .
Can AbbVie continue its winning ways? I think so. The company appears to be poised for strong earnings growth. Wall Street analysts, for example, project that AbbVie will increase its earnings by more than 14% annually over the next five years.
AbbVie should be able to achieve this level of growth thanks, in large part, to its solid current product lineup. Humira, the top-selling drug in the world, continues to generate impressive sales growth. Worries that AbbVie could face major competition in the U.S. have been largely alleviated after the company struck a deal recently with Amgen . Under the terms of the deal, Amjevita, Amgen's biosimilar to Humira, won't be marketed in the U.S. until early 2023. In addition, AbbVie will get royalties on all sales of Amjevita.
Cancer drug Imbruvica is also gaining momentum. In the third quarter , AbbVie reported sales for the drug totaling $626 million, a 42.5% year-over-year increase. Imbruvica is on track to generate more than $2.3 billion in revenue this year. Market research firm EvaluatePharma projects the drug will rake in $7.5 billion by 2022. However, AbbVie will split this revenue with its partner, Johnson & Johnson (NYSE: JNJ) .
The company has a couple of promising newer products that have already won approval. The U.S. Food and Drug Administration (FDA) gave a thumbs-up in April for Venclexta in treating patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion.
AbbVie and Roche are also evaluating Venclexta in clinical studies for several other indications. The FDA approved hepatitis C virus (HCV) drug Mavyret in August. Both drugs could become blockbusters.
AbbVie's pipeline also looks great. In the autoimmune-disease therapeutic category, upadacitinib and risankizumab are two promising late-stage assets. Turning to oncology, AbbVie has Rova-T and veliparib. Elagolix could be another potential blockbuster in treating endometriosis and uterine fibroids.
Dividend
There aren't many healthcare stocks with more attractive dividends than AbbVie. Its dividend yield currently stands at 3.09%. And that's lower than it's been for most of the last few years, because AbbVie stock has performed so well.
Because of its connection with Abbott Labs, AbbVie boasts an impressive track record of increasing its dividend for 45 consecutive years. That includes growing its dividend by nearly 90% over the last five years, even faster than its parent company has increased its dividend.
AbbVie just announced its latest dividend hike a few days ago. The company appears to be in solid shape to keep the dividend increases coming. AbbVie uses less than 60% of earnings to fund the dividend program. And both earnings and cash flow continue to grow.
Value
You may think that AbbVie, with its excellent growth prospects and mouth-watering dividend, might be priced for perfection. It's not.
The stock currently trades at less than 14 times expected earnings. That's less expensive than several peers with lower growth opportunities and dividend yields. Johnson & Johnson stock, for example, trades at nearly 18 times expected earnings, but Wall Street projects annual earnings growth of around 7%. J&J's dividend yield of 2.37% is also well below AbbVie's.
Some risks
AbbVie isn't without some risks. Humira will face biosimilar competition in Europe beginning in 2018. There's always the possibility that one or more of the company's pipeline candidates could flop.
I'm not too concerned, though. Two-thirds of Humira's sales are made in the U.S. Johnson & Johnson's experience with biosimilar threats to its blockbuster autoimmune-disease drug Remicade hasn't been overly negative so far.
AbbVie probably won't have an immediate revenue cliff when biosimilars to Humira hit the market, either. Although the pipeline risk is real, AbbVie appears to have several solid candidates that should be able to advance to approval.
There's no such thing as a perfect stock. But for investors who, like me, seek growth, dividends, and value, AbbVie checks off the boxes really well.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017
Keith Speights owns shares of AbbVie. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | That's because the biotech wasn't traded as an independent entity until 2013, after being spun off from parent Abbott Labs (NYSE: ABT) . Worries that AbbVie could face major competition in the U.S. have been largely alleviated after the company struck a deal recently with Amgen . The U.S. Food and Drug Administration (FDA) gave a thumbs-up in April for Venclexta in treating patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion. | That's because the biotech wasn't traded as an independent entity until 2013, after being spun off from parent Abbott Labs (NYSE: ABT) . Under the terms of the deal, Amjevita, Amgen's biosimilar to Humira, won't be marketed in the U.S. until early 2023. Because of its connection with Abbott Labs, AbbVie boasts an impressive track record of increasing its dividend for 45 consecutive years. | That's because the biotech wasn't traded as an independent entity until 2013, after being spun off from parent Abbott Labs (NYSE: ABT) . There's at least one alternative on the market that is a growth stock, a dividend stock, and a value stock all rolled into one. Dividend There aren't many healthcare stocks with more attractive dividends than AbbVie. | That's because the biotech wasn't traded as an independent entity until 2013, after being spun off from parent Abbott Labs (NYSE: ABT) . Everyone wants their stocks to appreciate in value. There's at least one alternative on the market that is a growth stock, a dividend stock, and a value stock all rolled into one. |
33411.0 | 2017-10-31 00:00:00 UTC | Notable ETF Outflow Detected - IVE, MDT, ABT, ORCL | ABT | https://www.nasdaq.com/articles/notable-etf-outflow-detected-ive-mdt-abt-orcl-2017-10-31 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $98.1 million dollar outflow -- that's a 0.7% decrease week over week (from 131,700,000.0 to 130,800,000.0). Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is trading flat, Abbott Laboratories (Symbol: ABT) is trading flat, and Oracle Corp (Symbol: ORCL) is up by about 0.3%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average:
Looking at the chart above, IVE's low point in its 52 week range is $92.04 per share, with $110.30 as the 52 week high point - that compares with a last trade of $109.20. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is trading flat, Abbott Laboratories (Symbol: ABT) is trading flat, and Oracle Corp (Symbol: ORCL) is up by about 0.3%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $92.04 per share, with $110.30 as the 52 week high point - that compares with a last trade of $109.20. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is trading flat, Abbott Laboratories (Symbol: ABT) is trading flat, and Oracle Corp (Symbol: ORCL) is up by about 0.3%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $92.04 per share, with $110.30 as the 52 week high point - that compares with a last trade of $109.20. Click here to find out which 9 other ETFs experienced notable outflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is trading flat, Abbott Laboratories (Symbol: ABT) is trading flat, and Oracle Corp (Symbol: ORCL) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $98.1 million dollar outflow -- that's a 0.7% decrease week over week (from 131,700,000.0 to 130,800,000.0). For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $92.04 per share, with $110.30 as the 52 week high point - that compares with a last trade of $109.20. | Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is trading flat, Abbott Laboratories (Symbol: ABT) is trading flat, and Oracle Corp (Symbol: ORCL) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $98.1 million dollar outflow -- that's a 0.7% decrease week over week (from 131,700,000.0 to 130,800,000.0). For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $92.04 per share, with $110.30 as the 52 week high point - that compares with a last trade of $109.20. |
33412.0 | 2017-10-31 00:00:00 UTC | HCA Healthcare (HCA) Posts In-Line Q3 Earnings, Keeps View | ABT | https://www.nasdaq.com/articles/hca-healthcare-hca-posts-in-line-q3-earnings-keeps-view-2017-10-31 | nan | nan | HCA Healthcare, Inc . HCA reported third-quarter 2017 adjusted earnings of $1.21 per share, which came in line with the Zacks Consensus Estimate. The bottom line declined nearly 25% year over year.
HCA Holdings, Inc. Price, Consensus and EPS Surprise
HCA Holdings, Inc. Price, Consensus and EPS Surprise | HCA Holdings, Inc. Quote
Improvement in revenues was offset by an increase in expenses. Shares were down 0.07% in pre-market trading .
HCA Healthcare posted revenues of $10.7 billion, almost in line with the Zacks Consensus Estimate. The reported figure was up 3.9% from the year-ago quarter.
Provision for doubtful accounts surged 51% year over year to $1.3 million.
Quarterly Details
Adjusted EBITDA totaled $1.8 billion, up 9.2% year over year.
Same facility equivalent admissions inched up 0.3% year over year, while same facility admissions nudged up 0.6%. Same facility revenue per equivalent admission increased 2%.
Salaries and benefits, supplies and other operating expenses increased 7.2% year over year to $8.9 billion.
As of Sep 30, 2017, HCA Healthcare ran 177 hospitals and 119 free-standing surgery centers.
Financial Update
As of Sep 30, 2017, the company had cash and cash equivalents of $718 million, total debt of $32.6 billion and total assets of $35.7 billion.
During the reported quarter, capital expenditures totaled $729 million, excluding acquisitions. Cash flows provided by operating activities totaled $1 billion, down 16.4% year over year.
As of Sep 30, 2017, the company's total debt/adjusted EBITDA was 4.1x compared with 3.8x as of Dec 31, 2016.
During the quarter under review, the company spent $509 million to buy back 6.3 million shares. The board of directors approved an additional share repurchase program for up to $2 billion.
Following the latest authorization, the company has about $2.2 million remaining under its existing repurchase authorization as of Oct 31, 2017.
Guidance
The company expects 2017 revenues in the range of $43-$44 billion, adjusted EBIDTA of $8-$8.2 billion, EPS of $6.45-$6.70 and capital expenditures of about $3 billion.
Zacks Rank and Performance of Other Companies From Medical Sector
HCA Healthcare presently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today's Zacks #1 Rank stocks here .
AbbVie Inc. ABBV , ABIOMED, Inc. ABMD and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate during the last quarter.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
ABIOMED, Inc. (ABMD): Free Stock Analysis Report
HCA Holdings, Inc. (HCA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ABBV , ABIOMED, Inc. ABMD and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate during the last quarter. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report HCA Holdings, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. HCA reported third-quarter 2017 adjusted earnings of $1.21 per share, which came in line with the Zacks Consensus Estimate. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report HCA Holdings, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV , ABIOMED, Inc. ABMD and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate during the last quarter. HCA Holdings, Inc. Price, Consensus and EPS Surprise HCA Holdings, Inc. Price, Consensus and EPS Surprise | HCA Holdings, Inc. Quote Improvement in revenues was offset by an increase in expenses. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report HCA Holdings, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV , ABIOMED, Inc. ABMD and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate during the last quarter. HCA Holdings, Inc. Price, Consensus and EPS Surprise HCA Holdings, Inc. Price, Consensus and EPS Surprise | HCA Holdings, Inc. Quote Improvement in revenues was offset by an increase in expenses. | AbbVie Inc. ABBV , ABIOMED, Inc. ABMD and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate during the last quarter. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report HCA Holdings, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. HCA reported third-quarter 2017 adjusted earnings of $1.21 per share, which came in line with the Zacks Consensus Estimate. |
33413.0 | 2017-10-30 00:00:00 UTC | The 3 Best Diabetes Stocks to Buy in 2018 | ABT | https://www.nasdaq.com/articles/3-best-diabetes-stocks-buy-2018-2017-10-30 | nan | nan | Diabetes is a chronic condition that occurs when the body loses its ability to properly metabolize sugar. Without treatment, people with diabetes end up with too much sugar flowing through their bloodstream, which can lead to a wide range of health problems.
More than 30 million Americans already have diabetes, and another 84 million are at risk of developing the disease. Given these massive numbers, perhaps it isn't shocking to learn that diabetes costs the U.S. healthcare system more than $245 billion annually.
A market opportunity that large has attracted the attention of plenty of publicly traded companies:
Data source: Yahoo! Finance. Market cap data as of 10/25/17.
But which of these diabetes stocks is the best bet for investors heading into 2018? Here are my three favorites.
A big competitor throws in the towel
Roughly 3 million Americans require artificial insulin to keep their blood sugar levels in a healthy range. While the majority of them rely on pens or needles for insulin delivery, another option is to use an insulin pump.
For decades, insulin pump therapy required users to wear a pager-like device and tubing all day, every day, but a decade ago Insulet introduced the first fully programmable patch pump to market. Called the OmniPod , this waterproof device sits directly on the skin and automatically inserts a small cannula into the body. Insulin dosage instructions are transmitted to the device by using a wireless handheld controller.
Understandably, the tube-free nature of this product become highly appealing to patients who were resistant to the idea of using a pump. As a result, Insulet has been stealing market share away from industry leader Medtronic for years. Revenue has grown at a brisk pace since the company's IPO, and Insulet's stock has crushed the market.
Is it too late to get in? This Fool doesn't think so. One reason for my bullishness is that Johnson & Johnson recently decided to exit the insulin-pump market altogether. Although J&J is steering the 90,000 stranded patients towards Medtronic, many patients will probably view the OmniPod as an attractive alternative to their tubed pump. This should make it easier for Insulet to hit CEO Patrick Sullivan's target of $1 billion in revenue by 2021, about triple what it pulled in last year. If so, then this stock stands a good chance of continuing to outperform from here.
A reasonable valuation
Dexcom is a diabetes company that I've long admired . The company is a leading manufacturer of continuous glucose monitoring (CGM) system that enables people with diabetes to see their blood glucose levels in nearly real time. Since high or low blood glucose readings can require immediate medical attention, being able to constantly track changes in glucose levels can allow a patient to take action before things get out of hand.
Given the huge consumer appeal of adoption of a CGM system, Dexcom's growth rate over the past decade has been nothing short of extraordinary.
DXCM Revenue (TTM) data by YCharts
Wall Street caught on to this growth story years ago and bid up shares to an extreme valuation . That fact largely kept me on the sidelines. However, Dexcom's stock took a nose-dive in late 2017, after the FDA approved Abbott Laboratories' FreeStyle Libre Flash Glucose Monitoring System. The Libre has a few advantages that give it strong consumer appeal. That caused traders to worry that Dexcom's glory days have finally come to an end.
While I'm mindful of Libre's benefits, I don't think this is a winner-take-all market. Only a small fraction of patients who use insulin are on a CGM today, so there should be ample room for Abbott, Dexcom, and other CGM systems to succeed. That's especially true now that Medicare is starting to cover CGM systems for the first time. With Dexcom's stock finally trading at a reasonable valuation, I think this stock stands a great chance of bouncing back in 2018.
The comeback kid
Novo Nordisk has long been the top dog in insulin therapy. That fact has taken long-term investors on a wildly profitable ride . However, Novo's stock was thrashed in late 2016, after management cut its long-term profit growth targets in half. The company stated that U.S. insurers were demanding lower prices on its legacy insulin products. That pressure forced Novo to give in if it wanted to keep its market share.
However, Novo's stock came roaring back to life in 2017 after the company posted upbeat earnings for several quarters in a row. The results were largely driven by strong growth in the company's next-generation drugs, such as Victoza, Tresiba, Xultophy, and Ryzodeg. When combined with more disciplined expense control and label expansion claims, Novo's profit growth hasn't had any trouble exceeding the lowered hurdle rate.
Looking ahead, Novo's next-generation drugs should continue to power overall revenue higher, even in the face of continued pricing pressure on its legacy business. When combined with new drug launches and the general rise in diabetes diagnosis, this Fool thinks Novo's rebound is easily sustainable. Adding in a dividend yield of 2.4% is just icing on the cake.
10 stocks we like better than Novo Nordisk
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Novo Nordisk wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017
Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool owns shares of Medtronic. The Motley Fool recommends Becton Dickinson, Insulet, and Novo Nordisk. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A big competitor throws in the towel Roughly 3 million Americans require artificial insulin to keep their blood sugar levels in a healthy range. DXCM Revenue (TTM) data by YCharts Wall Street caught on to this growth story years ago and bid up shares to an extreme valuation . When combined with more disciplined expense control and label expansion claims, Novo's profit growth hasn't had any trouble exceeding the lowered hurdle rate. | The company is a leading manufacturer of continuous glucose monitoring (CGM) system that enables people with diabetes to see their blood glucose levels in nearly real time. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market. The Motley Fool owns shares of and recommends Johnson & Johnson. | For decades, insulin pump therapy required users to wear a pager-like device and tubing all day, every day, but a decade ago Insulet introduced the first fully programmable patch pump to market. The company is a leading manufacturer of continuous glucose monitoring (CGM) system that enables people with diabetes to see their blood glucose levels in nearly real time. With Dexcom's stock finally trading at a reasonable valuation, I think this stock stands a great chance of bouncing back in 2018. | This Fool doesn't think so. The company is a leading manufacturer of continuous glucose monitoring (CGM) system that enables people with diabetes to see their blood glucose levels in nearly real time. With Dexcom's stock finally trading at a reasonable valuation, I think this stock stands a great chance of bouncing back in 2018. |
33414.0 | 2017-10-28 00:00:00 UTC | 3 High-Yield Dividend Aristocrat Stocks | ABT | https://www.nasdaq.com/articles/3-high-yield-dividend-aristocrat-stocks-2017-10-28 | nan | nan | If dividend stocks were like golf, there would be an elite group of stocks with green jackets like golfing greats who win the Masters tournament get to wear. This group of winners is called the Dividend Aristocrats. It's comprised of S&P 500 stocks that have raised dividends for at least 25 years in a row.
Not all of these Dividend Aristocrats have particularly impressive yields. But we asked three Motley Fool investors to point out high-yield Dividend Aristocrat stocks that could be good picks right now. Here's why they chose ExxonMobil (NYSE: XOM) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) .
35 years and counting
Matt DiLallo (ExxonMobil): Big oil behemoth ExxonMobil has paid its investors a dividend for more than a century, including increasing it for the past 35 straight years. That's an impressive feat for an oil company given the volatility of oil prices , especially considering the deep downturn of the last few years, which led several rivals to reduce their payouts. However, because of the strength of Exxon's balance sheet and its underlying operations, the company has had the financial resources to continue returning cash to investors.
ExxonMobil's balance sheet strength, which includes the industry's best credit rating, provided the company with the financial flexibility to continue paying dividends and investing in new growth projects during the sector's recent downturn, giving it time to reposition its cost structure and adjust to lower oil prices. Those strategic initiatives started bearing fruit last quarter, enabling the company to generate a whopping $7.1 billion in cash, which was enough to easily cover the $3.3 billion quarterly dividend outlay as well as the bulk of its $3.9 billion capex tab. Those results show that the oil giant's dividend is on solid ground even in the current low oil price environment.
Meanwhile, because Exxon has kept growing during the downturn, it currently yields an impressive 3.8%. That certainly qualifies it as a high yielder since it's nearly double the yield of the S&P 500. That growing income stream should continue heading to investors for at least the next several years considering that oil demand keeps rising, meaning the oil giant should remain a reliable option for investors seekers.
A sustainable retail dividend
Tim Green(Target): Shares of retailer Target have slumped nearly 13% this year, dragged down by pessimism surrounding brick-and-mortar retailers. This has boosted Target's dividend yield to about 3.9%, making the stock an attractive option for dividend investors. Target has increased its dividend for 46 years in a row, and it has paid a quarterly dividend uninterrupted since 1967.
Target is in the process of adapting to a changing retail industry. It's investing in its e-commerce business, launching initiatives like next-day delivery for household essentials. The e-commerce business grew by 32% year over year during the second quarter, double the rate Target managed during the second quarter of 2016.
Exclusive brands and small-format stores are also part of the plan. Target has launched a handful of private-label brands this year, including A New Day, Goodfellow & Co, and Project 62. More new brands are in the pipeline, with the company betting that these new products will give customers a reason to visit its stores. Target also plans to open dozens of small-format stores in cities over the next couple of years, diversifying away from its big-box model.
Target's dividend growth will likely be slow for the foreseeable future as the company invests in these initiatives. The payout ratio is a bit below 50% for the past 12 months, so there's still some room for the dividend to expand even if earnings growth remains sluggish. Target's dividend growth track record should give investors some confidence that those dividend checks will continue getting a little bigger each year.
A three-in-one aristocrat
Keith Speights (AbbVie): 1972. That's the year that started AbbVie's remarkable streak of dividend hikes. Granted, for most of the ensuing period, AbbVie was part of its parent company, Abbott Labs . However, the drugmaker still qualifies as a Dividend Aristocrat. I think AbbVie is a "growth aristocrat" and "value aristocrat," too.
First, though, there's AbbVie's dividend yield of over 3% (boosted by a just-announced dividend hike for 2018). That's lower than its yield for most of its history as a stand-alone company. The reason why is AbbVie's tremendous stock performance in 2017. With the drugmaker continuing to raise its dividend, the yield will either go higher or its stock will. Either way, investors win.
That leads to my view of AbbVie as a "growth aristocrat." The stock has soared close to 50% this year. Wall Street analysts expect AbbVie to grow earnings by more than 15% annually over the next five years. With the top-selling drug in the world (Humira), one of the fastest-growing cancer drugs in the world (Imbruvica), and the third-best pipeline in the biopharmaceutical industry , it's easy to see how that growth can be achieved.
What about the "value aristocrat" status? Despite its huge gains, AbbVie stock trades at only 14 times expected earnings. That's a downright bargain considering the company's excellent dividend and strong growth potential. I have no doubt that AbbVie will remain a Dividend Aristocrat and a "growth aristocrat" for years to come, but that "value aristocrat" designation might not last much longer.
10 stocks we like better than ExxonMobil
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and ExxonMobil wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017
Keith Speights owns shares of AbbVie. Matthew DiLallo has no position in any of the stocks mentioned. Timothy Green has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, because of the strength of Exxon's balance sheet and its underlying operations, the company has had the financial resources to continue returning cash to investors. ExxonMobil's balance sheet strength, which includes the industry's best credit rating, provided the company with the financial flexibility to continue paying dividends and investing in new growth projects during the sector's recent downturn, giving it time to reposition its cost structure and adjust to lower oil prices. Target also plans to open dozens of small-format stores in cities over the next couple of years, diversifying away from its big-box model. | ExxonMobil's balance sheet strength, which includes the industry's best credit rating, provided the company with the financial flexibility to continue paying dividends and investing in new growth projects during the sector's recent downturn, giving it time to reposition its cost structure and adjust to lower oil prices. A sustainable retail dividend Tim Green(Target): Shares of retailer Target have slumped nearly 13% this year, dragged down by pessimism surrounding brick-and-mortar retailers. The e-commerce business grew by 32% year over year during the second quarter, double the rate Target managed during the second quarter of 2016. | This has boosted Target's dividend yield to about 3.9%, making the stock an attractive option for dividend investors. Target's dividend growth track record should give investors some confidence that those dividend checks will continue getting a little bigger each year. I have no doubt that AbbVie will remain a Dividend Aristocrat and a "growth aristocrat" for years to come, but that "value aristocrat" designation might not last much longer. | Not all of these Dividend Aristocrats have particularly impressive yields. But we asked three Motley Fool investors to point out high-yield Dividend Aristocrat stocks that could be good picks right now. ExxonMobil's balance sheet strength, which includes the industry's best credit rating, provided the company with the financial flexibility to continue paying dividends and investing in new growth projects during the sector's recent downturn, giving it time to reposition its cost structure and adjust to lower oil prices. |
33415.0 | 2017-10-27 00:00:00 UTC | Integra LifeSciences (IART) Misses on Q3 Earnings & Revenues | ABT | https://www.nasdaq.com/articles/integra-lifesciences-iart-misses-on-q3-earnings-revenues-2017-10-27 | nan | nan | Integra LifeSciences Holdings CorporationIART reported adjusted earnings per share (EPS) of 45 cents in the third quarter of 2017, which declined 2.2% from the year-ago figure.
Adjusted EPS also missed the Zacks Consensus Estimate of 47 cents. Including one-time items, the company reported earnings of 4 cents per share, down 54% from the year-ago quarter.
Revenue Discussion
Total revenue in the reported quarter increased 11.4% year over year to $278.8 million, which lagged the Zacks Consensus Estimate of $286 million. Excluding revenues from acquisitions, discontinued products and the effect of currency exchange rates, organic revenues rose 1.5% year over year.
The solid revenue growth in the third quarter was primarily driven by strong contribution from the Orthopedics and Tissue Technologies segments.
Coming to product categories, revenues from the company's Specialty Surgical Solutions segment increased 3.4% to $164.8 million.
Orthopedics and Tissue Technologies revenues came in at $114.1 million in the third quarter, up 25.5% year over year.
Margin Trend
Gross margin contracted 81 basis points (bps) to 63.5% in the reported quarter. Per the company, adjusted gross margin contracted 60 bps to 68.7%.
Selling, general and administrative expenses increased 29.9% to $145.9 million in the reported quarter, while research and development expenses contracted 0.6% to $15 million. Adjusted operating margin saw a 763-bps contraction to 5.8% in the third quarter.
Financial Position
Integra LifeSciences exited third-quarter 2017 with cash and cash equivalents of $481.9 million, up from $154.6 million recorded at the end of second-quarter 2017. As of Sep 30, 2017, net cash flow from operating activities was $102.9 million, down from $109.9 million in the year-ago quarter.
2017 Outlook Tweaked
Management has raised the full-year 2017 revenue guidance from $1.125-$1.140 billion to $1.165-$1.175 billion. Meanwhile, full-year 2017 organic revenue growth range was lowered to 4% from 6% to 7%. The Zacks Consensus Estimate for full-year 2017 revenues is $1.20 billion, below the guided range.
The company has revised its full-year 2017 adjusted EPS guidance to$1.83-$1.87 from the previous range of $1.88-$1.94. The Zacks Consensus Estimate for 2017 adjusted earnings is pegged at $1.91, above the company's guided range.
Our Take
Integra LifeSciences exited the third quarter of 2017 on a disappointing note. Also, contraction in adjusted operating margin and adjusted gross margin adds to the woes. Moreover, the drop in year-over-year investments in research and development is discouraging. In spite of the raised full-year revenue guidance, the slashed full-year adjusted earnings range adds to the woes.
However, the strong year-over-year increase in revenues on the back of its Orthopedics and Tissue Technologies segment buoys optimism. We are also encouraged to note that the company's segments saw year-over-year revenue growth in the quarter. Nonetheless, we believe the company is trying to execute its growth plan through an efficient management team.
Zacks Rank & Key Picks
Integra LifeSciences has a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Notably, PetMed sports a Zacks Rank #1 (Strong Buy), while Abbott and Intuitive Surgical carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
PetMed reported EPS of 43 cents in the second quarter of fiscal 2018, up 79.2% from the year-ago quarter's 24 cents. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Abbott reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Also, third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year.
Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report To read this article on Zacks.com click here. Integra LifeSciences Holdings CorporationIART reported adjusted earnings per share (EPS) of 45 cents in the third quarter of 2017, which declined 2.2% from the year-ago figure. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . In spite of the raised full-year revenue guidance, the slashed full-year adjusted earnings range adds to the woes. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Revenue Discussion Total revenue in the reported quarter increased 11.4% year over year to $278.8 million, which lagged the Zacks Consensus Estimate of $286 million. | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report To read this article on Zacks.com click here. Revenue Discussion Total revenue in the reported quarter increased 11.4% year over year to $278.8 million, which lagged the Zacks Consensus Estimate of $286 million. |
33416.0 | 2017-10-27 00:00:00 UTC | Align Technology (ALGN) Q3 Earnings Top on Invisalign Sales | ABT | https://www.nasdaq.com/articles/align-technology-algn-q3-earnings-top-on-invisalign-sales-2017-10-27 | nan | nan | Align Technology, Inc.ALGN reported earnings per share (EPS) of $1.01 in the third quarter of 2017, substantially up 60.3% year over year. Earnings were also higher than the company's guided range of 78-81 cents. The figure comfortably beat the Zacks Consensus Estimate of 82 cents.
Revenues
Revenues grew 38.3% year over year to $385.3 million in the quarter, surpassing the Zacks Consensus Estimate of $360 million. This also remained well ahead of the company's guided range of $355-$360 million.
Per management, a strong top line was driven by robust Invisalign case shipments of 32.8% year over year to 236.1 thousand during the third quarter. This upside was backed by growth in North America and international regions. Also a 46.3% year-over-year surge in teenage cases across the board, reflecting a very strong summer teen season, contributed to the top-line growth.
Segments in Detail
Revenues at the Clear Aligner segment (88.7% of total revenue) soared 40.2% year over year to $341.6 million in the reported quarter, primarily driven by continued strong Invisalign case volume growth across all customer channels and geographical regions.
In the third quarter, Invisalign case shipments amounted to 236,065, up 32.8% year over year, aided by growth across all regions as well as the expansion of customer base. During the quarter, Align Technology Invisalign cases were shipped to 42,605 doctors worldwide, of which, 24,845 were from North America while 17,760 were from international regions.
Revenues from Scanner and Service (11.3%) improved significantly by 25% to $43.7 million.
Margins
Gross margin in the third quarter was up 82 basis points (bps) year over year to 75.9% on a 33.7% rise in cost of net revenue.
During the quarter, Align Technology witnessed a 33.8% year-over-year increase in selling, general and administrative expenses to $169.5 million and an 18.5% rise in research and development (R&D) expenses to $24.2 million. The operating margin, however, expanded 335 bps to 25.6%.
Financial Details
Align Technology exited the third quarter with cash and cash equivalents and short-term marketable securities of $679.1 million, which marked a 12.8% rise from the preceding quarter.
In the reported quarter, Align Technology closed its earlier-announced $50 million accelerated stock repurchase program (ASR) receiving a total of 0.4 million shares at a weighted average share price of $146.48. Management currently has $250 million available for repurchase under the existing stock repurchase authorization.
Guidance
For the fourth quarter of 2017, the company projects EPS of 92-95 cents on revenues of $391-$398 million. The company also expects Invisalign case shipments in the band of 245,000- 250,000, up 29-32% over the same period a year ago.
Our Take
Align Technology ended the third quarter on a solid note with both earnings and revenues beating the Zacks Consensus Estimate. We are upbeat about the continued strong Invisalign volumes. An extremely strong summer teen season drove the company's Invisalign growth within the global teen market.
Within Scanners and Service, the company witnessed a nice uptake of iTero scanners by GP dentists. With record contracts coming from the GP summit last September, the company expects this bullish trend to continue for the rest of 2017. Align is also looking forward to its recently-inked distribution agreement with Patterson Dental for Align's iTero Element intraoral scanning system.
Additionally, the company has a strong cash balance that enables it to carry out share repurchase programs and in turn provide solid returns to its investors.
On the flip side, the company is exposed to foreign exchange fluctuations, seasonal demand fluctuations, higher operating expenses pertaining to an increased head count along with higher investments targeted toward growth acceleration in geographical expansion and portfolio extension.
Zacks Rank & Key Picks
Currently, Align Technology carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Notably, PetMed sports a Zacks Rank #1 (Strong Buy), while Abbott and Intuitive Surgical carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
PetMed reported EPS of 43 cents for the second quarter of fiscal 2018, up 79.2% from the year-ago quarter's 24 cents. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Abbott reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Also, third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year.
Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues rallied 18% year over year to $806.1 million.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Also a 46.3% year-over-year surge in teenage cases across the board, reflecting a very strong summer teen season, contributed to the top-line growth. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Segments in Detail Revenues at the Clear Aligner segment (88.7% of total revenue) soared 40.2% year over year to $341.6 million in the reported quarter, primarily driven by continued strong Invisalign case volume growth across all customer channels and geographical regions. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Revenues Revenues grew 38.3% year over year to $385.3 million in the quarter, surpassing the Zacks Consensus Estimate of $360 million. | Some better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Align Technology, Inc.ALGN reported earnings per share (EPS) of $1.01 in the third quarter of 2017, substantially up 60.3% year over year. |
33417.0 | 2017-10-27 00:00:00 UTC | Chemed (CHE) Beats on Q3 Earnings & Revenues, View Revised | ABT | https://www.nasdaq.com/articles/chemed-che-beats-on-q3-earnings-revenues-view-revised-2017-10-27 | nan | nan | Chemed Corp. 's CHE third-quarter 2017 adjusted earnings per share (EPS) were $2.15, as compared to the year-ago figure of $1.73. The figure also surpassed the Zacks Consensus Estimate of $2.00.
Quarter in Details
Revenues in the quarter increased 6.3% year over year to $417.4 million, beating the Zacks Consensus Estimate of $415 million.
Chemed currently operates through two wholly-owned subsidiaries, namely, VITAS Healthcare Corporation - a major provider of end-of-life care - and Roto-Rooter - a leading commercial and residential plumbing and drain cleaning service provider.
In the third quarter, net revenues at VITAS Healthcare totaled $288.9 million, reflecting an increase of 2.2% year over year. Revenues were driven by a 1.3% increase in the average net Medicare reimbursement rate and a 2.8% rise in average daily census. However, this was offset by acuity mix shift which impacted revenues by 2.2%.
Roto-Rooter reported sales of $128.5 million in the third quarter were up 17.1% year over year. According to the company, revenues from water restoration increased 77.2% year over year to $21.1 million.
Gross margin expanded 274 basis points (bps) year over year to 30.9%. Adjusted operating margin expanded 183 bps to 14.9% in the quarter on a 12.7% rise in selling, general and administrative expenses to $66.9 million.
Chemed exited the third quarter of 2017 with total cash and cash equivalents of $18.9 million, up from $13.8 million at the end of second-quarter 2017. The company had total debt of $82.5 million at the end of the third quarter, compared with $125 million at the end of the preceding quarter. As of Sep 30, 2017, the company had approximately $309 million in undrawn borrowing capacity under its existing five-year credit agreement.
During the third quarter, the company repurchased shares worth $9.6 million. In March 2017, the board had authorized an additional 100 million for Chemed's existing share repurchase plan. As of Sep 30, 2017, the company had $55.5 million of remaining share repurchase authorization under the plan.
2017 Outlook
The company continues to project VITAS Healthcare revenue growth for 2017 in the range of 2% to 3%, prior to the Medicare Cap. Also, the admissions and Average Daily Census in 2017 is expected to increase 2% to 3% (earlier it was 3% to 5%). Medicare Cap billing limitations are expected at around $1.5 million in 2017, while it was earlier projected at around $2.5 million.
The Roto-Rooter business is estimated to grow 13% to 14% in the full year, as compared with the earlier range of 12% to 13%. The raised guidance was backed by a 2% increase in job pricing and water restoration services growth.
Full-year adjusted EPS is expected to grow in the range of $8.35 to $8.40 ($8.10 to $8.20 previously) as compared with $7.24 reported in 2016.
Our Take
Chemed exited the third quarter on a solid note. Also, the company witnessed year-over-year growth on both the fronts. Moreover, we are encouraged to note that both of the company's subsidiaries saw year-over-year revenue growth in the quarter. The expansion in gross and operating margin and strong bottom-line projections also buoy optimism.
Further, reimbursement-related issues, seasonality in business, a competitive landscape and dependence on government mandates continue to pose challenges to Chemed.
Zacks Rank & Key Picks
Chemedhas a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Notably, PetMed sports a Zacks Rank #1 (Strong Buy), while Abbott and Intuitive Surgical carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
PetMed reported EPS of 43 cents for the second quarter of fiscal 2018, up 79.2% from the year-ago quarter's 24 cents. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Abbott reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Also, third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year.
Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Chemed Corp. (CHE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Chemed Corp. (CHE): Free Stock Analysis Report To read this article on Zacks.com click here. Further, reimbursement-related issues, seasonality in business, a competitive landscape and dependence on government mandates continue to pose challenges to Chemed. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Chemed Corp. (CHE): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . In the third quarter, net revenues at VITAS Healthcare totaled $288.9 million, reflecting an increase of 2.2% year over year. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Chemed Corp. (CHE): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Quarter in Details Revenues in the quarter increased 6.3% year over year to $417.4 million, beating the Zacks Consensus Estimate of $415 million. | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Chemed Corp. (CHE): Free Stock Analysis Report To read this article on Zacks.com click here. Quarter in Details Revenues in the quarter increased 6.3% year over year to $417.4 million, beating the Zacks Consensus Estimate of $415 million. |
33418.0 | 2017-10-27 00:00:00 UTC | ResMed (RMD) Q1 Earnings Top on Growth in All Business Lines | ABT | https://www.nasdaq.com/articles/resmed-rmd-q1-earnings-top-on-growth-in-all-business-lines-2017-10-27 | nan | nan | ResMed Inc. RMD announced first-quarter fiscal 2018 adjusted earnings per share (EPS) of 66 cents, up 6.5% from the prior-year quarter. Earnings also beat the Zacks Consensus Estimate by a penny.
Including one-time items, ResMed reported EPS of 60 cents in the quarter, up 11.1% year over year.
Revenues in Details
Revenues in the reported quarter increased 12.5% year over year (up 11% at constant exchange rate or CER) to $523.7 million. The figure also beat the Zacks Consensus Estimate of $501 million.
On a geographic basis, excluding Brightree, revenues in the Americas totaled $296.6 million, reflecting an 11% increase over the prior-year quarter. Moreover, revenues from Brightree in the reported quarter totaled $38.1 million, up 15% year over year. Revenues in combined EMEA and APAC were $189 million, highlighting an 11% year over year rise at CER.
Adjusted gross margin contracted 56 basis points (bps) year over year to 58.4% in the reported quarter. Selling, general and administrative expenses were up 11.6% year over year to $143.8 million, while there was an 8.6% increase in Research and Development expenses to $37.4 million. This led to an 11% rise in adjusted operating expenses, which amounted to $181.2 million. Accordingly, adjusted operating margin in the quarter contracted 9 bps to 23.7%.
Financial Update
ResMed exited first-quarter fiscal 2018 with cash and cash equivalents of $811.1 million, compared with $821.9 million at the end of fiscal 2017.
Year to date, the company generated $93.9 million of cash flow from operations, up from the year-ago figure of $86.2 million.
Concurrent to its first-quarter earnings release, ResMed announced a regular quarterly dividend of 35 cents per share. The dividend will be paid on Dec 14, to shareholders of record as on Nov 9.
As previously declared, ResMed temporarily suspended its share repurchase program due to the recent acquisitions. However, the company still expects to recommence the buy-back program sometime in fiscal 2018.
Guidance
Management expects SG&A expenses, as a percentage of revenues, at around 26% at the end of fiscal 2018. R&D expenses, as a percentage of revenues, are projected at 7% for fiscal 2018. This reflects marketing expenses associated with product launches along with the ongoing legal expenses.
Our Take
ResMed exited the first quarter on a promising note. On the brighter side, the company achieved solid double-digit global revenue growth this quarter, led by sales from Software-as-a-Service businesses as well as its new mask products and devices. The company also recently launched the AirFit N20 Classic nasal mask for positive airway pressure (PAP) treatment in Europe. All these factors boost investor faith in the stock.
However, challenges like competitive bidding and reimbursement issues continue to plague the stock. The company also remains exposed to foreign exchange fluctuations.
Zacks Rank & Key Picks
ResMed currently carries a Zacks Rank #4 (Sell).
A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Notably, PetMed sports a Zacks Rank #1 (Strong Buy), while Abbott and Intuitive Surgical carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
PetMed reported EPS of 43 cents in the second quarter of fiscal 2018, up 79.2% from the year-ago quarter's 24 cents. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Abbott reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Also, third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year.
Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
ResMed Inc. (RMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report To read this article on Zacks.com click here. On the brighter side, the company achieved solid double-digit global revenue growth this quarter, led by sales from Software-as-a-Service businesses as well as its new mask products and devices. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . ResMed Inc. RMD announced first-quarter fiscal 2018 adjusted earnings per share (EPS) of 66 cents, up 6.5% from the prior-year quarter. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Revenues in Details Revenues in the reported quarter increased 12.5% year over year (up 11% at constant exchange rate or CER) to $523.7 million. | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues in Details Revenues in the reported quarter increased 12.5% year over year (up 11% at constant exchange rate or CER) to $523.7 million. |
33419.0 | 2017-10-27 00:00:00 UTC | Cerner (CERN) Misses on Q3 Earnings, Bookings Decline Y/Y | ABT | https://www.nasdaq.com/articles/cerner-cern-misses-on-q3-earnings-bookings-decline-y-y-2017-10-27 | nan | nan | Cerner CorpCERN reported adjusted third-quarter 2017 earnings of 61 cents per share, missing the Zacks Consensus Estimate by a penny. The lackluster third-quarter performance can be primarily attributed to the year-over-year decline in bookings, which had scaled an all-time high in the last quarter. However, earnings rose 3.4% on a year-over-year basis.
The company reported net revenues of $1.28 billion, falling short of the Zacks Consensus Estimate of $1.29 billion. However, revenues rose 7.7% on a year-over-year basis. Cerner holds a Zacks Rank #2 (Buy).
Bookings Disappoint
In the third quarter, Cerner registered bookings worth $1.111 billion, down 22.5% on a year-over-year basis. In fact, bookings were below the company's previously issued guidance owing to the postponement of several big contracts from this quarter to tentatively the fourth quarter of 2017.
Notably, bookings in the last quarter totaled $1.64 billion, up 16% on a year-over-year basis.
Nonetheless, Cerner is well positioned for a strong full-year performance based on solid bookings guidance for the fourth quarter. Next-quarter bookings are expected in the band of $1.75 billion to $2 billion, with the midpoint reflecting 30% growth on a year-over-year basis. The midpoint of the fourth-quarter booking guidance would increase full year 2017 bookings guidance by 8% on a year-over-year basis.
Segment Details
Systems sales increased 8% to $324 million. Sales were buoyed by licensed software and subscriptions, partially offset by a decline in technology resale.
Total support, maintenance and services , including professional and managed services, rose 7.8% from the year-ago quarter to $927.8 million. This reflects solid execution by the company's service organizations. Revenue Cycle has also been a strong contributor, courtesy of strong sales and contribution from RevWorks services (revenue management services). Population Health service businesses also drove revenues in the third quarter on solid growth in the flagship HealtheIntent solutions. The company has been targeting the broader shift from fee-for-service to value-based care for long. Cerner also posted an impressive performance in the ambulatory and small hospital market.
Reimbursement Travel revenues increased 8.7% in the quarter, slightly below the company's full-year expected growth rate.
Geographically, domestic revenues increased 7% from the year-ago quarter to $1.13 billion, while non-U.S. revenues increased 10% to $142 million.
Margin & Balance Sheet Details
Gross margin in the third quarter was 82.7% of revenues, down 50 basis points (bps) from a year ago. The decline was due to the lower mix of sublicensed software and lackluster performance by the technology resale business. Adjusted operating margin in the third quarter was 23.1% of net sales, down 130 bps from a year ago.
Cerner ended the third quarter of 2017 with $964 million in total cash and investments. Total debt for Cerner, including capital lease obligations, was $535 million.
FY17 Guidance Lowered
For the fourth quarter, Cerner forecasts revenues between $1.3 billion and $1.35 billion, with the midpoint reflecting growth of 5% on a year-over-year basis. Adjusted earnings are expected in the band of 60 cents to 62 cents per share, midpoint of which is flat on a year-over-year basis.
For the full year, management expects revenues at around $5.15 billion, which is at the low end of the previously issued range of $5.15 billion to $5.25 billion, thanks to lower bookings in the third quarter. Cerner currently forecasts 2017 adjusted earnings at $2.42, lower than the previously issued range of $2.46 and $2.54.
Companies Reporting Solid Earnings Results
Intuitive Surgical Inc. ISRG posted adjusted earnings of $2.77 per share in the third quarter of 2017, beating the Zacks Consensus Estimate of $1.97 on stellar revenue growth. The stock has a Zacks Rank #2.
PetMed Express, Inc.'s PETS adjusted earnings per share of 43 cents for the second quarter of fiscal 2018 were up 79.2% from the year-ago quarter. Also, earnings surpassed the Zacks Consensus Estimate by 43.3%. The stock has a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year. Abbott carries Zacks Rank #2.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Cerner Corporation (CERN): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Cerner Corporation (CERN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Cerner CorpCERN reported adjusted third-quarter 2017 earnings of 61 cents per share, missing the Zacks Consensus Estimate by a penny. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Cerner Corporation (CERN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. FY17 Guidance Lowered For the fourth quarter, Cerner forecasts revenues between $1.3 billion and $1.35 billion, with the midpoint reflecting growth of 5% on a year-over-year basis. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Cerner Corporation (CERN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. FY17 Guidance Lowered For the fourth quarter, Cerner forecasts revenues between $1.3 billion and $1.35 billion, with the midpoint reflecting growth of 5% on a year-over-year basis. | Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Cerner Corporation (CERN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. FY17 Guidance Lowered For the fourth quarter, Cerner forecasts revenues between $1.3 billion and $1.35 billion, with the midpoint reflecting growth of 5% on a year-over-year basis. |
33420.0 | 2017-10-27 00:00:00 UTC | Stryker (SYK) Earnings and Revenues Beat Estimates in Q3 | ABT | https://www.nasdaq.com/articles/stryker-syk-earnings-and-revenues-beat-estimates-in-q3-2017-10-27 | nan | nan | Stryker CorpSYK reported adjusted earnings of $1.52 per share in the third quarter of 2017, which comfortably beat the Zacks Consensus Estimate by 2 cents. Earnings improved from $1.39 per share in the year-ago quarter.
The company, based in Kalamazoo, MI, has maintained its streak of positive earnings surprise. Meanwhile, in the trailing four quarters, the company posted earnings beats, with an average of 1.86%. Currently, Stryker carries a Zacks Rank #3 (Hold).
The upside in earnings was primarily driven by a rise in revenues to $3.01 billion, which beat the Zacks Consensus Estimate of $2.97 billion. At constant currency (cc), net sales improved 5.8% from the year-ago quarter.
Segment Details
Orthopaedics net sales of $1.1 billion increased 5.1% year over year in the reported quarter. Excluding the 0.3% impact of acquisitions, net sales in the quarter increased 4.5% in cc, including 6.5% from increased unit volume. This was partially offset due to lower prices.
MedSurg net sales of $1.3 billion increased 6.7% in the reported quarter. Excluding the 0.6% impact of acquisitions, net sales in the quarter increased 5.6% in cc, including 5.6% increased unit volume.
Neurotechnology and Spine net sales of $0.5 billion increased 6.9% in the reported quarter. Net sales in the quarter increased 8.1% from increased unit volume. This was partially offset due to lower prices.
Guidance
For the fourth quarter of 2017, Stryker expects adjusted earnings in the range of $1.92-$1.97 per share. For full year, the company expects adjusted earnings in the band of $6.45 to $6.50. Stryker expects organic sales growth of 6.5% to 7.0% for full-year 2017.
Our Take
We believe Stryker's innovative product pipeline will be a key catalyst in the near term. Furthermore, growing adoption of MAKO will drive sales in the orthopedic and reconstructive surgery market.
On the flip side, China might prove to be a challenging market for the company. Coming to supply-related headwinds, the company has been grappling with issues in the spine business for long. We believe that this may prove to be a major drawback in the quarters ahead. Nevertheless, Stryker's efforts in sales force management should bode well.
Companies Reporting Solid Earnings Results
Intuitive Surgical Inc ISRG posted adjusted earnings of $2.77 per share in the third quarter of 2017, beating the Zacks Consensus Estimate of $1.97 on stellar revenue growth. The stock holds a Zacks Rank #2 (Buy).
PetMed Express, Inc's PETS adjusted earnings per share of 43 cents for the second quarter of fiscal 2018 were up 79.2% from the year-ago quarter. Also, earnings surpassed the Zacks Consensus Estimate by 43.3%. The stock sports a Zacks Rank #1 (Strong Buy). ou can see the complete list of today's Zacks #1 Rank stocks here.
Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Third-quarter worldwide sales amounted $6.83 billion, up 28.8% year over year. Abbott carries a Zacks Rank #2.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. Stryker CorpSYK reported adjusted earnings of $1.52 per share in the third quarter of 2017, which comfortably beat the Zacks Consensus Estimate by 2 cents. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Excluding the 0.6% impact of acquisitions, net sales in the quarter increased 5.6% in cc, including 5.6% increased unit volume. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Stryker CorpSYK reported adjusted earnings of $1.52 per share in the third quarter of 2017, which comfortably beat the Zacks Consensus Estimate by 2 cents. | Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. Stryker CorpSYK reported adjusted earnings of $1.52 per share in the third quarter of 2017, which comfortably beat the Zacks Consensus Estimate by 2 cents. |
33421.0 | 2017-10-27 00:00:00 UTC | How Electricity Could Replace Opioids In Treating Chronic Pain | ABT | https://www.nasdaq.com/articles/how-electricity-could-replace-opioids-treating-chronic-pain-2017-10-27 | nan | nan | It was nearly 13 years ago that Lori Swearingen changed her life forever after a fall on the job - and it took a decade for her to discover what it was like to be relatively pain-free again.
A Reno, Nev., firefighter at the time, Swearingen was helping a rig back down an ice-packed hill on New Year's Eve 2004. When she slipped and landed on her backside, she was the only woman in the crew.
"I got right back up, shook it off and kept going," she recalls.
But Swearingen soon began experiencing pelvic pain radiating into her lower back that affected her daily for another decade. No one thought to check her tailbone which, as it turns out, had been fractured. After a number of surgeries and drugs failed to relieve the mind-numbing pain, she discovered the answer: an implantable device called a neuromodulator.
[ibd-display-video id=2326965 width=50 float=left autostart=true] Such implants are now part of a big business that could well someday do the job of opioids and other medications for treating pain. All told, it's estimated to be a $3.9 billion total addressable market this year, Needham analyst Mike Matson wrote in a recent note to clients.
Matson expects the neuromodulation market to grow in the upper-single digit range for the next few years. The leader in the space is Medtronic ( MDT ) with 52.3% of the market, while Abbott Laboratories ( ABT ) and Boston Scientific ( BSX ) on its heels, Matson says.
But competition is mounting. Matson estimates that Medtronic's neuromodulation sales were down 6% in its fiscal first quarter, reported in August, to about $416 million, short of his original forecast. Medtronic doesn't break out its neuromodulation sales. Companies like Nevro ( NVRO ) and LivaNova ( LIVN ) are swiping share.
Neuromodulation, also called neurostimulation, has been around for decades. It's only been in recent years, though, that the techniques have become less "crude," says Dr. Mark Malone, founder of Advanced Pain Care in Austin, Texas. Malone, who uses one of the devices himself as a patient, sees neuromodulation becoming mainstream in coming years.
"In the last 18 months or so, a new generation has come out including (Abbott's) Burst and Dorsal Root Ganglion," Malone told Investor's Business Daily. "These two techniques are far more effective and it's really an amazing revolution. For the first time ever, we've been able to say things like 'cure chronic pain.'"
So, What Is It?
Neuromodulation essentially tricks the brain into thinking a region of the body is no longer in pain, says Dr. Allen Burton, Abbott's medical director for neuromodulation, movement disorders and pain. The modern iteration is the result of a better understanding of the nervous system.
"This is the application of electrical energy in the nervous system to quiet down pain impulses," he told IBD. "It's more of a language. You're speaking to the nervous system in the language of the nervous system and telling the brain the pain is no longer important."
Burton explains the difference in old vs. new technology in terms of a hammer. When you hammer a nail and miss, hitting your thumb, you rub the thumb to dull the pain. That introduces a new sensory signal, thereby blocking the pain signal. It's called tonic stimulation.
With the new technology, neuromodulation has adopted the electrical signals of the nervous system. Abbott uses what it calls BurstDR and Dorsal Root Ganglion stimulation, the latter of which treats a mysterious pain condition called complex regional pain syndrome.
Boston's Precision Spectra System, Precision Novi and Precision Montage MRI products use software called Illumina 3D to treat chronic pain, including complex regional pain syndrome and failed back surgery syndrome.
All About Pain Relief
For patients like Swearingen, it's not the specific device maker that matters - though she did a lot of research before settling on a device from Boston Scientific - it's the pain relief.
Swearingen had her tailbone removed several years after the incident, plus an appendectomy, a partial hysterectomy and back surgery - all in an effort to ease the pain in her pelvis. None of it helped.
She worked for another few years, staving off the pain on a cocktail of opioids, antidepressants, epidurals, radio-frequency ablation and acupuncture. Sometimes Swearingen worked in emergency medical, other times she went back on the fire line, pain permitting. After eight years, Swearingen finally took a medical retirement.
IBD'S TAKE:The 119-company Medical-Products industry group is now ranked No. 23 out of 197 groups tracked. It's led by Align Technology, which has a best-possible Composite Rating of 99, meaning it performs in the top 1% of all stocks. Head to IBD Stock Checkup for a look at other strong medtech players.
"I met with a psychologist to learn coping skills and techniques for my family to not focus on my pain," she told IBD. "I was pretty depressed. I was gaining weight because I had a very physical job and a very physical lifestyle. I was kind of circling that depression drain."
Two years later, she discovered the neuromodulator.
After retiring from firefighting, Swearingen moved to Seattle, where she began seeing a pain management doctor. Her doctor's office featured a poster on neuromodulation. Swearingen says she didn't know anything about the devices when she first saw the poster.
"I thought maybe it was a delivery system for drugs," she said. "Then I realized those were leads going up my spinal cord and I thought, 'Oh, heck no.' I spent two years looking at that poster."
Unintended Consequences
Physicians are looking at neuromodulation as a first step to treat some forms of chronic pain - often in the back - replacing doctors' penchant for prescribing an addictive course of opioids. Opioids are a huge drug market, projected to reach $17.7 billion by 2021 in the U.S. alone.
Opioids are also tied to major unintended consequences, including addiction and dependence, often leading to overdoses. There's also a major black market for opioids, which has created somewhat of a stigma for patients seeking pain treatment, Malone says.
"Doctors question the motives," he said. "It's a mess out there. All of that on top of the current opioid crisis on the news everyday. So it's really an amazing gift that we suddenly have this treatment that's so effective for even the worst pain patients and it's completely drug free."
Malone has had his own neuromodulator for more than six months. Before his implant, he was on disability for a year and had worked part-time for several years following a back injury. When he saw the success of 80%-100% in his own patients, he had his medical practice partner implant an Abbott device.
The difference was night and day. Malone gets choked up talking about it. His relief is near 100%.
"I can tell patients I've been through it, it's very real," he said. "Even my own wife was wondering, 'Has he given up? He doesn't want to work anymore.' I was just laying in bed day after day. The pain is real."
Potential Markets In Migraines, Depression
During the trial period, a temporary device is implanted under sedation and attached to an external battery taped to the skin. The patient can use a remote control to flick through different signal settings and strength, Malone said. Abbott's Burton estimates nine in 10 opt for the permanent implant.
Neuromodulators differ from opioids in that they are completely drug-free and reversible. Before they are implanted, a patient learns the potential risks and benefits. And the patient has a unique chance to try out the device before going the permanent - though still reversible - route, Burton said.
"One of the big problems with opioids is people are often initiated without much talk about the risks and benefits," he said. "The first prescription comes from the ER for a pain pill, a short, low dose. But as the pain becomes chronic and doesn't turn around or heal up, suddenly the patient becomes resistant."
What started as a traumatic injury often leads to a chronic pain problem, and the need for sleeping meds and/or antidepressants, he said. Now, a patient who never before needed medications is on three or four of them, all of which interact with one another.
Electricity isn't addictive, Burton said. And there's no euphoric side effect.
Still, neuromodulation isn't the end-all answer for every type of pain. It has its limitations. The most notable uses are in chronic back pain including complex regional pain syndrome and failed back surgery syndrome. But it wouldn't work in widespread pain like fibromyalgia.
The lion's share of Malone's patients are those who've gone ahead with back surgery and attained no relief. But Needham's Matson says there's also a market for neuromodulation in Parkinson's disease, essential tremors, incontinence, epilepsy, depression, migraines and obesity.
Still, neuromodulation remains the best, accidental secret in the pain community. Interventional pain is a new specialty, Malone says. Most neurosurgeons and orthopedists aren't aware of it.
The Road Back
For Swearingen, she was finally persuaded to give neuromodulation a shot after attending a patient seminar and doing exhaustive research on her own part - a recommendation she would give to anyone considering an implant. Indeed, days into her trial implant, she was ready for the permanent device.
Today, she's back in the gym, strengthening her core and has lost the weight she gained due to immobility. She rides her bicycle and horses, and lifts hay bales on her property in Seattle. Walking to the mailbox is no longer a daunting prospect, she said.
"In the last couple of years, my husband says, 'I have my Lors back,'" she said. "And I am back."
Meanwhile Swearingen is left to wonder if she could she have stayed on at the firehouse.
"I will never know that. There would be a possibility, but I'm 54 now. I retired on medical and at this point I don't care to (return to work)," she said. Instead, she's focused on the positive.
"This was life-changing for me, for my family, for everyone around me," she said.
RELATED:
Abbott Zeros In On A 2-Year High After Topping Q2 Sales, Profits
This Drug Bellwether's Sales Miss Actually Bodes Well For The Sector
Medtronic Sinks After Sales Lag, Though Earnings Beat Views
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The leader in the space is Medtronic ( MDT ) with 52.3% of the market, while Abbott Laboratories ( ABT ) and Boston Scientific ( BSX ) on its heels, Matson says. All told, it's estimated to be a $3.9 billion total addressable market this year, Needham analyst Mike Matson wrote in a recent note to clients. Unintended Consequences Physicians are looking at neuromodulation as a first step to treat some forms of chronic pain - often in the back - replacing doctors' penchant for prescribing an addictive course of opioids. | The leader in the space is Medtronic ( MDT ) with 52.3% of the market, while Abbott Laboratories ( ABT ) and Boston Scientific ( BSX ) on its heels, Matson says. "In the last 18 months or so, a new generation has come out including (Abbott's) Burst and Dorsal Root Ganglion," Malone told Investor's Business Daily. Boston's Precision Spectra System, Precision Novi and Precision Montage MRI products use software called Illumina 3D to treat chronic pain, including complex regional pain syndrome and failed back surgery syndrome. | The leader in the space is Medtronic ( MDT ) with 52.3% of the market, while Abbott Laboratories ( ABT ) and Boston Scientific ( BSX ) on its heels, Matson says. Neuromodulation essentially tricks the brain into thinking a region of the body is no longer in pain, says Dr. Allen Burton, Abbott's medical director for neuromodulation, movement disorders and pain. All About Pain Relief For patients like Swearingen, it's not the specific device maker that matters - though she did a lot of research before settling on a device from Boston Scientific - it's the pain relief. | The leader in the space is Medtronic ( MDT ) with 52.3% of the market, while Abbott Laboratories ( ABT ) and Boston Scientific ( BSX ) on its heels, Matson says. After eight years, Swearingen finally took a medical retirement. Swearingen says she didn't know anything about the devices when she first saw the poster. |
33422.0 | 2017-10-27 00:00:00 UTC | See Which Of The Latest 13F Filers Holds Abbott Laboratories | ABT | https://www.nasdaq.com/articles/see-which-latest-13f-filers-holds-abbott-laboratories-2017-10-27 | nan | nan | At Holdings Channel , we have reviewed the latest batch of the 21 most recent 13F filings for the 09/30/2017 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 14 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed, it is important to point out that 13F filings do not tell the whole story, because these funds are only required to disclose their long positions with the SEC, but are not required to disclose their short positions. A fund making a bearish bet against a stock by shorting calls, for example, might also be long some amount of stock as they trade around their overall bearish position. This long component could show up in a 13F filing and everyone might assume the fund is bullish, but this tells only part of the story because the bearish/short side of the position is not seen .
Having given that caveat, we believe that looking at groups of 13F filings can be revealing, especially when comparing one holding period to another. Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers:
In terms of shares owned, we count 5 of the above funds having increased existing ABT positions from 06/30/2017 to 09/30/2017, with 6 having decreased their positions.
Looking beyond these particular funds in this one batch of most recent filers, we tallied up the ABT share count in the aggregate among all of the funds which held ABT at the 09/30/2017 reporting period (out of the 838 we looked at in total). We then compared that number to the sum total of ABT shares those same funds held back at the 06/30/2017 period, to see how the aggregate share count held by hedge funds has moved for ABT. We found that between these two periods, funds reduced their holdings by 2,656,677 shares in the aggregate, from 77,884,557 down to 75,227,880 for a share count decline of approximately -3.41%. The overall top three funds holding ABT on 09/30/2017 were:
We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like Abbott Laboratories (Symbol: ABT).
10 S&P 500 Components Hedge Funds Are Buying »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At Holdings Channel , we have reviewed the latest batch of the 21 most recent 13F filings for the 09/30/2017 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 14 of these funds. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like Abbott Laboratories (Symbol: ABT). Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers: In terms of shares owned, we count 5 of the above funds having increased existing ABT positions from 06/30/2017 to 09/30/2017, with 6 having decreased their positions. | At Holdings Channel , we have reviewed the latest batch of the 21 most recent 13F filings for the 09/30/2017 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 14 of these funds. We then compared that number to the sum total of ABT shares those same funds held back at the 06/30/2017 period, to see how the aggregate share count held by hedge funds has moved for ABT. Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers: In terms of shares owned, we count 5 of the above funds having increased existing ABT positions from 06/30/2017 to 09/30/2017, with 6 having decreased their positions. | Looking beyond these particular funds in this one batch of most recent filers, we tallied up the ABT share count in the aggregate among all of the funds which held ABT at the 09/30/2017 reporting period (out of the 838 we looked at in total). We then compared that number to the sum total of ABT shares those same funds held back at the 06/30/2017 period, to see how the aggregate share count held by hedge funds has moved for ABT. The overall top three funds holding ABT on 09/30/2017 were: We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. | We then compared that number to the sum total of ABT shares those same funds held back at the 06/30/2017 period, to see how the aggregate share count held by hedge funds has moved for ABT. The overall top three funds holding ABT on 09/30/2017 were: We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. At Holdings Channel , we have reviewed the latest batch of the 21 most recent 13F filings for the 09/30/2017 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 14 of these funds. |
33423.0 | 2017-10-26 00:00:00 UTC | Health Care Sector Update for 10/26/2017: JNJ, PFE, ABT, MRK, AMGN, INSY, ABMD, THC | ABT | https://www.nasdaq.com/articles/health-care-sector-update-10262017-jnj-pfe-abt-mrk-amgn-insy-abmd-thc-2017-10-26 | nan | nan | Top Health Care Stocks
JNJ, -0.3%
PFE, -1.2%
ABT, +0.01%
MRK, -0.8%
AMGN, -0.9%
Health care continued to be the lone decliner among sectors ahead of the closing bell, with the NYSE Health Care Index sinking almost 0.9% while shares of health care companies in the S&P 500 were down 1.6% as a group.
In company news, Insys Therapeutics ( INSY ) shares fell 20.2% to their lowest level in nearly four years after the company's founder and six former executives were arrested for allegedly offering bribes to doctors to oversubscribe opiods. This is the second time in less than a year that executives from the company have been charged with conspiring to pay bribes to doctors to prescribe the company's pain medication, Subsys. According to a statement from the US Attorney's office in Massachusetts, John Kapoor, the founder and majority owner of Insys Therapeutics, "was arrested today and charged with leading a nationwide conspiracy to profit by using bribes and fraud to cause the illegal distribution of a Fentanyl spray intended for cancer patients experiencing breakthrough pain."
In other sector news,
(+) ABMD, Posts fiscal Q2 results above estimates, issues in-line FY18 guidance; reports first patient in Japan to be treated with the Impella heart pump
(-) THC, Company reportedly has taken itself off the auction block after the departure of CEO Trevor Fetter
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news, Insys Therapeutics ( INSY ) shares fell 20.2% to their lowest level in nearly four years after the company's founder and six former executives were arrested for allegedly offering bribes to doctors to oversubscribe opiods. According to a statement from the US Attorney's office in Massachusetts, John Kapoor, the founder and majority owner of Insys Therapeutics, "was arrested today and charged with leading a nationwide conspiracy to profit by using bribes and fraud to cause the illegal distribution of a Fentanyl spray intended for cancer patients experiencing breakthrough pain." In other sector news, (+) ABMD, Posts fiscal Q2 results above estimates, issues in-line FY18 guidance; reports first patient in Japan to be treated with the Impella heart pump (-) THC, Company reportedly has taken itself off the auction block after the departure of CEO Trevor Fetter The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news, Insys Therapeutics ( INSY ) shares fell 20.2% to their lowest level in nearly four years after the company's founder and six former executives were arrested for allegedly offering bribes to doctors to oversubscribe opiods. In other sector news, (+) ABMD, Posts fiscal Q2 results above estimates, issues in-line FY18 guidance; reports first patient in Japan to be treated with the Impella heart pump (-) THC, Company reportedly has taken itself off the auction block after the departure of CEO Trevor Fetter The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care continued to be the lone decliner among sectors ahead of the closing bell, with the NYSE Health Care Index sinking almost 0.9% while shares of health care companies in the S&P 500 were down 1.6% as a group. In company news, Insys Therapeutics ( INSY ) shares fell 20.2% to their lowest level in nearly four years after the company's founder and six former executives were arrested for allegedly offering bribes to doctors to oversubscribe opiods. In other sector news, (+) ABMD, Posts fiscal Q2 results above estimates, issues in-line FY18 guidance; reports first patient in Japan to be treated with the Impella heart pump (-) THC, Company reportedly has taken itself off the auction block after the departure of CEO Trevor Fetter The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care Stocks Health care continued to be the lone decliner among sectors ahead of the closing bell, with the NYSE Health Care Index sinking almost 0.9% while shares of health care companies in the S&P 500 were down 1.6% as a group. In company news, Insys Therapeutics ( INSY ) shares fell 20.2% to their lowest level in nearly four years after the company's founder and six former executives were arrested for allegedly offering bribes to doctors to oversubscribe opiods. |
33424.0 | 2017-10-26 00:00:00 UTC | Varian Medical (VAR) Misses on Q4 Earnings, Issues FY18 View | ABT | https://www.nasdaq.com/articles/varian-medical-var-misses-on-q4-earnings-issues-fy18-view-2017-10-26 | nan | nan | Varian Medical Systems, Inc.VAR reported adjusted earnings of $1.09 per share in the fourth quarter of fiscal 2017, missing the Zacks Consensus Estimate of $1.19. Adjusted earnings also declined 21% on a year-over-year basis.
Meanwhile, revenues of $739 million were down 1% from the year-ago quarter. Revenues missed the Zacks Consensus Estimate of $742 million by a narrow margin. Varian Medical ended the year with $3.5 billion in backlog, up 10% on a year-over-year basis.
Unfavorable performance in the company's proton therapy unit is the primary cause for the lackluster fourth-quarter performance. However, a solid guidance for fiscal 2018 instills confidence in the stock.
This Palo Alto, CA-based manufacturer of medical devices and software carries a Zacks Rank #3 (Hold).
Varian Medical Systems, Inc. Price, Consensus and EPS Surprise
Varian Medical Systems, Inc. Price, Consensus and EPS Surprise | Varian Medical Systems, Inc. Quote
Segment Details
Oncology Systems: At this segment, revenues totaled $686 million, up 1% year over year at constant currency (cc). Oncology growth was driven by double-digit services growth and newly issued upgrades for hardware and software. Notably, Varian Medical registered 40 orders for the HyperArc platform in the fourth quarter. HyperArc is a recently-launched high definition radiotherapy technology.
Gross orders in the segment totaled $964 million, up 7% at cc from the year-ago quarter. In the United States, gross orders increased 2% at cc. In the EMEA region, gross orders rose 29% on a year-over-year basis, courtesy of solid growth in France, Germany, Poland and India. On the flipside, gross orders declined 9% at cc in the APAC region, thanks to weakness in Japan.
Proton Therapy: Fourth-quarter revenues at the segment were $52 million, down 23% on a year-over-year basis. During the quarter, Varian Medical booked two orders including the Concord Medical Proton Center in Guangzhou, China for $52 million and HCG in India for $19 million. Proton therapy orders growth was 94% on a year-over year basis.
Halcyon Drives Growth
Varian Medical has been taking initiatives to gain customer attention for its broad spectrum of products. The company unveiled the Halcyon radiotherapy treatment system at the ASTRO conference in Vienna last quarter. The Halcyon radiotherapy treatment system has been designed to offer cost-effective cancer care worldwide. The platform had 23 orders in the fourth quarter, of which 12 orders were from EMEA, 10 orders from North Africa and one from APAC.
Margins
In the fourth quarter, gross margin contracted 50 basis points (bps) to 42.3% of revenues. Oncology Systems gross margin contracted nearly 26 bps to 45 % owing to supply chain inefficiencies.
As a percentage of revenues, expenses on research and development (R&D) remained flat on a year-over-year basis. Meanwhile, selling, general and administrative (SG&A) expenses in the quarter were $136.8 million, up 180 bps a year-over-year basis. Operating margin in the quarter under review was 14.8% of net revenues, down 410 bps year over year. Notably, the fourth quarter of last year included a favorable $4-million bad debt release.
In addition to investments in R&D, Varian Medical had spent $18.7 million in CapEx and $25 million to buy back 250,000 shares of the company's stock. As of the end of the fourth quarter, Varian Medical had 5.25 million shares remaining under its existing repurchase authorization.
FY17 at a Glance
For fiscal 2017, Varian Medical registered adjusted earnings of $3.60 per share. Revenues of $2.7 billion were up 2% at cc in the year. Oncology revenues of $2.5 billion were up 1% at cc. For the full year, revenues in the proton therapy unit totaled $182 million, up 12% year over year. The company booked six proton therapy orders in fiscal 2017.
Fiscal 2017 was favorable for Varian Medical in terms of product launches as well. The successful launches of Halcyon Therapy System and HyperArc Technology deserve a mention in this regard.
FY18 View
For fiscal 2018, management estimates adjusted earnings per share in the $4.20 to $4.32 range. Cash flow from operations is projected between $475 million and $550 million. Fiscal 2018 revenues are estimated to grow 2% to 4% year over year.
Companies Reporting Solid Earnings Results
Intuitive Surgical Inc . ISRG posted adjusted earnings of $2.77 per share in the third quarter of 2017, beating the Zacks Consensus Estimate of $1.97 on stellar revenue growth. The stock carries a Zacks Rank #2 (Buy).
PetMed Express, Inc. 's PETS adjusted earnings per share of 43 cents for the second quarter of fiscal 2018 were up 79.2% from the year-ago quarter. Also, earnings surpassed the Zacks Consensus Estimate by 43.3%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
AbbottABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year. Abbott carries a Zacks Rank #2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Varian Medical Systems, Inc.VAR reported adjusted earnings of $1.09 per share in the fourth quarter of fiscal 2017, missing the Zacks Consensus Estimate of $1.19. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Varian Medical Systems, Inc.VAR reported adjusted earnings of $1.09 per share in the fourth quarter of fiscal 2017, missing the Zacks Consensus Estimate of $1.19. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Varian Medical Systems, Inc.VAR reported adjusted earnings of $1.09 per share in the fourth quarter of fiscal 2017, missing the Zacks Consensus Estimate of $1.19. | AbbottABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Varian Medical Systems, Inc.VAR reported adjusted earnings of $1.09 per share in the fourth quarter of fiscal 2017, missing the Zacks Consensus Estimate of $1.19. |
33425.0 | 2017-10-26 00:00:00 UTC | Cardiovascular Systems (CSII) Q1 Earnings Top, Revenues Lag | ABT | https://www.nasdaq.com/articles/cardiovascular-systems-csii-q1-earnings-top-revenues-lag-2017-10-26 | nan | nan | Cardiovascular Systems, Inc.CSII reported adjusted loss per share of 6 cents in first-quarter fiscal 2018, flat with the year-ago quarter's adjusted loss of 6 cents. The figure was narrower than the earlier provided guided range of loss per share of 9-7 cents. The figure compared favorably with the Zacks Consensus Estimate of a loss of 7 cents.
Results in Details
Cardiovascular Systems posted revenues of $49.7 million in the fiscal first quarter, marking a year-over-year decline of 0.2%. Also, the figure was lower than the guided range of $52.6-$53.6 million for the first quarter of fiscal 2018. The figure also missed the Zacks Consensus Estimate of $51 million.
Per management, procedure volumes in first-quarter fiscal 2018 were impacted by hurricanes. Moreover, the saline infusion pump recall during the quarter resulted in lower-than-estimated usage of the coronary device. These factors played significant roles which resulted in the revenue miss in the quarter.
Cardiovascular Systems, Inc. Price, Consensus and EPS Surprise
Cardiovascular Systems, Inc. Price, Consensus and EPS Surprise | Cardiovascular Systems, Inc. Quote
To date, Cardiovascular Systems has sold over 340,000 devices to leading institutions in the United States. The company added 36 new peripheral accounts and 29 coronary accounts in the fiscal first quarter. Coronary device revenues declined 0.6% year over year to $11.5 million and peripheral device revenues inched down 0.2% to $38.2 million.
Margin
Gross margin in the reported quarter was 81.5%, up 48 basis points (bps) year over year.
Meanwhile, selling and administrative (SG&A) expenses contracted 2.6% to $35.9 million and research and development (R&D) expenses were up 18.2% to $6.3 million. Resultantly, adjusted operating expenses inched up 0.1% to $42.2 million. Per management, operating expenses were lower than the earlier provided guidance due to lower incentive compensation as a result of deterioration in financial performance. Operating loss was around $1.8 million, compared to the loss of $1.9 million in the year-ago quarter.
Financial position
The company exited the first quarter of fiscal 2018 with cash and cash equivalents of $104.7 million, compared with $107.9 million at the end of fiscal 2017.
Outlook
Cardiovascular Systems reaffirmed its fiscal 2018 revenue guidance at the range of $226-$233 million. The current Zacks Consensus Estimate for fiscal 2018 revenues is pegged at $228.25 million, which is within the company's guided range.
The company expects revenues in the range of $52.5-$54 million for second-quarter fiscal 2018.The current Zacks Consensus Estimate is pegged at $55.79 million, above the company's guided range.
Moreover, the company expects gross profit to account for 81% of revenues, while operating expenses are estimated at around $44.5 million for second-quarter fiscal 2018.
The company expects to incur net loss of $1.9-$1 million or loss per share of 6-3 cents in the second quarter of fiscal 2018.The current Zacks Consensus Estimate is pegged at a loss of a penny, above the company's guided range.
Our Take
Cardiovascular Systems exited the first quarter fiscal 2018 on a mixed note . The decline in year-over-year revenues at Coronary device and peripheral device was disappointing. Fiscal first-quarter revenues declined on a year-over-year basis owing to the impact of hurricanes.
On a positive note, the reported loss in the quarter was narrower than the guided range of the company. Also, the expansion is gross margin was impressive. The company's reaffirmed revenue guidance for fiscal 2018 buoys optimism. Moreover, the company is putting efforts in product innovation through R&D investments. During the quarter, the company released one-year data from its LIBERTY 360° clinical study in a late-breaking presentation at the 2017 Amputation Prevention Symposium (AMP) in Chicago. LIBERTY 360° showed that peripheral endovascular intervention can help prevent amputation for patients with peripheral artery disease.
Zacks Rank & Key Picks
Currently, Cardiovascular Systems has a Zacks Rank #4 (Sell).
A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Notably, PetMed sports a Zacks Rank #1 (Strong Buy), while Abbott and Intuitive Surgical carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
PetMed reported EPS of 43 cents for the second quarter of fiscal 2018, up 79.2% from the year-ago quarter's 24 cents. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Abbott reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Also, third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year.
Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Results in Details Cardiovascular Systems posted revenues of $49.7 million in the fiscal first quarter, marking a year-over-year decline of 0.2%. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Cardiovascular Systems, Inc. Price, Consensus and EPS Surprise Cardiovascular Systems, Inc. Price, Consensus and EPS Surprise | Cardiovascular Systems, Inc. Quote To date, Cardiovascular Systems has sold over 340,000 devices to leading institutions in the United States. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . The company expects revenues in the range of $52.5-$54 million for second-quarter fiscal 2018.The current Zacks Consensus Estimate is pegged at $55.79 million, above the company's guided range. | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Cardiovascular Systems, Inc.CSII reported adjusted loss per share of 6 cents in first-quarter fiscal 2018, flat with the year-ago quarter's adjusted loss of 6 cents. |
33426.0 | 2017-10-26 00:00:00 UTC | GNC Holdings (GNC) Lags Q3 Earnings & Revenues, Margins Down | ABT | https://www.nasdaq.com/articles/gnc-holdings-gnc-lags-q3-earnings-revenues-margins-down-2017-10-26 | nan | nan | GNC Holdings, Inc.GNC reported third-quarter 2017 adjusted earnings per share (EPS) of 32 cents, reflecting a massive 45.8% year-over-year deterioration. Adjusted EPS also missed the Zacks Consensus Estimate by a penny. Per management, the hurricanes Harvey, Irma and Maria have dented the adjusted EPS figure to the tune of 2 cents.
The year-over-year decline can be attributed to a dull revenue performance in the reported quarter, primarily because of underperformance by the U.S. & Canada and manufacturing/wholesale segments.
Including one-time items, the company reported earnings of 31 cents per share, down 34% year over year.
Revenues
Revenues during the reported quarter dropped 2.9% year over year to $609.5 million. The figure also missed the Zacks Consensus Estimate of $616 million.
The lower sales at the U.S. & Canada and manufacturing/wholesale segments can be cited as the major reason for the disappointing numbers.
Same-store sales increased 1.3% in domestic company-owned stores (including GNC.com sales) in the third quarter of 2017. In domestic franchise locations, same-store sales declined 1.7%.
GNC Holdings, Inc. Price, Consensus and EPS Surprise
GNC Holdings, Inc. Price, Consensus and EPS Surprise | GNC Holdings, Inc. Quote
Segments in Details
GNC Holdings reports operations under three segments: U.S. & Canada (including company-owned stores in the United States, Puerto Rico and Canada, franchise stores in the United States and e-commerce); International (including franchise locations in approximately 50 countries, The Health Store and China operations); and Manufacturing/Wholesale (comprising manufactured products sold to other segments, third-party contract manufacturing and sales to wholesale partners).
During the reported quarter, GNC Holdings' revenues from the U.S. & Canada segment dropped 3.5% to $507.1 million, primarily owing to a $12-million decrease due to the discontinuation of the Gold Card program in the United States and the introduction of the company's new loyalty programs. In domestic franchise locations as well, revenues declined nearly $7.5 million, partially offset by a 1.3% increase in retail same-store sales. However, GNC.com sales were up 41.9% in the third quarter.
Revenues at the international segment increased 19.3% to $49.1 million. Revenues from international franchisees rose $2.8 million. Revenues from the China business increased $4.8 million in the reported quarter.
Revenues at the manufacturing/wholesale segment (excluding intersegment revenues) decreased 13.1% to $53.3 million. Within this segment, third-party contract manufacturing sales fell 14.9% to $31.2 million owing to lower demand related to reduced sales for some customers. Sales to wholesale partners decreased 10.5% year over year from $24.7 million to $22.1 million in the quarter. However, Intersegment sales increased to $58 million in the quarterfrom the year-ago $53 million on the company's increased focus on proprietary products.
Margin
Gross profit deteriorated 8.6% in the reported quarter to $196.8 million. Consequently, gross margin contracted 200 basis points (bps) to 32.3%.
Selling, general and administrative expenses rose 1.7% to $150.9 million. Accordingly, adjusted operating margin deteriorated 320 bps to 7.5%.
Financial Position
GNC Holdings exited the third quarter with cash and cash equivalents of $40.1 million, down from $51.9 million at the end of second-quarter 2017. Long-term debt was $1.38 billion at the end of the quarter, compared with $1.51 billion at the end of second-quarter 2017. Year to date, the net cash flow from operating activities was $149.6 million, compared with $169.7 million a year ago.
Further, the company generated year-to-date free cash flow of $124.8 million as compared with $162.8 million in the year-ago quarter.
'One New GNC' Plan Update
Earlier, management had announced plans to revamp its existing business model, dubbed as the 'One New GNC'. The company has been seeing transformational changes during the third quarter of 2017 as well. Transaction growth was up 12.4% in the third quarter. As of Oct 25, 9.6 million consumers had joined the company's loyalty programs, including approximately 585,000 customers enrolled in the PRO Access membership.
Our Take
GNC Holdings exited the third quarter of 2017 on a disappointing note with revenues and earnings missing the Zacks Consensus Estimate. The underperformance can be attributed to lower sales in the company's U.S. & Canada and manufacturing/wholesale segments. Also, the decline in gross and adjusted operating margin is a matter of concern.
On a positive note, during the third quarter, management witnessed positive response for its New GNC Plan. New consumer enrollment under the myGNC Rewards Program. The company has also been witnessing improvement in transactions and e-commerce business, which buoys optimism.
Zacks Rank & Key Picks
Currently, GNC Holdings has a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Notably, PetMed sports a Zacks Rank #1 (Strong Buy), while Abbott and Intuitive Surgical carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
PetMed reported EPS of 43 cents in the second quarter of fiscal 2018, up 79.2% from the year-ago quarter's 24 cents. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Abbott reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Also, third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year.
Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
GNC Holdings, Inc. (GNC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report GNC Holdings, Inc. (GNC): Free Stock Analysis Report To read this article on Zacks.com click here. GNC Holdings, Inc.GNC reported third-quarter 2017 adjusted earnings per share (EPS) of 32 cents, reflecting a massive 45.8% year-over-year deterioration. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report GNC Holdings, Inc. (GNC): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . GNC Holdings, Inc.GNC reported third-quarter 2017 adjusted earnings per share (EPS) of 32 cents, reflecting a massive 45.8% year-over-year deterioration. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report GNC Holdings, Inc. (GNC): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Revenues Revenues during the reported quarter dropped 2.9% year over year to $609.5 million. | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report GNC Holdings, Inc. (GNC): Free Stock Analysis Report To read this article on Zacks.com click here. However, GNC.com sales were up 41.9% in the third quarter. |
33427.0 | 2017-10-26 00:00:00 UTC | McKesson (MCK) Beats Earnings & Revenue Estimates in Q2 | ABT | https://www.nasdaq.com/articles/mckesson-mck-beats-earnings-revenue-estimates-in-q2-2017-10-26 | nan | nan | McKesson CorporationMCK reported second-quarter fiscal 2018 (ended Sep 30, 2017) earnings of $3.28 per share, beating the Zacks Consensus Estimate of $2.78. Earnings also surpassed the year-ago figure of $2.96.
McKesson posted sales of $52.1 billion, beating the Zacks Consensus Estimate of $51.6 billion. This was up from $50.0 billion last year.
Quarter in Detail
McKesson operates through two segments, Distribution Solutions and Technology Solutions. All growth rates given below are on a year-over-year basis.
Distribution Solutions revenues were $51.9 billion for the quarter, up 5% on a reported and constant currency basis.
However, revenues from the Technology Solutions business declined from $680 million in the year-ago quarter to $120 million. This was due to the bifurcation of the Technology Solutions businesses to the Change Healthcare joint venture on Mar 1. The segment reflects only the numbers from the Enterprise Information Solutions business.
McKesson Corporation Price, Consensus and EPS Surprise
McKesson Corporation Price, Consensus and EPS Surprise | McKesson Corporation Quote
Financial Condition
As of Sep 30, McKesson had $2.6 billion in cash and cash equivalents against $2.8 billion as of Mar 31. During the reported quarter (ended Sep 30), the company generated cash worth $1.3 million from operations. During the first half of the year, McKesson repaid $545 million in long-term debt, paid $1.9 billion for acquisitions, repurchased $650 million of its common stock, invested $255 million internally and paid $121 million in dividends.
Fiscal 2018 Outlook
McKesson expects GAAP earnings per diluted share in the range of $4.80 to $6.90 for the fiscal year ending Mar 31, 2018. Adjusted Earnings for the same are expected in the range of $11.80 to $12.50.
Zacks Rank
McKesson currently carries a Zacks Rank #3 (Hold).
Companies Reporting Solid Earnings Results
Intuitive Surgical Inc ISRG posted adjusted earnings of $2.77 per share in the third quarter of 2017, beating the Zacks Consensus Estimate of $1.97 on stellar revenue growth. The stock has a Zacks Rank #2 (Buy).
PetMed Express, Inc's PETS adjusted earnings per share of 43 cents for the second quarter of fiscal 2018 were up 79.2% from the year-ago quarter. Also, earnings surpassed the Zacks Consensus Estimate by 43.3%. The stock has a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year. Abbott carries a Zacks Rank #2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
McKesson Corporation (MCK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report To read this article on Zacks.com click here. McKesson CorporationMCK reported second-quarter fiscal 2018 (ended Sep 30, 2017) earnings of $3.28 per share, beating the Zacks Consensus Estimate of $2.78. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. McKesson Corporation Price, Consensus and EPS Surprise McKesson Corporation Price, Consensus and EPS Surprise | McKesson Corporation Quote Financial Condition As of Sep 30, McKesson had $2.6 billion in cash and cash equivalents against $2.8 billion as of Mar 31. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. McKesson Corporation Price, Consensus and EPS Surprise McKesson Corporation Price, Consensus and EPS Surprise | McKesson Corporation Quote Financial Condition As of Sep 30, McKesson had $2.6 billion in cash and cash equivalents against $2.8 billion as of Mar 31. | Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report To read this article on Zacks.com click here. However, revenues from the Technology Solutions business declined from $680 million in the year-ago quarter to $120 million. |
33428.0 | 2017-10-26 00:00:00 UTC | Boston Scientific's (BSX) Q3 Earnings In Line, Guidance Up | ABT | https://www.nasdaq.com/articles/boston-scientifics-bsx-q3-earnings-in-line-guidance-up-2017-10-26 | nan | nan | Boston Scientific CorporationBSX posted adjusted earnings per share (EPS) of 31 cents in the third quarter of 2017, up 14.8% from the year-ago quarter. This figure remained in line with the Zacks Consensus Estimate, and fell exactly at the upper end of the company's adjusted EPS guidance range of 29-31 cents.
Without these adjustments, the company reported earnings of 20 cents per share, up 17.6% from the year-ago period.
Revenues in Detail
Revenues in the third quarter were up 5.6% year over year on reported basis and up 5.7% on operational basis (at constant exchange rate or CER) to $2.22 billion. The figure topped the company's guidance of $2.18-$2.21 billion and also exceeded the Zacks Consensus Estimate of $2.20 billion.
Boston Scientific Corporation Price, Consensus and EPS Surprise
Boston Scientific Corporation Price, Consensus and EPS Surprise | Boston Scientific Corporation Quote
Organic revenue growth in the third quarter (excluding the impact of changes in foreign currency exchange rates and sales from the acquisitions of EndoChoice Holdings and Symetis SA) was 4.3% year over year.
Geographically, in the third quarter, the company achieved operational growth of 4.2% in the U.S. (up 2.8% organically), up 8.8% in Europe (up 5.3%); up 7.8% in the Asia, Middle East and Africa region (same) and up 18.3% in the emerging markets (up 18%).
Segment Analysis
Boston Scientific currently has three global reportable segments: Cardiovascular, Rhythm Management and MedSurg.
The company generates maximum revenues from Cardiovascular. Sales from its subsegments - Interventional Cardiology and Peripheral Interventions - were $589 million (up 4.2% year over year at CER) and $268 million (up 5.1%), respectively, during the third quarter.
The second largest contributor to Boston Scientific's top line was Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology. CRM reflected a 0.9% year-over-year increase in sales to $463 million at CER in the reported quarter.
Worldwide, sales from pacemakers (within CRM) declined 4.5% to $149 million while defibrillators were up 0.9% to $314 million.
Electrophysiology sales went up 17.6% year over year at CER to $71 million.
Other segments like Endoscopy, Urology and Pelvic Health and Neuromodulation (under the MedSurg broader group) recorded sales of $403 million (up 10% at CER), $274 million (up 10.2%) and $154 million (up 11%), respectively.
Margins
Gross margin contracted 45 basis points (bps) year over year to 71.3% on 7.2% rise in cost of products sold. Adjusted operating margin improved by a marginal 4 bps to 23.2% in the reported quarter. During the quarter, selling, general and administrative expenses went up 3.6% to $800 million, while research and development expenses increased 9.5% to $254 million. Royalty expenses reduced 20% to $16 million in the quarter.
Balance Sheet
Boston Scientific exited the third quarter with cash and cash equivalents of $210 million, up from $195 million at the end of the sequential last quarter. At the end of the third quarter, the company had a total long-term debt of $5.68 billion, a marginal decline from $5.84 billion at the end of the second quarter.
Guidance
Boston Scientific has provided an update to its full-year 2017 guidance.
Banking on a solid third-quarter show and a gradually improving foreign exchange scenario, the company raised its 2017 revenue guidance to the range of $8.985-$9.015 billion (annualized growth of 7-8% on reported basis and growth of 7% on operational basis including contribution of approximately 120 bps from EndoChoice and Symetis) from the earlier band of $8.89-$8.99 billion (annualized growth of 6-7% on reported basis and growth of 6-8% on operational basis). The current Zacks Consensus Estimate for revenues is $8.95 billion, below the guided range.
Adjusted EPS guidance range for 2017, has been slightly narrowed to $1.24-$1.27 from the earlier range of $1.23-$1.27. The Zacks Consensus Estimate of $1.25 is within this guided range.
The company also provided its fourth-quarter 2017 financial guidance. Adjusted earnings are expected in the band of 32-35 cents per share on revenues of $2.345-$2.375 billion. The Zacks Consensus Estimate for EPS stands at 34 cents while for revenues, it is $2.32 billion.
Our Take
Despite back-to-back natural disasters, Boston Scientific managed to register solid third-quarter performance with earnings in line with the Zacks Consensus Estimate and revenues, ahead of the mark. A gradually improving foreign exchange scenario has also started to contribute to the company's overall topline performance.The raised guidance is all the more impressive and indicative of this overall bullish trend to continue through the rest of 2017.
Boston Scientific is leaving no stone unturned to strengthen its core businesses and invest in new technologies and global markets, which accounted for higher sales across all its geographies in the third quarter. We are also encouraged with the company gaining a number of approvals for its products, both in the domestic and overseas markets.
Among the recent developments, worth mentioning is the company's recent acquisition of Apama Medical, the developer of the single-shot Apama Radiofrequency (RF) Balloon Catheter System for the treatment of atrial fibrillation.This apart, the company received an FDA approval forMRI labeling and announced the U.S. launch of the Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems. This combines the HeartLogic Heart Failure Diagnostic, EnduraLife battery technology and SmartCRT Technology.
This apart, the company received CE Mark for updated 'Directions for Use' for the WATCHMAN LAAC Device in Europe. The company's ACURATE neo Transapical Aortic Valve System has also gained CE Mark. The company expects to begin a controlled launch throughout Europe during the fourth quarter of 2017.
Zacks Rank & Other Key Picks
Currently, Boston Scientific carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Notably, PetMed sports a Zacks Rank #1 (Strong Buy), while Abbott and Intuitive Surgical carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
PetMed reported EPS of 43 cents in second-quarter fiscal 2018, up 79.2% from the year-ago quarter's 24 cents. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Abbott reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Also, third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year.
Intuitive Surgical posted adjusted earnings of $2.77 per share in third-quarter 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some other top-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report To read this article on Zacks.com click here. Our Take Despite back-to-back natural disasters, Boston Scientific managed to register solid third-quarter performance with earnings in line with the Zacks Consensus Estimate and revenues, ahead of the mark. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Boston Scientific Corporation Price, Consensus and EPS Surprise Boston Scientific Corporation Price, Consensus and EPS Surprise | Boston Scientific Corporation Quote Organic revenue growth in the third quarter (excluding the impact of changes in foreign currency exchange rates and sales from the acquisitions of EndoChoice Holdings and Symetis SA) was 4.3% year over year. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Boston Scientific Corporation Price, Consensus and EPS Surprise Boston Scientific Corporation Price, Consensus and EPS Surprise | Boston Scientific Corporation Quote Organic revenue growth in the third quarter (excluding the impact of changes in foreign currency exchange rates and sales from the acquisitions of EndoChoice Holdings and Symetis SA) was 4.3% year over year. | Some other top-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report To read this article on Zacks.com click here. Banking on a solid third-quarter show and a gradually improving foreign exchange scenario, the company raised its 2017 revenue guidance to the range of $8.985-$9.015 billion (annualized growth of 7-8% on reported basis and growth of 7% on operational basis including contribution of approximately 120 bps from EndoChoice and Symetis) from the earlier band of $8.89-$8.99 billion (annualized growth of 6-7% on reported basis and growth of 6-8% on operational basis). |
33429.0 | 2017-10-26 00:00:00 UTC | Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific. | ABT | https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-johnson-johnson-abbott-labs-medtronic-and-boston | nan | nan | For Immediate Release
Chicago, IL - October 26, 2017 - Today, Zacks Equity Research discusses the MedTech, including Johnson & Johnson JNJ , Abbott LabsABT , MedtronicMDT and Boston ScientificBSX .
Industry: MedTech, Part 2
Link: https://www.zacks.com/commentary/133749/medtech-growing-on-emerging-markets-ma-stocks-to-buy
A survey report by Gallup Analytics last month revealed that U.S. adults cited healthcare, the wider industry of medical devices, as the second major problem faced by the country under the new presidential administration. Given the current lack of clarity, let's concentrate on some powerful long-term tailwinds of the medical device industry like emerging market expansion, mergers & acquisitions (M&A), positive demographic trends and new product innovation. These have been driving the sector's impressive performance despite severe socio-economic and political instability.
Let's elaborate some of the major long-term drivers of the MedTech sector.
Emerging Market Openings
It has been seen that even considering the dull performance of the U.S. medical device market (that still holds the leading position with almost one-third of the world market share) on rising regulatory and legislative uncertainty, global growth has been strong. In 2016, this industry grew 5%, a pace last seen before the financial crisis.
And when along with the health policy debacle in the United States we also consider the worsening economic condition in Europe, we can conclude that this encouraging global growth comes mainly from the emerging markets like China, India, Latin America and others.
Going by a recent BCG report, the share of emerging markets, which is currently less than a quarter of global MedTech revenues, is likely to increase to nearly one-third of revenues by 2022. The MedTech market in China, currently the second largest in the world, is projected to grow about 13% annually from 2015 through 2022. India's MedTech market, the fifth largest in the world, is currently demonstrating 17% annual growth. If this continues, India may give good competition to Japan and Germany by 2022.
Among other emerging geographical regions, Latin America, even in the face of general economic stagnation, holds enormous potential. Per a January 2017 report by MedTech Intelligence, the Central and South American nations significantly increased per capita spending on healthcare between 2008 and 2014.
Given the huge potential in these regions, long back, Johnson & Johnson had set up manufacturing and R&D centers in Brazil, China and India. The company's medical device segment of emerging markets is growing three to four times faster than the developed markets.
Abbott Labs continues to lead the emerging market investment trend with about 50% of sales from this region. In recent quarters, sales in key emerging markets were up in double digits, driven by strength in BRIC as well as strong growth in several countries throughout Latin America, including Colombia, Mexico, Peru and Argentina.
At Medtronic , in the last-reported first quarter of fiscal 2017, businesses in China, Latin America, and Southeast Asia showed sustained strength, growing in double digits. Overall, Medtronic remains confident about its long-term outlook on emerging markets. The company is focused on developing new public and private partnerships as well as executing channel optimization strategies.
Boston Scientific 's emerging markets business registered 14% organic growth in second-quarter 2017, reflecting a significant increase from 8% growth in 2013. Business in China was once again remarkable (up 20% year over year). The company is currently looking forward to much better performance ahead in China, banking on the recent approval of SYNERGY in China.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubles the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For Immediate Release Chicago, IL - October 26, 2017 - Today, Zacks Equity Research discusses the MedTech, including Johnson & Johnson JNJ , Abbott LabsABT , MedtronicMDT and Boston ScientificBSX . Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Given the current lack of clarity, let's concentrate on some powerful long-term tailwinds of the medical device industry like emerging market expansion, mergers & acquisitions (M&A), positive demographic trends and new product innovation. | For Immediate Release Chicago, IL - October 26, 2017 - Today, Zacks Equity Research discusses the MedTech, including Johnson & Johnson JNJ , Abbott LabsABT , MedtronicMDT and Boston ScientificBSX . Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Boston Scientific 's emerging markets business registered 14% organic growth in second-quarter 2017, reflecting a significant increase from 8% growth in 2013. Business in China was once again remarkable (up 20% year over year). | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL - October 26, 2017 - Today, Zacks Equity Research discusses the MedTech, including Johnson & Johnson JNJ , Abbott LabsABT , MedtronicMDT and Boston ScientificBSX . Emerging Market Openings It has been seen that even considering the dull performance of the U.S. medical device market (that still holds the leading position with almost one-third of the world market share) on rising regulatory and legislative uncertainty, global growth has been strong. | For Immediate Release Chicago, IL - October 26, 2017 - Today, Zacks Equity Research discusses the MedTech, including Johnson & Johnson JNJ , Abbott LabsABT , MedtronicMDT and Boston ScientificBSX . Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Emerging Market Openings It has been seen that even considering the dull performance of the U.S. medical device market (that still holds the leading position with almost one-third of the world market share) on rising regulatory and legislative uncertainty, global growth has been strong. |
33430.0 | 2017-10-25 00:00:00 UTC | Abaxis (ABAX) Posts In-Line Earnings in Q2, Lags Revenues | ABT | https://www.nasdaq.com/articles/abaxis-abax-posts-in-line-earnings-in-q2-lags-revenues-2017-10-25 | nan | nan | Abaxis, Inc.ABAX reported second-quarter fiscal 2018 adjusted earnings per share of 29 cents, in line with the Zacks Consensus Estimate. However, the adjusted EPS figure declined 42% from the year-ago figure of 50 cents.
Total Revenue
In the fiscal second quarter, Abaxis recorded revenues of $58.9 million, reflecting an increase of 0.5% from a year ago. The top line however missed the Zacks Consensus Estimate of $61 million. According to the company, foreign currency exchange rate fluctuations had a negligible or 0.4% impact on Abaxis' top line.
Segments in Detail
On a geographic basis, revenues from North America (accounting for 79.7% of total revenue) declined 0.2% to $46.9 million in the reported quarter. Revenues from the international markets (accounting for the rest) improved 3.5% to $11.9 million.
Abaxis operates through three main segments, namely, Veterinary, Medical and Other. In the reported quarter, Veterinary sales accounted for 82.5% of total sales, Medical contributed 15.8% while the remaining 1.8% was generated from Other.
ABAXIS, Inc. Price, Consensus and EPS Surprise
ABAXIS, Inc. Price, Consensus and EPS Surprise | ABAXIS, Inc. Quote
Veterinary market revenues improved 0.5% year over year to $48.5 million, driven by a 3% uptick in veterinary consumable revenues to $39.3 million. Veterinary instrument revenues were down 10% year over year to $7.5 million.
Revenues from the medical market were down from $9.4 million in the same quarter last year to $9.3 million as strength in Piccolo instrument was offset by decline in medical rotors. Also, revenues at the North American medical division totaled $6.8 million, up 1.5% year over year. On a global basis, Abaxis sold 225 Piccolos in the quarter compared with 208 a year ago.
Abaxis exhibited strong consumable growth, up 2% year over year to $46.4 million in the quarter. Within the consumable product lines, total rotor revenues were $31.6 million, almost in line with $31.7 million in the year-ago quarter. On a global basis, Abaxis sold 2.55 million rotor units in the quarter under review, down from 2.57 million units in the year-ago quarter. Hematology reagents and rapid assays drove growth in consumable revenues in the reported quarter.
However, total instruments' sales decreased 7% to $9.2 million due to lower veterinary instrument sales.
Operational Updates
Fiscal second-quarter's gross profit dropped 0.3% to $32.2 million. Gross margin contracted 50 basis points (bps) to 54.6%.
Research and development expenses increased 23.8% year over year to $6.1 million and sales and marketing expenses rose 10.9% to $12.5 million. General and administrative expenses however declined 4.3% to $4.2 million. However, the resultant operating income was down 19.7% to $9.4 million in the quarter, while operating margin declined 410 bps to 16%.
Financial Update
Abaxis exited the fiscal second quarter with cash, cash equivalents and short-term investments of $148.8 million, compared with $137.7 million in first-quarter fiscal 2018.
Our Take
Abaxis exited the second quarter of fiscal 2018 on a disappointing with revenues lagging the Zacks Consensus Estimate. Also, a decline in both gross and operating margin is a matter of concern. However, a year-over-year increase in revenues buoys optimism. We are looking forward to improved consumable revenues that boosted veterinary sales performance at Abaxis in the quarter.
Meanwhile, we are encouraged to note that the company is initiating new sales and marketing strategies. In this regard, the company recently started shipping VetScan UA, a hand-held urine chemistry analyzer in September. Moreover, the latest launches of VetScan Phenobarbital Profile and VetScan Canine Pancreatic Lipase Rapid Test buoy optimism. Abaxis plans additional product launches in fiscal 2018, including the VetScan FUSE connectivity system. According to the company, addition of these products will drive growth over the long haul.
Zacks Rank & Key Picks
Currently, Abaxis has a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Notably, PetMed sports a Zacks Rank #1 (Strong Buy), while Abbott and Intuitive Surgical carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
PetMed reported EPS of 43 cents in the second quarter of fiscal 2018, up 79.2% from the year-ago quarter's 24 cents. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Abbott reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Also, third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year on a reported basis.
Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
ABAXIS, Inc. (ABAX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report ABAXIS, Inc. (ABAX): Free Stock Analysis Report To read this article on Zacks.com click here. Abaxis, Inc.ABAX reported second-quarter fiscal 2018 adjusted earnings per share of 29 cents, in line with the Zacks Consensus Estimate. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report ABAXIS, Inc. (ABAX): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Abaxis, Inc.ABAX reported second-quarter fiscal 2018 adjusted earnings per share of 29 cents, in line with the Zacks Consensus Estimate. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report ABAXIS, Inc. (ABAX): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Total Revenue In the fiscal second quarter, Abaxis recorded revenues of $58.9 million, reflecting an increase of 0.5% from a year ago. | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report ABAXIS, Inc. (ABAX): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues from the medical market were down from $9.4 million in the same quarter last year to $9.3 million as strength in Piccolo instrument was offset by decline in medical rotors. |
33431.0 | 2017-10-25 00:00:00 UTC | Thermo Fisher (TMO) Q3 Earnings & Sales Top, Guidance Up | ABT | https://www.nasdaq.com/articles/thermo-fisher-tmo-q3-earnings-sales-top-guidance-up-2017-10-25 | nan | nan | Thermo Fisher Scientific Inc.TMO reported better-than-expected performance in third-quarter 2017. Adjusted EPS came in at $2.31, beating the Zacks Consensus Estimate by 3.1% and the year-ago quarter figure by 13.8%.
On a reported basis, second-quarter EPS of $1.34 marked a 12.6% year-over-year rise.
Revenues in the quarter came in at $5.12 billion, up 14% year over year. Sales also exceeded the Zacks Consensus Estimate of $5.03 billion by 1.7%.
Thermo Fisher Scientific Inc Price, Consensus and EPS Surprise
Thermo Fisher Scientific Inc Price, Consensus and EPS Surprise | Thermo Fisher Scientific Inc Quote
Quarter in Detail
Organic revenues in the third quarter grew 5% year over year while acquisitions increased revenues by 8%. Currency translation positively impacted total revenues by 1%.
Thermo Fisher currently operates under four business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Services.
Revenues at the Life Sciences Solutions segment (27% of total revenues) improved 5% year over year to $1.38 billion while Analytical Instruments Segment sales (23.3%) rose 32% to $1.19 billion, reflecting the acquisition of FEI Company.
Revenues at the Laboratory Products and Services segment (37.8%) rallied 15% to $1.93 billion, while the Specialty Diagnostics segment (16.5%) recorded a 6% increase to $844 million.
Gross margin of 47.5% during the third quarter was down 67 basis points (bps) year over year, despite a 12.3% rise in gross profits. Adjusted operating margin expanded approximately 43 bps to 21.3%, despite a 7.6% rise in selling, general and administrative expenses and 18.9% increase in research and development expenses.
The company exited the third quarter with cash and cash equivalents of $741.1 million compared with $611 million at the end of the previous quarter. Year-to-date net cash provided by operating activities was $2.13 billion compared with $2.05 billion in the year-ago period.
Guidance Raised
Backed by a solid third-quarter performance, a favorable foreign exchange environment forecast and also considering the recently-closed acquisition of Patheon, Thermo Fisher has raised its full-year 2017 financial guidance.
The revenue guidance has been raised to a range of $20.50-$20.66 billion (growth of 12-13% from the previous year) from the earlier band of $19.71-$19.89 billion (growth of 8-9%). The current Zacks Consensus Estimate of $20.48 billion falls below this guided range.
The company has also raised its adjusted EPS guidance to a range of $9.29-$9.38, reflecting growth of 12-13% from the previous year. The earlier prediction was in the $9.15-$9.28 range (growth of 11-12%). The Zacks Consensus Estimate of $9.33 per share remains within the guided band.
Bottom Line
Thermo Fisher ended the third quarter on a promising note with both adjusted earnings and revenues beating the Zacks Consensus Estimate.
We are encouraged by the company's series of product launches along with major progress in precision medicine initiatives. Thermo Fisher's acquisition of FEI Company has already started to boost its analytical instruments portfolio.
In the quarter, the company launched four new electron microscopy systems for structural biology and materials science research. Also, it has released a new iQ Series air-quality monitoring platform and enabled the first FDA-approved gene therapy. This apart, the company has opened Precision Medicine Customer Experience Center in Guangzhou, China.
We are currently looking forward to the recently completed $7.2 billion acquisition of Patheon. This is going to significantly enhance the company's value proposition for biopharma customers by adding leading contract development and manufacturing outsourcing services.The raised guidance is all the more impressive and indicative of this overall bullish trend to continue through 2017.
Zacks Rank & Other Key Picks
Currently, Thermo Fisher has a Zacks Rank #2 (Buy).
A few other stocks worth considering in the broader medical sector are PetMed Express, Inc. PETS , Abbott Labs ABT and Intuitive Surgical, Inc. ISRG . Notably, PetMed sports a Zacks Rank #1 (Strong Buy), while both Abbott and Intuitive Surgical carry a Zacks Rank of 2 as well. You can see the complete list of today's Zacks #1 Rank stocks here.
PetMed reported EPS of 43 cents for the second quarter of fiscal 2018, up 79.2% from 24 cents, reported in the year-ago quarter. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Abbott reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Also, third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year.
Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few other stocks worth considering in the broader medical sector are PetMed Express, Inc. PETS , Abbott Labs ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Thermo Fisher currently operates under four business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Services. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. A few other stocks worth considering in the broader medical sector are PetMed Express, Inc. PETS , Abbott Labs ABT and Intuitive Surgical, Inc. ISRG . Thermo Fisher Scientific Inc Price, Consensus and EPS Surprise Thermo Fisher Scientific Inc Price, Consensus and EPS Surprise | Thermo Fisher Scientific Inc Quote Quarter in Detail Organic revenues in the third quarter grew 5% year over year while acquisitions increased revenues by 8%. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. A few other stocks worth considering in the broader medical sector are PetMed Express, Inc. PETS , Abbott Labs ABT and Intuitive Surgical, Inc. ISRG . Thermo Fisher Scientific Inc Price, Consensus and EPS Surprise Thermo Fisher Scientific Inc Price, Consensus and EPS Surprise | Thermo Fisher Scientific Inc Quote Quarter in Detail Organic revenues in the third quarter grew 5% year over year while acquisitions increased revenues by 8%. | A few other stocks worth considering in the broader medical sector are PetMed Express, Inc. PETS , Abbott Labs ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues in the quarter came in at $5.12 billion, up 14% year over year. |
33432.0 | 2017-10-25 00:00:00 UTC | Walgreens Boots (WBA) Tops Q4 Earnings, Issues 2018 View | ABT | https://www.nasdaq.com/articles/walgreens-boots-wba-tops-q4-earnings-issues-2018-view-2017-10-25 | nan | nan | Walgreens Boots Alliance, Inc.WBA reported adjusted earnings per share (EPS) of $1.31 in fourth-quarter fiscal 2017, up 22.4% year over year. Adjusted EPS surpassed the Zacks Consensus Estimate of $1.22.
On a reported basis, net earnings came in at $802 million, reflecting a decrease of 22.1% from the prior-year quarter. Reported earnings came in at 76 cents per share, showing a 20% decline on a year-over-year basis.
For full-year 2017, adjusted EPS came in at $5.10, up 11.1% from the year-ago quarter. The figure also surpassed the Zacks Consensus Estimate of $5.01.
Total Sales
Walgreens Boots recorded total sales of $30.15 billion in the fiscal fourth quarter, up 5.3% year over year and up 6.4% at constant exchange rate (CER). The top line outpaced the Zacks Consensus Estimate of $30.05 billion.
Fiscal 2017 sales totaled $118.21 billion, up 0.7% from the year-ago period. Moreover, the figure beat the Zacks Consensus Estimate of $118.16 billion by a slight margin.
Walgreens Boots Alliance, Inc. Price, Consensus and EPS Surprise
Walgreens Boots Alliance, Inc. Price, Consensus and EPS Surprise | Walgreens Boots Alliance, Inc. Quote
Segments in Detail
Walgreens Boots currently reports under three operating segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale.
The Retail Pharmacy USA division recorded sales of $22.3 billion in the fourth quarter, highlighting an increase of 7.5% on a year-over-year basis. Within this segment, total sales at comparable drugstores rose 3.1%, while prescriptions filled in comparable stores grew 8.7% on account of Medicare Part D growth and volume growth from previously announced strategic pharmacy collaborations. Comparable retail sales dropped 2.1% due to lower sales at the consumables and general merchandise category and the personal care category, partially offset by increased sales in the health and wellness as well as beauty categories.
Pharmacy sales, which accounted for 72.1% of the Retail Pharmacy USA division's sales in the quarter, increased 12.6% from the year-ago quarter, and pharmacy sales at comparable stores rose 5.6% on higher volumes.
Revenues at the Retail Pharmacy International division declined 3.2% on a year-over-year basis (down 0.4% at CER) to $2.9 billion owing to currency fluctuations. At CER, comparable store sales in the fourth quarter decreased 0.2% year over year, while comparable pharmacy sales increased 0.5% led by growth in the U.K.
The Pharmaceutical Wholesale division recorded quarterly sales of $5.4 billion, up 0.8% year over year (up 5.4% at CER).
Margins
Gross profit in the reported quarter declined 2.6% year over year to $7.34 billion. Accordingly, reported gross margin contracted 70 basis points (bps) to 24.3%.
Selling, general and administrative (SG&A) expenses were up 2.8% year over year to $6.22 billion. However, adjusted operating income increased 1.4% to $1.12 billion as the rise in revenues outweighed the increase in operating expenses. In contrast, adjusted operating margin contracted 20 bps to 3.7%.
Financial Condition
Walgreens Boots exited fiscal 2017 with cash and cash equivalents of $3.30 billion, compared with $9.81 billion at the end of fiscal 2016. Long-term debt was $12.68 billion, compared with $18.71 billion at the end of the prior fiscal.
The company generated operating cash flow of $7.25 billion in fiscal 2017 compared with $7.85 billion a year ago. The resultant free cash flow was $5.9 billion in fiscal 2017.
Guidance
Walgreens Boots has issued the fiscal 2018 guidance. The company expects adjusted EPS in the $5.40-$5.70 range for the fiscal. The current Zacks Consensus Estimate for fiscal 2017 earnings is pegged at $5.48, within but near to the lower end of the company's guided range.
Our Take
Walgreens Boots reported an impressive fourth quarter of fiscal 2017 with both earnings and sales surpassing the Zacks Consensus Estimate. However, declining sales at the Retail Pharmacy International was a disappointment. Nevertheless, Walgreens Boots has been gaining on account of the company's strategic tie-ups which brought more patients to its U.S. pharmacies.
In September, Walgreens Boots announced the receipt of U.S. Federal Trade Commission (FTC) approval for the purchase of 1,932 stores, three distribution centers and related inventory from Rite Aid for a total of $4.375 billion. Synergies of $300 million are expected to be realized within four years of initial closing of the transaction, achieved majorly from procurement, cost savings and other operational areas.
Per Walgreens Boots, this modified merger contract is in line with its growth strategy and offers additional operational benefits. It will also help the company expand and optimize retail pharmacy network in key U.S. markets, including the Northeast.
Zacks Rank & Key Picks
Currently, Walgreens Boots has a Zacks Rank #4 (Sell).
A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Notably, PetMed sports a Zacks Rank #1 (Strong Buy), while Abbott and Intuitive Surgical carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
PetMed reported EPS of 43 cents in the second quarter of fiscal 2018, up 79.2% from the year-ago quarter's 24 cents. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Abbott reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Also, third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year.
Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. In September, Walgreens Boots announced the receipt of U.S. Federal Trade Commission (FTC) approval for the purchase of 1,932 stores, three distribution centers and related inventory from Rite Aid for a total of $4.375 billion. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Walgreens Boots Alliance, Inc. Price, Consensus and EPS Surprise Walgreens Boots Alliance, Inc. Price, Consensus and EPS Surprise | Walgreens Boots Alliance, Inc. Quote Segments in Detail Walgreens Boots currently reports under three operating segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Total Sales Walgreens Boots recorded total sales of $30.15 billion in the fiscal fourth quarter, up 5.3% year over year and up 6.4% at constant exchange rate (CER). | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. Walgreens Boots Alliance, Inc.WBA reported adjusted earnings per share (EPS) of $1.31 in fourth-quarter fiscal 2017, up 22.4% year over year. |
33433.0 | 2017-10-25 00:00:00 UTC | Baxter (BAX) Beats on Earnings & Sales in Q3, 2017 View Up | ABT | https://www.nasdaq.com/articles/baxter-bax-beats-on-earnings-sales-in-q3-2017-view-up-2017-10-25 | nan | nan | Baxter International Inc.BAX reported third-quarter 2017 adjusted earnings per share of 64 cents, which beat the Zacks Consensus Estimate by 5 cents and improved from the year-ago figure of 56 cents. Baxter currently has a Zacks Rank #2 (Buy).
The figure was also above the company's guided range of 58 cents to 60 cents. Interestingly, over the last four quarters, the company delivered positive earnings surprises, the average being 15.3%.
Baxter posted sales of $2.71 billion, beating the Zacks Consensus Estimate of $2.66 billion. At constant currency (cc), revenues increased 6% on a year-over-year basis. U.S. sales were up 8% year over year to $1.6 billion. International sales increased 4% at cc to almost $1.5 billion.
Baxter International Inc. Price, Consensus and EPS Surprise
Baxter International Inc. Price, Consensus and EPS Surprise | Baxter International Inc. Quote
Segmental Details
Sales at the hospital products segment climbed 7% at cc on a year-over-year basis to $1.7 billion. Hospital Products sales in the quarter were driven by solid sales in the U.S. fluid systems and select anesthesia and critical care products. Hospital Sales were also driven by solid demand for injectable pharmaceuticals and hospital pharmacy compounding services.
Meanwhile, sales increased 3% at cc to $1 billion at the renal products segment. Renal products sales were supported by improved performance across all major product lines and therapies globally.
Quarterly Highlights
Baxter Acquires Claris: In the third quarter, Baxter completed the acquisition of India-based Claris Injectables, a global generic injectables pharmaceutical company for almost $625 million. In December 2016, Baxter had initiated the agreement. Per management, the acquisition will bolster Baxter's foothold in the generic pharmaceuticals space.
New Patients Enrolled: In the third quarter, Baxter registered patients under two new clinical trials for a unique expanded hemodialysis therapy enabled by THERANOVA, a dialyzer for treatment of chronic and acute renal failure. In fact, Baxter is expected to launch hemodialysis enabled by THERANOVA in Australia, New Zealand, France, Germany, Switzerland and Belgium by the end of this year.
Hurricanes Deal a Blow: Management at Baxter announced a possibility of shortfall in supply of certain products in the next quarter. This is because the company is still grappling with limited production at all three manufacturing sites in Puerto Rico Hurricane Maria. However, the company has been granted regulatory approval by the FDA for special importation of products from facilities in Ireland, Australia, Canada and Mexico to maintain the product supply balance in the U.S. market.
International Foothold Fortified: Baxter launched the oXIRIS set for continuous renal replacement therapy (CRRT) and sepsis management protocols in select markets of Europe, Middle East and Africa in the quarter. Notably, oXIRIS, which leverages on the company's flagship PRISMAFLEX system, is expected to lend Baxter a competitive edge in the global market.
Guidance Lifted
For full-year 2017, Baxter estimates sales growth of approximately 4% at cc. Adjusted earnings for the full year are expected in the band of $2.40 to $2.43 per diluted share, up from the previous band of $2.34 to $2.40.
Baxter expects fourth-quarter revenues to face a negative impact of approximately $70 million, thanks to the operational disruption resulting from hurricane Maria. Adjusted earnings for the fourth quarter are expected in the band of 56 cents to 59 cents per diluted share. Net sales in the fourth quarter are expected to rise 2% at cc.
Other Companies With Solid Earnings Results
Intuitive Surgical Inc. ISRG posted adjusted earnings of $2.77 per share in the third quarter of 2017, beating the Zacks Consensus Estimate of $1.97 on stellar revenue growth. The stock has a Zacks Rank #2.
PetMed Express, Inc. PETS adjusted announced earnings per share of 43 cents for the second quarter of fiscal 2018, up 79.2% from the year-ago quarter. Also, earnings surpassed the Zacks Consensus Estimate by 43.3%. The stock has a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year. Abbott carries Zacks Rank #2.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Baxter International Inc. (BAX): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report To read this article on Zacks.com click here. In fact, Baxter is expected to launch hemodialysis enabled by THERANOVA in Australia, New Zealand, France, Germany, Switzerland and Belgium by the end of this year. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Baxter International Inc. Price, Consensus and EPS Surprise Baxter International Inc. Price, Consensus and EPS Surprise | Baxter International Inc. Quote Segmental Details Sales at the hospital products segment climbed 7% at cc on a year-over-year basis to $1.7 billion. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Baxter International Inc.BAX reported third-quarter 2017 adjusted earnings per share of 64 cents, which beat the Zacks Consensus Estimate by 5 cents and improved from the year-ago figure of 56 cents. | Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, sales increased 3% at cc to $1 billion at the renal products segment. |
33434.0 | 2017-10-25 00:00:00 UTC | LabCorp (LH) Beats Q3 Earnings Estimates, Raises Guidance | ABT | https://www.nasdaq.com/articles/labcorp-lh-beats-q3-earnings-estimates-raises-guidance-2017-10-25 | nan | nan | Laboratory Corporation of America HoldingsLH or LabCorp reported third-quarter 2017 adjusted earnings per share (EPS) of $2.46, up 9.3% from the year-ago quarter. The quarter's adjusted EPS also exceeded the Zacks Consensus Estimate by 3.4%. Simultaneous hurricanes in the reported quarter, adversely affected adjusted EPS by 9 cents approximately.
On a reported basis, LabCorp's net earnings came in at $1.74 per share, a 1.8% increase year over year.
Net revenue for the third quarter increased 9.5% year over year to $2.59 billion. The increase in net revenues was due to growth from acquisitions of 6.9%, organic growth (net revenue growth less revenue from acquisitions for the first twelve months after the close of each acquisition) of 2.3%, and the benefit from foreign currency translation of approximately 30 basis points. However, this was partially offset by a 0.7% adverse impact of multiple hurricanes during the quarter.
Laboratory Corporation of America Holdings Price, Consensus and EPS Surprise
Laboratory Corporation of America Holdings Price, Consensus and EPS Surprise | Laboratory Corporation of America Holdings Quote
Quarter under Review
Currently, LabCorp reports under two operating segments: LabCorp Diagnostics and Covance Drug Development.
In the reported quarter, LabCorp Diagnostics reported net revenue of $1.84 billion, up 9.9% year over year, fueled by price, mix, tuck-in acquisitions, organic volume (measured by requisitions excluding requisitions from acquisitions for the first 12 months after the close of each acquisition) and the benefit from foreign currency translation of approximately 20 basis points. The company reported 7.3% increase in total volume (measured by requisition) and a 2.4% increase in revenue per requisition in the quarter.
After several quarters of drag in sales, Covance Drug Development reported an 8.6% rise in net revenue to $761.1 million in the third quarter. This was primarily on the back of the acquisition of Chiltern, organic growth and the benefit from foreign currency translation of approximately 60 basis points.
Gross margin expanded 75 bps to 33.9% in the quarter. Adjusted operating income increased 7.6% year over year to $417.5 million. Adjusted operating margin contracted 28 bps from the year-ago quarter to 16.1% on a 16.2% rise in selling, general and administrative expenses to $465.3 million.
LabCorp exited the quarter with cash and cash equivalents of $409.3 million compared with $299.9 million at the end of the second quarter. Year-to-date operating cash flow was $895.4 million, up from $727 million in the year-ago period. Free cash flow came in at $678.6 million, up from $522.4 million in the year-ago period. During the quarter, the company returned $42.1 million to shareholders through share repurchases and currently has $444.7 million of authorization, remaining under its existing share repurchase plan.
Outlook
Based on a strong third-quarter show and considering a gradually improving foreign exchange scenario, the company increased its earlier provided 2017 outlook.
Net revenue growth is now expected to remain in the band of 8-8.5% year over year, ahead of the earlier range of 5-6.5%. This includes a 10 bps impact from an unfavorable foreign exchange headwind. The current Zacks Consensus Estimate for revenues is pegged at $10.13 billion.
Adjusted EPS guidance for 2017 has been narrowed to the range of $9.40−$9.60 (previous range: $9.30−$9.65). The current Zacks Consensus Estimate of $9.51 falls within the guided range.
Free cash flow expectation has been raised to a new band of $970−$1010 million (previous range: $925−$975 million) up 8-13% from the prior year.
Our Take
LabCorp's third-quarter earnings topped the Zacks Consensus Estimate. Strong year-over-year increase in both earnings and revenues were encouraging too. LabCorp Diagnostics business was strong on improving price, mix, acquisition and favorable foreign exchange scenario.
Also after several quarters of dull performance, Covance Drug Development reported strong growth. This was primarily on the back of the acquisition of Chiltern, strong organic growth and favorable foreign currency translation. An increased guidance for 2017 boosts investors' confidence indicating chances of this bullish trend to be maintained in the fourth quarter too.
We believe that with the integration of newer acquisitions, LabCorp is perfectly positioned to drive long-term profitable growth through a combination of world-class diagnostics, drug development expertise and knowledge services.
Zacks Rank & Other Key Picks
Currently, LabCorp has a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Notably, PetMed sports a Zacks Rank #1 (Strong Buy), while both Abbott and Intuitive Surgical carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
PetMed reported EPS of 43 cents for the second quarter of fiscal 2018, up 79.2% from 24 cents, reported in the year-ago quarter. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Abbott reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Also, third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year.
Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few other top-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report To read this article on Zacks.com click here. Laboratory Corporation of America HoldingsLH or LabCorp reported third-quarter 2017 adjusted earnings per share (EPS) of $2.46, up 9.3% from the year-ago quarter. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Laboratory Corporation of America Holdings Price, Consensus and EPS Surprise Laboratory Corporation of America Holdings Price, Consensus and EPS Surprise | Laboratory Corporation of America Holdings Quote Quarter under Review Currently, LabCorp reports under two operating segments: LabCorp Diagnostics and Covance Drug Development. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Laboratory Corporation of America Holdings Price, Consensus and EPS Surprise Laboratory Corporation of America Holdings Price, Consensus and EPS Surprise | Laboratory Corporation of America Holdings Quote Quarter under Review Currently, LabCorp reports under two operating segments: LabCorp Diagnostics and Covance Drug Development. | A few other top-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report To read this article on Zacks.com click here. The increase in net revenues was due to growth from acquisitions of 6.9%, organic growth (net revenue growth less revenue from acquisitions for the first twelve months after the close of each acquisition) of 2.3%, and the benefit from foreign currency translation of approximately 30 basis points. |
33435.0 | 2017-10-25 00:00:00 UTC | Illumina (ILMN) Tops Q3 Earnings & Revenues, Raises Guidance | ABT | https://www.nasdaq.com/articles/illumina-ilmn-tops-q3-earnings-revenues-raises-guidance-2017-10-25 | nan | nan | Illumina, Inc.ILMN reported adjusted earnings per share (EPS) of $1.11 in the third quarter of 2017, which beat the Zacks Consensus Estimate of 98 cents. Adjusted earnings also surpassed the year-ago number by 14.4%.
Including one-time items, the company reported EPS of $1.11, compared with 87 cents a year ago.
Revenues
In the reported quarter, Illumina's revenues grew 17.6% year over year to $714 million. Moreover, the top line beat the Zacks Consensus Estimate by 2.9%.
Illumina, Inc. Price, Consensus and EPS Surprise
Illumina, Inc. Price, Consensus and EPS Surprise | Illumina, Inc. Quote
Per management, top-line growth in the third quarter can be attributed to strong uptake of sequencing consumables and instruments as well as microarray portfolios. Moreover, the NovaSeq platform continued to drive growth with close to 200 NovaSeq systems currently at customers' hands since the launch in January 2017. Management is also hopeful that recent launches like S4 flow cell, Xp workflow and Nextera DNA Flex library preparation kit will drive NovaSeq demand.
Product revenues (83.5% of total revenue) increased 15.9% year over year to $596 million. Service and Other (15.5%) revenues were up 26.9% year over year to $118 million.
Operational Update
Illumina's adjusted gross margin came in at 67.5%, reflecting a contraction of 267 basis points (bps) year over year owing to NovaSeq introduction, higher array services revenues and product mix within sequencing consumables. Excluding amortization of acquired intangible assets and including stock-based compensation expenses, adjusted gross margin was 68.8%, highlighting a contraction of 320 bps from a year ago.
Research and development expenses were up 20.1% year over year to $134 million and selling, general & administrative expenses rose 6.3% to $167 million. Consequently, the adjusted operating margin of 25.4% reflected a decline of 117 bps from the year-ago period.
Financial Update
Illumina exited the third quarter with cash and cash equivalents and short-term investments of $2.04 billion, up from $1.89 billion in the third quarter. Year-to-date net cash provided by operating activities was $581 million, compared with $517 million in the year-ago period.
2017 Guidance
Banking on the solid third-quarter performance, Illumina has raised its full-year 2017 revenue growth expectations to 13% from the earlier provided range of 12%. Meanwhile, the Zacks Consensus Estimate for full-year 2017 revenues is pegged at $2.69 billion.
The company raised its adjusted EPS to the band of $3.73-$3.78 from the earlier $3.60-$3.70. The Zacks Consensus Estimate for Illumina's 2017 bottom line stands at $3.64, far below the low end of the guided range.
Our Take
Illumina exited the third quarter on a solid note. We are also encouraged by the year-over-year increase in both the fronts. The company has also raised its full-year 2017 revenue guidance and the adjusted EPS range. We are looking forward to the performance of NovaSeq S4 flow cell, reagent kit and NovaSeq Xp workflow for its NovaSeq 6000 System.
On the flip side, weak margins owing to the lower instrument margin associated with NovaSeq launch and higher array services mix will continue to act as deterrents. Also, a tough competitive landscape is a concern.
Zacks Rank & Key Picks
Currently, Illumina has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Notably, PetMed sports a Zacks Rank #1 (Strong Buy), while Abbott and Intuitive Surgical carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
PetMed reported EPS of 43 cents for the second quarter of fiscal 2018, up 79.2% from the year-ago quarter's 24 cents. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Abbott reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Also, third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year.
Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Illumina, Inc. (ILMN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Management is also hopeful that recent launches like S4 flow cell, Xp workflow and Nextera DNA Flex library preparation kit will drive NovaSeq demand. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Illumina, Inc. Price, Consensus and EPS Surprise Illumina, Inc. Price, Consensus and EPS Surprise | Illumina, Inc. Quote Per management, top-line growth in the third quarter can be attributed to strong uptake of sequencing consumables and instruments as well as microarray portfolios. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Revenues In the reported quarter, Illumina's revenues grew 17.6% year over year to $714 million. | Some better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Illumina, Inc.ILMN reported adjusted earnings per share (EPS) of $1.11 in the third quarter of 2017, which beat the Zacks Consensus Estimate of 98 cents. |
33436.0 | 2017-10-25 00:00:00 UTC | Edwards Lifesciences (EW) Q3 Earnings, Sales Lag, View Intact | ABT | https://www.nasdaq.com/articles/edwards-lifesciences-ew-q3-earnings-sales-lag-view-intact-2017-10-25 | nan | nan | Edwards Lifesciences CorporationEW reported third-quarter 2017 adjusted earnings per share (EPS) of 84 cents, which missed the Zacks Consensus Estimate of 86 cents by 2.3%. However, adjusted earnings improved 23.5% year over year, primarily driven by strong sales growth at the company's transcatheter heart valves business.
Excluding one-time items, net income in the third quarter came in at $170.1 million or 79 cents per share, up 20.3% or 21.5% year over year, respectively.
Sales Details
Edwards Lifesciences' third-quarter sales improved 11.1% to $821.5 million. However, the figure missed the Zacks Consensus Estimate of $834 million by 1.5%. Underlying sales increased 12.9% (including the impact of Germany stocking sales as customers in the nation chose to purchase additional inventory of the SAPIEN 3 valve in anticipation of a potential supply interruption resulting from recent intellectual property litigation).
Revenues were primarily driven by considerable growth in transcatheter heart valve sales as well as strong performance by Surgical Heart Valve Therapy and Critical Care product lines too across all regions.
Edwards Lifesciences Corporation Price, Consensus and EPS Surprise
Edwards Lifesciences Corporation Price, Consensus and EPS Surprise | Edwards Lifesciences Corporation Quote
Segments Details
For the third quarter, the company reported Transcatheter Heart Valve Therapy (THVT) sales of $481.2 million, reflecting 17.3% growth over the prior-year quarter. In the United States, THVT sales in the quarter totaled $311.6 million, up 20.1% year over year. Growth was driven by excellent clinical performance by SAPIEN 3 as well continued strong therapy implementation across all regions.
Surgical Heart Valve Therapy sales in the quarter were $195.6 million, up 2.4% from the prior-year quarter. This was led by strong demand for the EDWARDS INTUITY Elite valve system and strong uptake of core products outside the United States, partially offset by the continuing shift from surgical aortic valves to the SAPIEN 3 valves in the United States and Europe.
Critical Care sales were $144.7 million in the reported quarter, representing an increase of 4.5% from third-quarter 2016. Solid growth across all product categories was driven by strong growth in the company's core products and the Enhanced Surgical Recovery Program, mainly in the United States and Asia Pacific.
Margins
In the third quarter, gross margin expanded 120 basis points (bps) to 74% owing to a more profitable product mix, led by growing sales of transcatheter valves as well as a favorable comparison of supply chain expenditures. This was however partially offset by expenses incurred due to flooding from Hurricane Maria in Puerto Rico and the shutdown of the company's manufacturing plant in Switzerland.
SG&A expenses rose 6.5% year over year to $244.6 million on account of sales and personnel-related expenses, primarily in the Transcatheter Valve (THV) segment.R&D expenditures increased 26.5% year over year to $142.9 million owing to continued investments in the company's transcatheter aortic valve and mitral valve program. Adjusted operating margin in the quarter expanded 50 bps to 26.9% as the rise in revenues outweighed the increase in operating expenses.
Cash Position
Edwards Lifesciences exited the third quarter with cash and cash equivalents and short-term investments of $1.4 billion, compared with $1.13 billion at the end of the second quarter. Long-term debt in the quarter totaled $1.03 billion, compared with $1.02 billion reported in the previous quarter.
Cash flow from operating activities was $310.8 million in the third quarter, compared with $197.7 million in the previous quarter. Excluding capital spending of $42.3 million, free cash flow was $268.5 million. During the quarter, average diluted shares outstanding were 216.2 million.
2017 Guidance Stays
Edwards Lifesciences has reaffirmed its full-year 2017 sales expectations at the high end of the previously projected range of $3.2-$3.4 billion. The Zacks Consensus Estimate for full-year revenue is $3.40 billion, coinciding with the high end of the guided range. Adjusted EPS expectations have also been reinstated at $3.65-$3.85. The Zacks Consensus Estimate for full-year adjusted EPS stands at $3.78, within the company's guided range.
For the fourth quarter of 2017, the company projects sales (after adjusting for the effect of Germany stocking sales) between $855 million and $895 million. The Zacks Consensus Estimate for revenues is $874.2 million, within the company's projected range. The company estimates adjusted EPS between 84 cents and 94 cents. Meanwhile, the Zacks Consensus Estimate for adjusted EPS is 92 cents, which is also within the company's forecasted range.
Our Take
Edwards Lifesciences exited the third quarter on a disappointing note with both earnings and revenues lagging the respective Zacks Consensus Estimate. The company's business was affected by the recent natural disasters in the Caribbean and the United States. Edwards Lifesciences has principal manufacturing locations for its Critical Care products in Puerto Rico and the Dominican Republic. In Puerto Rico, the company had to discontinue production due to floods which affected the top line to some extent. The company also had to postpone a number of procedures in Houston and Florida. Per management, natural disasters negatively impacted third-quarter sales to the tune of $2 million.
Nevertheless, strong transcatheter valve sales in the domestic market as well as overseas is a major positive. The company also performed well on its gross margin front, which raises optimism.
Management expects to gain traction in the ever-expanding TAVR market, based on increasing preference in favor of transcatheter aortic valve replacement as well as compelling clinical evidence, leading to strong adoption of THV therapy. However, tough competition in the cardiac devices market and reimbursement issues continue to pose challenges.
Zacks Rank & Key Picks
Currently, Edwards Lifesciences has a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Notably, PetMed sports a Zacks Rank #1 (Strong Buy), while Abbott and Intuitive Surgical carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
PetMed reported EPS of 43 cents for the second quarter of fiscal 2018, up 79.2% from the year-ago quarter's 24 cents. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Abbott reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Also, third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year.
Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. This was however partially offset by expenses incurred due to flooding from Hurricane Maria in Puerto Rico and the shutdown of the company's manufacturing plant in Switzerland. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Edwards Lifesciences Corporation Price, Consensus and EPS Surprise Edwards Lifesciences Corporation Price, Consensus and EPS Surprise | Edwards Lifesciences Corporation Quote Segments Details For the third quarter, the company reported Transcatheter Heart Valve Therapy (THVT) sales of $481.2 million, reflecting 17.3% growth over the prior-year quarter. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Edwards Lifesciences Corporation Price, Consensus and EPS Surprise Edwards Lifesciences Corporation Price, Consensus and EPS Surprise | Edwards Lifesciences Corporation Quote Segments Details For the third quarter, the company reported Transcatheter Heart Valve Therapy (THVT) sales of $481.2 million, reflecting 17.3% growth over the prior-year quarter. | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. However, adjusted earnings improved 23.5% year over year, primarily driven by strong sales growth at the company's transcatheter heart valves business. |
33437.0 | 2017-10-25 00:00:00 UTC | Anthem's (ANTM) Q3 Earnings Beat Estimates, Improve Y/Y | ABT | https://www.nasdaq.com/articles/anthems-antm-q3-earnings-beat-estimates-improve-y-y-2017-10-25 | nan | nan | Anthem Inc.'sANTM third-quarter 2017 adjusted net income per share of $2.65 surpassed the Zacks Consensus Estimate of $2.41 by 10%. The bottom line also jumped 8.2% year over year.
Operating revenues of $22.1 billion missed the Zacks Consensus Estimate by 0.1%. The top line, however, grew 4.6% year over year due to premium rate increases as well as higher enrollment in the Medicaid, Medicare, and Local Group insured and self-funded businesses.
Operational Update
Medical enrollment increased 0.9% year over year to 40.3 million members. The rise was primarily recorded by commercial & specialty business as well as fully insured and self-funded Local Group businesses. Medicare and Medicaid enrollment also contributed to the appreciation. This upside was partially offset by a decline in membership in the National Account and Individual businesses.
Total expenses increased nearly 5.1% to $21.3 billion in the reported quarter, mainly due to a 7% rise in benefitexpenses and 3% increase in selling expenses, both on a year-over-year basis.
Anthem's benefit expense ratio of 87% deteriorated 150 basis points (bps) from the prior-year quarter. This was largely due to the one-year waiver of the health insurance tax in 2017. However, the impact of a retroactive revenue adjustment in the Medicaid business and improved medical cost performance in the Individual and Large Group businesses were offsets.
The Selling, General & Administrative (SG&A) expense ratio of 13.6% increased 120 bps from the year-ago quarter. This was due to one-year waiver of the health insurance tax in 2017 and the impact of fixed cost leverage on operating revenue growth. However, the rise was partially offset by increased spend to support growth initiatives during the quarter.
Segment Update
Commercial & Specialty Business
Operating revenues were $10 billion in the third quarter, up 4.1% year over year.
Operating gain totaled $534.6 million, down 16.2% year over year due to increased spend to support growth initiatives during the quarter and the impact of the one-year waiver of the health insurance tax in 2017. The decrease was partially offset by improved medical cost performance in the Local Group and Individual businesses.
Operating margin was 5.3%, down 130 bps year over year.
Government Business
Operating revenues were $12 billion in the third quarter, up 5% from the prior-year quarter.
Operating gain was $457.5 million, down 4.5% year over year. The downside reflected increased spend to support growth initiatives during the quarter and the impact of the one-year waiver of the health insurance tax in 2017. However, the deterioration was partially offset by the timing impact of a retroactive revenue adjustment in the Medicaid business.
Operating margin was 3.8%, declining 40 bps year over year.
Other
Operating revenues were $7.3 million in the third quarter, up 21.7% from the prior-year quarter.
The segment reported an operating loss of $10.1 million, narrower than an operating loss of $38.5 million in the prior-year quarter. The improvement was primarily driven by lower expenses related to the terminated Cigna acquisition.
Operating margin was 4.4%, down 70 bps year over year.
Anthem, Inc. Price, Consensus and EPS Surprise
Anthem, Inc. Price, Consensus and EPS Surprise | Anthem, Inc. Quote
Financial Update
As of Sep 30, 2017, Anthem had cash and cash equivalents of $6.1 billion, up 49.6% from year-end 2016.
As of Sep 30, 2017, its long-term debt declined 4% to $13.8 billion from year-end 2016.
As of Sep 30, 2017, shareholder equity was $25.9 billion, up 3.3% from year-end 2016.
Operating cash flow was $5.5 billion for the first nine months of 2017, reflecting year-over-year growth of 83%.
Share Repurchase and Dividend Update
During the quarter, Anthem repurchased 5.9 million shares of its common stock for $1.1 billion.
During the first nine months of 2017, it repurchased 8.8 million shares of its common stock for $1.6 billion.
As of Sep 30, 2017, it had approximately $2.5 billion of share repurchase authorization remaining.
During the third quarter, Anthem paid a quarterly dividend of 70 cents per share, representing a distribution of cash totaling $181.4 million.
On Oct 24, 2017, the Audit Committee declared third-quarter dividend of 70 cents per share, payable on Dec 21, 2017 to shareholders of record at the close of business on Dec 5, 2017.
Guidance for 2017
Anthem expects adjusted net income in the range of $11.90 to $12.00 per share while in the previous quarter the company expected the same to be more than $11.70.
The company has lowered its guidance for medical enrollment. Medical membership is now expected in the range of 40-40.2 million compared with the previous expectation of 40.2-40.4 million.
Fully insured membership and self-funded membership are likely to be in the band of 15.1-15.2 million and 24.9-25 million, as against the previously guided range of 15.2-15.3 million and 25-25.1 million, respectively.
Operating revenues are projected in the range of $88.5-$89.5 billion, unchanged from the previous guidance.
Benefit expense ratio is expected to be around 86.8% against the earlier projection of 87%, with adjustment of 30 bps.
SG&A ratio is expected to be around 13.8% compared with the earlier projection of 13.6%, with adjustment of 30 bps
Anthem expects operating cash flow to be more than $4 billion compared with the previous projection of more than $3.5 billion.
Zacks Rank and Performance of Other Peers
Anthem presently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Among other players in the Medical sector that have reported their third-quarter earnings so far, Abbott Laboratories. ABT , Johnson & Johnson JNJ and UnitedHealth Group Incorporated UNH beat their respective Zacks Consensus Estimate.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
Anthem, Inc. (ANTM): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT , Johnson & Johnson JNJ and UnitedHealth Group Incorporated UNH beat their respective Zacks Consensus Estimate. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Anthem, Inc. (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. This was due to one-year waiver of the health insurance tax in 2017 and the impact of fixed cost leverage on operating revenue growth. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Anthem, Inc. (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. ABT , Johnson & Johnson JNJ and UnitedHealth Group Incorporated UNH beat their respective Zacks Consensus Estimate. Operating gain totaled $534.6 million, down 16.2% year over year due to increased spend to support growth initiatives during the quarter and the impact of the one-year waiver of the health insurance tax in 2017. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Anthem, Inc. (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. ABT , Johnson & Johnson JNJ and UnitedHealth Group Incorporated UNH beat their respective Zacks Consensus Estimate. Segment Update Commercial & Specialty Business Operating revenues were $10 billion in the third quarter, up 4.1% year over year. | ABT , Johnson & Johnson JNJ and UnitedHealth Group Incorporated UNH beat their respective Zacks Consensus Estimate. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Anthem, Inc. (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. The top line, however, grew 4.6% year over year due to premium rate increases as well as higher enrollment in the Medicaid, Medicare, and Local Group insured and self-funded businesses. |
33438.0 | 2017-10-25 00:00:00 UTC | NuVasive (NUVA) Q3 Earnings Top, Revenues Lag, Guidance Cut | ABT | https://www.nasdaq.com/articles/nuvasive-nuva-q3-earnings-top-revenues-lag-guidance-cut-2017-10-25 | nan | nan | NuVasive, Inc.NUVA reported third-quarter 2017 adjusted earnings per share (EPS) of 52 cents, reflecting a 30% rise from the year-ago quarter. The figure also surpassed the Zacks Consensus Estimate of 48 cents.
Solid revenue growth primarily led to this year-over-year bottom-line improvement.
Including one-time items, the company reported third-quarter 2017 net income per share of 64 cents, a significant improvement from the year-ago figure of 7 cents per share.
Revenues in the reported quarter increased 3.2% year over year to $247.4 million (up 3.4% at constant exchange rate or CER). The figure however, missed the Zacks Consensus Estimate of $255 million.
The above upside in revenues was driven by a robust performance in the international market on strong growth across all geographical regions. In the United States, procedural volumes were sluggish, unable to meet the company's expectations.
NuVasive, Inc. Price, Consensus and EPS Surprise
NuVasive, Inc. Price, Consensus and EPS Surprise | NuVasive, Inc. Quote
However, putting together the impact of hurricanes Harvey and Irma on NuVasive's U.S. results and Maria on the company's international results along with one less selling day, the revenue growth would have been approximately 6% year over year.
In the reported quarter, the company's U.S. Spinal Hardware business registered more than 2% growth backed by introduction of new products. Adjusting the impact of the hurricanes and offsetting the effect of one less selling day, the U.S. Spinal Hardware business approximately grew 5% year-over-year.
The U.S. Surgical Support business declined 12.7% in the third quarter, primarily on continued softness in biologics business. With new competitive products entering the market, the company faces challenges in the field. Also, procedural issues are affecting revenue volumes.
However, the international business recorded 46% growth at CER on continued strong demand of the company's spine technology outside the United States, particularly in the key markets of Italy, Germany and Japan.
In the quarter under review, there was a 10.8% increase in cost of goods sold. Despite that, gross profits inched up 0.8% to $181.8 million. Yet the company reported a 180-basis point (bps) year-over-year contraction in gross margin to 73.5% in the third quarter that includes a 90-bps year-over-year impact from low-margin businesses.
Sales, marketing and administrative expenses went down 4.6% to $125.8 million, while research and development expenses increased 1.6% to $12.7 million.
NuVasive posted adjusted operating income of $43.3 million in the reported quarter, reflecting a 20.1% rise from the year-ago number. Adjusted operating margin expanded 247 bps to 17.5% in the quarter under review.
The company exited third-quarter 2017 with cash, cash equivalents and short-term investments of $62.2 million, down from $130.9 million at the end of the previously reported quarter.
Outlook
In view of the continued impact of Maria in Puerto Rico in the fourth quarter as well as the anticipated lower U.S. procedural volumes, NuVasive has updated its full-year 2017 guidance.
Currently, the company expects to report revenue growth of 7.2%, lower than the earlier expected rate of 11.1% at CER to approximately $1.030 billion (earlier it was $1.065 billion) in 2017. The figure also remains lower than the current Zacks Consensus Estimate of $1.06 billion.
NuVasive also lowered its guidance for full-year 2017 adjusted earnings per share to $1.91 as compared to the previous expectation of $2 per share. The current Zacks Consensus Estimate of $1.99 remains significantly above the company's guidance. Additionally, adjusted operating margin for the year is currently expected at 16.6% compared with the former projection of 17.1%.
Our Take
NuVasive exited the third quarter with better-than-expected earnings and revenue numbers. This quarter, the company's performance was significantly dependent on stellar international growth. The company noted that the reported quarter marked the fourth consecutive one, registering more than 20% growth in international business. However, overall sales in the quarter were grossly impacted by procedural volumes related challenges in the United States and the adverse impact of Harvey and Irma on NuVasive's U.S. results and Maria on the international front.
With chances of the fourth-quarter revenues being affected by Maria in Puerto Rico and due to the anticipated lower U.S. procedural volumes continuing into the same period, NuVasive is pressed to reduce its full-year guidance, which is disappointing.
Zacks Rank & Key Picks
Currently, NuVasive has a Zacks Rank #4 (Sell).
A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Notably, PetMed sports a Zacks Rank #1 (Strong Buy), while both Abbott and Intuitive Surgical carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
PetMed reported EPS of 43 cents for the second quarter of fiscal 2018, up 79.2% from 24 cents, reported in the year-ago quarter. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Abbott reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Also, third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year.
Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
NuVasive, Inc. (NUVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report NuVasive, Inc. (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. However, the international business recorded 46% growth at CER on continued strong demand of the company's spine technology outside the United States, particularly in the key markets of Italy, Germany and Japan. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report NuVasive, Inc. (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . NuVasive, Inc. Price, Consensus and EPS Surprise NuVasive, Inc. Price, Consensus and EPS Surprise | NuVasive, Inc. Quote However, putting together the impact of hurricanes Harvey and Irma on NuVasive's U.S. results and Maria on the company's international results along with one less selling day, the revenue growth would have been approximately 6% year over year. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report NuVasive, Inc. (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . NuVasive, Inc. Price, Consensus and EPS Surprise NuVasive, Inc. Price, Consensus and EPS Surprise | NuVasive, Inc. Quote However, putting together the impact of hurricanes Harvey and Irma on NuVasive's U.S. results and Maria on the company's international results along with one less selling day, the revenue growth would have been approximately 6% year over year. | A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report NuVasive, Inc. (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. Yet the company reported a 180-basis point (bps) year-over-year contraction in gross margin to 73.5% in the third quarter that includes a 90-bps year-over-year impact from low-margin businesses. |
33439.0 | 2017-10-24 00:00:00 UTC | PetMed (PETS) Tops Q2 Earnings & Sales Estimates, Margins Up | ABT | https://www.nasdaq.com/articles/petmed-pets-tops-q2-earnings-sales-estimates-margins-up-2017-10-24 | nan | nan | PetMed Express, Inc. PETS announced earnings per share (EPS) of 43 cents for the second quarter of fiscal 2018, up 79.2% from the year-ago quarter's 24 cents. Also, earnings surpassed the Zacks Consensus Estimate by 43.3%.
The year-over-year rise in earnings was driven by an increase in sales and improved margins.
Net sales in the reported quarter rose 10% year over year to $66.7 million, outpacing the Zacks Consensus Estimate by 5.9%.
PetMed Express, Inc. Price, Consensus and EPS Surprise
PetMed Express, Inc. Price, Consensus and EPS Surprise | PetMed Express, Inc. Quote
Per this leading pet pharmacy in Americas, the upside in sales was a result of increased new orders and reorders during the quarter.
In the reported quarter, reorder sales increased 9.9% to $55.1 million on a year-over-year basis, while new order sales rose 8.8% to $11.6 million.
Average order value was approximately $85 in the quarter compared with $82 in the year-ago quarter. We note that the variation in average order value is mainly driven by a shift of sales to higher priced items.
Per the company, the seasonality in its business is mainly because of the proportion of flea, tick and heartworm medications in the product mix. Spring and summer are considered peak seasons while fall and winter represent off-seasons.
During the quarter under review, PetMed acquired 134,000 new customers, up from 131,000 a year ago. Roughly, 84% of all orders was generated from its website (versus 82% in the prior-year quarter).
Gross margin expanded 548 basis points (bps) year over year to 35.2% in the reported quarter. General and administrative expenses were up 7.5% year over year to $6.2 million. Also, advertising expenses rose 3.3% to $4.5 million. This led to a 5.6% increase in adjusted operating expenses (without depreciation expense), which amounted to $10.7 million. Nevertheless, adjusted operating margin in the quarter rose 610 bps to 19.1% from the year-ago quarter.
PetMed exited the fiscal second quarter with cash and cash equivalents of $68.4 million compared with $68.5 million at the end of the first-quarter fiscal 2017. The company also announced a quarterly dividend of 20 cents per share, payable to shareholders of record as of Nov 17, 2017.
Our Take
PetMed successfully delivered yet another quarter of solid results. In the fiscal second quarter, the company once again topped the Zacks Consensus Estimate on both revenues and earnings. We are also encouraged to note the stellar increase in reorder and new order sales in the quarter.
The company is also striving to implement several strategies to revitalize its top line. These include increased focus on advertising efficiency to boost new order sales and shifting sales to higher margin items, while also expanding product offerings.
PetMed currently offers a wide range of products catering to dogs, cats and horses besides working on upgrading its existing portfolio.
Zacks Rank & Key Picks
PetMed currently has a Zacks Rank #3(Hold). A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO , all three carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term expected earnings growth rate of 10.7%. The stock rallied roughly 39.5% over the last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock surged 48.2% last year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock gained 31.4% last year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO , all three carrying a Zacks Rank #2 (Buy). Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. We note that the variation in average order value is mainly driven by a shift of sales to higher priced items. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO , all three carrying a Zacks Rank #2 (Buy). PetMed Express, Inc. Price, Consensus and EPS Surprise PetMed Express, Inc. Price, Consensus and EPS Surprise | PetMed Express, Inc. Quote Per this leading pet pharmacy in Americas, the upside in sales was a result of increased new orders and reorders during the quarter. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO , all three carrying a Zacks Rank #2 (Buy). Net sales in the reported quarter rose 10% year over year to $66.7 million, outpacing the Zacks Consensus Estimate by 5.9%. | A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO , all three carrying a Zacks Rank #2 (Buy). Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. Net sales in the reported quarter rose 10% year over year to $66.7 million, outpacing the Zacks Consensus Estimate by 5.9%. |
33440.0 | 2017-10-24 00:00:00 UTC | Centene (CNC) Tops Q3 Earnings & Revenues, Raises '17 View | ABT | https://www.nasdaq.com/articles/centene-cnc-tops-q3-earnings-revenues-raises-17-view-2017-10-24 | nan | nan | Centene Inc.CNC reported third-quarter 2017 adjusted net income per share of $1.35, which beat the Zacks Consensus Estimate by 8%. Earnings also improved 20.5% year over year, primarily on the back of higher revenues.
Operational Update
For the quarter, total revenues grew 10% to $11.9 billion year over year, primarily driven by growth in the Health Insurance Marketplace business in 2017 and expansions and new programs in many states in 2016 and 2017.This was partially offset by the moratorium of the Health Insurer Fee in 2017 and lower membership in the commercial business in California. Revenues surpassed the Zacks Consensus Estimate of $11.8 billion by 1%.
At the end of the quarter, managed care membership of 12.3 million reflected an increase of 8% from the third quarter of 2016.
Health Benefit Ratio (HBR) for the quarter was 88% compared with 87% in the prior-year quarter. This improvement of 100 basis points (bps) was a result of new and expanded health plans with higher HBR, an increase in higher acuity members and a premium rate reduction for California Medicaid Expansion effective Jul 1, 2017.
In the third quarter, adjusted selling, general and administrative expenses ratio was 8.9%, down 20 bps year over year. This improvement reflects the leveraging of expenses over higher revenues in 2017. Total operating expenses of $11.5 billion increased 9.5% from the prior-year quarter.
Centene Corporation Price, Consensus and EPS Surprise
Centene Corporation Price, Consensus and EPS Surprise | Centene Corporation Quote
Financial Update
As of Sep 30, 2017, Centene had cash and cash equivalents of $4.3 billion, up 8.9% from 2016 year end.
Total assets of $22 billion grew 8.9% from 2016 year end.
As of Sep 30, 2017, Centene's long-term debt totaled $4.7 billion, up 1.4% from 2016 year end.
For the first nine months of 2017, cash inflow from operations was $1,039 million compared with $259 million in the prior-year period.
2017 Guidance
Centene expects adjusted earnings per diluted share to be in the range of $4.86-$5.04 against the previously guided range of $4.70-$5.06.
Total revenues are expected to be in the range of $47.4-48.2 billion compared with the earlier guidance of $46.4-$47.2 billion.
HBR is expected in the range of 87-87.4%, unchanged from the previous guidance.
Adjusted Selling, General & Administrative expense ratio is expected in the range of 9.3-9.7%, unchanged from the previous guidance.
Diluted shares outstanding is expected be between 176.3 million and 177.3 million.
Zacks Rank and Performance of Other Peers
Centene currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Among other players in the Medical sector that have reported their third-quarter earnings so far, Abbott Laboratories. ABT , Johnson & Johnson. JNJ and UnitedHealth Group Incorporated UNH beat their respective Zacks Consensus Estimate.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
Centene Corporation (CNC): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT , Johnson & Johnson. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. Centene Inc.CNC reported third-quarter 2017 adjusted net income per share of $1.35, which beat the Zacks Consensus Estimate by 8%. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. ABT , Johnson & Johnson. Operational Update For the quarter, total revenues grew 10% to $11.9 billion year over year, primarily driven by growth in the Health Insurance Marketplace business in 2017 and expansions and new programs in many states in 2016 and 2017.This was partially offset by the moratorium of the Health Insurer Fee in 2017 and lower membership in the commercial business in California. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. ABT , Johnson & Johnson. Operational Update For the quarter, total revenues grew 10% to $11.9 billion year over year, primarily driven by growth in the Health Insurance Marketplace business in 2017 and expansions and new programs in many states in 2016 and 2017.This was partially offset by the moratorium of the Health Insurer Fee in 2017 and lower membership in the commercial business in California. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. ABT , Johnson & Johnson. Earnings also improved 20.5% year over year, primarily on the back of higher revenues. |
33441.0 | 2017-10-23 00:00:00 UTC | Health Care Sector Update for 10/23/2017: JNJ, PFE, ABT, MRK, AMGN, TIG, AZN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-10232017-jnj-pfe-abt-mrk-amgn-tig-azn-2017-10-23 | nan | nan | Top Health Care Stocks:
JNJ: +0.5%
PFE: -0.1%
ABT: +0.5%
MRK: +0.3%
AMGN: flat
Health care shares were mostly higher in pre-market trade Monday.
In sector news, Johnson & Johnson ( JNJ ) shares were up 0.4% after it said late Friday that the US Food and Drug Administration has approved Simponi Aria for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis based on pivotal phase 3 studies involving more than 600 patients that demonstrated the significant efficacy of the drug over placebo. Simponi Aria was previously approved for the treatment of moderately to severely active rheumatoid arthritis.
In other sector news,
(+) TIG (+1.3%) Gets FDA Orphan Designation for bowel disease drug
(-) AZN (-0.4%) Gets FDA approval for type-2 diabetes injectable medicine, Bydureon BCise
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In sector news, Johnson & Johnson ( JNJ ) shares were up 0.4% after it said late Friday that the US Food and Drug Administration has approved Simponi Aria for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis based on pivotal phase 3 studies involving more than 600 patients that demonstrated the significant efficacy of the drug over placebo. Simponi Aria was previously approved for the treatment of moderately to severely active rheumatoid arthritis. In other sector news, (+) TIG (+1.3%) Gets FDA Orphan Designation for bowel disease drug (-) AZN (-0.4%) Gets FDA approval for type-2 diabetes injectable medicine, Bydureon BCise The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In sector news, Johnson & Johnson ( JNJ ) shares were up 0.4% after it said late Friday that the US Food and Drug Administration has approved Simponi Aria for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis based on pivotal phase 3 studies involving more than 600 patients that demonstrated the significant efficacy of the drug over placebo. In other sector news, (+) TIG (+1.3%) Gets FDA Orphan Designation for bowel disease drug (-) AZN (-0.4%) Gets FDA approval for type-2 diabetes injectable medicine, Bydureon BCise The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In sector news, Johnson & Johnson ( JNJ ) shares were up 0.4% after it said late Friday that the US Food and Drug Administration has approved Simponi Aria for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis based on pivotal phase 3 studies involving more than 600 patients that demonstrated the significant efficacy of the drug over placebo. In other sector news, (+) TIG (+1.3%) Gets FDA Orphan Designation for bowel disease drug (-) AZN (-0.4%) Gets FDA approval for type-2 diabetes injectable medicine, Bydureon BCise The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Unauthorized reproduction is strictly prohibited. | Top Health Care Stocks: AMGN: flat Health care shares were mostly higher in pre-market trade Monday. In sector news, Johnson & Johnson ( JNJ ) shares were up 0.4% after it said late Friday that the US Food and Drug Administration has approved Simponi Aria for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis based on pivotal phase 3 studies involving more than 600 patients that demonstrated the significant efficacy of the drug over placebo. |
33442.0 | 2017-10-20 00:00:00 UTC | Notable ETF Inflow Detected - ITOT, HON, MDT, ABT | ABT | https://www.nasdaq.com/articles/notable-etf-inflow-detected-itot-hon-mdt-abt-2017-10-20 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $76.2 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 200,250,000.0 to 201,550,000.0). Among the largest underlying components of ITOT, in trading today Honeywell International Inc (Symbol: HON) is up about 0.2%, Medtronic PLC (Symbol: MDT) is off about 0.1%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.2%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average:
Looking at the chart above, ITOT's low point in its 52 week range is $47.42 per share, with $58.89 as the 52 week high point - that compares with a last trade of $58.82. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of ITOT, in trading today Honeywell International Inc (Symbol: HON) is up about 0.2%, Medtronic PLC (Symbol: MDT) is off about 0.1%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.2%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $47.42 per share, with $58.89 as the 52 week high point - that compares with a last trade of $58.82. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of ITOT, in trading today Honeywell International Inc (Symbol: HON) is up about 0.2%, Medtronic PLC (Symbol: MDT) is off about 0.1%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.2%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $47.42 per share, with $58.89 as the 52 week high point - that compares with a last trade of $58.82. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of ITOT, in trading today Honeywell International Inc (Symbol: HON) is up about 0.2%, Medtronic PLC (Symbol: MDT) is off about 0.1%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $76.2 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 200,250,000.0 to 201,550,000.0). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $47.42 per share, with $58.89 as the 52 week high point - that compares with a last trade of $58.82. | Among the largest underlying components of ITOT, in trading today Honeywell International Inc (Symbol: HON) is up about 0.2%, Medtronic PLC (Symbol: MDT) is off about 0.1%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $76.2 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 200,250,000.0 to 201,550,000.0). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $47.42 per share, with $58.89 as the 52 week high point - that compares with a last trade of $58.82. |
33443.0 | 2017-10-20 00:00:00 UTC | Varian Medical (VAR) Q4 Earnings: Is a Surprise in Store? | ABT | https://www.nasdaq.com/articles/varian-medical-var-q4-earnings%3A-is-a-surprise-in-store-2017-10-20 | nan | nan | Varian Medical Systems Inc.VAR is scheduled to report fourth-quarter fiscal 2017 earnings on Oct 25, after the market closes .
Last quarter, the company delivered earnings of $1.04 per share, which beat the Zacks Consensus Estimate of 95 cents. However, adjusted earnings declined from $1.22 in the year-ago period.
Factors at Play
We are upbeat about Varian Medical's oncology business that accounted for around 95% of the company's total revenue in fourth-quarter 2017. Notably, the company has been addressing both the tier 1 and mid-tier markets through its Edge, Truebeam and VitalBeam products and has also been winning international contracts in the oncology space. For the fourth quarter of 2017, Varian expects adjusted earnings per share in the range of $1.15-$1.23. Revenues are expected to increase about 3% on a year-over-year basis.
The company recently launched its FDA-approved product Halcyon, to strengthen foothold in the oncology business. Varian Medical also signed an agreement with Vijametech and UPMC to establish radiation oncology centers in Vietnam. We are also upbeat about Varian's prospects internationally, where it primarily banks on proton therapy as an advanced treatment option for cancer patients. In this regard, we note that Varian Medical recently received Shonin approval in Japan to market the ProBeam system for proton therapy.
Varian Medical recently entered into two international agreements concerning its Proton therapy platform. Bangkok-based King Chulalongkorn Memorial Hospital has selected its ProBeam Compact single-room proton therapy system for cancer treatment in Thailand along with Delray Medical Center in Florida.
We believe Western Europe, China and Africa present significant top-line growth opportunities in the near term. The company is opening offices in Africa and the Middle East, which depicts that it is aware of opportunities in the region. Moreover, Varian Medical's strong product pipeline is a key catalyst.
Nevertheless, increasing local competition is a primary headwind. Unfavorable foreign currency might affect the company's revenues in the to-be-reported quarter. Also, the company is exposed to seasonal demand fluctuations and higher operating expenses pertaining to increased investments targeted toward growth acceleration in geographical expansion and portfolio expansion.
Earnings Whispers
Our proven model does not conclusively show earnings beat for Varian Medical this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: Varian Medical currently has an Earnings ESP of 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at $1.19. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Varian Medical carries a Zacks Rank #3 which increases the predictive power of ESP. However, the company's 0.00% ESP makes surprise prediction difficult.
Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revision.
Varian Medical Systems, Inc. Price and EPS Surprise
Varian Medical Systems, Inc. Price and EPS Surprise | Varian Medical Systems, Inc. Quote
Stocks to Consider
Here are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter:
Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
Align Technology, Inc ALGN has an Earnings ESP of +2.06% and carries a Zacks Rank #3.
Henry Schein, Inc HSIC has an Earnings ESP of +0.33% and carries a Zacks Rank #3.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Varian Medical Systems, Inc. Price and EPS Surprise Varian Medical Systems, Inc. Price and EPS Surprise | Varian Medical Systems, Inc. Quote Stocks to Consider Here are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter: Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, the company has been addressing both the tier 1 and mid-tier markets through its Edge, Truebeam and VitalBeam products and has also been winning international contracts in the oncology space. | Varian Medical Systems, Inc. Price and EPS Surprise Varian Medical Systems, Inc. Price and EPS Surprise | Varian Medical Systems, Inc. Quote Stocks to Consider Here are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter: Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Rank: Varian Medical carries a Zacks Rank #3 which increases the predictive power of ESP. | Varian Medical Systems, Inc. Price and EPS Surprise Varian Medical Systems, Inc. Price and EPS Surprise | Varian Medical Systems, Inc. Quote Stocks to Consider Here are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter: Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Rank: Varian Medical carries a Zacks Rank #3 which increases the predictive power of ESP. | Varian Medical Systems, Inc. Price and EPS Surprise Varian Medical Systems, Inc. Price and EPS Surprise | Varian Medical Systems, Inc. Quote Stocks to Consider Here are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter: Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks ESP: Varian Medical currently has an Earnings ESP of 0.00%. |
33444.0 | 2017-10-20 00:00:00 UTC | Baxter International (BAX) Q3 Earnings: What's in Store? | ABT | https://www.nasdaq.com/articles/baxter-international-bax-q3-earnings%3A-whats-in-store-2017-10-20 | nan | nan | Baxter International Inc.BAX is scheduled to report third-quarter 2017 earnings on Oct 25, before the opening bell.
In the last reported quarter, the company delivered a positive earnings surprise of 10.5%, taking the four-quarter average to 15.3%.
Let's see how things are shaping up prior to this release.
Factors at Play
We are encouraged by the company's guidance for third-quarter 2017 and full-year 2017. For the third quarter, Baxter anticipates sales growth of about 4% at constant currency. Adjusted earnings per share are forecasted in the range of 58-60 cents versus the year-ago figure of 56 cents. Also, for full-year 2017, the company projects earnings in the band of $2.34 to $2.40 per share (from continuing operations, before special items), up from full-year 2016 earnings of $1.95. Of late, Baxter International has accelerated pace of acquisitions and strategic collaborations to enhance its product portfolio, thereby opening up significant long-term opportunities. Also, several recent FDA approvals are likely to drive growth in the yet-to-be-reported third quarter of 2017.
The company's estimate revision trend is also encouraging. For the current year, Baxter International witnessed two upward estimate revisions with no movement in the opposite direction over the last one month.
However, lower cyclophosphamide sales pose a threat to the company's Integrated Pharmacy Solutions franchise. For the third quarter, a decline in cyclophosphamide sales is expected to impact top line by low-single digits. Also, the foray of group purchasing organizations (GPOs) in the United States intensifies competition for the company.
Earnings Whispers
Our quantitative model doesn't point to an earnings beat this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: The Earnings ESP for Baxter International is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 59 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Baxter International carries a Zacks Rank #3, which increases the predictive power of ESP. However, the company's ESP of 0.00% makes surprise prediction difficult.
We caution against stocks with a Zacks Ranks #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Baxter International Inc. Price and EPS Surprise
Baxter International Inc. Price and EPS Surprise | Baxter International Inc. Quote
Stocks to Consider
Here are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter:
Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
Align Technology, Inc ALGN has an Earnings ESP of +2.06% and carries a Zacks Rank #3.
Henry Schein, Inc HSIC has an Earnings ESP of +0.33% and carries a Zacks Rank #3.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Baxter International Inc. (BAX): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Baxter International Inc. Price and EPS Surprise Baxter International Inc. Price and EPS Surprise | Baxter International Inc. Quote Stocks to Consider Here are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter: Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Of late, Baxter International has accelerated pace of acquisitions and strategic collaborations to enhance its product portfolio, thereby opening up significant long-term opportunities. | Baxter International Inc. Price and EPS Surprise Baxter International Inc. Price and EPS Surprise | Baxter International Inc. Quote Stocks to Consider Here are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter: Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Baxter International Inc. Price and EPS Surprise Baxter International Inc. Price and EPS Surprise | Baxter International Inc. Quote Stocks to Consider Here are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter: Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Rank: Baxter International carries a Zacks Rank #3, which increases the predictive power of ESP. | Baxter International Inc. Price and EPS Surprise Baxter International Inc. Price and EPS Surprise | Baxter International Inc. Quote Stocks to Consider Here are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter: Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks ESP: The Earnings ESP for Baxter International is 0.00%. |
33445.0 | 2017-10-19 00:00:00 UTC | Company News For Oct 19, 2017 | ABT | https://www.nasdaq.com/articles/company-news-for-oct-19-2017-2017-10-19 | nan | nan | Shares of Fogo De Chao IncFOGO tanked 7.5% after the company expects adjusted earnings of 77 cents to 80 cents a share for the year, lower than analysts' expectations of 91 cents
Shares of Abbott LaboratoriesABT gained 1.3% after the company reported third quarter earnings per share of 66 cents, ahead of the Zacks Consensus Estimate by a penny
Allergan plc's AGN shares slumped 5.3% after a Texas district court judge ruled against the company in a patent lawsuit
Shares of Electronic Arts Inc.EA declined 2.4% on news that the company is closing the unit that was working on a coming "Star Wars" videogame
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Allergan PLC. (AGN): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Fogo de Chao, Inc. (FOGO): Free Stock Analysis Report
Electronic Arts Inc. (EA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of Fogo De Chao IncFOGO tanked 7.5% after the company expects adjusted earnings of 77 cents to 80 cents a share for the year, lower than analysts' expectations of 91 cents Shares of Abbott LaboratoriesABT gained 1.3% after the company reported third quarter earnings per share of 66 cents, ahead of the Zacks Consensus Estimate by a penny Allergan plc's AGN shares slumped 5.3% after a Texas district court judge ruled against the company in a patent lawsuit Shares of Electronic Arts Inc.EA declined 2.4% on news that the company is closing the unit that was working on a coming "Star Wars" videogame Want the latest recommendations from Zacks Investment Research? (AGN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Fogo de Chao, Inc. (FOGO): Free Stock Analysis Report Electronic Arts Inc. (EA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of Fogo De Chao IncFOGO tanked 7.5% after the company expects adjusted earnings of 77 cents to 80 cents a share for the year, lower than analysts' expectations of 91 cents Shares of Abbott LaboratoriesABT gained 1.3% after the company reported third quarter earnings per share of 66 cents, ahead of the Zacks Consensus Estimate by a penny Allergan plc's AGN shares slumped 5.3% after a Texas district court judge ruled against the company in a patent lawsuit Shares of Electronic Arts Inc.EA declined 2.4% on news that the company is closing the unit that was working on a coming "Star Wars" videogame Want the latest recommendations from Zacks Investment Research? (AGN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Fogo de Chao, Inc. (FOGO): Free Stock Analysis Report Electronic Arts Inc. (EA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of Fogo De Chao IncFOGO tanked 7.5% after the company expects adjusted earnings of 77 cents to 80 cents a share for the year, lower than analysts' expectations of 91 cents Shares of Abbott LaboratoriesABT gained 1.3% after the company reported third quarter earnings per share of 66 cents, ahead of the Zacks Consensus Estimate by a penny Allergan plc's AGN shares slumped 5.3% after a Texas district court judge ruled against the company in a patent lawsuit Shares of Electronic Arts Inc.EA declined 2.4% on news that the company is closing the unit that was working on a coming "Star Wars" videogame Want the latest recommendations from Zacks Investment Research? (AGN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Fogo de Chao, Inc. (FOGO): Free Stock Analysis Report Electronic Arts Inc. (EA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of Fogo De Chao IncFOGO tanked 7.5% after the company expects adjusted earnings of 77 cents to 80 cents a share for the year, lower than analysts' expectations of 91 cents Shares of Abbott LaboratoriesABT gained 1.3% after the company reported third quarter earnings per share of 66 cents, ahead of the Zacks Consensus Estimate by a penny Allergan plc's AGN shares slumped 5.3% after a Texas district court judge ruled against the company in a patent lawsuit Shares of Electronic Arts Inc.EA declined 2.4% on news that the company is closing the unit that was working on a coming "Star Wars" videogame Want the latest recommendations from Zacks Investment Research? (AGN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Fogo de Chao, Inc. (FOGO): Free Stock Analysis Report Electronic Arts Inc. (EA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33446.0 | 2017-10-19 00:00:00 UTC | Varian Medical (VAR) Initiates Halcyon Treatment in Europe | ABT | https://www.nasdaq.com/articles/varian-medical-var-initiates-halcyon-treatment-in-europe-2017-10-19 | nan | nan | Strengthening its focus on image-guided volumetric intensity modulated radiotherapy to cancer patients, Varian Medical Systems Inc.VAR announced that it has initiated treatment with its latest Halcyon radiotherapy treatment system in Europe. Notably, treatment was provided to an 80-year-old male with head and neck cancer at Belgium-based University Hospitals Leuven (UZ Leuven) just two months after the hospital had ordered the new system.
The Halcyon radiotherapy treatment system has been designed to offer cost-effective cancer care worldwide. The platform received both 510(k) clearance and CE Mark from the European directive, allowing Varian to start selling the system in the United States and Europe. The company unveiled the Halcyon radiotherapy treatment system at the ASTRO conference in Vienna in the third quarter.
Notably, treatment using the Halcyon platform was cost effective and of short duration. The system has been ergonomically designed to provide a user-friendly platform for clinical staff and patients.
Halcyon Fortifies Varian's Global Foothold
Varian has a long-term goal to treat 6 million cancer patients every year with its highly exclusive radiotherapy treatments. By the end of the third quarter, management at Varian announced that Halcyon has received orders from 10 countries. In North America, Varian struck a strategic deal with PetCure to deliver six Halcyon units for a veterinary oncology network. Per management, regulatory clearances from China and Japan should follow next year.
Furthermore, Varian received orders for two Halcyon systems from the Icon Group in Australia. The company booked several orders from countries like India, Morocco, Romania, Russia, Turkey and the U.K.
Market Prospects
Varian has been taking initiatives to gain customers for its broad spectrum of products, especially targeting the emerging markets. Strong revenue opportunity from its Oncology and Imaging Component products, growing adoption of Proton Therapy, strong overseas presence, particularly in emerging countries, and new partnership deals are positives for Varian. Data from Markets And Markets reveals that the global radiotherapy market is projected to reach a worth of $9.47 billion by 2022, at a CAGR of 6.8%.
Other Companies Eyeing Emerging Markets
The ongoing political uncertainty in the United States along with the deteriorating economic condition in Europe automatically shifted focus of several MedTech players to emerging geographies like China, India, Latin America and others.
Johnson & Johnson JNJ had set up manufacturing and R&D centers in Brazil, China and India. It has been doing business in China for nearly 30 years and is expanding further on the back of the Synthes acquisition.
Thermo Fisher TMO is also leaving no stone unturned to expand its presence in emerging markets. The company garnered 20% of total revenue from the high-growth Asia Pacific and emerging markets in 2016, up from 10% in 2006.
Abbott ABT continues to lead the emerging market investment trend with about 50% of sales from this region. In recent quarters, sales in key emerging markets were up double digits, driven by strong growth in countries like Colombia, Mexico, Peru and Argentina.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ABT continues to lead the emerging market investment trend with about 50% of sales from this region. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. The platform received both 510(k) clearance and CE Mark from the European directive, allowing Varian to start selling the system in the United States and Europe. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT continues to lead the emerging market investment trend with about 50% of sales from this region. Strengthening its focus on image-guided volumetric intensity modulated radiotherapy to cancer patients, Varian Medical Systems Inc.VAR announced that it has initiated treatment with its latest Halcyon radiotherapy treatment system in Europe. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT continues to lead the emerging market investment trend with about 50% of sales from this region. Strengthening its focus on image-guided volumetric intensity modulated radiotherapy to cancer patients, Varian Medical Systems Inc.VAR announced that it has initiated treatment with its latest Halcyon radiotherapy treatment system in Europe. | Abbott ABT continues to lead the emerging market investment trend with about 50% of sales from this region. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Strengthening its focus on image-guided volumetric intensity modulated radiotherapy to cancer patients, Varian Medical Systems Inc.VAR announced that it has initiated treatment with its latest Halcyon radiotherapy treatment system in Europe. |
33447.0 | 2017-10-19 00:00:00 UTC | 2 Great Stocks For Retirees | ABT | https://www.nasdaq.com/articles/2-great-stocks-retirees-2017-10-19 | nan | nan | Just because you've retired doesn't mean you want to spend all your new-found free time fretting over risky stocks. You'll want to limit your focus to companies that are already generating steadily growing profits that they can return to you.
Adults over 65 years old are the fastest growing age group in developed nations across the globe, and they'll be spending their hard-earned retirement incomes on products from AbbVie (NYSE: ABBV) , and Pfizer (NYSE: PFE) . Read on to see how this demographic trend makes these great stocks for retirement portfolios.
AbbVie Inc.: A sense of Humira
This drugmaker descended from healthcare conglomerate Abbott , which recently increased its dividend for the 40th year in a row. Since spinning off from Abbott in 2013, AbbVie continues to serve up annual dividend increases. The company has already boosted the payout by 60% since its inception and will probably announce the next bump soon.
At recent prices, AbbVie shares offer a decent 2.8% yield that retirees can reasonably expect to rise in the months ahead. Last October AbbVie announced a 12.3% boost to quarterly payments. Despite the hefty bump, bottom-line growth has been strong enough to lower the company's payout ratio to just 59.2% from 62.3% at the beginning of the year.
The largest factor driving earnings growth for AbbVie is its rheumatoid arthritis drug, Humira. Since its launch in 2002, the anti-inflammatory injection has become the world's best-selling drug. Thanks to a recent deal that will delay U.S. entry of Amgen 's biosimilar version of Humira until 2023, global sales will continue to rise from an annualized $17.9 billion based on second-quarter sales to more than $20 billion by the time competition begins diminishing this blockbuster drug's pricing power.
Getting a better sense of the direction Humira sales will take isn't the only thing going well for AbbVie. By the time the revenue stream responsible for 63% of the company's top line begins drying up, growing sales of more recently launched drugs, and some still in development, could more than offset the losses. For example, blood cancer blockbuster Imbruvica became the first chemotherapy-free treatment option for newly diagnosed patients with the most common form of leukemia last March. These patients tend to stay on therapy for a long time, which helped drive second-quarter sales of the drug 44% higher than the same period last year to an annualized $2.4 billion.
AbbVie's share of annual Imbruvica sales is expected to peak above $7 billion. That will go a long way toward filling Humira's enormous shoes, along with potential blockbusters in late-stage development. A recent report ranked AbbVie's pipeline as the industry's third most valuable, projecting $20.4 billion in sales between now and 2022.
Pfizer Inc.: A two for one deal?
AbbVie isn't the only big pharma positioned to treat retirees to years of growing dividends. Pfizer's more recently launched drugs are driving profits higher, and a potential spin-off of its consumer healthcare business could also be a big win for investors. Since splitting from Pfizer in 2013, shares of animal health focused Zoetis have more than doubled.
At the moment, Pfizer stock offers a juicy 3.6% dividend that ate up just 56.5% of free cash flow over the past year. The company has increased the payout each year since 2009, and surging sales of recently launched drugs could keep the party going well into your golden years. At the moment, sales of three blockbuster drugs, Ibrance, Eliquis, and Xeljanz comprise just 14% of total revenue, but they're quickly gaining popularity. Year-over-year sales of all three rose by 50% or more in the second quarter, to a combined run rate of $7.2 billion.
Few big pharmaceutical companies spend as much on research and development, and those investments are starting to pay off. Pfizer's pipeline boasts 12 programs in late-stage development plus six biosimilars that reference some of today's best-selling drugs.
Protecting your principal
Both of these big pharma stocks boast well-funded dividend programs that should provide a steadily growing income stream no matter what turns the broader economy takes, but what about your principal investment?
Perhaps the best way to protect your principal from general economic downturns, and company-specific rough patches, is to wait for a nice price. Luckily, neither of these big pharma stocks are about to test your patience. AbbVie has gained about 47% this year, but still trades at just 16.7 times this year's earnings expectations.
The average stock in the benchmark S&P 500 index is currently going for 19.4 times estimates, which also makes Pfizer seem cheap by comparison. You can still scoop up shares of the pharma giant for just 14.1 times estimates. There are no guarantees these multiples will hold, but altogether these two look like they would make great additions to most retirement portfolios right now.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By the time the revenue stream responsible for 63% of the company's top line begins drying up, growing sales of more recently launched drugs, and some still in development, could more than offset the losses. These patients tend to stay on therapy for a long time, which helped drive second-quarter sales of the drug 44% higher than the same period last year to an annualized $2.4 billion. Pfizer's more recently launched drugs are driving profits higher, and a potential spin-off of its consumer healthcare business could also be a big win for investors. | Thanks to a recent deal that will delay U.S. entry of Amgen 's biosimilar version of Humira until 2023, global sales will continue to rise from an annualized $17.9 billion based on second-quarter sales to more than $20 billion by the time competition begins diminishing this blockbuster drug's pricing power. AbbVie isn't the only big pharma positioned to treat retirees to years of growing dividends. Pfizer's more recently launched drugs are driving profits higher, and a potential spin-off of its consumer healthcare business could also be a big win for investors. | Thanks to a recent deal that will delay U.S. entry of Amgen 's biosimilar version of Humira until 2023, global sales will continue to rise from an annualized $17.9 billion based on second-quarter sales to more than $20 billion by the time competition begins diminishing this blockbuster drug's pricing power. By the time the revenue stream responsible for 63% of the company's top line begins drying up, growing sales of more recently launched drugs, and some still in development, could more than offset the losses. The company has increased the payout each year since 2009, and surging sales of recently launched drugs could keep the party going well into your golden years. | Just because you've retired doesn't mean you want to spend all your new-found free time fretting over risky stocks. AbbVie's share of annual Imbruvica sales is expected to peak above $7 billion. AbbVie isn't the only big pharma positioned to treat retirees to years of growing dividends. |
33448.0 | 2017-10-19 00:00:00 UTC | Abbott Laboratories Q3 2017 Earnings Conference Call Transcript (ABT) | ABT | https://www.nasdaq.com/articles/abbott-laboratories-q3-2017-earnings-conference-call-transcript-abt-2017-10-19 | nan | nan | Abbott Laboratories (NYSE: ABT)
Q3 2017 Earnings Conference Call
Oct. 18, 2017, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning, and thank you for standing by. Welcome to Abbott's third quarter 2017 earnings conference call. All participants will be able to listen only until the question and answer portion of this call. During the question and answer session, you will be able to ask your question by pressing the *1 keys on your touchtone phone. Should you become disconnected throughout this conference call, please redial the number provided to you and reference the Abbott earnings call. This call is being recorded by Abbott. With the exception of any participant's questions asked during the question and answer session, the entire call, including the question and answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's express written permission. I would now like to introduce Mr. Scott Leinenweber, Vice President, Investor Relations.
Scott Leinenweber -- Vice President of Investor Relations
Good morning, and thank you for joining us. With me today are Miles White, Chairman of the Board and Chief Executive Officer; and Brian Yoor, Executive Vice President of Finance, and Chief Financial Officer. Miles will provide opening remarks, and Brian will discuss our performance outlook in our detail. Following our comments, Miles, Brian, and I will take your questions.
Before we get started, some statements today may be forward-looking for the purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2017. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological, and other factors that may affect Abbott's operations are discussed in Item 1A, Respectors to our Annual Report, and Securities and Exchange Commission Form 10K for the year ending December 31, 2016. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Please note that third quarter financial results and guidance provided on the call today for sales, EPS , and line items of the P&L will be for continuing operations only.
On today's conference call, as in the past, non-GAAP financial measures will be used to help investors understand Abbott's ongoing business performance. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings release and regulatory findings from today, which are available on our website at Abbott.com. Unless otherwise noted, our commentary on sales growth refers to comparable operational sales growth, which adjusts the 2016 basis of comparison to include results for St. Jude Medical, and to exclude the impact of exchange, as well as current and historical results for Abbott's medical optics and St. Jude's vascular closure businesses, which were divested during the first quarter of 2017.
Comparable growth also reflects a reduction in St. Jude's historic sales related to administrative fees paid to Group Purchasing Organization in order to conform with Abbott's presentation. Earlier this month, Abbott concluded its acquisition of Alere. Given there are only three months remaining in the year, I'd note that comparable sales growth guidance for the fourth quarter and full year 2017 do not include Alere, which is consistent with the guidance methodology we've utilized since the beginning of the year. With that, I will now turn the call to Miles.
Miles White -- Chairman of the Board and Chief Executive Officer
Okay. Thanks, Scott, and good morning. Today, we report an ongoing earnings per share of 66 cents at the high end of our guidance range and reflecting double digit growth. We also raised the midpoint of our 2017 adjusted earnings per share guidance and narrowed the range to 248 to 250, which is at the upper end of the range we set at the beginning of the year. Sales increased more than 5.5% in the quarter, led by strong performance in established pharmaceuticals and medical devices. At the beginning of the year, I commented that we were entering a period where innovation and new product launches would enhance our competitiveness and fortify our leading market positions. We're seeing this play out through the first three quarters of the year, with significant growth contributions from several recently launched products and important advancements across our innovative new product pipeline.
I'll highlight several examples as I summarize our third quarter results in more detail before turning the call over to Brian. I'll start with diagnostics, where we achieved sales growth of more than five% in the quarter, which was led by strong international performance. During the quarter, we continued the initial European launch of our new Alinity family of systems, which now includes five recently launched instruments in the areas of immuno assay , clinical chemistry, blood screening, hematology, and point of care testing. As we've stated previously, our primary focus during this initial launch period has been to convert a number of long-tenured Abbott customers to Alinity, and we continue to make progress on that front across all the major European countries. We continue to anticipate CE mark for our Alinity molecular diagnostic system in the coming months, and expect to begin the Alinity launch of the Alinity instruments in the U.S. in 2018.
During the quarter, we also announced our acquisition of Alere, establishing Abbott as the global leader in point of care testing. This combination creates the broadest point of care testing portfolio in the world, with leading positions across cardio, metabolic, infectious disease, and toxicology testing.
In nutrition, sales grew very modestly in the quarter. In pediatric nutrition, continued above market performance in the U.S. was led by recently launched infant formula products and strong growth of our PediaSure toddler brand. Internationally, we've seen some market stabilization in China, and we prepared for pending new food safety regulations that are set to go into effect on January 1 st of next year. Outside of China, as expected, we continue to see soft market conditions across a few international markets, and in adult nutrition, international growth of 5.5% was led by our market leading Ensure and Glucerna brands.
In established pharmaceuticals, or EPD, double digit sales growth was led by strong performance across our key emerging markets, including double digit growth in Brazil, Russia, India, and China. As expected, as contemplated in our third quarter guidance, we saw a modest level of channel restocking in India after the implementation of a new tax system in that country on July 1 st , which contributed approximately two-and-a-half percentage points of growth in the quarter. Excluding this impact, total EPD sales would have grown around 12% in the quarter. With our unique geographic footprint and business model, as well as our scale and leading positions in several geographies, EPD is well-positioned for sustained above market performance.
And in medical devices, sales growth was led by double digit growth in heart failure, electrophysiology, structural heart, neuromodulation, and diabetes care. In addition to strong growth, we achieved several new product approvals and clinical trial milestones across our portfolio during the third quarter. In heart failure, we received U.S. FTA approval and launched our HeartMate 3 pump, which provides crucial support for advanced heart failure patients as they wait for their treatment, including heart transplants. HeartMate3 offers a number of advantages compared to existing options, and further strengthens our global leadership position in this area.
During the quarter, we also received U.S. FTA approval of our MRI-compatible ICD, or implantable defibrillator, which follows up the approval of our MRI-compatible pacemaker earlier this year. These approvals significantly enhance our competitive position in the U.S. cardiac rhythm management market. In structural heart, double digit growth was drive by continued global update microclip . During the quarter, we achieved several important clinical milestones, including completion of enrollment in our U.S. trial for Portico , our Taber product. And we began enrolling patients in a new bicuspid valve disease trial, which utilizes our market leading trans-catheter valve repair system. In neuromodulation, we achieved growth of approximately 50% for the third consecutive quarter, driven by recently launched products that offer improved relieve for chronic pain patients, and help for those suffering from movement disorders.
With our broad portfolio of innovative solutions, we continue to advance our leadership position in this fast growing market. I'll wrap up with diabetes care, where an international sales growth of nearly 35% was driven by FreeStyle Libre, our innovate glucose monitoring system that eliminates the need for routine finger sticks. Libre now has more than 4,000 users internationally. And during the quarter, we obtained national reimbursement status in Japan and the United Kingdom, which represent two of the largest diabetes markets in the world. In the U.S. during the quarter, Libre received U.S. FDA approval as a replacement for blood glucose monitoring. This revolutionary technology is the only system available that comes factory-calibrated, thus eliminating the need for daily finger sticks that are required to calibrate other systems currently available.
So, in summary, we exceeded expectations for the quarter and raised the midpoint of our full year EPS guidance, which is now at the upper end of the range we set at the beginning of the year. Our sales growth increased sequentially, and recently launched products are contributing significant growth across our portfolio. And we're particularly pleased with the productivity we're seeing across our new product pipeline, which is delivering a steady cadence of approvals and launches of innovative technologies. I'll now turn the call over to Brian to discuss our results and outlook for the year in more detail. Brian?
Brian Yoor -- Executive Vice President of Finance and Chief Financial Officer
Thanks, Miles. As Scott mentioned earlier, please note that all references to sales growth rates, unless otherwise noted, are on a comparable basis and do not include Alere, which is consistent with the guidance methodology we've utilized since the beginning of the year. Turning to our results, sales for the third quarter increased 5.6% on an operational basis. Exchange had a positive impact on sales at 0.6%, resulting in a reported sales growth of 6.2% in the quarter. The favorable impact of exchange rates on our sales this quarter was driven primarily by strengthening of the euro and other developed market currencies, which, considering our European cost base and hedging program, have a relatively modest follow through impact on our earnings. Regarding other aspects of the P&L, the adjusted gross margin ratio was 59.3% of sales. Adjusted R&D investment was 6.9% of sales, and adjusted SG&A expenses was 29.4% of sales.
Turning to our outlook for the full year 2017, today we narrowed and raised at the midpoint our adjusted earnings per share guidance range to $2.48 to $2.50. Before reviewing our outlook in more detail, I'd note that Alere, which we acquired earlier this month, is expected to contribute around $475 million dollars to our reported sales, and we forecast a mutual impact on adjusted earnings per share this year. We continue to forecast full year 2017 comparable operational sales growth in the mid-single digits. And based on current exchange rates, would expect exchange to have a positive impact of nearly 0.5% on our full year reported sales. We forecast an adjusted gross margin ratio of around 59.5% of sales, adjusted R&D investment of approximately 7.5%, and SG&A expense of approximately 30% of sales.
Turning to our outlook for the fourth quarter of 2017, we forecast an adjusted earnings per share of 72 to 74 cents. We forecast comparable operational sales growth in the mid to high single digits, and at current rates, would expect exchange to have a positive impact of somewhat above two% on our fourth quarter [inaudible] [0:12:34] sales. Before I open the call for questions, I'll now provide a quick overview of our fourth quarter operational sales growth outlook by business.
For established pharmaceuticals, we forecast double digit sales growth. In nutrition, we forecast low single digit sales growth. In diagnostics, we forecast sales to increase mid-single digits. And in medical devices, we forecast sales to increase mid to high single digits, which reflects continued double digit growth in diabetes care, as well as several areas in our cardiovascular and neuromodulation business. With that, we will now open the call for questions.
Questions and Answers:
Operator
Thank you. Ladies and gentlemen, if you have a question at this time, please press the star and then the number one key on your touchtone telephone. If your question has been answered or you wish to remove yourself from the queue, please press the pound key. We kindly ask that if you are using a speakerphone, to please pick up the handset before asking your question. And again, that's *1 to ask a question. Our first question comes from Mike Weinstein from J.P. Morgan. Your line is open.
Mike Weinstein -- JP. Morgan -- Analyst
Good morning, and thank you for taking the question. Miles, I was hoping we could touch on two topics. First is Alere, now that it's closed, and second is Libre, now that you have an FDA approval. First, Alere. Can you talk now about how we should think about the outlook for Alere, both top line growth and then accretion? Obviously, everybody's familiar with what you initially were expecting from accretion, with 12 to 13 cents year one, more than 20 cents, year two. But a lot happened with your business over that time. You renegotiated terms, you had to divest some assets. So, I think everybody would appreciate an update on how you're viewing that business, and then we'll circle back on Libre. Thanks.
Miles White -- Chairman of the Board and Chief Executive Officer
Yeah, I think it's premature, Mike, to get real specific about Alere. We closed the deal a couple of weeks ago literally. And our new management team has taken over the business, but obviously very rapidly getting up to speed, meeting all their employees, going through all the things you do to start integration and so forth. And I'd say, first of all, that's gone very well. The management team we've put in place has moved very quickly, and I have to say, very deliberately to get their hands around everything. But that takes some time. So, as we've said to people, given the timing of when we closed it, we expect no accretion this year, so I wouldn't look for any particular impact on the bottom line in 2017. With regard to '18, since our initial estimates of accretion that were quite some time ago, as you know, when we first announced this deal, because it's taken a very long time to close, there have been a number of changes, including divestitures and so forth. So, I don't want to give you a specific number. I'd say it's fair to think that the accretion will be much more modest than what we initially indicated for the first year.
We will get a full year. We'll get a quarter's headstart, and obviously, our intent is to be accretive to our company and our business, so we believe that with the acquisition, we've positioned ourselves as the leader in point of care testing worldwide. All of that has the intent of good solid growth and profit growth for our investors. But I'm gonna be cautious about what I communicate for '18 at this point until we've really had a chance to assess it more thoroughly
Mike Weinstein -- JP. Morgan -- Analyst
And do you think that business kind of as you own it, and call it the pro forma Alere under Abbott, does that business grow in 2018, and is low single digits an appropriate expectation?
Miles White -- Chairman of the Board and Chief Executive Officer
I think it's a good target. I don't know that we know yet. But that's certainly, I think, an expectation we at Abbott ought to have. And the question is how rapidly we can do that. So, yeah, look, I think it's a fair expectation. And if I was -- and I am -- totally honest with you, yeah, I wouldn't have a lesser expectation.
Mike Weinstein -- JP. Morgan -- Analyst
Okay. All right. Let me switch to Libre, if I can, and maybe try asking you a couple questions then. So, one, obviously everybody's excited, not only based on all your success outside the U.S. with Libre, but now that you have this opportunity in the U.S. What would you view as a successful launch for Libre in 2018? Is there something you could characterize [inaudible] [0:17:10] than a number? Is it 50 million? Is it 100 million? If you want to take a stab at that. And then second, what is your expectation for commercial payers? Can you tell us about the conversations you've had and the willingness and the timing that you see commercial payers getting on board? Thanks.
Miles White -- Chairman of the Board and Chief Executive Officer
Well, I'd say a couple things. Your estimate is -- let's just say your estimate, I'll take, and you gave me a nice range there, so thank you. And I think that you can assume that we'll be looking at this from a lot of perspectives, because we've got a lot of data. Having had a run rate in Europe -- we launched in Europe, and it basically went country by country. We started it as full patient pay, and we had really terrific uptake and consumer interest. And that was the first introduction of Libre to the market. The fact that there was no reimbursement early on was an unknown to us. And it was a new concept and a new way for diabetics to test. And we experienced tremendous demand. Our first year, we were capacity limited, and yet we had a fair bit of demand. The second year, obviously, has gone exceptionally well. And so, as I indicated, we've got over 400,000 customers. It was remarkably well-embraced for reimbursement by government bodies in Europe and regions in Germany, etc. That's extremely gratifying, that the value proposition that we see with Libre is strong, and it's intended to be.
And consequently, we believe that part of the appeal is not just what Libre can do and the information that it provides to a diabetic, who's a very informed patient and a very self-managing patient. It provides them tremendous information from just guidance and the management of diabetes. And I know that firsthand. I wear one. And I gotta tell you, it's just a phenomenal device. It's a super product. I can see why consumers like it as much as they do. And that's true for both type ones and type twos. And we're seeing the universally across the board. They use it in different ways, or at least information means something to them in different ways, whether they're managing insulin or whether they're managing diet and exercise and other things. So, I'd say first of all, I expect demand to be pretty strong. Secondly, the U.S. market knows about Libre. It knows a lot about Libre because of all the experience that we've had in the last year in Europe. So, I do expect a more educated, ready, prepared, anticipating, demanding market in the U.S.
As relates to payers, which I would call the second dimension of this, I think our value proposition is quite strong. The product is priced at a very economic and affordable level. The intention there is as much and broad access as possible and as rapidly as possible. And I think that value proposition is stunning compared to competitive offerings, and I think that's gonna make it strong. We are in discussions with payers, and we are in discussion with payers about that value proposition, and I believe that will all go very well. I know that's not as much detail as you'd like to have, but it's as much as I'm willing to share at this point, because right now, I would tell you we expect a good strong out of the box performance, like you described.
And beyond that, I mean, right now, Mike, we're adding about 50,000 patients a quarter, and that's across a continent that we had to go at one country at a time, one reimbursement system at a time. Of course, the U.S. is quite large, and Japan and the U.K. in addition to this are also quite large. So, I mean, we have a fair amount of optimism, and try not to get too far ahead of ourselves.
Mike Weinstein -- JP. Morgan -- Analyst
Sounds good. I have a lot more questions, but I'll let some others jump in. Thank you, Miles.
Miles White -- Chairman of the Board and Chief Executive Officer
Thank you.
Operator
Thank you. Our next question comes from Matt Taylor from Barclays. Your line is open.
Matt Taylor -- Barclays Capital -- Analyst
Hey, good morning. Thanks for taking the question. The first thing I wanted to ask about was certainly, it was encouraging that you got MRI conditional labeling for your ICD in the quarter. So, I was hoping we could get an update on how things are going in Somar, and then when we might expect the approval for CRTD, and maybe the ICM as well.
Miles White -- Chairman of the Board and Chief Executive Officer
Yeah, I'd say a couple things, Matt. First of all, let me back up and give a bigger context
to this. Over the course of the year, there was a lot of skepticism on the part of analysts and/or investors about all the things that we had to get accomplished that were backend loaded. A lot of third quarter, fourth quarter things. And depending on how you're looking at it, it looks pretty daunting. But we all know everything doesn't go right. And the
Somar inspection put some of that in doubt. Now, having said that, we stuck to our guns on what our estimates were and our projections were about when we would get product approvals and claim approvals, licensure approvals, and so forth. And the third quarter alone here has been pretty gratifying, in that we basically got every approval we forecasted, and within -- let's call it within 30 days or so of what we forecasted.
And I think that's been pretty gratifying, that what we said is what happened. And that includes Libre, that includes the high voltage MRI claim, that includes HeartMate, in includes the closure of Alere, it includes Libre -- it includes a lot of things. I don't generally like being backend loaded because it feels like a lot of risk that everything has to go right. But everything did. And our progress with Somar is no exception, because I've indicated on prior calls our team that has been working with the Somar team and so forth has done an exceptional job. We've provided all information, taken all actions, done all remediation, everything basically done on time, delivered to FTA , discussed with FTA, etc. And at this point, we're just experiencing those new systems, populating them with new experience, new data, new decision making, etc.
And all of that is going exactly as planned, exactly as forecasted, exactly as communicated with the FTA, and thus far, without a hiccup. And I think that's recognized by the FTA. I think it's recognized they have discretion. They don't have to license new products out of that facility, but they have. And I think that that is evidence of how we're progressing with Somar, and the fact that the FTA is giving it all the scrutiny that they would and should, and that what we've submitted to them for approvals has been given fair and objective consideration, and we've gotten our approval so far. With that said, the remaining ones, I'm not gonna change my estimates on. I'm not gonna change what we forecasted. I have no reason to believe otherwise. They clearly have the discretion not to, but that's not been our experience. And so, consequently, I remain optimistic that we're on a track that will deliver what we said.
Matt Taylor -- Barclays Capital -- Analyst
Thanks. And I wanted to turn to another thing that you mentioned in the prepared remarks. On China, you said that you're preparing for the regulations, the change in nutrition in the new year, and did improve a little bit sequentially. Could you talk about what kind of opportunity you could have in China if that comes to pass on time with regards to being able to maybe soak up some of the capacity that gets lost as local players have to shut down or change their operations?
Miles White -- Chairman of the Board and Chief Executive Officer
Well, I'll tell you what. I'm not sure. I would tell you this. First of all, we have the product approvals we need. We're ready for the transition, building inventory for such, etc. So, as far as responding to the new law -- and I think this is true for at least the large multinational competitors, I think most of us, if not all of us, have our product approvals. We're ready to transition, etc. How we all manage that, who knows? But I think at least we are, and I think others are, ready with new approved replacement products, etc., as we've been required to do. So, I think we're all ready for the transition on January 1st. What you can't know very well, at least about everybody else, is how much inventory everybody has in various channels -- how long that transition'll take for any given competitor and so forth. We're comfortable with our inventory levels. We're comfortable with our inventory levels both on current product and post-Jan. 1 st product.
So, we're comfortable with what we think we have to do with our own transition. What's hard to project is not just multinationals, but all the hundreds of other Chinese competitors that are facing the same regulations. So, I'd say we've seen a stabilizing of China. It hasn't been as choppy as it was in the last two years. I'd say our estimates around market growth are hard to pin down. We were more conservative on market growth than recent data we've seen. Market growth is better than we indicated or better than we believe, or better than we thought, and we're looking pretty closely at all the sources of our market data, because there are many, and they're not all perfectly comprehensive across all channels and in all sources of products, or even all geographies. So, it's a hard one. China's a particularly difficult one to pin down because there are a number of channels. There are a lot of competitors. There are a lot of data sources. It's not like going to A.C. Nielsen in the U.S. or something.
So, I'm cautious about it. I think we've seen the tough part, and I think we're going back into a phase where it's the same kind of end to end competition we've opened across multiple channels. I like that. I think that's better, because at least then whether we do well or don't do well is a function of our execution. I haven't been particularly pleased with our execution, and I don't exclude a number of other countries where we do see soft market conditions, but I also see less than great execution on our part. So, this business is getting a lot of attention from us and from all of us top to bottom. And it will get some attention. I think it's probably the one soft spot in our release. I think a lot of things are going awfully well, as I just commented to you in the device area. But this one's gonna get a lot more attention.
I feel that China is at least reasonably stable or predictable. We haven't been right about the market growth rates. Those look better than we expected. So, that's a plus. And I guess I'll just leave it there.
Matt Taylor -- Barclays Capital -- Analyst
Great. Thanks, Miles.
Operator
Thank you. Our next question comes from Bob Hopkins from Bank of America. Your line is open.
Bob Hopkins -- Bank of America -- Analyst
Hi, thanks and good morning. So, first, I just wanted to clarify something you said on Alere. Obviously, I heard you that the accretion for '18 will be lower than you originally thought. That's not surprising. But I just wanted to confirm, do you still think it'll be accretive in 2018? And is roughly half the original accretion a reasonable placeholder?
Miles White -- Chairman of the Board and Chief Executive Officer
Yeah, I expect it to be accretive. We've got a lot of work to do to identify our synergies and identify our growth opportunities. We're going through a reorganization of the business right now, and I mean, that's actually gonna be a plus. I don't want to describe how it was organized, because I think that's kind of a waste of time and will take a long time. But we went through a restructuring of the ordering structure of St. Jude. And we did it within six months, and as you know, organized integrated business units that -- I'd say that organization is still kind of setting. The glue is still kind of setting. But we moved to it within six months. That might have been aggressive, but the organization's very stable. The restructuring activities that we had to go through and a lot of synergizing as far as people go -- we've gone through changes in management, we've gone through -- etc. That all got done at about the six-month level at St. Jude. It all got done at Alere in six days.
So, that's a running start. And what we're moving to, I think it's an organization -- look, all organizations, all people want to do well. They want to achieve. They want to grow. They want to be proud of the businesses they're running. They do want to do well. And I'd say our early days with the employees of Alere have been positive. And we announced that we're gonna go to that kind of a structure. We've announced how we're gonna do it, why we're gonna do it, etc. And I think that's well-received at this point. So, as far as we look into 2018, I think your question about is half of that a good placeholder, yeah, it's a good placeholder. I can't tell you with any precision that that's what it'll be. But I think it's a good placeholder.
Bob Hopkins -- Bank of America -- Analyst
Okay. That's very helpful, thank you. And then I'm sure there will be a lot of other questions on Libre. But I wanted to focus on the rest of the pipeline for a second, because there are a number of other things in addition to Libre that could help in 2018. And you touched on the MRI Safe approvals. But I just want kind of ask specifically on some of the other things that you've got in the pipeline, and just to make sure that the timelines and your thoughts on those haven't changed at all relative to what you've been saying previously. And so, that would include things like the new stents that you talked about, Sierra, the Confirm implantable cardiac monitor that's entering what is a very attractive market. And so, I'm just curious on those couple things that the timeline's still the same as what you've been saying previously.
Miles White -- Chairman of the Board and Chief Executive Officer
Well, a couple things. First of all, with regard to Sierra, the stent, yeah, same schedule, no change. That'll be first quarter of the year, we think. And with regard to Confirm, it's partly approved already. As you may understand, it gets approved in pieces, and so far, so good. There are some peripheral pieces we are waiting for approval on. But the first and very critical portion of that is approved, so yeah, I think that's -- so far, everything we've seen is very encouraging, and no change.
Bob Hopkins -- Bank of America -- Analyst
No change. So, Confirm can be a full launch in 2018?
Miles White -- Chairman of the Board and Chief Executive Officer
Well, right now, that's what I'd bet on.
Bob Hopkins -- Bank of America -- Analyst
Okay. Great. Thanks a lot. That's all I have.
Miles White -- Chairman of the Board and Chief Executive Officer
Okay.
Operator
Thank you. And our next question comes from Rick Wise from Seful . Your line is open.
Rick Wise -- Seful --Analyst
Good morning, Miles. Miles, just after a solid quarter, again, coming out in '17 to the upper end of the range, I know it's early to put all this pieces together in '18. But as I reflect on it, in '18, with multiple large new product opportunities, launching St. Jude, Alere working, shouldn't we expect at least similar top line growth and potentially better, if not accelerating top line growth against -- especially when you think about some of the headwinds you've faced and worked through in '17? Is that the right way to think about it?
Miles White -- Chairman of the Board and Chief Executive Officer
I'm trying to think about how to sound conservative to you. Look, we got our acquisitions closed. We're gonna have a number of product approvals that happened in the third quarter and fourth quarter that obviously should hit their stride. I mean, ideally, you look at '18, and you'd like to have your product approvals exactly where we got them, going into the next year. We got a really good 2017. We beat all expectations, not just in the numbers, but in the approvals. And you all have to admit you had a lot of skepticism about some of this. And maybe rightly so, after 2016. But look, we've hit every target we had for this year. And with all those approvals, one ought to think that should bode positively for 2018. That said, we go through our budgeting every year. It's kind of a negotiating hustle with our managers around the world about what's possible in their given markets and so forth.
But yeah, we ought to have pretty good momentum going into '18. What can I say? All the organic R&D projects, and system projects, and launches, and approvals, and so forth, they're all happening. And the Alinity products, probably most miraculously, five of those have begun their launch process in Europe, and they'll start in the U.S. next year. That's been a huge, huge undertaking. We're extremely excited about Libre. We're excited about all the medical device products. Everything that St. Jude represented to Abbott about its pipeline has come to fruition and is coming to fruition. And so, we're very, very bullish about all that, and I think there's an awful lot of validation in this about that acquisition. We don't know as much about Alere yet, but we will. And whether it's a big impact during '18, or if it's beyond '18, either way, I think we're pretty happy to have that business. So, Rick, I think your assessment's right. I mean, it'd be kind of hard for me to say, no, it's gonna be a tough year.
Rick Wise -- Seful --Analyst
All right. Well, that's a great answer, and I'll take it. Another big picture reflection. One of the concerns, obviously, with two major acquisitions was balance sheet, cash flow. But my sense is, in the first half, at least, you ran ahead of your cash flow generation commitments and goals. Can you give us any feeling about how the third quarter went? Remind us what your targets are in terms of leverage, and just again, as we think about the next six, 12 months, where do you think you'll be from a leverage and cash position? Thank you. Any color would be welcome.
Miles White -- Chairman of the Board and Chief Executive Officer
Okay. Well, first, I'd tell you that this got great leadership and attention from our CFO and our EVPs and SVPs from day one. And I'm gonna let him answer that question, because they've exceeded all of our targets, not just by a little, but a lot. Cash flow is strong, and I'll let him tell you about it.
Brian Yoor -- Executive Vice President of Finance and Chief Financial Officer
All right, thanks, Miles. Yeah, we continue to make great progress in our programs. If you recall, I talked about operating cash flow being around four-and-a-half billion for the full year. I won't quote you an exact number for Q3, but I think you'll safely assume that when you see the quarter filed, that we are well on track to that, and I would say ahead of it. And so, we are going to continue to make that progress. As you talk about some of the ratios, I think it's important to keep in mind both that and that debt. So, at the end of the year, we projected a debt to EBITDA dollar ratio of around four. However, when you look at the cash flow programs and look at our net debt position, we'll be closer to three when you look at the net debt as a ratio to EBITDA. So, we're in great shape, and we want to keep the momentum going, because this is the number one priority to build max strategic flexibility here.
Miles White -- Chairman of the Board and Chief Executive Officer
I think, Rick, I would comment -- I just want to get a commercial out there. This all gets even better if there's tax reforms. So, I'm hopeful. I wouldn't put it odds on it anymore than anybody else watching our government. But we are extremely hopeful of a territorial system that gives us access to our cash flows and earnings around the world at a reasonable rate and at a competitive rate. And that does make a difference to us in addressing current debt and cash flows. But cash flow itself? Super good.
Rick Wise -- Seful --Analyst
Appreciate it. Thank you.
Operator
Thank you. Our next question comes from Larry Biegelsen from Wells Fargo. Your line is open.
Larry Biegelsen -- Wells Fargo --Analyst
Good morning, everyone. Thanks for taking the questions, and congratulations on a strong quarter. Just two. One, it was noteworthy that you didn't mention the impact from the weather. You still had a strong quarter despite the weather. I imagine it had to have some impact. So, is there any color you can provide? And I have one follow-up.
Miles White -- Chairman of the Board and Chief Executive Officer
Yeah, it did. I would comment on a couple of things. First of all, it was a strange quarter for us, in that multiple hurricanes, whether in the Texas Gulf Coast or across Puerto Rico, impacted anybody who had operations there. The earthquake in Mexico impacted us. The brushfires and forest fires in California actually impacted us the day after we closed the Alere -- a key Alere facility there. And to be honest, it was more an impact on our employees than on our plant operations. We had a little bit of roof damage and a little water leakage here and there. But it would appear the hurricane affected different countries different ways going across Puerto Rico, because I've noted that some competitors have indicated more damage or more impact than we've experienced. It took a superhuman effort by a lot of our people to try to address some of that, which we did. The biggest issue was access to power generation in Puerto Rico. And our folks addressed that really rapidly, and we're very happy about that.
Our plants are -- I guess back up and running is the right way to say it. There's one that we're starting this week, and we're back up, is what it amounts to. And so, I would call it a modest impact. It's affected us, I'd say, at a modest level, not a material level. Our first priority was to find all of our people and aid them, which we've done. And so, in Puerto Rico, we have not experienced the kind of disruption that some others have. I noted that another large healthcare company yesterday I think had similar comments, that they've been able to address it. We're kind of large in Puerto Rico, so it could have been worse, but it wasn't. And the St. Jude facilities that we inherited there with the acquisition of St. Jude were not particularly impacted. I mean, they were, but not to the degree we might have expected. I mean, everything has been more about power generation than damage. And unfortunately, that's not true for our employees, and it's not true for some other competitors, and I wouldn't wish that on anybody. But we've been pretty fortunate to get everything back up and running.
So, we don't have an impact to report for the fourth quarter that we haven't somehow managed or absorbed already in our estimates. The facility that was threatened in California was not damaged. We were able to move things out of that facility and prepare for damage, but there wasn't damage. And so, we'll be back up and running soon. We did have employees who unfortunately lost homes and so forth, and we're dealing with that as a company. But from the standpoint of the operation of the business, we are in good shape, relatively speaking, and to the extent that there's any impact, we've already included it in our estimates for this quarter and absorbed it.
Larry Biegelsen -- Wells Fargo --Analyst
That's good to hear. For my follow-up, I wanted to ask about whetherRX management -- it's the one business where if you improve that dramatically, it could really impact positively your growth. So, I'm just curious what your expectations are for that business going forward. Could it be potentially flat in 2018, and just if you could clarify or confirm RX is gonna be booked in that line or not? Thanks for taking the questions.
Miles White -- Chairman of the Board and Chief Executive Officer
Okay. I'm gonna have Scott answer that one for you.
Scott Leinenweber -- Vice President of Investor Relations
Good morning, Larry. Yeah, as you know, on the MRI Safe side, we continue to see good progress on the pacemaker. We received approval for the ICD very late in the quarter, so that certainly didn't have an impact this quarter, here in the third quarter. But we do expect it to have an impact, a positive impact, in the fourth quarter. So, yes, I do think you will see a nice step up in growth, starting, quite frankly, next quarter, and then as we move into 2018.
Miles White -- Chairman of the Board and Chief Executive Officer
And it's gratifying that our experience with the pacemaker has matched our experience in Japan and Europe with the MRI approvals in terms of share recovery and so forth. So, I think that bodes well for the ICD as well.
Larry Biegelsen -- Wells Fargo --Analyst
Thanks for taking the questions, guys.
Operator
Thank you. Our next question comes from Glen Novarro from RBC Capital Markets. Your line is open.
Glen Novarro -- RBC Capital Markets -- Analyst
Hey, good morning. Thanks for taking the question. Miles, you guys are doing a great job in terms of cash flow generation. You're gonna get to your targets faster for 2018. But it sounds from Brian's commentary that 2018 is not gonna be any type of deal here. It's gonna be paying down debt. Is that a fair assumption, or do you actually have more flexibility, that if something does pop up that's really interesting, that you can do it next year? Then I have just some housekeeping questions after that.
Miles White -- Chairman of the Board and Chief Executive Officer
Well, let me answer it this way. I don't really want the organization focused on M&A right now. And I think I'd give you that answer regardless of what Brian said about debt and cash flow and so forth. And secondly, I wouldn't forecast it even if I had it in my gun sights. My experience with you guys over the past 19 years has been you like to have some indication of what's coming. And usually, I surprised you with most of the acquisitions or other things that we've done. That hasn't always been particularly well received, but they've always turned out pretty well. But I generally don't like to forecast where we're going and what we're going until we announce it. And so, I probably wouldn't tell you anyway.
Glen Novarro -- RBC Capital Markets -- Analyst
But is there some power for next year, or is next year really, let's focus on St. Jude, let's focus on Alere before we think about anything else?
Miles White -- Chairman of the Board and Chief Executive Officer
Well, honestly, I think there is a focus on St. Jude and Alere. And right now, that is paying off. Look, the focus on St. Jude, it's clearly paying off. The focus on Alere will pay off. The focus on the internal product launches of Alinity and so forth, these things will pay off. These are fundamental drivers of sustained growth. I mean, if the hallmark and the identity of the company is sustained growth, and we target double digit earnings growth every single year, your organic performance, both in terms of R&D, pipeline, commercial performance, etc., has to be sustainable. And that is where the focus is. And we've acquired a couple of businesses that initially were criticized as not growth, and I beg to differ. And I think that we're demonstrating so far with St. Jude that there's a terrific pipeline and growth and share gain, etc., and I think you can see that. And you can see that in the initial couple of quarters here, so yeah, I think there's gonna be a lot of focus on not just St. Jude and Alere, but the fundamental organic performance of all of our business.
It took a while for analysts and investors to appreciate the uniqueness of our strategy in established pharma, and I think it sort of called out that there's a segment of pharma that's not commodity generic, that's branded generic, that's higher market and higher growth, etc., in pretty key markets around the world. And right now, that's our fastest growing business, other than neuromod. And the neuromod's hard to touch. But we're growing that business at double digits. But the team is doing a terrific job. Those markets represent the kind of opportunity we said they did. And those kinds of growths, from an operating standpoint, growth rates out of the business, that's what you want. So, to some point, if we can add to our footprints and add to our strategies, if we want to be in a flexible position to do that, we obviously want to get to a position where we have the strategic flexibility that we've always felt we had.
So, I don't think it's a bad idea for us to focus on the operations, keep pushing our cash flow, keep pushing that debt down. So, that's where the focus will be next year. And I think we get ourselves back to strategic flexibility quicker that way, which is a good thing.
Glen Novarro -- RBC Capital Markets -- Analyst
Yeah. Okay, and just -- I agree with everything you just said. Just some housekeeping that's maybe for Scott. You said Portico , you finished enrolling, that's the U.S. trial. Would that put you on pace for a 2019 U.S. launch? And then I think you talked about Mitro , which is the Tendine program, and I think you said you started enrolling. Is that enrolling in the European trial, and then is there an update on the start of the U.S. trial? Thanks.
Miles White -- Chairman of the Board and Chief Executive Officer
I'm gonna let Scott answer that.
Scott Leinenweber -- Vice President of Investor Relations
Sure. Glen, on Portico, we would expect to file in the U.S. in the first quarter of 2019, to your question, so now you have the regulatory process after that. With respect to the Tendine in Europe, we expect to complete enrollment here in the first quarter. It's a one year endpoint, so you can kind of do that math after that. We're on the 2020 range or so on approval on the Tendine product. Really great opportunity, though, really. And the structural heart portfolio here in portfolio has really come together with the [inaudible] [0:49:01] which St. Jude brought to bear here, so we're excited about Avonaterm .
Miles White -- Chairman of the Board and Chief Executive Officer
Yeah, it's a really good one to note. I mean, that's one that came out of our own venture group from our own investments and so forth. And we've been able to combine these things with St. Jude in a way that I think is pretty synergistic, pretty favorable. So, we're pretty excited about that one.
Glen Novarro -- RBC Capital Markets -- Analyst
Any update on when you start a U.S. trial for Tendine?
Scott Leinenweber -- Vice President of Investor Relations
Yeah. We could initiate a U.S. trial here in 2018.
Glen Novarro -- RBC Capital Markets -- Analyst
Okay, great. Thank you.
Scott Leinenweber -- Vice President of Investor Relations
Okay, thanks. Operator, we'll take one more question.
Operator
Thank you. And our final question comes from David Lewis from Morgan Stanley. Your line is open.
David Lewis -- Morgan Stanley -- Analyst
Thank you. Good morning. Miles, I thought I'd end on a couple of questions on growth. And I guess I'm a little surprised the neuromodulation has not come up in this call, given it's been the biggest growth driver for St. Jude this year, 50% growth through the first three quarters. I think every single quarter, we expect that growth rate to come in a little bit. It's been extremely durable across the three quarters. Can you just give us a sense of factors that are driving that growth and sort of how you think about the sustainability of that growth into 2018? And I have a quick follow-up for Scott.
Miles White -- Chairman of the Board and Chief Executive Officer
I mean, I think anybody that claimed a 50% growth rate was sustainable would be an idiot, but -- so, I'm not gonna be one. Look, we're very pleased with the performance of neuromod. I think it's obviously drive by the fact we've got three great products there. They're being exceptionally well received by the market. They have an impact on real life on patients and their pain levels. We're seeing great real world results from Burst and ERG. I think it's a really great group of products and a strong organization. I think that products hit a segment that's in crying need of improvements for patients, and particularly at a time when pain drugs and so forth are a national issue. So, I don't know. I think the new products are driving the growth, and the execution's been strong. The uptake's been strong. We've had three quarters in a row of 50% or better growth. How long will it be like that? We'll start to lap it, and the law of big numbers will start to diminish the growth rat. But the actual raw growth will still be pretty strong. So, I don't know. I like what we see, but it's hard for me to hold it up as an example to all the other businesses that you should do this.
David Lewis -- Morgan Stanley -- Analyst
Sure, very clear. And then, hey, Brian or Scott, just to wrap up here, into the fourth quarter, because I think it could set the tone for investors as they think about next year's growth rate, you're certainly guiding to sequential acceleration, sort of mid to high. Can you just kind of run through kind of sequentially, what are those key components that get that acceleration? Because as I said, I think it sets the tone for '18. Thanks so much.
Brian Yoor -- Executive Vice President of Finance and Chief Financial Officer
Hey, I'll take this. I think it's just been what Miles has talked about, the continued growth of our brand and generics business. It's been performing at the double digit range, and I think you should expect more of the same there. If we look in diagnostics, to sustain what you're doing, we do expect improvement of that business over time as we continue to roll out our Alinity platforms across the globe. Diabetes care, you know that story. It's growing very strong, and we're excited to bring that here to the U.S. And most notably -- and I mentioned this in my guidance on the medical device side -- that's where the step-up is, where I talked about a mid to high single digit, and Scott kind of brought color to that by saying you should expect further sequential improvement on the Sierra RM side of the business. Because we've always had the magic formula, is just bring that back to flat, and the double digit growth of all these high growth areas will shine through and deliver five or six% on our medical device business. Those are really the key catalysts here, so we're looking forward to a good fourth quarter here.
David Lewis -- Morgan Stanley -- -- Analyst
Okay. Thanks so much.
Scott Leinenweber -- Vice President of Investor Relations
Very good. Thank you, operator, and thank you for all of your questions. And that concludes Abbott's conference call. A replay of this call will be available after 11:00 AM Central Time today on Abbott's investor relations website at abbottinvestor.com. And after 11:00 AM Central Time via telephone at 404-537-3406, passcode 88967373. The audio replay will be available until 9:00 AM Central Time on November 1 st . Thank you for joining us today.
Operator
Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Everyone have a great day.
Duration: 54 minutes
Call participants:
Scott Leinenweber-- Vice President of Investor Relations
Miles White-- Chairman of the Board and Chief Executive Officer
Brian Yoor -- Executive Vice President of Finance and Chief Financial Officer
Mike Weinstein -- J.P. Morgan-- Analyst
Matt Taylor -- Barclays Capital-- Analyst
Bob Hopkins -- Bank of America-- Analyst
Rick Wise -- Seful-- Analyst
Larry Biegelsen -- Wells Fargo-- Analyst
Glen Novarro -- RBC Capital Markets -- Analyst
David Lewis -- Morgan Stanley -- Analyst
More ABT analysis
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see ourTerms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (NYSE: ABT) Q3 2017 Earnings Conference Call Oct. 18, 2017, 9:00 a.m. Duration: 54 minutes Call participants: Scott Leinenweber-- Vice President of Investor Relations Miles White-- Chairman of the Board and Chief Executive Officer Brian Yoor -- Executive Vice President of Finance and Chief Financial Officer Mike Weinstein -- J.P. Morgan-- Analyst Matt Taylor -- Barclays Capital-- Analyst Bob Hopkins -- Bank of America-- Analyst Rick Wise -- Seful-- Analyst Larry Biegelsen -- Wells Fargo-- Analyst Glen Novarro -- RBC Capital Markets -- Analyst David Lewis -- Morgan Stanley -- Analyst More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. Economic, competitive, governmental, technological, and other factors that may affect Abbott's operations are discussed in Item 1A, Respectors to our Annual Report, and Securities and Exchange Commission Form 10K for the year ending December 31, 2016. | Duration: 54 minutes Call participants: Scott Leinenweber-- Vice President of Investor Relations Miles White-- Chairman of the Board and Chief Executive Officer Brian Yoor -- Executive Vice President of Finance and Chief Financial Officer Mike Weinstein -- J.P. Morgan-- Analyst Matt Taylor -- Barclays Capital-- Analyst Bob Hopkins -- Bank of America-- Analyst Rick Wise -- Seful-- Analyst Larry Biegelsen -- Wells Fargo-- Analyst Glen Novarro -- RBC Capital Markets -- Analyst David Lewis -- Morgan Stanley -- Analyst More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q3 2017 Earnings Conference Call Oct. 18, 2017, 9:00 a.m. Unless otherwise noted, our commentary on sales growth refers to comparable operational sales growth, which adjusts the 2016 basis of comparison to include results for St. Jude Medical, and to exclude the impact of exchange, as well as current and historical results for Abbott's medical optics and St. Jude's vascular closure businesses, which were divested during the first quarter of 2017. | Duration: 54 minutes Call participants: Scott Leinenweber-- Vice President of Investor Relations Miles White-- Chairman of the Board and Chief Executive Officer Brian Yoor -- Executive Vice President of Finance and Chief Financial Officer Mike Weinstein -- J.P. Morgan-- Analyst Matt Taylor -- Barclays Capital-- Analyst Bob Hopkins -- Bank of America-- Analyst Rick Wise -- Seful-- Analyst Larry Biegelsen -- Wells Fargo-- Analyst Glen Novarro -- RBC Capital Markets -- Analyst David Lewis -- Morgan Stanley -- Analyst More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q3 2017 Earnings Conference Call Oct. 18, 2017, 9:00 a.m. Unless otherwise noted, our commentary on sales growth refers to comparable operational sales growth, which adjusts the 2016 basis of comparison to include results for St. Jude Medical, and to exclude the impact of exchange, as well as current and historical results for Abbott's medical optics and St. Jude's vascular closure businesses, which were divested during the first quarter of 2017. | Duration: 54 minutes Call participants: Scott Leinenweber-- Vice President of Investor Relations Miles White-- Chairman of the Board and Chief Executive Officer Brian Yoor -- Executive Vice President of Finance and Chief Financial Officer Mike Weinstein -- J.P. Morgan-- Analyst Matt Taylor -- Barclays Capital-- Analyst Bob Hopkins -- Bank of America-- Analyst Rick Wise -- Seful-- Analyst Larry Biegelsen -- Wells Fargo-- Analyst Glen Novarro -- RBC Capital Markets -- Analyst David Lewis -- Morgan Stanley -- Analyst More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q3 2017 Earnings Conference Call Oct. 18, 2017, 9:00 a.m. That'll be first quarter of the year, we think. |
33449.0 | 2017-10-18 00:00:00 UTC | Mid-Day Market Update: IBM Surges After Strong Q3 Results; Mobileiron Shares Plunge | ABT | https://www.nasdaq.com/articles/mid-day-market-update-ibm-surges-after-strong-q3-results-mobileiron-shares-plunge-2017-10 | nan | nan | Midway through trading Wednesday, the Dow traded up 0.64 percent to 23,145.57 while the NASDAQ climbed 0.13 percent to 6,632.59. The S&P also rose, gaining 0.13 percent to 2,562.70.
Leading and Lagging Sectors
On Wednesday, the financial shares surged 0.46 percent. Meanwhile, top gainers in the sector included Assurant, Inc. (NYSE: AIZ ), up 6 percent, and Community Trust Bancorp, Inc. (NASDAQ: CTBI ), up 6 percent.
In trading on Wednesday, basic materials shares fell 0.63 percent. Meanwhile, top losers in the sector included KMG Chemicals, Inc. (NYSE: KMG ), down 7 percent, and Rio Tinto plc (ADR) (NYSE: RIO ) down 4 percent.
Top Headline
Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter.
Abbott posted quarterly adjusted earnings of $0.66 per share on revenue of $6.8 billion. However, analysts expected earnings of $0.65 per share on revenue of $6.72 billion.
Abbott narrowed FY17 adjusted earnings outlook from $2.43 to $2.53 per share, to $2.48-$2.50 per share.
Equities Trading UP
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) shares shot up 50 percent to $21.68. Spectrum Pharmaceuticals highlighted poziotinib data in NSCLC at 18th IASLC World Conference on lung cancer in Japan.
Shares of Krystal Biotech Inc (NASDAQ: KRYS ) got a boost, shooting up 16 percent to $11.29. Ladenburg Thalmann initiated coverage on Krystal Biotech with a Buy rating and a $23.00 price target.
International Business Machines Corp. (NYSE: IBM ) shares were also up, gaining 10 percent to $160.30 after the company reported stronger-than-expected results for its third quarter.
Equities Trading DOWN
Akari Therapeutics PLC (ADR) (NASDAQ: AKTX ) shares dropped 27 percent to $4.70 following news of a common stock offering.
Shares of Social Reality Inc (NASDAQ: SRAX ) were down 26 percent to $3.62. Social Reality shares surged 70.73 percent on Tuesday after the announcement of its own Initial Coin Offering: BIGtoken.
Mobileiron Inc (NASDAQ: MOBL ) was down, falling around 10 percent to $3.42 after the company issued weak sales forecast and disclosed that CEO Barry Mainz was leaving the company.
Commodities
In commodity news, oil traded up 0.01 percent to $51.88 while gold traded down 0.25 percent to $1,283.00.
Silver traded down 0.06 percent Wednesday to $17.03, while copper fell 0.61 percent to $3.176.
Eurozone
European shares were higher today. The eurozone's STOXX 600 gained 0.29 percent, the Spanish Ibex Index rose 0.55 percent, while Italy's FTSE MIB Index gained 0.08 percent. Meanwhile the German DAX rose 0.37 percent, and the French CAC 40 climbed 0.42 percent while U.K. shares rose 0.36 percent.
Economics
U.S. housing starts dropped 4.7 percent at an annual rate of 1.13 million in September. Economists expected a rate of 1.18 million.
Domestic crude supplies declined 5.7 million barrels for the week ended October 13, the U.S. Energy Information Administration reported. However, analsyts projected a fall of 3.9 million barrels. Gasoline stockpiles rose 900,000 barrels, while distillate stockpiles gained 500,000 barrels for the week.
The Federal Reserve will release its latest Beige Book report at 2:00 p.m. ET.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Headline Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter. International Business Machines Corp. (NYSE: IBM ) shares were also up, gaining 10 percent to $160.30 after the company reported stronger-than-expected results for its third quarter. Equities Trading DOWN Akari Therapeutics PLC (ADR) (NASDAQ: AKTX ) shares dropped 27 percent to $4.70 following news of a common stock offering. | Top Headline Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter. Meanwhile, top losers in the sector included KMG Chemicals, Inc. (NYSE: KMG ), down 7 percent, and Rio Tinto plc (ADR) (NYSE: RIO ) down 4 percent. Abbott posted quarterly adjusted earnings of $0.66 per share on revenue of $6.8 billion. | Top Headline Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter. Midway through trading Wednesday, the Dow traded up 0.64 percent to 23,145.57 while the NASDAQ climbed 0.13 percent to 6,632.59. The eurozone's STOXX 600 gained 0.29 percent, the Spanish Ibex Index rose 0.55 percent, while Italy's FTSE MIB Index gained 0.08 percent. | Top Headline Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter. Equities Trading UP Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) shares shot up 50 percent to $21.68. Economists expected a rate of 1.18 million. |
33450.0 | 2017-10-18 00:00:00 UTC | Mid-Morning Market Update: Markets Mostly Higher; Abbott Tops Q3 Views | ABT | https://www.nasdaq.com/articles/mid-morning-market-update-markets-mostly-higher-abbott-tops-q3-views-2017-10-18 | nan | nan | Following the market opening Wednesday, the Dow traded up 0.44 percent to 23,097.85 while the NASDAQ declined 0.06 percent to 6,619.39. The S&P also rose, gaining 0.04 percent to 2,560.26.
Leading and Lagging Sectors
Wednesday morning, the financial shares surged 0.32 percent. Meanwhile, top gainers in the sector included Interactive Brokers Group, Inc. (NASDAQ: IBKR ), up 6 percent, and Northern Trust Corporation (NASDAQ: NTRS ), up 5 percent.
In trading on Wednesday, basic materials shares fell 0.27 percent. Meanwhile, top losers in the sector included KMG Chemicals, Inc. (NYSE: KMG ), down 3 percent, and Coeur Mining Inc (NYSE: CDE ) down 3 percent.
Top Headline
Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter.
Abbott posted quarterly adjusted earnings of $0.66 per share on revenue of $6.8 billion. However, analysts expected earnings of $0.65 per share on revenue of $6.72 billion.
Abbott narrowed FY17 adjusted earnings outlook from $2.43 to $2.53 per share, to $2.48-$2.50 per share.
Equities Trading UP
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) shares shot up 37 percent to $19.77. Spectrum Pharmaceuticals highlighted poziotinib data in NSCLC at 18th IASLC World Conference on lung cancer in Japan.
Shares of Ignyta Inc (NASDAQ: RXDX ) got a boost, shooting up 13 percent to $16.16 after the company disclosed positive NSC lung cancer data.
International Business Machines Corp. (NYSE: IBM ) shares were also up, gaining 9 percent to $159.74 after the company reported stronger-than-expected results for its third quarter.
Equities Trading DOWN
Akari Therapeutics PLC (ADR) (NASDAQ: AKTX ) shares dropped 24 percent to $4.89 following news of a common stock offering.
Shares of Social Reality Inc (NASDAQ: SRAX ) were down 21 percent to $3.87. Social Reality shares surged 70.73 percent on Tuesday after the announcement of its own Initial Coin Offering: BIGtoken.
Mobileiron Inc (NASDAQ: MOBL ) was down, falling around 9 percent to $3.45 after the company issued weak sales forecast and disclosed that CEO Barry Mainz was leaving the company.
Commodities
In commodity news, oil traded up 0.62 percent to $52.20 while gold traded down 0.16 percent to $1,284.10.
Silver traded down 0.09 percent Wednesday to $17.025, while copper fell 0.39 percent to $3.183.
Eurozone
European shares were higher today. The eurozone's STOXX 600 gained 0.36 percent, the Spanish Ibex Index rose 0.01 percent, while Italy's FTSE MIB Index gained 0.05 percent. Meanwhile the German DAX rose 0.56 percent, and the French CAC 40 climbed 0.54 percent while U.K. shares rose 0.41 percent.
Economics
U.S. housing starts dropped 4.7 percent at an annual rate of 1.13 million in September. Economists expected a rate of 1.18 million.
The Energy Information Administration's weekly report on petroleum inventories in the U.S. is schedule for release at 10:30 a.m. ET.
The Federal Reserve will release its latest Beige Book report at 2:00 p.m. ET.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Headline Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter. Shares of Ignyta Inc (NASDAQ: RXDX ) got a boost, shooting up 13 percent to $16.16 after the company disclosed positive NSC lung cancer data. International Business Machines Corp. (NYSE: IBM ) shares were also up, gaining 9 percent to $159.74 after the company reported stronger-than-expected results for its third quarter. | Top Headline Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter. Abbott posted quarterly adjusted earnings of $0.66 per share on revenue of $6.8 billion. Equities Trading UP Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) shares shot up 37 percent to $19.77. | Top Headline Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter. Meanwhile, top gainers in the sector included Interactive Brokers Group, Inc. (NASDAQ: IBKR ), up 6 percent, and Northern Trust Corporation (NASDAQ: NTRS ), up 5 percent. The eurozone's STOXX 600 gained 0.36 percent, the Spanish Ibex Index rose 0.01 percent, while Italy's FTSE MIB Index gained 0.05 percent. | Top Headline Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter. Equities Trading UP Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) shares shot up 37 percent to $19.77. International Business Machines Corp. (NYSE: IBM ) shares were also up, gaining 9 percent to $159.74 after the company reported stronger-than-expected results for its third quarter. |
33451.0 | 2017-10-18 00:00:00 UTC | Can Illumina (ILMN) Maintain Balanced Growth in Q3 Earnings? | ABT | https://www.nasdaq.com/articles/can-illumina-ilmn-maintain-balanced-growth-in-q3-earnings-2017-10-18 | nan | nan | Illumina, Inc.ILMN is slated to report third-quarter fiscal 2017 results, after markets close on Oct 24. Last quarter, the company delivered a positive earnings surprise of 20.6% with average earnings beat of 9.3% in three of the trailing four quarters. Let's see how things are shaping up for this announcement.
Key Catalysts
Similar to the prior quarter, Illumina is expected to gain from strong performance in Product revenues as well as Service and other revenue segments. Over the last few quarters, the company's product revenues increased primarily onrising sequencing consumable revenues. Total Service and other revenues are demonstrating strong growth led by continued demand for NextSeq from NIPT customers and partners. We expect these factors to drive the yet-to-be reported quarter's performance as well.
The Zacks Consensus Estimate for Product revenues of $579 million reflects an increase of 12.6% from the year-ago quarter. Also, the Zacks Consensus Estimate for Service and other revenues of $116 million indicates a rise of 24.7% from the year-ago quarter.
Overall, third-quarter 2017 total revenues are projected at $694 million, up 14.3% from the prior-year quarter.
Illumina, Inc. Price and EPS Surprise
Illumina, Inc. Price and EPS Surprise | Illumina, Inc. Quote
Here are the other factors that might influence Illumina's third-quarter results:
Illumina earlier announced that its FDA-approved next-generation sequencing (NGS) -- Extended RAS Panel has met the Current Colorectal Cancer Guidelines. This new kit fulfills the most up-to-date guidance for RAS testing to determine eligibility of epidermal growth factor receptor (EGFR) inhibitors in metastatic colorectal cancer. Management expected the shipment of this kit to start in the third quarter of 2017. Hence, we expect this to drive the top line.
In the second quarter, Illumina witnessed 12% growth in the Asia-Pacific region, propelled by 16% rise in China. Among the emerging markets, China currently offers the most favorable space for Illumina's business growth. In recent times, management has noticed a considerable rise in demand from customers looking to set up NIPT operations in China. With China currently being the fourth largest developing nation (in terms of nominal GDP), we believe the progress in the country will open up channels for Illumina, thereby driving its top line in the yet-to-be reported quarter.
Also, encouraged by the solid second-quarter performance, Illumina has raised its full-year 2017 revenue growth expectations to 12% from the earlier provided range of 10-12%.
On the flip side, a tough competitive landscape may pose a challenge for the company. We are also apprehensive about issues pertaining to NIH funding which Illumina has been facing for quite some time now.
Here is what our quantitative model predicts:
Illumina does not have the right combination of two main ingredients - a positive Earnings ESP and a Zacks Rank #3 (Hold) or better - for increasing the odds of an earnings beat.
Zacks ESP : The Earnings ESP for Illumina i s -0.93%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank : Illumina carries a Zacks Rank #3, which increases the predictive power of ESP. However, we also need to have a positive ESP to be confident of a positive earnings surprise.
Nonetheless, the Zacks Consensus Estimate for earnings of 98 cents reflects a 1% improvement on a year-over-year basis.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Align Technology, Inc. ALGN has an Earnings ESP of +2.06% and a Zacks Rank #3.
Henry Schein, Inc. HSIC has an Earnings ESP of +0.33% and a Zacks Rank #3.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Illumina, Inc. (ILMN): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. This new kit fulfills the most up-to-date guidance for RAS testing to determine eligibility of epidermal growth factor receptor (EGFR) inhibitors in metastatic colorectal cancer. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). The Zacks Consensus Estimate for Product revenues of $579 million reflects an increase of 12.6% from the year-ago quarter. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). Illumina, Inc. Price and EPS Surprise Illumina, Inc. Price and EPS Surprise | Illumina, Inc. Quote Here are the other factors that might influence Illumina's third-quarter results: Illumina earlier announced that its FDA-approved next-generation sequencing (NGS) -- Extended RAS Panel has met the Current Colorectal Cancer Guidelines. | Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. We expect these factors to drive the yet-to-be reported quarter's performance as well. |
33452.0 | 2017-10-18 00:00:00 UTC | Abbott (ABT) Beats Earnings and Sales in Q3, Tweaks View | ABT | https://www.nasdaq.com/articles/abbott-abt-beats-earnings-and-sales-in-q3-tweaks-view-2017-10-18 | nan | nan | AbbottABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market.
Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. The company has reshaped its portfolio through strategic acquisitions/divestitures in recent times. It has also been taking strategic steps to expand its footprint in the growing geographies and investing in R&D, which has resulted in numerous new product launches across its businesses.
In Feb 2015, Abbott completed the sale of its branded generics pharmaceuticals business in developed markets. Realignment of the EPD division through acquisitions in Latin America and Russia, along with business divestitures in developed markets, has positioned the company well for the coming quarters. However, unfavorable movement in foreign currency rates is affecting the top line adversely.
Abbott Labs has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 4.6%.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
Currently, Abbott Labs has a Zacks Rank #2 (Buy), but that could definitely change following the company's third quarter 2017 earnings report which was just released. (You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. ) We have highlighted some of the key stats from this just-revealed announcement below:
Earnings : The Zacks Consensus Estimate remained steady at 65 cents per share over the last 60 days. Abbott's third quarter 2017 earnings per share from continuing operations of 66 cents outpaced this estimate by a penny.
Revenues : Abbott Labs posted third quarter revenues of $6.82 billion surpassing behind the Zacks Consensus Estimate for revenues of $6.71 billion.
Key Stats: Worldwide Nutrition sales increased 0.8% on a reported basis in the third quarter to $1.76 billion while worldwide Diagnostics sales increased 5.4% on a reported basis to $1.27 billion while total Established Pharmaceuticals sales increased 15.7% on a reported basis to $1.17 billion. Revenues of Worldwide Medical Devices increased 98.2% on a reported basis to $2.59 billion.
Major Factors: Per management, Abbott's third quarter results reflect a strong performance. The company is well positioned to achieve the upper end of the initial full-year EPS guidance range. Management narrowed its full-year 2017 EPS guidance which ranges from $2.48 to $2.50 now.The company has received many FDA approvals recently.
Stock Price: Following the earnings release, share prices rose 1.7% during the pre-market trading session.
Check back later for our full write up on this Abbott earnings report later!
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Realignment of the EPD division through acquisitions in Latin America and Russia, along with business divestitures in developed markets, has positioned the company well for the coming quarters. | AbbottABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. | AbbottABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote Currently, Abbott Labs has a Zacks Rank #2 (Buy), but that could definitely change following the company's third quarter 2017 earnings report which was just released. | AbbottABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote Currently, Abbott Labs has a Zacks Rank #2 (Buy), but that could definitely change following the company's third quarter 2017 earnings report which was just released. |
33453.0 | 2017-10-18 00:00:00 UTC | Will Edwards Lifesciences (EW) Gain on THVT in Q3 Earnings? | ABT | https://www.nasdaq.com/articles/will-edwards-lifesciences-ew-gain-on-thvt-in-q3-earnings-2017-10-18 | nan | nan | Edwards Lifesciences CorporationEW is scheduled to report third-quarter 2017 earnings on Oct 24, after market close.
Last quarter, the company had posted a positive earnings surprise of 22.7%. It is worth noting that Edwards Lifesciences has outperformed the Zacks Consensus Estimate in three of the preceding four quarters, with an average positive earnings surprise of 10.8%. Let's take a look at how things are shaping up prior to this announcement.
Key Catalyst
Similar to the prior quarter, Edwards Lifesciences is expected to gain from strength in Transcatheter Heart Valve Therapy segment (THVT). Banking on continued therapy adoption across all geographies with notable strength in the United States, the company is expected to maintain this bullish trend in the third quarter of 2017 as well.
Growth in THVT was driven by excellent clinical performance results from SAPIEN 3 as well continued strong therapy implementation across all regions in the last reported quarter. Moreover, with the receipt of expanded FDA approval for SAPIEN 3 valve in early June 2017 is expected to further boost the top line at the THVT segment in the to-be-reported quarter.
Also, the Zacks Consensus Estimate for THVT net sales of $496 million reflects an increase of 20.9% from the year-ago quarter. The Zacks Consensus Estimate for transcatheter heart valves (THV) sales in the United States of $322 million shows an increase of 23.8% from the year-ago quarter. Overall, third-quarter revenues are projected at $833.89 million.
Edwards Lifesciences Corporation Price and EPS Surprise
Edwards Lifesciences Corporation Price and EPS Surprise | Edwards Lifesciences Corporation Quote
Here are the other factors that might influence Edwards Lifesciences' third-quarter results:
In the domestic market, Edwards Lifesciences is expected to continue with its strong performance based on strength in THVT and two other segments - Surgical Heart Valve Therapy and Critical Care.
The company witnessed strength in Surgical Heart Valve Therapy on the back of strong uptake of the EDWARDS INTUITY Elite valve system. Progressing in Surgical Heart Valve Therapy, the company received FDA approval for INSPIRIS RESILIA aortic valves in July 2017. On the other hand, growth in Critical Care group was led by double-digit growth in Enhanced Surgical Recovery Program, especially in the United States.
Also, the Zacks Consensus Estimate for net sales in the United States of $467 million reflects an increase of 11.9% from the year-ago quarter.
Edwards Lifesciences earlier raised its full-year 2017 sales expectations to the high end of the previously provided range of $3.2-$3.4 billion.
Moreover, we note that the company projected total sales between $810 million and $850 million and adjusted earnings per share of 80 cents to 90 cents for the third quarter.
On the flip side, tough competition in the cardiac devices market and reimbursement issues continue to challenge the company.
We also believe that unfavorable foreign currency will affect the company's gross margin in the to-be-reported quarter. Also, management expects the third quarter to be the seasonally lowest quarter, which adds to the concerns.
Here is what our quantitative model predicts:
Edwards Lifesciencesdoes not have the right combination of two main ingredients - a positive Earnings ESP and Zacks Rank #3 (Hold) or higher - for increasing the odds of an earnings beat.
Zacks ESP : The Earnings ESP forEdwards Lifesciences is -1.83%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank : Edwards Lifesciences carries a Zacks Rank #3, which increases the predictive power of ESP. However, we also need to have a positive ESP to be confident of a positive earnings surprise.
Nonetheless, the Zacks Consensus Estimate for earnings of 87 cents reflects a 27.9% improvement on a year-over-year basis.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Align Technology, Inc. ALGN has an Earnings ESP of +2.06% and a Zacks Rank #3.
Henry Schein, Inc. HSIC has an Earnings ESP of +0.33% and a Zacks Rank #3.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Key Catalyst Similar to the prior quarter, Edwards Lifesciences is expected to gain from strength in Transcatheter Heart Valve Therapy segment (THVT). | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). Key Catalyst Similar to the prior quarter, Edwards Lifesciences is expected to gain from strength in Transcatheter Heart Valve Therapy segment (THVT). | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). It is worth noting that Edwards Lifesciences has outperformed the Zacks Consensus Estimate in three of the preceding four quarters, with an average positive earnings surprise of 10.8%. | Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. It is worth noting that Edwards Lifesciences has outperformed the Zacks Consensus Estimate in three of the preceding four quarters, with an average positive earnings surprise of 10.8%. |
33454.0 | 2017-10-18 00:00:00 UTC | Morning Movers: Chipotle Drops, Transocean Slips, Electronic Arts Slumps | ABT | https://www.nasdaq.com/articles/morning-movers%3A-chipotle-drops-transocean-slips-electronic-arts-slumps-2017-10-18 | nan | nan | The Dow Jones Industrial Average looks set to open well above 23,000 this morning as tax cuts look to be inching closer to becoming a reality.
Agence France-Presse/Getty Images
S&P 500 futures have risen 0.2%, while Dow Jones Industrial Average futures have gained 0.4%. Nasdaq Composite futures have advanced 0.1%.
Abbott Laboratories (ABT) has advanced 1% to $55.60 after beating earnings forecasts and offering in-line guidance.
Chipotle Mexican Grill (CMG) has dropped 2.7% to $320.33 after getting cut to Underperform from Neutral at BofA Merrill Lynch.
CVS Health (CVS) has risen 1.3% to $73.60 after signing a a fiver-year agreement withAnthem (ANTM). E xpress Scripts Holding (ESRX), which had previously been Anthem's pharmacy benefit manager, has dropped 3% to $55.50.
Electronic Arts (EA) has fallen 2% to $113.61 after closing of Visceral Games, which will delay a new Star Wars game.
Fortinet (FTNT) has gained 2.4% to $40.20 after getting upgraded to Buy from Hold at Deutsche Bank.
GoPro (GPRO) has climbed 4.6% to $9.65 after getting raised to Buy from Neutral at Longbow.
Merck (MRK) has risen 1.6% to $64.25 after getting upgraded to Buy from Neutral at Citigroup.
MetLife (MET) has advanced 1.2% to $53 after Goldman Sachs initiated it at Conviction Buy.
M&T Bank (MTB) has declined 1.2% to $162.25 after missing earnings forecasts.
Northern Trust (NTRS) has risen 1.6% to $92.56 after beating earnings forecasts and naming a new CEO.
Omnicom Group (OMC) has climbed 4.4% to $78.90 after getting raised to Outperform from Market Perform at Telsey Advisory.
Rio Tinto (RIO) has fallen 1.6% to $49.00 after the SEC accused it of fraud.
Transocean (RIG) has declined 1.3% to $10.65 after despite signing a new rig contract.
Ulta Beauty (ULTA) has dropped 1.9% to $198.50 after getting cut to Neutral from Overweight at Piper Jaffray.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT) has advanced 1% to $55.60 after beating earnings forecasts and offering in-line guidance. The Dow Jones Industrial Average looks set to open well above 23,000 this morning as tax cuts look to be inching closer to becoming a reality. Chipotle Mexican Grill (CMG) has dropped 2.7% to $320.33 after getting cut to Underperform from Neutral at BofA Merrill Lynch. | Abbott Laboratories (ABT) has advanced 1% to $55.60 after beating earnings forecasts and offering in-line guidance. The Dow Jones Industrial Average looks set to open well above 23,000 this morning as tax cuts look to be inching closer to becoming a reality. Agence France-Presse/Getty Images S&P 500 futures have risen 0.2%, while Dow Jones Industrial Average futures have gained 0.4%. | Abbott Laboratories (ABT) has advanced 1% to $55.60 after beating earnings forecasts and offering in-line guidance. Agence France-Presse/Getty Images S&P 500 futures have risen 0.2%, while Dow Jones Industrial Average futures have gained 0.4%. Merck (MRK) has risen 1.6% to $64.25 after getting upgraded to Buy from Neutral at Citigroup. | Abbott Laboratories (ABT) has advanced 1% to $55.60 after beating earnings forecasts and offering in-line guidance. Nasdaq Composite futures have advanced 0.1%. GoPro (GPRO) has climbed 4.6% to $9.65 after getting raised to Buy from Neutral at Longbow. |
33455.0 | 2017-10-18 00:00:00 UTC | Abbott Delivers $100 Million Sales Beat On Pharma, Devices Strength | ABT | https://www.nasdaq.com/articles/abbott-delivers-100-million-sales-beat-pharma-devices-strength-2017-10-18 | nan | nan | Abbott Laboratories ( ABT ) delivered a $100 million sales beat in the third quarter, helped by strength in its pharmaceutical and medical devices units, an analyst said Wednesday.
[ibd-display-video id=2376519 width=50 float=left autostart=true]By the closing bell on the stock market today , Abbott had gained 1.3% to finish at 55.77. Shares broke out of a flat base at a 51.23 buy point in early September and have since climbed 7.5% from that mark.
For its third quarter ended Sept. 30, Abbott reported adjusted earnings of 66 cents per share on revenue of $6.8 billion. Sales grew 5.6% on a comparable basis - excluding the impact of its St. Jude Medical acquisition. Earnings grew 11.9%.
Both metrics topped the consensus of analysts polled by Zacks Investment Research for adjusted profit of 65 cents a share on $6.71 billion in sales.
RBC analyst Glenn Novarro credited the $100 million sales beat to strong sales from Abbott's established pharmaceuticals, diabetes care, cardiovascular and neuromodulation products. He kept his outperform rating on Abbott stock.
IBD'S TAKE:A Washington, D.C.-based expert recently suggested President Donald Trump could sign an executive order to bring down drug prices "any day" now, prodding biotech stocks down a collective 0.2% on Monday. Head to IBD Industry Themes for more on what an executive order could mean for biotech and drug stocks.
During the quarter, established pharmaceuticals posted 14.3% year-over-year growth to $1.17 billion. This group doesn't sell in the U.S. Key emerging markets delivered 18% growth on a comparable year-over-year basis, helped by a quick recovery in India, Novarro said.
Worldwide medical device sales grew 5.6% vs. the year-earlier period on a comparable basis to $2.6 billion. That followed Dow stock Johnson & Johnson 's ( JNJ ) report Tuesday that saw medical devices grow 7.1%, but lag some views.
Neuromodulation sales grew 46.8% to $208 million globally. Neuromodulators are implantable devices that use electricity to deliver pain relief. Electrophysiology, tests that study the electrical activity of a heart, rose 10.7% on a comparable basis. Structural heart sales grew 11%.
In the same medical devices business, global diabetes care jumped 19.1%, driven by 33.9% growth internationally, which helped offset a 13% decline in the U.S. Rhythm management sales declined 12.1% vs. the year-earlier period.
Diagnostic sales grew 5.2% globally to $1.28 billion. Within core laboratory products, U.S. sales growth slowed to 4.6% compared with double-digit growth in the first half of 2017, Novarro wrote in a note to clients. But international sales growth improved again to 5.9%.
Abbott also narrowed its 2017 adjusted profit growth to $2.48-$2.50 per share, from its earlier view for $2.43-$2.53, Novarro said. The new guidance brackets the consensus for $2.49. For the year, analysts see Abbott pulling in $26.5 billion in sales.
RELATED:
Dow Component J&J Pops After Topping Views On Pharma Strength
IBD Rating Upgrades: Johnson & Johnson Shows Improved Relative Price Strength
FDA Chief Gottlieb Addresses Opioids, Cancer, New Therapeutics
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) delivered a $100 million sales beat in the third quarter, helped by strength in its pharmaceutical and medical devices units, an analyst said Wednesday. IBD'S TAKE:A Washington, D.C.-based expert recently suggested President Donald Trump could sign an executive order to bring down drug prices "any day" now, prodding biotech stocks down a collective 0.2% on Monday. This group doesn't sell in the U.S. Key emerging markets delivered 18% growth on a comparable year-over-year basis, helped by a quick recovery in India, Novarro said. | Abbott Laboratories ( ABT ) delivered a $100 million sales beat in the third quarter, helped by strength in its pharmaceutical and medical devices units, an analyst said Wednesday. RBC analyst Glenn Novarro credited the $100 million sales beat to strong sales from Abbott's established pharmaceuticals, diabetes care, cardiovascular and neuromodulation products. Dow Component J&J Pops After Topping Views On Pharma Strength IBD Rating Upgrades: Johnson & Johnson Shows Improved Relative Price Strength FDA Chief Gottlieb Addresses Opioids, Cancer, New Therapeutics The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) delivered a $100 million sales beat in the third quarter, helped by strength in its pharmaceutical and medical devices units, an analyst said Wednesday. RBC analyst Glenn Novarro credited the $100 million sales beat to strong sales from Abbott's established pharmaceuticals, diabetes care, cardiovascular and neuromodulation products. Dow Component J&J Pops After Topping Views On Pharma Strength IBD Rating Upgrades: Johnson & Johnson Shows Improved Relative Price Strength FDA Chief Gottlieb Addresses Opioids, Cancer, New Therapeutics The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) delivered a $100 million sales beat in the third quarter, helped by strength in its pharmaceutical and medical devices units, an analyst said Wednesday. Worldwide medical device sales grew 5.6% vs. the year-earlier period on a comparable basis to $2.6 billion. Neuromodulation sales grew 46.8% to $208 million globally. |
33456.0 | 2017-10-18 00:00:00 UTC | Noteworthy Wednesday Option Activity: BMRN, SALT, ABT | ABT | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-bmrn-salt-abt-2017-10-18 | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in BioMarin Pharmaceutical Inc. (Symbol: BMRN), where a total of 7,906 contracts have traded so far, representing approximately 790,600 underlying shares. That amounts to about 72.9% of BMRN's average daily trading volume over the past month of 1.1 million shares. Especially high volume was seen for the $100 strike call option expiring January 19, 2018 , with 4,064 contracts trading so far today, representing approximately 406,400 underlying shares of BMRN. Below is a chart showing BMRN's trailing twelve month trading history, with the $100 strike highlighted in orange:
Scorpio Bulkers Inc (Symbol: SALT) saw options trading volume of 4,035 contracts, representing approximately 403,500 underlying shares or approximately 64.9% of SALT's average daily trading volume over the past month, of 621,655 shares. Particularly high volume was seen for the | That amounts to about 72.9% of BMRN's average daily trading volume over the past month of 1.1 million shares. Especially high volume was seen for the $100 strike call option expiring January 19, 2018 , with 4,064 contracts trading so far today, representing approximately 406,400 underlying shares of BMRN. Below is a chart showing BMRN's trailing twelve month trading history, with the $100 strike highlighted in orange: Scorpio Bulkers Inc (Symbol: SALT) saw options trading volume of 4,035 contracts, representing approximately 403,500 underlying shares or approximately 64.9% of SALT's average daily trading volume over the past month, of 621,655 shares. | That amounts to about 72.9% of BMRN's average daily trading volume over the past month of 1.1 million shares. Especially high volume was seen for the $100 strike call option expiring January 19, 2018 , with 4,064 contracts trading so far today, representing approximately 406,400 underlying shares of BMRN. Below is a chart showing BMRN's trailing twelve month trading history, with the $100 strike highlighted in orange: Scorpio Bulkers Inc (Symbol: SALT) saw options trading volume of 4,035 contracts, representing approximately 403,500 underlying shares or approximately 64.9% of SALT's average daily trading volume over the past month, of 621,655 shares. | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in BioMarin Pharmaceutical Inc. (Symbol: BMRN), where a total of 7,906 contracts have traded so far, representing approximately 790,600 underlying shares. Especially high volume was seen for the $100 strike call option expiring January 19, 2018 , with 4,064 contracts trading so far today, representing approximately 406,400 underlying shares of BMRN. Below is a chart showing BMRN's trailing twelve month trading history, with the $100 strike highlighted in orange: Scorpio Bulkers Inc (Symbol: SALT) saw options trading volume of 4,035 contracts, representing approximately 403,500 underlying shares or approximately 64.9% of SALT's average daily trading volume over the past month, of 621,655 shares. | That amounts to about 72.9% of BMRN's average daily trading volume over the past month of 1.1 million shares. Especially high volume was seen for the $100 strike call option expiring January 19, 2018 , with 4,064 contracts trading so far today, representing approximately 406,400 underlying shares of BMRN. Below is a chart showing BMRN's trailing twelve month trading history, with the $100 strike highlighted in orange: Scorpio Bulkers Inc (Symbol: SALT) saw options trading volume of 4,035 contracts, representing approximately 403,500 underlying shares or approximately 64.9% of SALT's average daily trading volume over the past month, of 621,655 shares. |
33457.0 | 2017-10-18 00:00:00 UTC | Abbott (ABT) Exceeds Q3 Earnings, '17 Guidance Narrowed | ABT | https://www.nasdaq.com/articles/abbott-abt-exceeds-q3-earnings-17-guidance-narrowed-2017-10-18 | nan | nan | Abbott LabsABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, ahead of the Zacks Consensus Estimate by a penny and up 11.9% year over year. This adjusted quarterly number also remained at the upper end of the company's guidance range of 64 cents to 66 cents.
Reported earnings for the quarter came in at 32 cents per share, as compared to the year-ago loss of 24 cents per share.
Third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year on a reported basis. This quarterly figure also remains slightly ahead of the Zacks Consensus Estimate of $6.71 billion.
Abbott Laboratories Price, Consensus and EPS Surprise
Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote
On a comparable operational basis (adjusting the impact of foreign exchange, certain acquisitions and divestments), sales increased 5.6% year over year in the reported quarter.
Quarter in Detail
Abbott operates through four segments - Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics.
EPD sales were up 15.7% on a reported basis (up 14.3% on comparable operational basis) to $1,171 billion. There was a positive impact of 1.4% on the back of currency fluctuations. Sales in key emerging markets increased 18.5% (up 18%), driven by double-digit growth in Brazil, Russia, India and China. As expected, sales in India were positively impacted by purchasing patterns following the implementation of a new Goods and Services Tax system that lowered second quarter sales in that country.
The Medical Devices business sales spiked 98.2% on a reported basis to $2.59 billion. On a comparable operational basis, sales increased 5.6%.
Cardiovascular and Neuromodulation sales soared 214.1% on a reported basis (up 3.6% on comparable operational basis) on double-digit growth in Electrophysiology, Structural Heart, Heart Failure and Neuromodulation.
Vascular product sales growth however, was sluggish at 0.2% on a on a comparable operational basis. Within Rhythm Management, the company registered a loss of 12.1% on a comparable operational basis as sales in the U.S. were impacted by continued competitive dynamics in the magnetic resonance (MR)-conditional category of products.
Diabetes Care sales improved 19.1% on a comparable operational basis, driven by double-digit international sales growth, led by continued consumer uptake of FreeStyle Libre - the revolutionary continuous glucose monitoring system of Abbott.
Nutrition sales were up 0.8% year over year on a reported basis (same on a comparable operational basis). Foreign exchange favorably affected sales by a marginal 0.1%. Pediatric Nutrition sales increased 0.7% on a comparable operational basis. Adult Nutrition sales were up 0.9% on a comparable operational basis.
Diagnostics sales rose 5.4% year over year on a reported basis (up 5.2% on a comparable operational basis). Core Laboratory and Point of Care Diagnostics sales both grew 5.6%, on a comparable operational basis. Molecular Diagnostics sales were up 1.1% as strong growth in the infectious disease testing business was partially offset by the planned scale-down of the genetics business.
Guidance
Abbott has narrowed down its full-year 2017 guidance. Adjusting for certain net specified items for the full year, the adjusted earnings per share from continuing operations are now expected to stay within a band of $2.48-$2.50 (earlier guidance was $2.43-$2.53). The current Zacks Consensus Estimate is pegged at $2.49, at the midpoint of the projected range.
The company has also provided its fourth-quarter 2017 adjusted earnings per share guidance. It expects to report adjusted earnings from continuing operations in the range of 72 cents to 74 cents for the quarter. The current Zacks Consensus Estimate of 73 cents falls at the midpoint of the projected range.
Our Take
One more time, Abbott has successfully exceeded the Zacks Consensus Estimate on both earnings and sales front. We are optimistic about the company's strong and consistent EPD and Medical Devices performance. However, these strong performances were to some extent offset by sluggish Nutrition business.
The company continues to benefit from the recently completed acquisition of St. Jude Medical, which has started offering it an industry leading pipeline across cardiovascular, neuromodulation, diabetes and vision care.
In 2017, the company is effectively executing its existing operating model which focuses on selling portfolio in core therapeutic areas. Also, emerging market performance remains extremely promising on several new strategic developments.
Abbott currently carries a Zacks Rank #2 (Buy).
Stocks to Consider
A few other top-ranked stocks in the medical sector are Integra LifeSciences Holdings Corp. IART , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . While Integra LifeSciences sports a Zacks Rank #1 (Strong Buy), IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Integra LifeSciences has a long-term expected earnings growth rate of 10.8%. The stock rallied roughly 19.1% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock gained 40.9% last year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock gained 26.1% last year.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LabsABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, ahead of the Zacks Consensus Estimate by a penny and up 11.9% year over year. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report To read this article on Zacks.com click here. Quarter in Detail Abbott operates through four segments - Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LabsABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, ahead of the Zacks Consensus Estimate by a penny and up 11.9% year over year. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote On a comparable operational basis (adjusting the impact of foreign exchange, certain acquisitions and divestments), sales increased 5.6% year over year in the reported quarter. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LabsABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, ahead of the Zacks Consensus Estimate by a penny and up 11.9% year over year. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote On a comparable operational basis (adjusting the impact of foreign exchange, certain acquisitions and divestments), sales increased 5.6% year over year in the reported quarter. | Abbott LabsABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, ahead of the Zacks Consensus Estimate by a penny and up 11.9% year over year. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote On a comparable operational basis (adjusting the impact of foreign exchange, certain acquisitions and divestments), sales increased 5.6% year over year in the reported quarter. |
33458.0 | 2017-10-18 00:00:00 UTC | Mid-Afternoon Market Update: Dow Gains 160 Points; Akari Therapeutics Shares Plummet | ABT | https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-gains-160-points-akari-therapeutics-shares-plummet-2017-10 | nan | nan | Toward the end of trading Wednesday, the Dow traded up 0.70 percent to 23,158.02 while the NASDAQ climbed 0.15 percent to 6,633.65. The S&P also rose, gaining 0.16 percent to 2,563.49.
Leading and Lagging Sectors
Wednesday afternoon, the financial shares surged 0.44 percent. Meanwhile, top gainers in the sector included Assurant, Inc. (NYSE: AIZ ), up 6 percent, and Community Trust Bancorp, Inc. (NASDAQ: CTBI ), up 6 percent.
In trading on Wednesday, basic materials shares fell 0.60 percent. Meanwhile, top losers in the sector included KMG Chemicals, Inc. (NYSE: KMG ), down 6 percent, and Fibria Celulose SA (ADR) (NYSE: FBR ) down 4 percent.
Top Headline
Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter.
Abbott posted quarterly adjusted earnings of $0.66 per share on revenue of $6.8 billion. However, analysts expected earnings of $0.65 per share on revenue of $6.72 billion.
Abbott narrowed FY17 adjusted earnings outlook from $2.43 to $2.53 per share, to $2.48-$2.50 per share.
Equities Trading UP
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) shares shot up 47 percent to $21.27. Buyers are flocking to the stock after the company's oral presentation of data from a Phase 2 clinical study evaluating Poziotinib for the treatment of lung cancer while presenting at the 18th IASLC World Conference in Japan.
Shares of Krystal Biotech Inc (NASDAQ: KRYS ) got a boost, shooting up 17 percent to $11.38. Ladenburg Thalmann initiated coverage on Krystal Biotech with a Buy rating and a $23.00 price target.
Viveve Medical Inc (NASDAQ: VIVE ) shares were also up, gaining 14 percent to $5.49 as the company issued a strong sales forecast for the third quarter.
Equities Trading DOWN
Akari Therapeutics PLC (ADR) (NASDAQ: AKTX ) shares dropped 27 percent to $4.69 following news of a common stock offering.
Shares of Social Reality Inc (NASDAQ: SRAX ) were down 23 percent to $3.75. Social Reality shares surged 70.73 percent on Tuesday after the announcement of its own Initial Coin Offering: BIGtoken.
Mobileiron Inc (NASDAQ: MOBL ) was down, falling around 10 percent to $3.42 after the company issued weak sales forecast and disclosed that CEO Barry Mainz was leaving the company.
Commodities
In commodity news, oil traded up 0.35 percent to $52.06 while gold traded down 0.26 percent to $1,282.80.
Silver traded down 0.21 percent Wednesday to $17.005, while copper fell 0.63 percent to $3.1755.
Eurozone
European shares closed higher today. The eurozone's STOXX 600 gained 0.29 percent, the Spanish Ibex Index rose 0.55 percent, while Italy's FTSE MIB Index gained 0.08 percent. Meanwhile the German DAX rose 0.37 percent, and the French CAC 40 climbed 0.42 percent while U.K. shares rose 0.36 percent.
Economics
U.S. housing starts dropped 4.7 percent at an annual rate of 1.13 million in September. Economists expected a rate of 1.18 million.
Domestic crude supplies declined 5.7 million barrels for the week ended October 13, the U.S. Energy Information Administration reported. However, analsyts projected a fall of 3.9 million barrels. Gasoline stockpiles rose 900,000 barrels, while distillate stockpiles gained 500,000 barrels for the week.
The Federal Reserve released its latest Beige Book report.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Headline Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter. Viveve Medical Inc (NASDAQ: VIVE ) shares were also up, gaining 14 percent to $5.49 as the company issued a strong sales forecast for the third quarter. Equities Trading DOWN Akari Therapeutics PLC (ADR) (NASDAQ: AKTX ) shares dropped 27 percent to $4.69 following news of a common stock offering. | Top Headline Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter. Abbott posted quarterly adjusted earnings of $0.66 per share on revenue of $6.8 billion. Equities Trading DOWN Akari Therapeutics PLC (ADR) (NASDAQ: AKTX ) shares dropped 27 percent to $4.69 following news of a common stock offering. | Top Headline Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter. Toward the end of trading Wednesday, the Dow traded up 0.70 percent to 23,158.02 while the NASDAQ climbed 0.15 percent to 6,633.65. The eurozone's STOXX 600 gained 0.29 percent, the Spanish Ibex Index rose 0.55 percent, while Italy's FTSE MIB Index gained 0.08 percent. | Top Headline Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter. Toward the end of trading Wednesday, the Dow traded up 0.70 percent to 23,158.02 while the NASDAQ climbed 0.15 percent to 6,633.65. Economists expected a rate of 1.18 million. |
33459.0 | 2017-10-17 00:00:00 UTC | Will Intuitive Surgical (ISRG) Disappoint in Q3 Earnings? | ABT | https://www.nasdaq.com/articles/will-intuitive-surgical-isrg-disappoint-in-q3-earnings-2017-10-17 | nan | nan | Intuitive Surgical 's ISRG third-quarter results, scheduled for release on Oct 19, are expected to show steady growth in instruments and accessories revenues - one of the major revenue components. While this could majorly drive its third-quarter earnings, an expected improvement in revenues at all other segments should help the company generate solid results this season.
It is important to note that Intuitive Surgical delivered positive earnings surprises in the past four quarters, the average being 7.8%. Similar to the prior quarter, strong procedure growth and increased sales of stapling and vessel sealing products are expected to be the main factors driving the surge in instrument and accessories revenues.
The Zacks Consensus Estimate for instrument and accessories revenues stands at $394 million for the third quarter. This reflects an increase of 13.2% from the year-ago quarter. Continued development in European markets, solid access to the company's products in Asia and new platforms in imaging and advanced instruments are likely to drive revenues at the segment.
Intuitive Surgical, Inc. Price and Consensus
Intuitive Surgical, Inc. Price and Consensus | Intuitive Surgical, Inc. Quote
Other Factors at Play
We believe that the growing adoption of Intuitive Surgical's da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a catalyst for the third quarter. Overall, Q3 revenues are expected at around $752.3 million, up 10.2% from the prior-year quarter. Below are the other factors that might influence Intuitive Surgical's quarterly results this earnings season.
Solid Procedure Trends: Expectations of outperformance in the Mature and Growth procedures, especially in general and thoracic surgery, is likely to boost the company's top line. Added to this, solid growth in prostatectomy procedure volumes is likely to lend Intuitive Surgical a competitive edge in the broader prostate surgery market in the third quarter.
Geographically, procedure growth in the third quarter is expected to be led by China, Germany and Japan. In Germany, procedure growth is likely to be supported by solid installed base expansion.
Furthermore, procedure trends are expected to be solid globally, with growth led by general surgery and global urology segments.
Systems & Service Unit Hold Promise: Solid growth in the company's product and systems segment is expected to drive the company's third-quarter earnings. In fact, the Zacks Consensus Estimate for revenues at this segment stands at $216 million, up 5.4% on a year-over-year basis. The increase reflects higher system placements and operating lease revenues. However, this might be partially offset by lower average selling prices and lease buyout revenues at the segment.
Coming to revenues at the services segment, the Zacks Consensus Estimate stands at $145 million, up 11.5% on a year-over-year basis.
Growth in System's Installed Base: Buoyed by higher system placements and operating lease revenues, we expect the company's total systems installed base to be 4231 units, up 82 units from the last quarter. It is important to note that Intuitive Surgical generated approximately $6 million in revenues from operating leases last quarter, compared with 4 million in the second quarter of 2016.
Here is what our quantitative model predicts:
Intuitive Surgical does not have the right combination of two main ingredients - a positive Earnings ESP and Zacks Rank #3 (Hold) or higher - for increasing the odds of an earnings beat.
Zacks ESP: The Earnings ESP for Intuitive Surgical is -0.49%, as the Most Accurate estimate is $1.96 and the Zacks Consensus Estimates is pegged at $1.97. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Intuitive Surgical carries a Zacks Rank #3, which increases the predictive power of ESP. However, we also need a positive ESP to be confident of an earnings beat. In fact, the Zacks Consensus Estimate for earnings reflects a decline of 4.2% on a year-over-year basis.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Align Technology, Inc. ALGN has an Earnings ESP of +2.06% and a Zacks Rank #3.
Henry Schein, Inc. HSIC has an Earnings ESP of +0.33% and a Zacks Rank #3.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Similar to the prior quarter, strong procedure growth and increased sales of stapling and vessel sealing products are expected to be the main factors driving the surge in instrument and accessories revenues. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). Systems & Service Unit Hold Promise: Solid growth in the company's product and systems segment is expected to drive the company's third-quarter earnings. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). Intuitive Surgical, Inc. Price and Consensus Intuitive Surgical, Inc. Price and Consensus | Intuitive Surgical, Inc. Quote Other Factors at Play We believe that the growing adoption of Intuitive Surgical's da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a catalyst for the third quarter. | Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Consensus Estimate for instrument and accessories revenues stands at $394 million for the third quarter. |
33460.0 | 2017-10-17 00:00:00 UTC | Henry Schein (HSIC) Inks Distribution Agreement with Terason | ABT | https://www.nasdaq.com/articles/henry-schein-hsic-inks-distribution-agreement-with-terason-2017-10-17 | nan | nan | Henry Schein Medical, a subsidiary of Henry Schein, Inc.HSIC , announced an exclusive distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen. This development remains a part of Henry Schein Medical's Emergency Medical Services ("EMS") business.
Terason a division of Teratech Corporation is a manufacturer of portable ultrasound machine. uSmart 3200T is a portable ultrasound device that allows emergency responders to carry out exams in emergency medical transport vehicles and aircrafts. This reduces the need to speculate for EMS professionals. uSmart 3200T NexGen is a portable light-weight ultrasound tablet, easy to transport and operate.
The Terason uSmart 3200T features many advanced features including customized presets, fast boot-up, grab-and-go portability and Wi-Fi capabilities. Responders can recognize issues at the point-of-care, during transportation and also alert emergency room staff of important vitals with uSmart 3200T. According to the company, accessing patient's vitals will help emergency responders make more informed decisions on treatment. Also, it helps emergency room staff to prepare ahead of the patient's arrival.
Henry Schein is consistently working toward boosting its Medical segment. Notably, worldwide Medical revenues rose 6.1% year over year in the last reported second quarter. Henry Schein Medical recently inked an agreement with Cerebral Assessment Systems ("CAS") to distribute Cognivue. This is the first computerized cognitive assessment screening device cleared by the FDA for the detection of early signs of dementia. Moreover, Henry Schein announced a partnership with Simplifeye to create a mobile platform for health care providers who use its practice management and electronic health record software - MicroMD.
According to a report by Markets and Markets, the ultrasound market is expected to reach a value of $6.86 billion by 2021, at a CAGR of 5.2% during 2016 to 2021. Considering the substantial potential of the market, we believe the latest development is a strategic one.
Over the past year, Henry Schein has underperformed the broader industry . The stock has gained 6.8%, compared with the 10.3% gain of the broader industry.
Estimate Revision Trend
The estimate revision trend has been favorable for the company. For the current quarter, two estimates moved north compared with five movements in the opposite direction over the last two months. As a result, the Zacks Consensus Estimate for current-quarter earnings per share has increased to 90 cents from 89 cents.
Zacks Rank & Key Picks
Henry Schein has a Zacks Rank #3 (Hold). A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term expected earnings growth rate of 10.7%. The stock rallied roughly 32.7% over the last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock gained 40.9% last year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock gained 26.1% last year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Responders can recognize issues at the point-of-care, during transportation and also alert emergency room staff of important vitals with uSmart 3200T. | A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Henry Schein Medical, a subsidiary of Henry Schein, Inc.HSIC , announced an exclusive distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen. | A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Henry Schein Medical, a subsidiary of Henry Schein, Inc.HSIC , announced an exclusive distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen. |
33461.0 | 2017-10-17 00:00:00 UTC | What to Expect From Thermo Fisher (TMO) in Q3 Earnings | ABT | https://www.nasdaq.com/articles/what-to-expect-from-thermo-fisher-tmo-in-q3-earnings-2017-10-17 | nan | nan | Medical instruments manufacturer, Thermo Fisher Scientific, Inc.TMO is slated to release third-quarter 2017 results on Oct 25, before the market opens.
Last quarter, the company posted earnings of $2.30 per share, surpassing the Zacks Consensus Estimate by 1.3%. In fact, Thermo Fisher's earnings outpaced the Zacks Consensus Estimate in all the past four quarters with an average beat of 2.3%. Let's see how things are shaping up prior to this announcement.
Key Catalyst
The acquisition of FEI has already started generating synergies and largely contributing to this Waltham MA-based company's analytical instruments portfolio from the last two quarters. The acquisition has enabled Thermo Fisher to access FEI's industry leading high-performance electron microscopy platform used for protein study and facilitating life-science research. This is also a vital highlight of the quarter to be reported.
Thermo Fisher Scientific Inc Price and EPS Surprise
Thermo Fisher Scientific Inc Price and EPS Surprise | Thermo Fisher Scientific Inc Quote
Thermo Fisher anticipates realizing total synergies of approximately $80 million by the end of three years following the deal's closure with about $55 million of cost synergies and roughly $25 million of adjusted operating income benefits from revenue-related synergies. This should get reflected in third-quarter 2017 performance.
Overall, the company is gearing up for yet another quarter of strong analytical instruments segmental growth. In the third quarter, Thermo Fisher expects to see a positive impact from the electron microscopy business as well as strong volume leverage and productivity.
The Zacks Consensus Estimate for Analytical Instruments operating income is pegged at $233 million, in line with the sequentially last quarter's reported number. Total revenue estimate for this segment also remains at an impressive level of $1.11 billion.
Here are other factors that might influence Thermo Fisher's third-quarter results:
The company's focus to boost growth through implementation of strategies and strengthening of its product offerings is encouraging. These initiatives are likely to help it post solid results in the third quarter.
The company had spent $750 million on research and development in 2016 and the same trend is continuing through the last couple of quarters in 2017. A major development in this field is that Novartis' chimeric antigen receptor T cell (CAR-T) therapy Kymriah, the first FDA-approved cell therapy for Leukemia, utilizes Thermo Fisher's CTS Dynabeads Technology.
We expect all innovations and product launches to significantly contribute to the company's top line in the third quarter itself.
The company's aim to expand capabilities in the fast-growing Asia-Pacific zone as well as the emerging markets should also lead to impressive results. Standout contributors in recent times are China, India and South Korea. With strategic investments to support key customer applications, Thermo Fisher hopes to maintain this bullish momentum for the rest of 2017.
Growth is also likely to be seen in applied markets such as, environmental and food safeties apart from life science. In addition, the company is currently betting on some key areas under focus with enormous opportunities. These are advancing precision medicines from mass spectrometry to the targeted gene sequencing and structural biology.
However, we are apprehensive about Thermo Fisher citing a foreign exchange headwind on 2017 revenues and adjusted EPS. Also, an unfavorable macroeconomic condition continues to weigh heavily on the stock. Plus, stiff competition continues to impose challenges on the stock's value.
Here's what our quantitative model predicts:
Thermo Fisher has the right combination of the two main ingredients - a positive Earnings ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) - for an earnings beat. You can see the complete list of today's Zacks #1 Rank stocks here .
Zacks ESP: Thermo Fisher has an Earnings ESP of +0.37%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Thermo Fisher carries a Zacks Rank #2 (Buy), which increases the predictive power of ESP.
Other Stocks to Consider
Here are a few medical stocks worth considering as our model indicates them to consist of the right combination of elements to to post an earnings beat this quarter.
Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank of 2.
Align Technology, Inc. ALGN has an Earnings ESP of +2.06% with a Zacks Rank #3.
Henry Schein, Inc. HSIC has an Earnings ESP of +0.33% and aslo carries a Zacks Rank of 3.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank of 2. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Key Catalyst The acquisition of FEI has already started generating synergies and largely contributing to this Waltham MA-based company's analytical instruments portfolio from the last two quarters. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank of 2. Thermo Fisher Scientific Inc Price and EPS Surprise Thermo Fisher Scientific Inc Price and EPS Surprise | Thermo Fisher Scientific Inc Quote Thermo Fisher anticipates realizing total synergies of approximately $80 million by the end of three years following the deal's closure with about $55 million of cost synergies and roughly $25 million of adjusted operating income benefits from revenue-related synergies. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank of 2. Thermo Fisher Scientific Inc Price and EPS Surprise Thermo Fisher Scientific Inc Price and EPS Surprise | Thermo Fisher Scientific Inc Quote Thermo Fisher anticipates realizing total synergies of approximately $80 million by the end of three years following the deal's closure with about $55 million of cost synergies and roughly $25 million of adjusted operating income benefits from revenue-related synergies. | Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank of 2. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Overall, the company is gearing up for yet another quarter of strong analytical instruments segmental growth. |
33462.0 | 2017-10-17 00:00:00 UTC | Phibro Animal Banks on Diverse Portfolio, Competition Rife | ABT | https://www.nasdaq.com/articles/phibro-animal-banks-on-diverse-portfolio-competition-rife-2017-10-17 | nan | nan | On Oct 16, we issued an updated research report on Phibro Animal Health CorporationPAHC . This NJ-based company is a leading global diversified animal health and mineral nutrition company.
Over the last six months, Phibro has been trading above the broader industry . Currently, the stock has gained 35.9% compared with 10.9% of the broader industry.
Animal Health was a key contributor, delivering positive growth over the last few quarters. According to Phibro, its animal health products are excellent in preventing, controlling and treating diseases in animals as well as improving nutrition to improve health. We believe a diverse portfolio will allow the company to address the distinct growing conditions of livestock in different regions of the world.
Outside the United States, Phibro has extended its reach to Brazil and other countries in South America, China, India and Asia Pacific, Russia and Africa. This we feel will help the company counter competition.
The company continues to invest in the Far East Asia where the poultry and dairy industries are expected to grow exponentially. Currently, the company is expanding its dairy business in the markets of Australia, Brazil and Mexico. We believe that despite the turmoil in the economies of Russia, Greece, Brazil and China, Phibro has performed quite well and has the potential to maintain its performance.
On the flip side, Phibro operates in highly competitive industries. With respect to its major products, it faces threat from a substantial number of global and regional players. Furthermore, withdrawal of approval for Mecadox (carbadox) by the FDA is a concern. Additionally, Phibro conducts operations globally, which entails transactions in a variety of currencies. As a result, currency fluctuation is a major issue for the company.
Zacks Rank & Key Picks
Phibro carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term expected earnings growth rate of 10.7%. The stock rallied roughly 32.7% over the last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock gained 40.9% last year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock gained 26.1% last year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. Outside the United States, Phibro has extended its reach to Brazil and other countries in South America, China, India and Asia Pacific, Russia and Africa. | A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . This NJ-based company is a leading global diversified animal health and mineral nutrition company. | A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. Animal Health was a key contributor, delivering positive growth over the last few quarters. |
33463.0 | 2017-10-17 00:00:00 UTC | Can CR Bard (BCR) Spring a Surprise This Earnings Season? | ABT | https://www.nasdaq.com/articles/can-cr-bard-bcr-spring-a-surprise-this-earnings-season-2017-10-17 | nan | nan | CR Bard Inc.BCR is scheduled to report third-quarter 2017 earnings, after market closes on Oct 24. Last quarter, the company reported adjusted earnings of $2.92, exceeding the Zacks Consensus Estimate by 8 cents. Also, the company's earnings surpassed the Zacks Consensus Estimate in all the last four quarters with an average beat of 4.03%.
Delving into the fundamentals of the stock, let's see how things are shaping up prior to this release.
Factors at Play
We believe that the growing adoption of the company's flagship Lutonix drug coated-balloon (DCB) will continue to be the key growth catalyst in the to-be-reported quarter. In this regard, Lutonix DCB is used to treat patients suffering from peripheral arterial disease (PAD). Within the Endovascular business, peripheral PTA line sales are solely driven by a | Last quarter, the company reported adjusted earnings of $2.92, exceeding the Zacks Consensus Estimate by 8 cents. Factors at Play We believe that the growing adoption of the company's flagship Lutonix drug coated-balloon (DCB) will continue to be the key growth catalyst in the to-be-reported quarter. In this regard, Lutonix DCB is used to treat patients suffering from peripheral arterial disease (PAD). | Last quarter, the company reported adjusted earnings of $2.92, exceeding the Zacks Consensus Estimate by 8 cents. Also, the company's earnings surpassed the Zacks Consensus Estimate in all the last four quarters with an average beat of 4.03%. In this regard, Lutonix DCB is used to treat patients suffering from peripheral arterial disease (PAD). | Last quarter, the company reported adjusted earnings of $2.92, exceeding the Zacks Consensus Estimate by 8 cents. Also, the company's earnings surpassed the Zacks Consensus Estimate in all the last four quarters with an average beat of 4.03%. Factors at Play We believe that the growing adoption of the company's flagship Lutonix drug coated-balloon (DCB) will continue to be the key growth catalyst in the to-be-reported quarter. | Last quarter, the company reported adjusted earnings of $2.92, exceeding the Zacks Consensus Estimate by 8 cents. Delving into the fundamentals of the stock, let's see how things are shaping up prior to this release. Factors at Play We believe that the growing adoption of the company's flagship Lutonix drug coated-balloon (DCB) will continue to be the key growth catalyst in the to-be-reported quarter. |
33464.0 | 2017-10-17 00:00:00 UTC | Can Nutrisystem (NTRI) Surprise Investors in Q3 Earnings? | ABT | https://www.nasdaq.com/articles/can-nutrisystem-ntri-surprise-investors-in-q3-earnings-2017-10-17 | nan | nan | Weight management products and service provider, Nutrisystem Inc.NTRI is scheduled to release third-quarter 2017 results on Oct 25.
Nutrisystem has an impressive track of beating estimates in all the four trailing quarters. Overall, the company's record is favorable as evident from its four-quarter average positive surprise of 28.47%. Let's see how things are shaping up prior to this quarter.
Factors at Play
Nutrisystem's innovative products are expected to expand customer base that will eventually drive reactivation revenues, which is generated from existing customers after the first nine months of their purchase. However, a sluggish dieting market and intense competition are primary headwinds in the near term.
For the third quarter of 2017, management expects revenues in the range of $153 million to $158 million. The Zacks Consensus Estimate for the third quarter revenues is currently pegged at $155.0 million, up 24.4%. Meanwhile, adjusted EBITDA is anticipated in the range of $25.6 million to $27.6 million. Earnings per share are expected in the band of 42-47 cents per share.
On a positive note, the company portrays an impressive price performance. In the past three months, shares of Nutrisystem have returned 3.5% as against the industry 's decline of 0.3%.
However, overall activities of Nutrisystem during the third quarter were inadequate to win analysts' confidence. As a result, the Zacks Consensus Estimate for the to-be-reported quarter fell 2 cents to 45 cents per share in the last 90 days.
Earnings Whispers
Our proven model does not conclusively show that Nutrisystem is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: Nutrisystem has an Earnings ESP of 0.00%. The Most Accurate estimate and the Zacks Consensus Estimate are pegged at 45 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Nutrisystem currently carries a Zacks Rank #3, which increases the predictive power of ESP. However, the company's ESP of 0.00% makes surprise prediction difficult.
We caution against stocks with a Zacks Ranks #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
NutriSystem Inc Price and EPS Surprise
NutriSystem Inc Price and EPS Surprise | NutriSystem Inc Quote
Stocks that Warrant a Look
Here are some companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter:
Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here . .
Align Technology, Inc ALGN has an Earnings ESP of +2.06% and carries a Zacks Rank #3.
Henry Schein, Inc HSIC has an Earnings ESP of +0.33% and carries a Zacks Rank #3.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
NutriSystem Inc (NTRI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | NutriSystem Inc Price and EPS Surprise NutriSystem Inc Price and EPS Surprise | NutriSystem Inc Quote Stocks that Warrant a Look Here are some companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter: Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report NutriSystem Inc (NTRI): Free Stock Analysis Report To read this article on Zacks.com click here. Weight management products and service provider, Nutrisystem Inc.NTRI is scheduled to release third-quarter 2017 results on Oct 25. | NutriSystem Inc Price and EPS Surprise NutriSystem Inc Price and EPS Surprise | NutriSystem Inc Quote Stocks that Warrant a Look Here are some companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter: Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report NutriSystem Inc (NTRI): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | NutriSystem Inc Price and EPS Surprise NutriSystem Inc Price and EPS Surprise | NutriSystem Inc Quote Stocks that Warrant a Look Here are some companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter: Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report NutriSystem Inc (NTRI): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Rank: Nutrisystem currently carries a Zacks Rank #3, which increases the predictive power of ESP. | NutriSystem Inc Price and EPS Surprise NutriSystem Inc Price and EPS Surprise | NutriSystem Inc Quote Stocks that Warrant a Look Here are some companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter: Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report NutriSystem Inc (NTRI): Free Stock Analysis Report To read this article on Zacks.com click here. Nutrisystem has an impressive track of beating estimates in all the four trailing quarters. |
33465.0 | 2017-10-17 00:00:00 UTC | 5 Must-See Big Cap Earnings Charts | ABT | https://www.nasdaq.com/articles/5-must-see-big-cap-earnings-charts-2017-10-17 | nan | nan | Earnings season kicks into high gear this week with over 190 companies reporting, including many big cap Dow and S&P 500 names.
If you want to know what is happening in certain industries, you should be sure to tune into this week's earnings. Healthcare, railroads, chemicals, restaurants, advertising and big financials are just a few of the industries that will be represented.
These big names are bellwether stocks. How they report will set a tone for their industry and, possibly, even the broader market.
These 5 big cap companies have good earnings beat records, but not all of the stocks are soaring. Still, they will be on investors watch-lists this week due to their great records.
5 Must-See Big Cap Earnings Charts
1. IBM IBM has been much maligned, especially since Warren Buffett decided to sell. But it has missed only twice in the last 5 years. Could this be a buying opportunity?
2. Abbott Labs ABT hasn't missed in 5 years and shares have finally busted out of the recent narrow trading range. Will another beat push shares even higher?
3. eBay EBAY is often overlooked by investors but it hasn't missed since 2014. Shares have been on the move higher. Will another beat get it noticed?
4. United Airlines UAL last missed in early 2016. It recently announced a big push in Hawaii, adding new flights from Chicago and Denver. Watch capacity expansion however.
5. United Rentals URI is the largest rental tool company in the United States. It has missed only one time in 5 years. A hot economy should boost business. Shares are at 5-year highs, can they go higher?
(In full disclosure, the author of this article owns shares of URI in her personal portfolio.)
Want to Learn How to Trade Options?
Have you always wanted to trade stock options but are unsure where to begin or what to look for?
Each week, Zacks' Dave Bartosiak will bring you a detailed explanation of the trades "live" on YouTube.
Watch him go through the trade as he answers your questions in real time.
Become one of Dave's minions. Join the Zacks Live Trader community today. It's free!
Click here to join Dave >>>
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
United Continental Holdings, Inc. (UAL): Free Stock Analysis Report
International Business Machines Corporation (IBM): Free Stock Analysis Report
eBay Inc. (EBAY): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
United Rentals, Inc. (URI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ABT hasn't missed in 5 years and shares have finally busted out of the recent narrow trading range. Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report International Business Machines Corporation (IBM): Free Stock Analysis Report eBay Inc. (EBAY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report To read this article on Zacks.com click here. Earnings season kicks into high gear this week with over 190 companies reporting, including many big cap Dow and S&P 500 names. | Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report International Business Machines Corporation (IBM): Free Stock Analysis Report eBay Inc. (EBAY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT hasn't missed in 5 years and shares have finally busted out of the recent narrow trading range. These 5 big cap companies have good earnings beat records, but not all of the stocks are soaring. | Abbott Labs ABT hasn't missed in 5 years and shares have finally busted out of the recent narrow trading range. Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report International Business Machines Corporation (IBM): Free Stock Analysis Report eBay Inc. (EBAY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report To read this article on Zacks.com click here. Earnings season kicks into high gear this week with over 190 companies reporting, including many big cap Dow and S&P 500 names. | Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report International Business Machines Corporation (IBM): Free Stock Analysis Report eBay Inc. (EBAY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT hasn't missed in 5 years and shares have finally busted out of the recent narrow trading range. If you want to know what is happening in certain industries, you should be sure to tune into this week's earnings. |
33466.0 | 2017-10-17 00:00:00 UTC | Pre-Market Earnings Report for October 18, 2017 : ABT, USB, ASML, MTB, NTRS, MTG, UNF, UBSH, CTBI, SVU, FCCO | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-october-18-2017-abt-usb-asml-mtb-ntrs-mtg-unf-ubsh-ctbi-svu | nan | nan | The following companies are expected to report earnings prior to market open on 10/18/2017. Visit our Earnings Calendar for a full list of expected earnings releases.
Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2017. The medical products company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.65. This value represents a 10.17% increase compared to the same quarter last year. In the past year ABT has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 3.33%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 21.94 vs. an industry ratio of 54.70.
U.S. Bancorp ( USB ) is reporting for the quarter ending September 30, 2017. The bank company's consensus earnings per share forecast from the 13 analysts that follow the stock is $0.88. This value represents a 4.76% increase compared to the same quarter last year. In the past year USB has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for USB is 15.82 vs. an industry ratio of 15.30, implying that they will have a higher earnings growth than their competitors in the same industry.
ASML Holding N.V. ( ASML ) is reporting for the quarter ending September 30, 2017. The capital goods company's consensus earnings per share forecast from the 4 analysts that follow the stock is $1.28. This value represents a 23.08% increase compared to the same quarter last year. ASML missed the consensus earnings per share in the 3rd calendar quarter of 2016 by -2.8%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ASML is 35.39 vs. an industry ratio of 20.90, implying that they will have a higher earnings growth than their competitors in the same industry.
M&T Bank Corporation ( MTB ) is reporting for the quarter ending September 30, 2017. The bank company's consensus earnings per share forecast from the 9 analysts that follow the stock is $2.40. This value represents a 12.68% increase compared to the same quarter last year. MTB missed the consensus earnings per share in the 4th calendar quarter of 2016 by -0.99%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for MTB is 17.70 vs. an industry ratio of 15.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Northern Trust Corporation ( NTRS ) is reporting for the quarter ending September 30, 2017. The bank company's consensus earnings per share forecast from the 8 analysts that follow the stock is $1.12. This value represents a 3.70% increase compared to the same quarter last year. Zacks Investment Research reports that the 2017 Price to Earnings ratio for NTRS is 19.56 vs. an industry ratio of 15.30, implying that they will have a higher earnings growth than their competitors in the same industry.
MGIC Investment Corporation ( MTG ) is reporting for the quarter ending September 30, 2017. The insurance company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.25. This value represents a no change for the same quarter last year. In the past year MTG has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 24%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for MTG is 11.77 vs. an industry ratio of 16.00.
Unifirst Corporation ( UNF ) is reporting for the quarter ending August 31, 2017. The uniform company's consensus earnings per share forecast from the 6 analysts that follow the stock is $1.24. This value represents a 2.36% decrease compared to the same quarter last year. UNF missed the consensus earnings per share in the 4th calendar quarter of 2016 by -12.66%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for UNF is 31.87 vs. an industry ratio of 26.60, implying that they will have a higher earnings growth than their competitors in the same industry.
Union Bankshares Corporation ( UBSH ) is reporting for the quarter ending September 30, 2017. The banks (southeast) company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.49. This value represents a 4.26% increase compared to the same quarter last year. UBSH missed the consensus earnings per share in the 2nd calendar quarter of 2017 by -2.13%. The "days to cover" for this stock exceeds 14 days. Zacks Investment Research reports that the 2017 Price to Earnings ratio for UBSH is 18.88 vs. an industry ratio of 17.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Community Trust Bancorp, Inc. ( CTBI ) is reporting for the quarter ending September 30, 2017. The banks (southeast) company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.72. This value represents a 2.86% increase compared to the same quarter last year. Zacks Investment Research reports that the 2017 Price to Earnings ratio for CTBI is 17.33 vs. an industry ratio of 17.20, implying that they will have a higher earnings growth than their competitors in the same industry.
SuperValu Inc. ( SVU ) is reporting for the quarter ending August 31, 2017. The food company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.38. This value represents a 45.71% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2018 Price to Earnings ratio for SVU is 7.84 vs. an industry ratio of -23.90, implying that they will have a higher earnings growth than their competitors in the same industry.
First Community Corporation ( FCCO ) is reporting for the quarter ending September 30, 2017. The banks (southeast) company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.29. This value represents a 16.00% increase compared to the same quarter last year. Zacks Investment Research reports that the 2017 Price to Earnings ratio for FCCO is 20.47 vs. an industry ratio of 17.20, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2017. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 21.94 vs. an industry ratio of 54.70. | Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2017. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 21.94 vs. an industry ratio of 54.70. | Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2017. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 21.94 vs. an industry ratio of 54.70. | In the past year ABT has beat the expectations every quarter. Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2017. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 21.94 vs. an industry ratio of 54.70. |
33467.0 | 2017-10-17 00:00:00 UTC | The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-abbvie-american-express-abbott-united-technologies-and | nan | nan | For Immediate Release
Chicago, IL - October 17, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AbbVie (NYSE: ABBV - Free Report ), American Express (NYSE: AXP - Free Report ), Abbott (NYSE: ABT - Free Report ), United Technologies (NYSE: UTX - Free Report ) and VMWare (NYSE: VMW - Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Monday's Analyst Blog:
Top Research Reports for AbbVie, American Express and Abbott Labs
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie (NYSE: ABBV - Free Report ), American Express (NYSE: AXP - Free Report ) and Abbott (NYSE: ABT - Free Report ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
AbbVie shares have gained +44.8% year to date, outperforming the Zacks Large Cap Pharmaceuticals industry, which has gained +18.3% over the same period. The Zacks analyst likes the strong performance of AbbVie's key drug Humira which should continue to do well. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases.
Meanwhile, AbbVie has promising pipeline with several pivotal data readouts and regulatory milestones due in the second half. Maviret, approved recently, has the potential to rejuvenate AbbVie's struggling HCV franchise. However, though Humira is doing well, the company is concerned about the product's long-term growth prospects, given potential biosimilar competition.
Viekira also faces intense pricing and competitive pressure in the HCV market. Estimates have gone up slightly ahead of the company's Q3 earnings release. AbbVie has had a mixed record of earnings surprises in the recent quarters.
(You can read the full research report on AbbVie here >>> ).
Shares of American Express are up +55.1% over the last one year, outperforming the Zacks Financial Miscellaneous Services industry, which has gained +34% over the same period. The Zacks analyst likes its solid market position, strength in card business and significant opportunities from the secular shift toward electronic payments.
The company is gaining from investments made in growth opportunities over the last couple of years. Strategic initiatives focusing on the platinum card portfolio and OptBlue program will drive business volume. Cost reduction and return of significant capital to shareholders through dividend and share buyback are other positives.
The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 0.5% upward over the last 90 days. However, an increase in provision for losses, foreign exchange volatility, loss of Costco as a client and intense competition remain major near-term concerns.
(You can read the full research report on American Express here >>> ).
Buy-rated Abbott 's shares have gained +12.1% over the last three months, outperforming the Zacks Medical Products industry, which has gained +0.3% over the same period. Ahead of Abbott's third-quarter 2017 earnings result, the Zacks analyst likes the promising full year guidance which is indicative of brighter prospects ahead. In fact, the strong guidance is backed by the company's expectations to gain more synergies from the St. Jude merger.
Overall, Abbott's plan to expand in core therapeutic areas is cause for encouragement. Recently, the company's FreeStyle Libre Flash received the FDA approval. Also, the company has received FDA approval for magnetic resonance-conditional labeling for its Ellipse implantable cardioverter defibrillator recently.
On the flip side, Abbott's sluggish pediatric business in China continues to dent growth. Management is also concerned about the economic problems in Venezuela that are expected to remain unresolved for some time.
(You can read the full research report on Abbott here >>> ).
Other noteworthy reports we are featuring today include United Technologies (NYSE: UTX - Free Report ) and VMWare (NYSE: VMW - Free Report ).
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on ABBV - FREE
Get the full Report on AXP - FREE
Get the full Report on ABT - FREE
Get the full Report on UTX - FREE
Get the full Report on VMW - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Vmware, Inc. (VMW): Free Stock Analysis Report
United Technologies Corporation (UTX): Free Stock Analysis Report
American Express Company (AXP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include AbbVie (NYSE: ABBV - Free Report ), American Express (NYSE: AXP - Free Report ), Abbott (NYSE: ABT - Free Report ), United Technologies (NYSE: UTX - Free Report ) and VMWare (NYSE: VMW - Free Report ). Today's Research Daily features new research reports on 16 major stocks, including AbbVie (NYSE: ABBV - Free Report ), American Express (NYSE: AXP - Free Report ) and Abbott (NYSE: ABT - Free Report ). Get the full Report on ABBV - FREE Get the full Report on AXP - FREE Get the full Report on ABT - FREE Get the full Report on UTX - FREE Get the full Report on VMW - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. | Stocks recently featured in the blog include AbbVie (NYSE: ABBV - Free Report ), American Express (NYSE: AXP - Free Report ), Abbott (NYSE: ABT - Free Report ), United Technologies (NYSE: UTX - Free Report ) and VMWare (NYSE: VMW - Free Report ). Today's Research Daily features new research reports on 16 major stocks, including AbbVie (NYSE: ABBV - Free Report ), American Express (NYSE: AXP - Free Report ) and Abbott (NYSE: ABT - Free Report ). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vmware, Inc. (VMW): Free Stock Analysis Report United Technologies Corporation (UTX): Free Stock Analysis Report American Express Company (AXP): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include AbbVie (NYSE: ABBV - Free Report ), American Express (NYSE: AXP - Free Report ), Abbott (NYSE: ABT - Free Report ), United Technologies (NYSE: UTX - Free Report ) and VMWare (NYSE: VMW - Free Report ). Get the full Report on ABBV - FREE Get the full Report on AXP - FREE Get the full Report on ABT - FREE Get the full Report on UTX - FREE Get the full Report on VMW - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vmware, Inc. (VMW): Free Stock Analysis Report United Technologies Corporation (UTX): Free Stock Analysis Report American Express Company (AXP): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include AbbVie (NYSE: ABBV - Free Report ), American Express (NYSE: AXP - Free Report ), Abbott (NYSE: ABT - Free Report ), United Technologies (NYSE: UTX - Free Report ) and VMWare (NYSE: VMW - Free Report ). Today's Research Daily features new research reports on 16 major stocks, including AbbVie (NYSE: ABBV - Free Report ), American Express (NYSE: AXP - Free Report ) and Abbott (NYSE: ABT - Free Report ). Get the full Report on ABBV - FREE Get the full Report on AXP - FREE Get the full Report on ABT - FREE Get the full Report on UTX - FREE Get the full Report on VMW - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. |
33468.0 | 2017-10-16 00:00:00 UTC | CHICAGO TRUST Co NA Buys Discover Financial Services, Dominion Energy Inc, DowDuPont Inc, Sells ... | ABT | https://www.nasdaq.com/articles/chicago-trust-co-na-buys-discover-financial-services-dominion-energy-inc-dowdupont-inc | nan | nan | CHICAGO TRUST Co NA
New Purchases: DFS , DWDP , ITW , AMZN, ENB, KORS, THR, UBNT,
Added Positions:D, HOG, MET, MCK, VZ, XOM, MDLZ, GOOG, T, ETN,
Reduced Positions:WFC, DUK, ACN, MO, MSFT, AMGN, AET, SHW, AMP, CI,
Sold Out:DD, AHL, LQ, SCSC, JLL, NWL, BW, RSYS,
For the details of CHICAGO TRUST Co NA's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=CHICAGO+TRUST+Co+NA
These are the top 5 holdings of CHICAGO TRUST Co NA
Apple Inc ( AAPL ) - 51,659 shares, 3.65% of the total portfolio. Shares added by 1.94%
AbbVie Inc ( ABBV ) - 86,041 shares, 3.51% of the total portfolio. Shares added by 1.33%
Microsoft Corp ( MSFT ) - 78,857 shares, 2.7% of the total portfolio. Shares reduced by 8.66%
Abbott Laboratories ( ABT ) - 108,584 shares, 2.66% of the total portfolio. Shares reduced by 1.09%
Exxon Mobil Corp ( XOM ) - 70,213 shares, 2.64% of the total portfolio. Shares added by 7.30%
New Purchase: Discover Financial Services (DFS)
CHICAGO TRUST Co NA initiated holdings in Discover Financial Services. The purchase prices were between $57.66 and $64.36, with an estimated average price of $60.6. The stock is now traded at around $64.48. The impact to the portfolio due to this purchase was 0.94%. The holdings were 31,717 shares as of 2017-09-30.
New Purchase: DowDuPont Inc (DWDP)
CHICAGO TRUST Co NA initiated holdings in DowDuPont Inc. The purchase prices were between $63.11 and $70.41, with an estimated average price of $65.88. The stock is now traded at around $71.20. The impact to the portfolio due to this purchase was 0.45%. The holdings were 14,008 shares as of 2017-09-30.
New Purchase: Illinois Tool Works Inc (ITW)
CHICAGO TRUST Co NA initiated holdings in Illinois Tool Works Inc. The purchase prices were between $135.6 and $148, with an estimated average price of $142.14. The stock is now traded at around $153.27. The impact to the portfolio due to this purchase was 0.18%. The holdings were 2,669 shares as of 2017-09-30.
New Purchase: Amazon.com Inc (AMZN)
CHICAGO TRUST Co NA initiated holdings in Amazon.com Inc. The purchase prices were between $938.6 and $1052.8, with an estimated average price of $981.92. The stock is now traded at around $1002.05. The impact to the portfolio due to this purchase was 0.13%. The holdings were 288 shares as of 2017-09-30.
New Purchase: Enbridge Inc (ENB)
CHICAGO TRUST Co NA initiated holdings in Enbridge Inc. The purchase prices were between $39.13 and $41.9, with an estimated average price of $40.64. The stock is now traded at around $41.39. The impact to the portfolio due to this purchase was 0.11%. The holdings were 5,536 shares as of 2017-09-30.
New Purchase: Michael Kors Holdings Ltd (KORS)
CHICAGO TRUST Co NA initiated holdings in Michael Kors Holdings Ltd. The purchase prices were between $33.25 and $48.55, with an estimated average price of $40.6. The stock is now traded at around $48.12. The impact to the portfolio due to this purchase was 0.11%. The holdings were 5,000 shares as of 2017-09-30.
Added: Dominion Energy Inc (D)
CHICAGO TRUST Co NA added to the holdings in Dominion Energy Inc by 605.07%. The purchase prices were between $75.6 and $80.24, with an estimated average price of $77.75. The stock is now traded at around $78.53. The impact to the portfolio due to this purchase was 0.76%. The holdings were 24,889 shares as of 2017-09-30.
Added: Harley-Davidson Inc (HOG)
CHICAGO TRUST Co NA added to the holdings in Harley-Davidson Inc by 27.77%. The purchase prices were between $45.93 and $54.83, with an estimated average price of $48.75. The stock is now traded at around $46.43. The impact to the portfolio due to this purchase was 0.27%. The holdings were 57,038 shares as of 2017-09-30.
Added: MetLife Inc (MET)
CHICAGO TRUST Co NA added to the holdings in MetLife Inc by 37.83%. The purchase prices were between $46.68 and $51.95, with an estimated average price of $48.71. The stock is now traded at around $52.91. The impact to the portfolio due to this purchase was 0.25%. The holdings were 38,071 shares as of 2017-09-30.
Added: McKesson Corp (MCK)
CHICAGO TRUST Co NA added to the holdings in McKesson Corp by 33.13%. The purchase prices were between $146 and $168.12, with an estimated average price of $156.11. The stock is now traded at around $146.90. The impact to the portfolio due to this purchase was 0.21%. The holdings were 12,099 shares as of 2017-09-30.
Added: Verizon Communications Inc (VZ)
CHICAGO TRUST Co NA added to the holdings in Verizon Communications Inc by 27.13%. The purchase prices were between $42.89 and $49.9, with an estimated average price of $47.03. The stock is now traded at around $48.09. The impact to the portfolio due to this purchase was 0.2%. The holdings were 41,582 shares as of 2017-09-30.
Added: Mondelez International Inc (MDLZ)
CHICAGO TRUST Co NA added to the holdings in Mondelez International Inc by 22.09%. The purchase prices were between $40.05 and $44.24, with an estimated average price of $42.5. The stock is now traded at around $41.68. The impact to the portfolio due to this purchase was 0.16%. The holdings were 46,753 shares as of 2017-09-30.
Sold Out: E.I. du Pont de Nemours & Co (DD)
CHICAGO TRUST Co NA sold out the holdings in E.I. du Pont de Nemours & Co. The sale prices were between $80.81 and $85.49, with an estimated average price of $82.78.
Sold Out: Aspen Insurance Holdings Ltd (AHL)
CHICAGO TRUST Co NA sold out the holdings in Aspen Insurance Holdings Ltd. The sale prices were between $36.45 and $51.75, with an estimated average price of $46.4.
Sold Out: ScanSource Inc (SCSC)
CHICAGO TRUST Co NA sold out the holdings in ScanSource Inc. The sale prices were between $36.55 and $44.2, with an estimated average price of $39.27.
Sold Out: La Quinta Holdings Inc (LQ)
CHICAGO TRUST Co NA sold out the holdings in La Quinta Holdings Inc. The sale prices were between $14.38 and $17.63, with an estimated average price of $15.5.
Sold Out: Jones Lang LaSalle Inc (JLL)
CHICAGO TRUST Co NA sold out the holdings in Jones Lang LaSalle Inc. The sale prices were between $116.7 and $132.87, with an estimated average price of $123.66.
Sold Out: Newell Brands Inc (NWL)
CHICAGO TRUST Co NA sold out the holdings in Newell Brands Inc. The sale prices were between $40.96 and $53.9, with an estimated average price of $48.97.
Reduced: Wells Fargo & Co (WFC)
CHICAGO TRUST Co NA reduced to the holdings in Wells Fargo & Co by 48.64%. The sale prices were between $49.58 and $55.78, with an estimated average price of $53.16. The stock is now traded at around $53.48. The impact to the portfolio due to this sale was -0.77%. CHICAGO TRUST Co NA still held 30,209 shares as of 2017-09-30.
Reduced: Duke Energy Corp (DUK)
CHICAGO TRUST Co NA reduced to the holdings in Duke Energy Corp by 61.57%. The sale prices were between $83.18 and $88.34, with an estimated average price of $85.61. The stock is now traded at around $86.52. The impact to the portfolio due to this sale was -0.52%. CHICAGO TRUST Co NA still held 8,064 shares as of 2017-09-30.
Reduced: Accenture PLC (ACN)
CHICAGO TRUST Co NA reduced to the holdings in Accenture PLC by 55.83%. The sale prices were between $122.94 and $138.16, with an estimated average price of $130.19. The stock is now traded at around $138.60. The impact to the portfolio due to this sale was -0.41%. CHICAGO TRUST Co NA still held 5,458 shares as of 2017-09-30.
Reduced: Altria Group Inc (MO)
CHICAGO TRUST Co NA reduced to the holdings in Altria Group Inc by 33.28%. The sale prices were between $61.22 and $74.61, with an estimated average price of $66.73. The stock is now traded at around $65.16. The impact to the portfolio due to this sale was -0.33%. CHICAGO TRUST Co NA still held 18,088 shares as of 2017-09-30.
Reduced: Sherwin-Williams Co (SHW)
CHICAGO TRUST Co NA reduced to the holdings in Sherwin-Williams Co by 24.41%. The sale prices were between $328.97 and $359.72, with an estimated average price of $344.34. The stock is now traded at around $383.11. The impact to the portfolio due to this sale was -0.17%. CHICAGO TRUST Co NA still held 3,096 shares as of 2017-09-30.
Reduced: Cigna Corp (CI)
CHICAGO TRUST Co NA reduced to the holdings in Cigna Corp by 39.94%. The sale prices were between $167.5 and $187.62, with an estimated average price of $177.97. The stock is now traded at around $184.73. The impact to the portfolio due to this sale was -0.11%. CHICAGO TRUST Co NA still held 1,958 shares as of 2017-09-30.
Warning! GuruFocus has detected 5 Warning Signs with D. Click here to check it out.
D 15-Year Financial Data
The intrinsic value of D
Peter Lynch Chart of D
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares reduced by 8.66% Abbott Laboratories ( ABT ) - 108,584 shares, 2.66% of the total portfolio. CHICAGO TRUST Co NA New Purchases: DFS , DWDP , ITW , AMZN, ENB, KORS, THR, UBNT, Added Positions:D, HOG, MET, MCK, VZ, XOM, MDLZ, GOOG, T, ETN, Reduced Positions:WFC, DUK, ACN, MO, MSFT, AMGN, AET, SHW, AMP, CI, Sold Out:DD, AHL, LQ, SCSC, JLL, NWL, BW, RSYS, For the details of CHICAGO TRUST Co NA's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=CHICAGO+TRUST+Co+NA These are the top 5 holdings of CHICAGO TRUST Co NA Apple Inc ( AAPL ) - 51,659 shares, 3.65% of the total portfolio. du Pont de Nemours & Co (DD) CHICAGO TRUST Co NA sold out the holdings in E.I. | Shares reduced by 8.66% Abbott Laboratories ( ABT ) - 108,584 shares, 2.66% of the total portfolio. CHICAGO TRUST Co NA New Purchases: DFS , DWDP , ITW , AMZN, ENB, KORS, THR, UBNT, Added Positions:D, HOG, MET, MCK, VZ, XOM, MDLZ, GOOG, T, ETN, Reduced Positions:WFC, DUK, ACN, MO, MSFT, AMGN, AET, SHW, AMP, CI, Sold Out:DD, AHL, LQ, SCSC, JLL, NWL, BW, RSYS, For the details of CHICAGO TRUST Co NA's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=CHICAGO+TRUST+Co+NA These are the top 5 holdings of CHICAGO TRUST Co NA Apple Inc ( AAPL ) - 51,659 shares, 3.65% of the total portfolio. Shares added by 7.30% New Purchase: Discover Financial Services (DFS) CHICAGO TRUST Co NA initiated holdings in Discover Financial Services. | Shares reduced by 8.66% Abbott Laboratories ( ABT ) - 108,584 shares, 2.66% of the total portfolio. CHICAGO TRUST Co NA New Purchases: DFS , DWDP , ITW , AMZN, ENB, KORS, THR, UBNT, Added Positions:D, HOG, MET, MCK, VZ, XOM, MDLZ, GOOG, T, ETN, Reduced Positions:WFC, DUK, ACN, MO, MSFT, AMGN, AET, SHW, AMP, CI, Sold Out:DD, AHL, LQ, SCSC, JLL, NWL, BW, RSYS, For the details of CHICAGO TRUST Co NA's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=CHICAGO+TRUST+Co+NA These are the top 5 holdings of CHICAGO TRUST Co NA Apple Inc ( AAPL ) - 51,659 shares, 3.65% of the total portfolio. New Purchase: Michael Kors Holdings Ltd (KORS) CHICAGO TRUST Co NA initiated holdings in Michael Kors Holdings Ltd. | Shares reduced by 8.66% Abbott Laboratories ( ABT ) - 108,584 shares, 2.66% of the total portfolio. CHICAGO TRUST Co NA New Purchases: DFS , DWDP , ITW , AMZN, ENB, KORS, THR, UBNT, Added Positions:D, HOG, MET, MCK, VZ, XOM, MDLZ, GOOG, T, ETN, Reduced Positions:WFC, DUK, ACN, MO, MSFT, AMGN, AET, SHW, AMP, CI, Sold Out:DD, AHL, LQ, SCSC, JLL, NWL, BW, RSYS, For the details of CHICAGO TRUST Co NA's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=CHICAGO+TRUST+Co+NA These are the top 5 holdings of CHICAGO TRUST Co NA Apple Inc ( AAPL ) - 51,659 shares, 3.65% of the total portfolio. New Purchase: Amazon.com Inc (AMZN) CHICAGO TRUST Co NA initiated holdings in Amazon.com Inc. |
33469.0 | 2017-10-13 00:00:00 UTC | Spin-Off ETF: Can the Outperformance Continue? | ABT | https://www.nasdaq.com/articles/spin-etf-can-outperformance-continue-2017-10-13 | nan | nan | Spin-off activities have stepped up lately, with biggies like Honeywell International HON and Pfizer PFE being the most active ones. Lately, the industrial giant Honeywell announced plans of spinning off its homes and global distribution units and its transportation systems unit into two publicly traded companies by 2018 end (read: 5 ETFs to Buy on 13-Year High Manufacturing Activity ).
On the other hand, Pfizer is exploring strategic alternatives to possibly bid good-bye to its Consumer Healthcare segment. A sale or spin-off of its consumer-health unit is expected next year. Pfizer's consumer sales have been essentially "flat for the past three years ."
This clearly explains why Pfizer intends to concentrate on the more promising, innovative pharmaceutical unit and separate it from Consumer Healthcare. The move also signifies the likely introduction of more deal-making, as per Wall Street Journal. However, the company also kept open chances of retaining the business .
Inside Spin-offs
Sometimes businesses form another autonomous entity from an existing business/division, when they believe that the separated line would add more value as an independent company. In such situations, the parent can focus on its core business management while the new entity can focus on its relative different goals.
How Profitable Spin-offs are to Investors?
According to Cantor Fitzgerald , "spinoffs completed between 2009 and 2013 outperformed the S&P 500 in their first year of trading by an average of more than 17 percent." As per an article published on benzinga , spun-off entities have been performing better than parent companies lately.
PayPal PYPL (up about 114%) generated higher gains than parent eBay EBAY (up about 56%) in the last two years (post spin-off). WhiteWave Foods CoWWAV gained about 67.8% in the last three years against an 11.2% decline in Dean Foods CoDF . WhiteWave Foods was spun off in May 2013. Abbot LaboratoriesABT cut ties with part of its business and formed a new company called AbbVie ABBV in Jan 2013. ABBV was up 85% while ABT gained 41% in the last three years (as of Oct 12, 2017).
What's Behind the Recent Surge in Spin-Off
A Chicago-based partner at The Boston Consulting Group recently commented that in a bull market, which we are witnessing currently, equities are overvalued. This makes materialization of mergers and acquisitions difficult. Instead, high valuations better justify " spinning off assets or divesting assets." If this logic holds good, we are likely to see more such actions in the coming days (read: 4 Bargain ETFs in a Pricey Market ).
Notably, the United States saw 88 completed spinoffs in 1999, which fell to 80 in 2000, when the dot-com bubble burst. The number further declined to 55 in 2001. The number of actions again rose from 24 in 2007 to 30 in 2008, before sliding to 17 in 2009 when the financial crisis kicked in, as per the data provided by Dealogic, quoted on CNBC. The momentum again gained momentum in 2015 by value, though 2016 and 2017 have been subdued.
ETFs to Play
There are always ways to play such corporate actions. Below we highlight two spin-off ETFs in detail. These ETFs can get further boost from Honeywell and Pfizer's announcements.
Guggenheim S&P Spin-Off ETF CSD
The 61-stock fund looks to track the S&P U.S. Spin-Off Index. Paypal Holdings (7.98%), Hewlett Packard Enterprise (7.85%) and Synchrony Financial (7.39%) are the top three holdings of the fund. CSD charges 65 bps in fees (read: PayPal's Strong Q2 Results Put These ETFs in Focus ).
VanEck Vectors Global Spin-Off ETF SPUN
The 95-stock fund follows the Horizon Kinetics Global Spin-Off Index, which is a rules-based, equal-weighted index intended to track the performance of listed, publicly held spin-offs that are domiciled and trade in the U.S. or developed markets of Western Europe and Asia. The net expense ratio of the fund is 0.55%. United States accounts for about 78.8% of the fund. Gannett Co (1.2%), Time Inc. (1.1%) and Timkensteel (1.1%) are top three stocks of the fund.
Want key ETF info delivered straight to your inbox?
Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
eBay Inc. (EBAY): Free Stock Analysis Report
PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report
Pfizer, Inc. (PFE): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Honeywell International Inc. (HON): Free Stock Analysis Report
Dean Foods Company (DF): Free Stock Analysis Report
GUGG-SPIN-OFF (CSD): ETF Research Reports
VANECK-GLB S-O (SPUN): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbot LaboratoriesABT cut ties with part of its business and formed a new company called AbbVie ABBV in Jan 2013. ABBV was up 85% while ABT gained 41% in the last three years (as of Oct 12, 2017). Click to get this free report eBay Inc. (EBAY): Free Stock Analysis Report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Honeywell International Inc. (HON): Free Stock Analysis Report Dean Foods Company (DF): Free Stock Analysis Report GUGG-SPIN-OFF (CSD): ETF Research Reports VANECK-GLB S-O (SPUN): ETF Research Reports To read this article on Zacks.com click here. | Click to get this free report eBay Inc. (EBAY): Free Stock Analysis Report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Honeywell International Inc. (HON): Free Stock Analysis Report Dean Foods Company (DF): Free Stock Analysis Report GUGG-SPIN-OFF (CSD): ETF Research Reports VANECK-GLB S-O (SPUN): ETF Research Reports To read this article on Zacks.com click here. Abbot LaboratoriesABT cut ties with part of its business and formed a new company called AbbVie ABBV in Jan 2013. ABBV was up 85% while ABT gained 41% in the last three years (as of Oct 12, 2017). | Click to get this free report eBay Inc. (EBAY): Free Stock Analysis Report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Honeywell International Inc. (HON): Free Stock Analysis Report Dean Foods Company (DF): Free Stock Analysis Report GUGG-SPIN-OFF (CSD): ETF Research Reports VANECK-GLB S-O (SPUN): ETF Research Reports To read this article on Zacks.com click here. Abbot LaboratoriesABT cut ties with part of its business and formed a new company called AbbVie ABBV in Jan 2013. ABBV was up 85% while ABT gained 41% in the last three years (as of Oct 12, 2017). | Click to get this free report eBay Inc. (EBAY): Free Stock Analysis Report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Honeywell International Inc. (HON): Free Stock Analysis Report Dean Foods Company (DF): Free Stock Analysis Report GUGG-SPIN-OFF (CSD): ETF Research Reports VANECK-GLB S-O (SPUN): ETF Research Reports To read this article on Zacks.com click here. Abbot LaboratoriesABT cut ties with part of its business and formed a new company called AbbVie ABBV in Jan 2013. ABBV was up 85% while ABT gained 41% in the last three years (as of Oct 12, 2017). |
33470.0 | 2017-10-13 00:00:00 UTC | Abbott Banks on FDA Approvals and Buyouts, Competition Rife | ABT | https://www.nasdaq.com/articles/abbott-banks-on-fda-approvals-and-buyouts-competition-rife-2017-10-13 | nan | nan | On Oct 12, we issued an updated research report on AbbottABT - a global healthcare company dedicated toward improving life through the development of products and technologies. The stock carries a Zacks Rank #3 (Hold).
Over the last three months, Abbott has been trading above the broader industry . The stock has gained 11.9% as against the industry's decline of 0.8%.
The market is upbeat about the several new initiatives adopted by Abbott. The latest buyout by the company is of Alere on Oct 3.
Apart from FDA approvals and buyouts, we are upbeat about Abbott's FreeStyle Libre Flash Glucose Monitoring System prospects post the receipt of full or partial reimbursement by the French Health Ministry in May 2017. At this platform, the company announced Health Canada License for FreeStyle Libre in June 2017. Abbott also announced that the FreeStyle Libre system is now available for reimbursement in the U.K.
On the flip side, Abbott's sluggish pediatric business in China continues to mar growth. Management is concerned about the economic problems in Venezuela that are expected to remain unresolved for some time. Also, foreign exchange is a major headwind for Abbott as a considerable portion of its revenues comes from outside the United States.
Key Stocks
A few better-ranked stocks in the medical sector are QIAGEN QGEN , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . QIAGEN, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
QIAGEN has a long-term expected earnings growth rate of 13.1%. The stock rallied roughly 26.8% last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock gained 45.6% last year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock gained 27.5% last year.
4 Stocks to Watch after the Massive Equifax Hack
Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?
Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor's Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.
Get the new Investing Guide now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
Qiagen N.V. (QGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On Oct 12, we issued an updated research report on AbbottABT - a global healthcare company dedicated toward improving life through the development of products and technologies. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from FDA approvals and buyouts, we are upbeat about Abbott's FreeStyle Libre Flash Glucose Monitoring System prospects post the receipt of full or partial reimbursement by the French Health Ministry in May 2017. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. On Oct 12, we issued an updated research report on AbbottABT - a global healthcare company dedicated toward improving life through the development of products and technologies. Key Stocks A few better-ranked stocks in the medical sector are QIAGEN QGEN , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. On Oct 12, we issued an updated research report on AbbottABT - a global healthcare company dedicated toward improving life through the development of products and technologies. Key Stocks A few better-ranked stocks in the medical sector are QIAGEN QGEN , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . | On Oct 12, we issued an updated research report on AbbottABT - a global healthcare company dedicated toward improving life through the development of products and technologies. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from FDA approvals and buyouts, we are upbeat about Abbott's FreeStyle Libre Flash Glucose Monitoring System prospects post the receipt of full or partial reimbursement by the French Health Ministry in May 2017. |
33471.0 | 2017-10-12 00:00:00 UTC | DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay | ABT | https://www.nasdaq.com/articles/dentsply-sirona-strong-on-deal-renewals-forex-woes-stay-2017-10-12 | nan | nan | On Oct 11, we issued an updated research report on New York-based DENTSPLY SIRONA Inc.XRAY - a global leader in the design, development, manufacture and marketing of dental consumables and dental laboratory products.
DENTSPLY recently announced the renewal of an existing distribution agreement with Henry Schein Canada, Inc, which will continue till Dec 31, 2020. Henry Schein's agreement with DENTSPLY was initiated in August 2005.
We feel that the deal extension is a smart move by DENTSPLY as the preexisting agreement did not include the CEREC CAD/CAM restoration system and the Schick line of imaging sensors. By including the aforementioned lines of products, the company will benefit from Henry Schein's distribution network in Canada.
Among the recent developments, DENTSPLY announced the renewal of its partnership with Pacific Dental Services. The duo's latest agreement extends for a period of five years which was signed in 2012.
This move is also a strategic one as Pacific Dental's network consists of over 580 centers across 17 states. During the tenure of the present agreement, management expects the number of such offices utilizing DENTSPLY technologies to exceed 800.
DENTSPLY's dual branding strategy, product innovation, growth opportunities in emerging markets (especially Asia-Pacific and Middle East/Africa), diversified product portfolio and recurring revenue base are key catalysts. The company expects a solid guidance for full-year 2017 projecting adjusted EPS in the range of $2.65-$2.75.
On the flip side, apart from a series of macroeconomic headwinds, currency fluctuation continues to be a major dampener. In fact, strengthening of the U.S. dollar against Euro and other emerging market currencies has dented the company's growth trajectory. Furthermore, higher capital expenditure on product development is expected to keep margins under pressure.
Share Price & Estimate Revisions Lack Luster
DENTSPLY's estimate revision trend looks unfavorable at the moment. For the third quarter, two analysts moved south, compared to no upward revision in the last two months. Notably, the current quarter estimates dropped 1.5% to 67 cents per share over the last 60 days.
DENTSPLY's share price movement has been unfavorable over the last three months. The company shed 11.7%, much higher than the industry 's decline of 4.4%.
Zacks Rank & Key Picks
DENTSPLY currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical sector are Abbott ABT , IDEXX Laboratories, Inc IDXX and Thermo Fisher Scientific Inc TMO . Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Abbott has a long-term expected earnings growth rate of 10.7%. The stock has rallied roughly 35.2% over a year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained 40.8% over a year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock has gained 25.3% last year.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked stocks in the broader medical sector are Abbott ABT , IDEXX Laboratories, Inc IDXX and Thermo Fisher Scientific Inc TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. We feel that the deal extension is a smart move by DENTSPLY as the preexisting agreement did not include the CEREC CAD/CAM restoration system and the Schick line of imaging sensors. | A few better-ranked stocks in the broader medical sector are Abbott ABT , IDEXX Laboratories, Inc IDXX and Thermo Fisher Scientific Inc TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are Abbott ABT , IDEXX Laboratories, Inc IDXX and Thermo Fisher Scientific Inc TMO . On Oct 11, we issued an updated research report on New York-based DENTSPLY SIRONA Inc.XRAY - a global leader in the design, development, manufacture and marketing of dental consumables and dental laboratory products. | A few better-ranked stocks in the broader medical sector are Abbott ABT , IDEXX Laboratories, Inc IDXX and Thermo Fisher Scientific Inc TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. On Oct 11, we issued an updated research report on New York-based DENTSPLY SIRONA Inc.XRAY - a global leader in the design, development, manufacture and marketing of dental consumables and dental laboratory products. |
33472.0 | 2017-10-12 00:00:00 UTC | Mazor Projects Higher Q3 Revenues, Clinches Mazor X Orders | ABT | https://www.nasdaq.com/articles/mazor-projects-higher-q3-revenues-clinches-mazor-x-orders-2017-10-12 | nan | nan | Developer of robotic technology and products Mazor Robotics LtdMZOR , recently announced that it expects to report third-quarter 2017 revenues of approximately $17.2 million compared with $8 million in the year-ago quarter. The bullishness comes from strength in Mazor X system sales and increased procedure volumes.
Stock Performance
Lately, the price performance of the Israel-based company has been encouraging. In the last three months, the stock has returned 28.9%, outperforming the industry 's gain of roughly 3.0%. The stock's current return was higher than the S&P 500's return of 4.1% over the same time frame.
Despite the bullish price trend, estimate revision for the stock has been quite disappointing. The full year saw two estimates moving south in the last two months, compared with no movement in the opposite direction. As a result, the estimate contracted to a loss of 86 cents per share from a loss of 88 cents during the aforementioned period.
Factors Behind Mazor X Strength
During the third quarter, the company received purchase orders for 19 Mazor X systems in the United States. In addition, Mazor received purchase orders for three Renaissance systems for the Chinese market.
Mazor X is a transformative guidance system for simplifying spine surgeries with advanced features and "sophisticated integrative abilities." Strong demand for Mazor X systems during the third quarter reached backlog to 17 since its introduction in the second half of 2016. The company is slated to report financial results for the third quarter ended Sep 30, in November.
Bottom Line
We are hopeful about the encouraging global spine surgery market. A research report by Markets And Markets suggests that the niche markets are estimated to reach $17.27 billion by 2021, at a CAGR of 5.3%.
In fact, the increasing utilization rate of Mazor X is quite compelling for the company. We believe that the commercialization cycle of the Mazor X platform is progressing per plans with a growing customer base.
Zacks Rank & Other Key Picks
Currently, Mazor has a Zacks Rank #1 (Strong Buy). A few other top-ranked stocks in the broader medical sector are Abbott ABT , IDEXX Laboratories, Inc IDXX and Thermo Fisher Scientific Inc TMO . Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott has a long-term expected earnings growth rate of 10.7%. The stock has rallied roughly 35.2% over last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained 40.8% last year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock has gained 25.3% last year.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
Mazor Robotics Ltd. (MZOR): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few other top-ranked stocks in the broader medical sector are Abbott ABT , IDEXX Laboratories, Inc IDXX and Thermo Fisher Scientific Inc TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Mazor Robotics Ltd. (MZOR): Free Stock Analysis Report To read this article on Zacks.com click here. Mazor X is a transformative guidance system for simplifying spine surgeries with advanced features and "sophisticated integrative abilities." | A few other top-ranked stocks in the broader medical sector are Abbott ABT , IDEXX Laboratories, Inc IDXX and Thermo Fisher Scientific Inc TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Mazor Robotics Ltd. (MZOR): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). | A few other top-ranked stocks in the broader medical sector are Abbott ABT , IDEXX Laboratories, Inc IDXX and Thermo Fisher Scientific Inc TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Mazor Robotics Ltd. (MZOR): Free Stock Analysis Report To read this article on Zacks.com click here. Factors Behind Mazor X Strength During the third quarter, the company received purchase orders for 19 Mazor X systems in the United States. | A few other top-ranked stocks in the broader medical sector are Abbott ABT , IDEXX Laboratories, Inc IDXX and Thermo Fisher Scientific Inc TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Mazor Robotics Ltd. (MZOR): Free Stock Analysis Report To read this article on Zacks.com click here. In the last three months, the stock has returned 28.9%, outperforming the industry 's gain of roughly 3.0%. |
33473.0 | 2017-10-12 00:00:00 UTC | MedTech Players Eyeing Emerging Market Growth Opportunities | ABT | https://www.nasdaq.com/articles/medtech-players-eyeing-emerging-market-growth-opportunities-2017-10-12 | nan | nan | A few months down the line, the Republicans will complete a full year in power. Unfortunately, since the political power change, the healthcare community hasn't had many opportunities to rejoice.
A survey report by Gallup Analytics last month revealed that U.S. adults cited healthcare as the second major problem faced by the country under the new presidential administration. In fact, the debate over repealing the Affordable Care Act (ACA) or Obamacare has been raging for a while now. Per the report, it peaked when it reached the Congress in August. Considering the prevailing uncertainty in the implementation of the health policy, any respite from it in the near term seems unlikely.
MedTech in the United States: A Blurred Picture
Needless to say, the current crisis in the U.S. MedTech industry, an integral part of the broader healthcare space, shows no signs of abating. A few months back, companies in the space were hopeful about the promised cancellation of the 2.3% MedTech tax of Obamacare under the new government. Unquestionably, the latest political developments have landed the MedTech space in an uncertain territory.
Investors are mulling over whether they should retain their existing MedTech stocks or forego their holdings in favor of companies in other industries to boost their financial resources. That said, in spite of what the future may hold, we believe investors should stick to the MedTech space as it has shown signs of prosperity in recent times globally.
Yes, you read that right. Even considering the dull performance of the U.S. medical device market (that still holds the leading position with almost one-third of the world market share) on rising regulatory and legislative uncertainty, global growth has been quite encouraging. In 2016, this industry grew 5%, a pace last seen before the financial crisis.
Emerging Markets Hold Immense Promise
The uncertainty in the United States along with the worsening economic condition in Europe automatically shifted the focus to emerging geographies like China, India, Latin America and others.
These emerging economies are seeing a rise in the uptake of medical devices largely due to growing medical awareness and economic prosperity. An aging population, increasing wealth, government focus on healthcare infrastructure and expansion of medical insurance coverage make these markets a happy hunting ground for global medical device players. Add to it, rising healthcare spending and improving healthcare infrastructure, this growth should continue in 2017 and beyond.
Going by a recent BCG report, the share of emerging markets, which is currently less than a quarter of global MedTech revenues, is likely to increase to nearly one-third of revenues by 2022. The MedTech market in China, currently the second largest in the world, is projected to grow about 13% annually from 2015 through 2022. India's Medtech market, the fifth largest in the world, is currently demonstrating 17% annual growth. If this continues, India may give good competition to Japan and Germany by 2022.
Among other emerging geographies, Latin America, even in the face of general economic stagnation, holds enormous potential. Per a January 2017 report by MedTech Intelligence, the Central and South American nations significantly increased per capita spending on healthcare in the period between 2008 and 2014. According to World Bank data, Guatemala increased spending by 27%, Brazil 31%, Chile 54%, Colombia 58%, Uruguay 95%, Paraguay 115%, Bolivia 138%, and Ecuador 139%. Lower domestic production in Latin America has made it as an open market for U.S. exporters.
Investment in Emerging Market Players Looks Sensible
In such a scenario, we believe it will be wise of investors who are keen on MedTech stocks to keep an eye on companies who have turned the emerging markets into a happy hunting ground with their expertise and network. No wonder, these stocks, cashing in on the enormous growth potential of these emerging geographies have perfectly shielded themselves from the political turmoil within the United States.
Let us look at a few MedTech players with significant emerging market presence.
Given the huge potential in these regions, long back, Johnson & JohnsonJNJ had set up manufacturing and R&D centers in Brazil, China and India. The company's medical device segment of emerging markets is growing three to four times faster than the developed markets. It has been doing business in China for nearly 30 years and is expanding further here on the back of the Synthes acquisition.
Johnson & Johnson Price and Consensus
Johnson & Johnson price-consensus-chart | Johnson & Johnson Quote
AbbottABT continues to lead the emerging market investment trend with about 50% of sales from this region. In recent quarters, sales in key emerging markets were up in double digits, driven by strength in BRIC as well as strong growth in several countries throughout Latin America, including Colombia, Mexico, Peru and Argentina.
Abbott Laboratories Price and Consensus
Abbott Laboratories price-consensus-chart | Abbott Laboratories Quote
At MedtronicMDT , in the last-reported first quarter of fiscal 2017, businesses in China, Latin America, and Southeast Asia showed sustained strength, growing in double digits. Overall, Medtronic remains confident about its long-term outlook for emerging markets. The company is focused on developing new public and private partnerships as well as executing channel optimization strategies.
Medtronic PLC Price and Consensus
Medtronic PLC price-consensus-chart | Medtronic PLC Quote
Boston Scientific 's BSX emerging markets business registered 14% organic growth in second-quarter 2017, a significant increase from 8% growth in 2013. Business in China was once again remarkable (up 20% year over year). The company is currently looking forward to much better performance ahead in China, banking on the recent approval of SYNERGY in China.
Boston Scientific Corporation Price and Consensus
Boston Scientific Corporation price-consensus-chart | Boston Scientific Corporation Quote
Thermo FisherTMO too is leaving no stone unturned to expand its presence in emerging markets. The company garnered 20% of total revenue from the high-growth Asia-Pacific and emerging markets in 2016 from 10% in 2006.
Thermo Fisher Scientific Inc Price and Consensus
Thermo Fisher Scientific Inc price-consensus-chart | Thermo Fisher Scientific Inc Quote
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Johnson & Johnson Price and Consensus Johnson & Johnson price-consensus-chart | Johnson & Johnson Quote AbbottABT continues to lead the emerging market investment trend with about 50% of sales from this region. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. A survey report by Gallup Analytics last month revealed that U.S. adults cited healthcare as the second major problem faced by the country under the new presidential administration. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Johnson & Johnson Price and Consensus Johnson & Johnson price-consensus-chart | Johnson & Johnson Quote AbbottABT continues to lead the emerging market investment trend with about 50% of sales from this region. Medtronic PLC Price and Consensus Medtronic PLC price-consensus-chart | Medtronic PLC Quote Boston Scientific 's BSX emerging markets business registered 14% organic growth in second-quarter 2017, a significant increase from 8% growth in 2013. Business in China was once again remarkable (up 20% year over year). | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Johnson & Johnson Price and Consensus Johnson & Johnson price-consensus-chart | Johnson & Johnson Quote AbbottABT continues to lead the emerging market investment trend with about 50% of sales from this region. Investment in Emerging Market Players Looks Sensible In such a scenario, we believe it will be wise of investors who are keen on MedTech stocks to keep an eye on companies who have turned the emerging markets into a happy hunting ground with their expertise and network. | Johnson & Johnson Price and Consensus Johnson & Johnson price-consensus-chart | Johnson & Johnson Quote AbbottABT continues to lead the emerging market investment trend with about 50% of sales from this region. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. The company's medical device segment of emerging markets is growing three to four times faster than the developed markets. |
33474.0 | 2017-10-11 00:00:00 UTC | QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife | ABT | https://www.nasdaq.com/articles/qiagen-banks-on-tie-ups-product-launches-competition-rife-2017-10-11 | nan | nan | On Oct 10, we issued an updated research report on Netherlands-based molecular diagnostics provider QIAGENQGEN . The company offers innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions.
We are upbeat about QIAGEN's partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio. Also, we are encouraged to note that post the receipt of FDA approval in June, QIAGEN announced the complete launch of the fourth generation of its blood test for tuberculosis (TB) infection - QuantiFERON-TB Gold Plus (QFT-Plus) - in the United States.
Moreover, the company's strategic focus to drive growth through Sample to Insight offerings buoys optimism. QIAGEN is forming collaborations in the personalized homecare space as well.
QIAGEN currently markets products in more than 100 countries. In the last reported second quarter of 2017, the company witnessed growth across all international regions, including the top seven emerging markets.
On the flip side, over the last three months, QIAGEN has been trading below the broader industry . As per the latest share price, the company has gained 2.9%, compared to 7.1% gain of the broader industry. Moreover, adverse currency translation continues to be a drag on overall sales. Furthermore, declining HPV sales in the United States continues to be a drag. Competitive landscape and heavy dependence on collaborations continue to be concerns.
Zacks Rank & Other Key Picks
QIAGEN currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Abbott has a long-term expected earnings growth rate of 10.7%. The stock has rallied roughly 35.2% over the last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained 40.8% last year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock has gained 25.3% last year.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
Qiagen N.V. (QGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other top-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Also, we are encouraged to note that post the receipt of FDA approval in June, QIAGEN announced the complete launch of the fourth generation of its blood test for tuberculosis (TB) infection - QuantiFERON-TB Gold Plus (QFT-Plus) - in the United States. | Other top-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2. | Other top-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Rank & Other Key Picks QIAGEN currently carries a Zacks Rank #2 (Buy). | Other top-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. The company offers innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. |
33475.0 | 2017-10-11 00:00:00 UTC | Express Scripts (ESRX) to Buy eviCore, Fortify PBM Business | ABT | https://www.nasdaq.com/articles/express-scripts-esrx-to-buy-evicore-fortify-pbm-business-2017-10-11 | nan | nan | Express Scripts Holding CompanyESRX recently inked an agreement to acquire privately-held eviCore healthcare from investors including General Atlantic, TA Associates and Ridgemont Equity Partners for $3.6 billion. The transaction is expected to close in the fourth quarter of 2017.
eviCore provides evidence-based and integrated medical benefit management services (MBM) solutions that drive cost reduction and quality care outcomes. Notably, eviCore will operate as a standalone business unit under Express Scripts.
Express Scripts' pharmacy benefit management coupled with eviCore's complementary medical benefits management is likely to build a comprehensive patient benefit management (PBM) solution. This buyout will provide Express Scriptsopportunities to cross-sell to both client bases.
Financial Impact
The acquisition is expected to prove accretive to Express Scripts' adjusted diluted earnings per share within the first full year of operation, excluding transaction-related expenses and amortization of intangibles.According to the company, this deal is likely to take care of the $1 trillion that is spent on healthcare annually.
Industry Prospects
Although PBM is a highly competitive industry, a report by Market Research projects the U.S. pharmacy benefit management market to see a CAGR of 7.2% between 2014 and 2019. According to a Markets and Markets report, the global healthcare provider network management market will value $2.96 billion by 2020, at a CAGR of 10.7% during the 2015 to 2020 period. Taking this into account, Express Scripts has been consistently trying to expand its core PBM business.
The company recently announced plans of expanding its customized workers' compensation pharmacy solutions through the acquisition of myMatrixx, a pharmacy benefit solutions provider for the workers' compensation industry. Furthermore, the company anticipates compounded annual EBITDA growth rate between 2% and 4% from 2017 through 2020 for the core PBM business. However, Express Scripts announced that its biggest customer, the leading health insurer Anthem Inc. (ANTM), is not likely to extend its pharmacy-benefits management agreement, which is slated for expiration by the end of 2019.
Price Performance
Express Scripts' stock has underperformed the broader industry in the last one year. Specifically, the stock has lost 15.9% during this period as against the industry's gain of 1.9%.
Zacks Rank & Key Picks
Express Scripts currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term expected earnings growth rate of 10.7%. The stock has rallied roughly 35.2% over the last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained 40.8% last year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock has gained 25.3% last year.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
Express Scripts Holding Company (ESRX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Express Scripts Holding Company (ESRX): Free Stock Analysis Report To read this article on Zacks.com click here. Express Scripts Holding CompanyESRX recently inked an agreement to acquire privately-held eviCore healthcare from investors including General Atlantic, TA Associates and Ridgemont Equity Partners for $3.6 billion. | A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Express Scripts Holding Company (ESRX): Free Stock Analysis Report To read this article on Zacks.com click here. The company recently announced plans of expanding its customized workers' compensation pharmacy solutions through the acquisition of myMatrixx, a pharmacy benefit solutions provider for the workers' compensation industry. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Express Scripts Holding Company (ESRX): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Express Scripts' pharmacy benefit management coupled with eviCore's complementary medical benefits management is likely to build a comprehensive patient benefit management (PBM) solution. | A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Express Scripts Holding Company (ESRX): Free Stock Analysis Report To read this article on Zacks.com click here. Industry Prospects Although PBM is a highly competitive industry, a report by Market Research projects the U.S. pharmacy benefit management market to see a CAGR of 7.2% between 2014 and 2019. |
33476.0 | 2017-10-11 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for October 12, 2017 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-october-12-2017-2017-10-11 | nan | nan | Abbott Laboratories ( ABT ) will begin trading ex-dividend on October 12, 2017. A cash dividend payment of $0.265 per share is scheduled to be paid on November 15, 2017. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that ABT has paid the same dividend. At the current stock price of $55.4, the dividend yield is 1.91%.
The previous trading day's last sale of ABT was $55.4, representing a 0.53% decrease from the 52 week high of $55.11 and a 48.21% increase over the 52 week low of $37.38.
ABT is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Pfizer, Inc. ( PFE ). ABT's current earnings per share, an indicator of a company's profitability, is $.71. Zacks Investment Research reports ABT's forecasted earnings growth in 2017 as 13.14%, compared to an industry average of 5.8%.
For more information on the declaration, record and payment dates, visit the ABT Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
iShares U.S. Medical Devices ETF ( IHI )
First Trust Nasdaq Pharmaceuticals ETF ( FTXH )
John Hancock Multifactor Healthcare ETF ( JHMH )
SPDR S&P Health Care Equipment ( XHE )
First Trust VL Dividend ( FVD ).
The top-performing ETF of this group is XHE with an increase of 11.98% over the last 100 days. IHI has the highest percent weighting of ABT at 9.56%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2017 as 13.14%, compared to an industry average of 5.8%. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. | The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) John Hancock Multifactor Healthcare ETF ( JHMH ) SPDR S&P Health Care Equipment ( XHE ) First Trust VL Dividend ( FVD ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) will begin trading ex-dividend on October 12, 2017. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) John Hancock Multifactor Healthcare ETF ( JHMH ) SPDR S&P Health Care Equipment ( XHE ) First Trust VL Dividend ( FVD ). | ABT's current earnings per share, an indicator of a company's profitability, is $.71. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) John Hancock Multifactor Healthcare ETF ( JHMH ) SPDR S&P Health Care Equipment ( XHE ) First Trust VL Dividend ( FVD ). Abbott Laboratories ( ABT ) will begin trading ex-dividend on October 12, 2017. |
33477.0 | 2017-10-10 00:00:00 UTC | QIAGEN Partners With CENTOGENE, Boosts Bioinformatics Suite | ABT | https://www.nasdaq.com/articles/qiagen-partners-with-centogene-boosts-bioinformatics-suite-2017-10-10 | nan | nan | QIAGEN QGEN has been hogging the limelight on its recent partnership and co-marketing agreement with CENTOGENE AG. The partnership aims at delivering complete Sample to Insight research and clinical testing solutions to end users in the field of rare genetic conditions.
Per the collaboration agreement, QIAGEN will integrate its bioinformatics suite with CENTOGENE's highly developed CentoMD rare disease variant database with the goal to improvise test understanding. Notably, this integration of CentoMD phenotype/genotype database is expected to considerably enhance QIAGEN Knowledge Base and QIAGEN Clinical Insight (QCI) bioinformatics solution.
Under the co-marketing agreement, QIAGEN will now act as the authorized and exclusive international commercial distribution partner of CentoMD. Also, QIAGEN's bioinformatics solutions will be licensed by CENTOGENE to support the latter's extensive rare disease diagnostic testing services.
In a bid to grow its bioinformatics portfolio that offers valuable observations into complex biological data, QIAGEN announced the acquisition of OmicSoft Corporation in January. Through this acquisition, QIAGEN gained access to OmicSoft's powerful multi-omics data management infrastructure solutions as well as 'omics' data bank.
We believe the company's latest partnership with CENTOGENE is strategic, taking into consideration the huge prospects of bioinformatics globally. According to a Markets and Markets report, the global bioinformatics market is projected to reach a worth of $16.18 billion by 2021, at a CAGR of 21.1%.
We believe increased spending on healthcare by government and private organizations, rising awareness triggering need for nucleic acid and protein sequencing and technological innovations and development on the back of successful partnerships between companies and research institutes will continue to drive growth in the bioinformatics market. Thus, the latest development will help QIAGEN cash in on the bountiful opportunities in the niche market.
Share Price Performance
QIAGEN has been gaining investor confidence on consistently encouraging results. Over the last six months, the company's share price has outperformed the broader industry . The stock has gained 25.9%, as compared to the broader industry's 12.3% gain. The company has also surpassed the 8.2% gain of the S&P 500 market over the same time frame.
Zacks Rank & Other Key Picks
QIAGEN currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term expected earnings growth rate of 10.7%. The stock has rallied roughly 25.4% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained 40.3% last year.
Thermo Fisher has a long-term expected earnings growth rate of 16.3%. The stock has gained 24.8% last year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
Qiagen N.V. (QGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other top-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Per the collaboration agreement, QIAGEN will integrate its bioinformatics suite with CENTOGENE's highly developed CentoMD rare disease variant database with the goal to improvise test understanding. | Other top-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Other top-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Notably, this integration of CentoMD phenotype/genotype database is expected to considerably enhance QIAGEN Knowledge Base and QIAGEN Clinical Insight (QCI) bioinformatics solution. | Other top-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Over the last six months, the company's share price has outperformed the broader industry . |
33478.0 | 2017-10-10 00:00:00 UTC | Pacific Biosciences, Bluebee Team Up for De Novo Sequencing | ABT | https://www.nasdaq.com/articles/pacific-biosciences-bluebee-team-up-for-de-novo-sequencing-2017-10-10 | nan | nan | Pacific Biosciences of California, Inc.PACB recently formed an alliance with genomic data-driven medicine company, Bluebee, to develop an advanced de novo assembly pipeline that integrates both the company's technologies. The combined solution will be introduced at the American Society of Human Genetics' (ASHG) annual meeting to be held next week in Orlando, FL.
Per the announcement, Menlo Park, CA-based Pacific Biosciences' de novo assembly pipeline will now be integrated into the Bluebee genomics analysis platform. This integration will offer a simplified workflow and fully automated end-to-end data analysis solution to allow assembly of genome of any size, including the human variety. This will also include a guaranteed turn-around time, enabling better planning and improved productivity.
With growing demand for Single Molecule, Real-Time (SMRT) sequencing in the genomics community, both the companies expect a huge customer adoption of this new cloud-based analysis option. Per Pacific Biosciences, this end-to-end solution integrates downstream data analysis in Bluebee's high-security and regulatory-compliant computing centers for Pacific Biosciences' global customers.
Notably, SMRT Sequencing provides a complete and an accurate picture of genomes, courtesy a superior performance of sequencing accuracy, uniformity of coverage, extremely long-read lengths and an ability to characterize DNA base modifications. It is the perfect tool to investigate high sequence genetic complexities, otherwise difficult to resolve using short-read technologies.
Industry Prospects
Significantly, the prospects for long-read sequencing market, where Pacific Biosciences is a leading name, are growing in leaps and bounds. Per a recent report by Decisive Bio-Insights, the Next Generation Sequencing (NGS) manufacturer market size will reach $3.2 billion in 2017 and grow at a 12% per annum rate to touch $4.6 billion by 2020, primarily driven by adoption from worldwide clinical customers. We believe, Pacific Biosciences' slew of latest developments to be well-timed within this industry.
Price Performance
Over the past three months, the stock has surged more than 40%, comparing favorably with the broader industry's gain of roughly 3.6%.
Zacks Rank & Key Picks
Pacific Biosciences currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the medical sector are Abbott ABT , Thermo Fisher Scientific Inc. TMO and IDEXX Laboratories, Inc. IDXX . All the three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Abbott has a long-term expected earnings growth rate of 10.7%. The stock has rallied roughly 25.4% over the last six months.
Thermo Fisher has a long-term expected earnings growth rate of 16.3%. The stock has gained 21.4% last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has surged 35.8% last year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
Pacific Biosciences of California, Inc. (PACB): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked stocks in the medical sector are Abbott ABT , Thermo Fisher Scientific Inc. TMO and IDEXX Laboratories, Inc. IDXX . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Pacific Biosciences of California, Inc. (PACB): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. Per the announcement, Menlo Park, CA-based Pacific Biosciences' de novo assembly pipeline will now be integrated into the Bluebee genomics analysis platform. | A few better-ranked stocks in the medical sector are Abbott ABT , Thermo Fisher Scientific Inc. TMO and IDEXX Laboratories, Inc. IDXX . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Pacific Biosciences of California, Inc. (PACB): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. Per the announcement, Menlo Park, CA-based Pacific Biosciences' de novo assembly pipeline will now be integrated into the Bluebee genomics analysis platform. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Pacific Biosciences of California, Inc. (PACB): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the medical sector are Abbott ABT , Thermo Fisher Scientific Inc. TMO and IDEXX Laboratories, Inc. IDXX . Pacific Biosciences of California, Inc.PACB recently formed an alliance with genomic data-driven medicine company, Bluebee, to develop an advanced de novo assembly pipeline that integrates both the company's technologies. | A few better-ranked stocks in the medical sector are Abbott ABT , Thermo Fisher Scientific Inc. TMO and IDEXX Laboratories, Inc. IDXX . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Pacific Biosciences of California, Inc. (PACB): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. We believe, Pacific Biosciences' slew of latest developments to be well-timed within this industry. |
33479.0 | 2017-10-10 00:00:00 UTC | Illumina (ILMN) Strong on Product Launches, Competition Rife | ABT | https://www.nasdaq.com/articles/illumina-ilmn-strong-on-product-launches-competition-rife-2017-10-10 | nan | nan | On Oct 9, we issued an updated research report on Illumina, Inc.ILMN . The stock currently carries a Zacks Rank #3 (Hold).
Over the last three months, this San Diego, CA-based company providing tools and integrated systems for the analysis of genetic variation and function, has been trading above the broader industry. The stock has gained 17.4% in this period, higher than the broader industry 's 7.9% gain.
Over the past few quarters, the company has delivered promising top-line performances primarily banking on strong product launches. The latest in the list includes the launch of VeriSeq NIPT Solution in Europe. Also overall strong uptake in NovaSeq is encouraging. Moreover, the rate of NIPT adoption is rising outside the United States.
We are also upbeat about Illumina's partnership with Telegraph Hill Partners to set up an independent company Verogen, Inc. The independent company is expected to boost Illumina's next-generation sequencing (NGS) business in the forensic genomics market. Along with having global commercial rights to these products, Illumina will be the only provider of the MiSeq FGx Forensic Genomics System, including the MiSeq FGx sequencer, ForenSeq DNA Signature Prep Kit and the ForenSeq Universal Analysis Software.
We are encouraged by the developments within the clinical markets where demand from customers undergoing oncology tests remains robust. Moreover, investors are awaiting response to the Extended RAS Panel which is slated for launch in the third quarter. In June, the company announced the receipt of FDA approval for the Extended RAS companion diagnostic kit (as the Class III PMA).
We are also looking forward to GRAIL, Illumina's own-developed company, focused on the cancer screening market.
On the flip side, weak margins due to the NovaSeq launch, higher array service revenues and product mix within sequencing consumables continue to raise concerns. Also, the National Institutes of Health (NIH) funding issue and a tough competitive landscape are a few challenges to deal with.
Key Picks
A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO , with a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 (Strong Buy) Rank stocks here.
Abbott has a long-term expected earnings growth rate of 10.7%. The stock has rallied roughly 25.4% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained 40.3% last year.
Thermo Fisher has a long-term expected earnings growth rate of 16.3%. The stock has gained 24.8% last year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
Illumina, Inc. (ILMN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Key Picks A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO , with a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Over the last three months, this San Diego, CA-based company providing tools and integrated systems for the analysis of genetic variation and function, has been trading above the broader industry. | Key Picks A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO , with a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Along with having global commercial rights to these products, Illumina will be the only provider of the MiSeq FGx Forensic Genomics System, including the MiSeq FGx sequencer, ForenSeq DNA Signature Prep Kit and the ForenSeq Universal Analysis Software. | Key Picks A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO , with a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Along with having global commercial rights to these products, Illumina will be the only provider of the MiSeq FGx Forensic Genomics System, including the MiSeq FGx sequencer, ForenSeq DNA Signature Prep Kit and the ForenSeq Universal Analysis Software. | Key Picks A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO , with a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Also overall strong uptake in NovaSeq is encouraging. |
33480.0 | 2017-10-10 00:00:00 UTC | Ex-Dividend Reminder: Abbott Laboratories, Becton, Dickinson and Pennymac Mortgage Investment Trust | ABT | https://www.nasdaq.com/articles/ex-dividend-reminder-abbott-laboratories-becton-dickinson-and-pennymac-mortgage-investment | nan | nan | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/17, Abbott Laboratories (Symbol: ABT), Becton, Dickinson & Co (Symbol: BDXA), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. Abbott Laboratories will pay its quarterly dividend of $0.265 on 11/15/17, Becton, Dickinson & Co will pay its quarterly dividend of $0.7656 on 11/1/17, and Pennymac Mortgage Investment Trust will pay its quarterly dividend of $0.47 on 10/30/17. As a percentage of ABT's recent stock price of $54.74, this dividend works out to approximately 0.48%, so look for shares of Abbott Laboratories to trade 0.48% lower - all else being equal - when ABT shares open for trading on 10/12/17. Similarly, investors should look for BDXA to open 1.39% lower in price and for PMT to open 2.70% lower, all else being equal.
Below are dividend history charts for ABT, BDXA, and PMT, showing historical dividends prior to the most recent ones declared.
Abbott Laboratories (Symbol: ABT) :
Becton, Dickinson & Co (Symbol: BDXA) :
Pennymac Mortgage Investment Trust (Symbol: PMT) :
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 1.94% for Abbott Laboratories, 5.56% for Becton, Dickinson & Co, and 10.79% for Pennymac Mortgage Investment Trust.
In Tuesday trading, Abbott Laboratories shares are currently up about 0.2%, Becton, Dickinson & Co shares are off about 0.1%, and Pennymac Mortgage Investment Trust shares are down about 1% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As a percentage of ABT's recent stock price of $54.74, this dividend works out to approximately 0.48%, so look for shares of Abbott Laboratories to trade 0.48% lower - all else being equal - when ABT shares open for trading on 10/12/17. Looking at the universe of stocks we cover at Dividend Channel , on 10/12/17, Abbott Laboratories (Symbol: ABT), Becton, Dickinson & Co (Symbol: BDXA), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. Below are dividend history charts for ABT, BDXA, and PMT, showing historical dividends prior to the most recent ones declared. | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/17, Abbott Laboratories (Symbol: ABT), Becton, Dickinson & Co (Symbol: BDXA), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. Abbott Laboratories (Symbol: ABT) : Becton, Dickinson & Co (Symbol: BDXA) : Pennymac Mortgage Investment Trust (Symbol: PMT) : In general, dividends are not always predictable, following the ups and downs of company profits over time. As a percentage of ABT's recent stock price of $54.74, this dividend works out to approximately 0.48%, so look for shares of Abbott Laboratories to trade 0.48% lower - all else being equal - when ABT shares open for trading on 10/12/17. | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/17, Abbott Laboratories (Symbol: ABT), Becton, Dickinson & Co (Symbol: BDXA), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. Abbott Laboratories (Symbol: ABT) : Becton, Dickinson & Co (Symbol: BDXA) : Pennymac Mortgage Investment Trust (Symbol: PMT) : In general, dividends are not always predictable, following the ups and downs of company profits over time. As a percentage of ABT's recent stock price of $54.74, this dividend works out to approximately 0.48%, so look for shares of Abbott Laboratories to trade 0.48% lower - all else being equal - when ABT shares open for trading on 10/12/17. | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/17, Abbott Laboratories (Symbol: ABT), Becton, Dickinson & Co (Symbol: BDXA), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. As a percentage of ABT's recent stock price of $54.74, this dividend works out to approximately 0.48%, so look for shares of Abbott Laboratories to trade 0.48% lower - all else being equal - when ABT shares open for trading on 10/12/17. Below are dividend history charts for ABT, BDXA, and PMT, showing historical dividends prior to the most recent ones declared. |
33481.0 | 2017-10-10 00:00:00 UTC | Health Care Sector Update for 10/10/2017: JNJ, PFE, ABT, MRK, AMGN, ANAB, VICL, LLY | ABT | https://www.nasdaq.com/articles/health-care-sector-update-10102017-jnj-pfe-abt-mrk-amgn-anab-vicl-lly-2017-10-10 | nan | nan | Top Health Care Stocks:
JNJ: flat
PFE: +1.1%
ABT: flat
MRK: +0.6%
AMGN: flat
Health care shares were mostly flat in pre-market trade Tuesday.
In sector news, AnaptysBio ( ANAB ) rose more than 37% after it said an ongoing phase 2a clinical trial in adult patients with moderate-to-severe atopic dermatitis demonstrated positive proof-of-concept data for ANB020, its investigational anti-IL-33 therapeutic antibody. The company said that after a single dose of ANB020, 75% of patients achieved an Eczema Area Severity Index (EASI) score improvement of 50% relative to enrollment baseline (EASI-50) at day 15, 83% of patients achieved EASI-50 at day 29 and 75% of patients achieved EASI-50 at day 57. All 12 patients achieved EASI-50 at one or more timepoints through day 57 post-ANB020 administration. ANB020 was generally well tolerated in all patients as of this interim analysis.
In other sector news,
(+) VICL (+11.6%) Completes phase 3 trial of cytomegalovirus vaccine in hematopoietic cell transplant recipients
(-) LLY (-3.5%) Phase 3 study of Verzenio in non-small cell lung cancer failed to meet its primary endpoint of overall survival.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat In sector news, AnaptysBio ( ANAB ) rose more than 37% after it said an ongoing phase 2a clinical trial in adult patients with moderate-to-severe atopic dermatitis demonstrated positive proof-of-concept data for ANB020, its investigational anti-IL-33 therapeutic antibody. The company said that after a single dose of ANB020, 75% of patients achieved an Eczema Area Severity Index (EASI) score improvement of 50% relative to enrollment baseline (EASI-50) at day 15, 83% of patients achieved EASI-50 at day 29 and 75% of patients achieved EASI-50 at day 57. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: flat The company said that after a single dose of ANB020, 75% of patients achieved an Eczema Area Severity Index (EASI) score improvement of 50% relative to enrollment baseline (EASI-50) at day 15, 83% of patients achieved EASI-50 at day 29 and 75% of patients achieved EASI-50 at day 57. | ABT: flat AMGN: flat Health care shares were mostly flat in pre-market trade Tuesday. The company said that after a single dose of ANB020, 75% of patients achieved an Eczema Area Severity Index (EASI) score improvement of 50% relative to enrollment baseline (EASI-50) at day 15, 83% of patients achieved EASI-50 at day 29 and 75% of patients achieved EASI-50 at day 57. | ABT: flat Top Health Care Stocks: JNJ: flat AMGN: flat Health care shares were mostly flat in pre-market trade Tuesday. |
33482.0 | 2017-10-08 00:00:00 UTC | News Flash: The FDA Just Approved a Breakthrough Diabetes Device | ABT | https://www.nasdaq.com/articles/news-flash-fda-just-approved-breakthrough-diabetes-device-2017-10-08 | nan | nan | Diabetes is often referred to in the medical community as the "silent killer." Affecting more than 30 million people in the U.S. (9.4% of the population), diabetes was listed the cause of death for nearly 80,000 people in 2016, according to the Centers for Disease Control and Prevention. Its comorbidities, such as hypertension, heart disease, and kidney disease, can also cause lifelong problems and themselves lead to death. Though it may not inspire the same fear in patients as a cancer diagnosis, it's a very serious disease.
Diabetes is also a costly disease to treat. The CDC's National Diabetes Statistics Report released earlier this year estimated the direct and indirect estimated costs of diagnosed diabetes at $245 billion as of 2012. Mind you, nearly 24% of the 30.3 million people with diabetes in the U.S. are undiagnosed, meaning this $245 billion estimate is probably conservative and underrepresenting the actual costs of treating diabetic patients. It probably also fails to fully account for the lost worker productivity as a result of diabetics missing work or passing away earlier than people who don't have diabetes.
These statistics demonstrate why research into new medicines and devices designed to improve the quality of life of diabetics is so important.
The FDA green-lights another breakthrough diabetes device
Well, folks, I have some good news to report. Last week, the Food and Drug Administration approved a breakthrough diabetes device from Abbott Laboratories (NYSE: ABT) that should make life considerably better, and less painful, for diabetics.
The device, known as the Freestyle Libre Flash, is a continuous glucose monitoring system that doesn't require adult diabetics to prick themselves with a needle to take blood glucose measurements on a regular basis. Instead, Freestyle Libre Flash uses a small wire inserted under the skin to determine glucose levels. Users then wave a mobile reader above the sensor wire to determine if their glucose levels are too high or too low and can utilize the sensor to monitor how their glucose levels change throughout the day. Following a 12-hour start-up period, the device can be worn for up to 10 days.
The approval of Abbott Labs' device isn't a complete shock, given that Freestyle Libre Flash was already approved in Europe and Canada. However, it should be rapidly adopted in the U.S. based on data the company provided at the Advanced Technologies and Treatments for Diabetes conference earlier this year. At this conference, Abbott Labs announced that data from more than 50,000 Freestyle Libre Flash users showed they were checking their blood glucose levels an average of just over 16 times a day. This was considerably higher than patients who have to prick their fingers to measure their blood glucose levels, suggesting that a healthier patient and higher demand could be around the corner.
Breakthroughs are becoming commonplace
Of course, Abbott Laboratories' approval isn't the only major advancement that diabetics have seen in recent years. A year ago, Medtronic (NYSE: MDT) introduced what could be the biggest breakthrough ever for type 1 diabetics , a group that includes those who have little or no insulin production from their pancreas, and often have diabetes because of genetics or specific viruses.
The MiniMed 670G is the world's first FDA-approved closed-loop system to measure blood glucose levels and administer insulin on an as-needed basis. The device uses a sensor with a protruding needle that's slipped under the user's skin and measures blood glucose. What's particularly intriguing about the MiniMed 670G is that it should reduce the potential for hypoglycemia from the over-administration of insulin.
We've also seen tech kingpin Apple (NASDAQ: AAPL) working on a non-invasive glucose-measuring device that works hand-in-hand with the Apple Watch. In May, CEO Tim Cook was spotted wearing the device. This would mark the next step forward for Apple, which in June 2014 introduced its Health app for users to track various aspects of health and fitness data.
Even the medicines diabetics have access to are taking giant leaps forward. SGLT-2 inhibitors, which work in the kidneys by blocking glucose absorption, and allowing the user to excrete excess glucose through the urine, have helped type 2 diabetics -- which comprise about 95% of all diabetes cases -- better control their blood sugar levels. They also come with the pleasant side effects of weight loss and lowered systolic blood pressure.
Lexicon Pharmaceuticals (NASDAQ: LXRX) currently has what could be a next-generation dual SGLT-1 and SGLT-2 inhibitor in development, known as sotagliflozin. The addition of SGLT-1 should help block glucose absorption in the intestines as well the kidneys (SGLT-2), possibly improving upon what SGLT-2 inhibitors bring to the table. With licensing partner Sanofi running late-stage studies involving sotagliflozin for type 2 diabetics, and Lexicon already reporting positive late-stage data for type 1 diabetics, we should know relatively soon if Lexicon's lead drug can offer new choices for all diabetics (type 1 and 2).
Without question, diabetes is a serious disease. But we can be thankful that drug and device developers are stepping up to the plate with serious solutions.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
Sean Williams has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Apple. The Motley Fool owns shares of Medtronic and has the following options: long January 2020 $150 calls on Apple and short January 2020 $155 calls on Apple. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last week, the Food and Drug Administration approved a breakthrough diabetes device from Abbott Laboratories (NYSE: ABT) that should make life considerably better, and less painful, for diabetics. However, it should be rapidly adopted in the U.S. based on data the company provided at the Advanced Technologies and Treatments for Diabetes conference earlier this year. At this conference, Abbott Labs announced that data from more than 50,000 Freestyle Libre Flash users showed they were checking their blood glucose levels an average of just over 16 times a day. | Last week, the Food and Drug Administration approved a breakthrough diabetes device from Abbott Laboratories (NYSE: ABT) that should make life considerably better, and less painful, for diabetics. The device, known as the Freestyle Libre Flash, is a continuous glucose monitoring system that doesn't require adult diabetics to prick themselves with a needle to take blood glucose measurements on a regular basis. With licensing partner Sanofi running late-stage studies involving sotagliflozin for type 2 diabetics, and Lexicon already reporting positive late-stage data for type 1 diabetics, we should know relatively soon if Lexicon's lead drug can offer new choices for all diabetics (type 1 and 2). | Last week, the Food and Drug Administration approved a breakthrough diabetes device from Abbott Laboratories (NYSE: ABT) that should make life considerably better, and less painful, for diabetics. The device, known as the Freestyle Libre Flash, is a continuous glucose monitoring system that doesn't require adult diabetics to prick themselves with a needle to take blood glucose measurements on a regular basis. SGLT-2 inhibitors, which work in the kidneys by blocking glucose absorption, and allowing the user to excrete excess glucose through the urine, have helped type 2 diabetics -- which comprise about 95% of all diabetes cases -- better control their blood sugar levels. | Last week, the Food and Drug Administration approved a breakthrough diabetes device from Abbott Laboratories (NYSE: ABT) that should make life considerably better, and less painful, for diabetics. Diabetes is also a costly disease to treat. SGLT-2 inhibitors, which work in the kidneys by blocking glucose absorption, and allowing the user to excrete excess glucose through the urine, have helped type 2 diabetics -- which comprise about 95% of all diabetes cases -- better control their blood sugar levels. |
33483.0 | 2017-10-08 00:00:00 UTC | 3 Best Healthcare Dividend Aristocrat Stocks You Can Buy Right Now | ABT | https://www.nasdaq.com/articles/3-best-healthcare-dividend-aristocrat-stocks-you-can-buy-right-now-2017-10-08 | nan | nan | "Dividend Aristocrat" just has a nice ring to it, doesn't it? The "dividend" part sounds great because it means a stock is going to pay you to own it. "Aristocrat" conveys nobility, an elite status that most don't have. Dividend Aristocrat stocks are magnets for income-seeking investors as a result of their sterling track records of dividend hikes.
The healthcare sector currently has the third-highest number of stocks in the Dividend Aristocrats, ranking behind only consumer staples and industrials. But some of these stocks are better than others. Here's why AbbVie (NYSE: ABBV) , Johnson & Johnson (NYSE: JNJ) , and Medtronic (NYSE: MDT) appear to be the best healthcare Dividend Aristocrat stocks you can buy right now.
AbbVie
Although AbbVie technically didn't begin operations as a standalone entity until 2013, the big drugmaker qualifies as a Dividend Aristocrat because it was part of Abbott Labs during a 40-year period where its parent company increased its dividend annually. Over the last five years, AbbVie has kept up the tradition, boosting its dividend by 60%.
AbbVie's dividend currently yields just under 2.9%. That's on the low end of the yield over the past few years, but it's due to a great reason: AbbVie stock has soared more than 40% so far in 2017.
A big reason behind the stock's performance was AbbVie's recently announced deal with Amgen that keeps a major threat to top-selling drug Humira off the U.S. market until early 2023. AbbVie now appears to be in a good position to roll out new drugs from its deep pipeline, which should fuel additional growth, while not having to worry too much about a major loss of revenue for Humira.
Johnson & Johnson
Healthcare giant Johnson & Johnson has increased its dividend for a remarkable 55 consecutive years. Its yield now stands just above 2.5%. That's higher the the S&P 500 average yield of roughly 2%.
There shouldn't be any concerns at all about J&J's ability to keep the dividends (and the dividend hikes) coming. The company uses less than 55% of its earnings to fund the dividend program. Johnson & Johnson also generates an enormous cash flow that would allow it to pay out dividends even if earnings dipped -- which happened in the company's second quarter .
Although J&J faces some headwinds for its pharmaceuticals segment (the company's biggest moneymaker), those should be temporary. The company is managing loss of exclusivity for autoimmune disease drug Remicade better than many expected. It also has one of the best pipelines in the biopharmaceutical industry (as does AbbVie). In addition, J&J completed the acquisition of Actelion this summer, a deal expected to boost future revenue and earnings growth.
Medtronic
Medtronic claims a 40-year streak of annual dividend increases. What's even more impressive is that the big medical-device maker has grown its dividend during that period by a compound annual growth rate of 17%.
The company's dividend yield of nearly 2.4% narrowly trails that of J&J. However, Medtronic's dividend hikes have been larger on a percentage basis than J&J's in recent years. If this trend continues, it won't be long before Medtronic has the more attractive yield.
Probably the best thing for investors to like about Medtronic is its moat . The company makes a wide array of medical devices and has strong relationships with hospitals and physicians. Medtronic also invests heavily in research and development for new products and partners with other companies (such as its collaboration with Mazor Roboticsto market robotic surgical systems for spine and brain procedures ). Like AbbVie and Johnson & Johnson, Medtronic appears to be a solid long-term pick for income-seeking investors.
10 stocks we like better than Medtronic
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Medtronic wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
Keith Speights owns shares of AbbVie. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool owns shares of Medtronic. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A big reason behind the stock's performance was AbbVie's recently announced deal with Amgen that keeps a major threat to top-selling drug Humira off the U.S. market until early 2023. AbbVie now appears to be in a good position to roll out new drugs from its deep pipeline, which should fuel additional growth, while not having to worry too much about a major loss of revenue for Humira. Medtronic also invests heavily in research and development for new products and partners with other companies (such as its collaboration with Mazor Roboticsto market robotic surgical systems for spine and brain procedures ). | Here's why AbbVie (NYSE: ABBV) , Johnson & Johnson (NYSE: JNJ) , and Medtronic (NYSE: MDT) appear to be the best healthcare Dividend Aristocrat stocks you can buy right now. Johnson & Johnson Healthcare giant Johnson & Johnson has increased its dividend for a remarkable 55 consecutive years. Like AbbVie and Johnson & Johnson, Medtronic appears to be a solid long-term pick for income-seeking investors. | Here's why AbbVie (NYSE: ABBV) , Johnson & Johnson (NYSE: JNJ) , and Medtronic (NYSE: MDT) appear to be the best healthcare Dividend Aristocrat stocks you can buy right now. AbbVie Although AbbVie technically didn't begin operations as a standalone entity until 2013, the big drugmaker qualifies as a Dividend Aristocrat because it was part of Abbott Labs during a 40-year period where its parent company increased its dividend annually. Johnson & Johnson Healthcare giant Johnson & Johnson has increased its dividend for a remarkable 55 consecutive years. | But some of these stocks are better than others. AbbVie's dividend currently yields just under 2.9%. Like AbbVie and Johnson & Johnson, Medtronic appears to be a solid long-term pick for income-seeking investors. |
33484.0 | 2017-10-06 00:00:00 UTC | Abbott (ABT) Hits a 52-Week High: What's Driving the Stock? | ABT | https://www.nasdaq.com/articles/abbott-abt-hits-a-52-week-high%3A-whats-driving-the-stock-2017-10-06 | nan | nan | Share price of Abbott ABT scaled a new 52-week high of $55.11 on Oct 6, eventually closing lower at $54.92. The company has gained 6.7% over the past month, much higher than the S&P 500's gain of 2.6%. Abbott has also outperformed the broader industry 's gain of 1.8% last month. The stock has a market cap of $95.42 billion.
Further, Abbott's estimate revision trend for the current year has been favorable. In the past 60 days, seven estimates moved up while one moved down. Estimates were up from $2.48 per share to $2.49 over the same time frame.
The company also has a trailing four-quarter average positive earnings surprise of 4.6%. Its positive long-term growth of 10.7% holds promise.
Abbott carries a Zacks Rank #3 (Hold). The company has an impressive Growth Style Score of B. Our Growth Style Score highlights all the vital metrics of a company's financials to obtain a clearer picture of the quality and sustainability of its growth. Our research shows that stocks with Style Scores of A or B when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 offer the best investment opportunities.
Growth Drivers
The market is upbeat about Abbott's acquisition of Alere that got completed on Oct 3, after facing several regulatory hurdles. The buyout should help the company gain access to new channels and geographies, including entries into fast growing outlets, such as doctors' offices, clinics, pharmacies and at-home testing.
Another major upside for the company is the recent FDA approval for the FreeStyle Libre Flash glucose monitoring system in the United States. The market is also optimistic about Abbott gaining national reimbursement for FreeStyleLibre glucose monitoring system from National Health Service (NHS) Business Services Authority in the U.K. This has been a major breakthrough in the company's diabetics business.
Also it is worth a mention that Abbott's Ellipse implantable cardioverter defibrillator (ICD) recently gained FDA approval for magnetic resonance (MR) conditional labeling.
All these factors are expected to drive the company's share price further.
Key Picks
A few better-ranked stocks in the medical sector are Orthofix International N.V. OFIX , Luminex Corporation LMNX and IDEXX Laboratories, Inc. IDXX . Orthofix International and Luminex sport a Zacks Rank #1 (Strong Buy), while IDEXX Laboratories carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Orthofix International has a long-term expected earnings growth rate of 11.8%. The stock has rallied roughly 9.2% over the last three months.
Luminex has a long-term estimated earnings growth rate of 16.3%. The stock gained 7.4% last month.
IDEXX Laboratorieshas a long-term expected earnings growth rate of 19.8%. The stock has gained 37.1% in the last year.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Luminex Corporation (LMNX): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
Orthofix International N.V. (OFIX): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Share price of Abbott ABT scaled a new 52-week high of $55.11 on Oct 6, eventually closing lower at $54.92. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Orthofix International N.V. (OFIX): Free Stock Analysis Report To read this article on Zacks.com click here. The buyout should help the company gain access to new channels and geographies, including entries into fast growing outlets, such as doctors' offices, clinics, pharmacies and at-home testing. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Orthofix International N.V. (OFIX): Free Stock Analysis Report To read this article on Zacks.com click here. Share price of Abbott ABT scaled a new 52-week high of $55.11 on Oct 6, eventually closing lower at $54.92. Key Picks A few better-ranked stocks in the medical sector are Orthofix International N.V. OFIX , Luminex Corporation LMNX and IDEXX Laboratories, Inc. IDXX . | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Orthofix International N.V. (OFIX): Free Stock Analysis Report To read this article on Zacks.com click here. Share price of Abbott ABT scaled a new 52-week high of $55.11 on Oct 6, eventually closing lower at $54.92. The company has gained 6.7% over the past month, much higher than the S&P 500's gain of 2.6%. | Share price of Abbott ABT scaled a new 52-week high of $55.11 on Oct 6, eventually closing lower at $54.92. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Orthofix International N.V. (OFIX): Free Stock Analysis Report To read this article on Zacks.com click here. Another major upside for the company is the recent FDA approval for the FreeStyle Libre Flash glucose monitoring system in the United States. |
33485.0 | 2017-10-06 00:00:00 UTC | Health Care Sector Update for 10/06/2017: JNJ, PFE, ABT, MRK, AMGN, KDMN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-10062017-jnj-pfe-abt-mrk-amgn-kdmn-2017-10-06 | nan | nan | Top Health Care Stocks:
JNJ: flat
PFE: flat
ABT: flat
MRK: flat
AMGN: flat
Health care shares were inactive in pre-market trade Friday.
In sector news, Johnson & Johnson ( JNJ ) reported that its subsidiary, Janssen Research & Development and development partner Bayer have stopped the Phase III NAVIGATE ESUS study early because the treatment was unlikely to show an overall benefit versus aspirin if the study were to be completed. The study evaluated the efficacy and safety of Xarelto or rivaroxaban for the secondary prevention of stroke and systemic embolism in patients with a recent embolic stroke of undetermined source (ESUS), compared with the efficacy of the standard of care, aspirin.
In other sector news,
(+) KDMN (+1%) Gets FDA Orphan Designation for graft-vs-host disease treatment
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care Stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were inactive in pre-market trade Friday. In sector news, Johnson & Johnson ( JNJ ) reported that its subsidiary, Janssen Research & Development and development partner Bayer have stopped the Phase III NAVIGATE ESUS study early because the treatment was unlikely to show an overall benefit versus aspirin if the study were to be completed. The study evaluated the efficacy and safety of Xarelto or rivaroxaban for the secondary prevention of stroke and systemic embolism in patients with a recent embolic stroke of undetermined source (ESUS), compared with the efficacy of the standard of care, aspirin. | Top Health Care Stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were inactive in pre-market trade Friday. In sector news, Johnson & Johnson ( JNJ ) reported that its subsidiary, Janssen Research & Development and development partner Bayer have stopped the Phase III NAVIGATE ESUS study early because the treatment was unlikely to show an overall benefit versus aspirin if the study were to be completed. In other sector news, (+) KDMN (+1%) Gets FDA Orphan Designation for graft-vs-host disease treatment The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care Stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were inactive in pre-market trade Friday. In sector news, Johnson & Johnson ( JNJ ) reported that its subsidiary, Janssen Research & Development and development partner Bayer have stopped the Phase III NAVIGATE ESUS study early because the treatment was unlikely to show an overall benefit versus aspirin if the study were to be completed. In other sector news, (+) KDMN (+1%) Gets FDA Orphan Designation for graft-vs-host disease treatment The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care Stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were inactive in pre-market trade Friday. In sector news, Johnson & Johnson ( JNJ ) reported that its subsidiary, Janssen Research & Development and development partner Bayer have stopped the Phase III NAVIGATE ESUS study early because the treatment was unlikely to show an overall benefit versus aspirin if the study were to be completed. The study evaluated the efficacy and safety of Xarelto or rivaroxaban for the secondary prevention of stroke and systemic embolism in patients with a recent embolic stroke of undetermined source (ESUS), compared with the efficacy of the standard of care, aspirin. |
33486.0 | 2017-10-05 00:00:00 UTC | Health Care Sector Update for 10/05/2017: JNJ, PFE, ABT, MRK, AMGN, DXTR, NBIX, RIGL | ABT | https://www.nasdaq.com/articles/health-care-sector-update-10052017-jnj-pfe-abt-mrk-amgn-dxtr-nbix-rigl-2017-10-05 | nan | nan | Top Health Care Stocks:
JNJ: +0.3%
PFE: +0.1%
ABT: +0.1%
MRK: flat
AMGN: +0.2%
Health care shares were mostly higher in pre-market trade Thursday.
In sector news, Dextera Surgical ( DXTR ) fell 30.5% after it said fiscal Q3 revenue will be approximately $568,000, missing the Street estimate of $1.1 million from three analysts polled. The company said there is backorder of approximately $178,000 for its MicroCutter Staplers and reloads.
In other sector news,
(+) NBIX (+3.6%) Gets FDA approval for tardive dyskinesia drug capsulea
(-) RIGL (-3%) Prices public sale of 18.1 million shares at $3.35 per share, or 7.5% discount
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care shares were mostly higher in pre-market trade Thursday. In sector news, Dextera Surgical ( DXTR ) fell 30.5% after it said fiscal Q3 revenue will be approximately $568,000, missing the Street estimate of $1.1 million from three analysts polled. In other sector news, (+) NBIX (+3.6%) Gets FDA approval for tardive dyskinesia drug capsulea (-) RIGL (-3%) Prices public sale of 18.1 million shares at $3.35 per share, or 7.5% discount The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care shares were mostly higher in pre-market trade Thursday. In other sector news, (+) NBIX (+3.6%) Gets FDA approval for tardive dyskinesia drug capsulea (-) RIGL (-3%) Prices public sale of 18.1 million shares at $3.35 per share, or 7.5% discount The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MRK: flat In other sector news, (+) NBIX (+3.6%) Gets FDA approval for tardive dyskinesia drug capsulea (-) RIGL (-3%) Prices public sale of 18.1 million shares at $3.35 per share, or 7.5% discount The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care Stocks: MRK: flat Health care shares were mostly higher in pre-market trade Thursday. |
33487.0 | 2017-10-04 00:00:00 UTC | 5 Top Stocks for October | ABT | https://www.nasdaq.com/articles/5-top-stocks-october-2017-10-04 | nan | nan | Summer is officially in the rearview mirror. That means the air is cooling down, the leaves are starting to change, and Halloween is right around the corner. How do we Fools celebrate the changing of the seasons? By finding great stocks to buy, of course!
So, which stocks do we think are top buys right now? We asked a team of investors to weigh in, and they picked Rigel Pharmaceuticals (NASDAQ: RIGL) , Hanesbrands (NYSE: HBI) , Walt Disney (NYSE: DIS) , Tile Shop Holdings (NASDAQ: TTS) , and Dexcom (NASDAQ: DXCM) .
An overlooked biotech gem
Cory Renauer (Rigel Pharmaceuticals): My stock pick this month has been under pressure thanks to a couple of issues, but I don't think either will stop this biotech from advancing its first drug from clinical trials to pharmacy shelves early next year.
Tavalisse, formerly fostamatinib, is an experimental therapy with a troubled past. Back in 2013, Rigel nearly imploded when the drug failed to show a clinical benefit for patients with rheumatoid arthritis. Success in the first of two pivotal trials for a rare disease called immune thrombocytopenic purpura (ITP) lifted the stock last year, only to come crashing down again after a single patient in the placebo group of the second trial rendered the study a statistical failure.
Rigel's lead candidate missed the mark in arthritis, but ITP is a different disease caused by the unwarranted destruction of the platelets that allow blood to clot properly. As for the second pivotal trial that failed due to a technicality, combined results from both pivotal trials showed a clear clinical benefit, with 29 of 101 ITP patients given the drug achieving higher platelet levels versus just one of 49 given a placebo.
Although the FDA generally doesn't accept combined trial results, a recent announcement that the Agency won't convene an independent advisory committee to discuss the mixed data suggest Rigel's candidate has a much better chance of earning an approval than the stock price suggests right now.
If approved, fostamatinib could generate around $350 million in sales each year at its peak, but Rigel's market cap is just $419 million at recent prices. Biotech stocks tend to trade at mid single-digit multiples of annual sales, which means an approval decision in the months ahead could send the stock rocketing higher.
An overlooked apparel company
Tim Green(Hanesbrands): With the market at all-time highs as we enter October, finding solid value stocks is hard. There are plenty of cheap- looking stocks, but those will burn you more often than not. Good companies trading for less than they're truly worth are in short supply.
Thankfully, there are still some good options for investors unwilling to pay sky-high prices. Hanesbrands, an apparel manufacturer known best for its innerwear, has seen its stock beaten down since peaking in 2015. Concerns about the health of brick-and-mortar retailers, where Hanesbrands generates the vast majority of its sales, have been weighing on the stock.
Hanesbrands' results in recent quarters have been mixed, with declines in innerwear sales offset by growth in activewear and international sales. The company expects organic sales to be up as much as 2% this year, which isn't as sluggish as it sounds given the current retail environment. Analysts expect adjusted earnings per share of $1.99 in 2017, putting the stock just shy of 12.5 times that number. For comparison, the S&P 500 trades for about 25 times trailing-12-month earnings.
Hanesbrands depended on Wal-Mart and Target for about 50% of its annual innerwear sales in 2016, so the fact that both of those retailers are reporting comparable sales increases is notable. During the latest quarter, Wal-Mart grew U.S. comparable sales by 1.8%, while Target boosted overall comparable sales by 1.3%. Growing store traffic was the main driver in both cases, which is good news for Hanesbrands.
Hanesbrands is not an exciting company, and its dependence on the megaretailers does introduce some concentration risk. But the price looks right for this overlooked apparel company.
One of the world's greatest companies at a reasonable price
Chuck Saletta (Walt Disney): Walt Disney is well known for Mickey Mouse, a string of worldwide amusement parks, and top-tier television and movie properties like ESPN, ABC, Pixar, Marvel Studios, and Star Wars. Few companies have anywhere near the reputation that Walt Disney does of successfully and consistently separating people from their money while those people thoroughly enjoy the experience.
Yet Walt Disney's shares have taken a tumble in recent months, and they now trade at less than 18 times trailing earnings and less than 16 times anticipated forward earnings. At a time when the overall S&P 500 trades at over 25 times trailing earnings, Walt Disney looks like a relative bargain.
While Hurricane Irma temporarily shut down Disney World , and there are lingering questions about the long term growth prospects of ESPN, the overall company looks solid. Despite those well-known challenges, Walt Disney as a whole is expected to be able to increase earnings by around 7.5% annualized over the next five years. Bargain prices on quality companies rarely last, which makes Walt Disney look like a potentially compelling investment this October.
Even if its shares don't quickly rebound, Walt Disney sports a 1.6% dividend yield -- which is better than the yield on 3-year Treasury bonds at the moment. Even better, unlike those bonds, Walt Disney has been able to increase its dividends for the past several years. With a payout ratio of only around 28%, Walt Disney likely has room to continue increasing that dividend.
A beatdown has created a bargain
JasonHall (Tile Shop Holdings): Since reaching its 2017 peak in June, shares of Tile Shop are down 61% at this writing, with the vast majority of that huge drop happening over the past week. The downhill roll started on September 27 when Piper Jaffray downgraded the stock over near-term inventory and competitive concerns, sending shares down 17% on the day, and culminated with the company's preliminary third-quarter earnings release on October 2, which indicated that Jaffray's analysts were right.
However, I'm of the strong opinion that this huge beatdown is overdone (though the stock could keep falling in the short term) and, more importantly, that Tile Shop's current problems will prove to be short term in nature.
The company said its third-quarter results are likely to show 7% sales growth overall, and 1% comps (sales at stores open more than one year) growth, similar to the second quarter's results, and that gross margins will take a big hit since the company had to more extensively discount in an increasingly competitive environment.
Here's the catch: The company says this is as much a mix problem as a pricing one, and that it is bringing in more entry-level products to meet customer demand. This should stabilize margins and drive sales higher, resulting in strong profit growth in future quarters. It could take another quarter for the results to pay off, but I think investors who buy shares after the recent drubbing will be glad they did in a few years' time.
This high-growth gem is finally trading at a reasonable price
Brian Feroldi (Dexcom): I've been an admirer of the diabetes darling Dexcom for years. Dexcom is a leading provider of continuous glucose monitoring system that allows people with diabetes to track their blood sugar levels in real time. Given the company's razor-and-blades business model and huge addressable market opportunity, Dexcom's top-line growth has been nothing short of amazing. In turn, the stock has been a home run for early investors.
DXCM Revenue (TTM) data by YCharts .
Despite my admiration for the company, I've never been comfortable with the stock's sky-high valuation . However, Dexcom's stock was clobbered last week after the FDA approved Abbott Laboratories 's (NYSE: ABT) FreeStyle Libre Flash Glucose Monitoring System. Since Libre users do not have to prick their finger for calibration, Wall Street freaked out over the belief that Dexcom's growth days were over.
While the Libre looks like a very cool device, I'm not nearly as bearish as Wall Street for three main reasons.
First, Abbott's Libre system requires users to wave a piece of hardware over their sensor to get a reading. By contrast, Dexcom's sensors communicate directly with an iPhone, Apple watch, or Android phone. That eliminates an extra piece of hardware from the picture. Dexcom's system also allows data to be shared over the web, which is a highly attractive feature for parents and caregivers.
Second, Dexcom's amazing revenue growth up until now has come without any coverage from Medicare. The company finally won Medicare reimbursement just a few months ago, so it just recently gained access to an enormous market opportunity.
Finally, there are 3 million intensively managed insulin users in the U.S. alone. By contrast, only a few hundred thousand patients are actively using continuous glucose monitoring systems. That means there is plenty of room for multiple winners.
These factors make me believe Dexcom will still be able to put up big growth numbers in the years ahead. With shares currently trading at a more reasonable valuation -- about 6 times sales, which is near a 10-year low -- I think it that right now is a great time to buy into this growth story.
Find out why Walt Disneyis one of the 10 best stocks to buy now
Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. (In fact, the newsletter they run, Motley Fool Stock Advisor, has tripled the market!*)
Tom and David just revealed their ten top stock picks for investors to buy right now. Walt Disney is on the list -- but there are nine others you may be overlooking.
Click here to get access to the full list!
*Stock Advisor returns as of September 5, 2017
Brian Feroldi owns shares of Walt Disney. Chuck Saletta has no position in any of the stocks mentioned. Cory Renauer has no position in any of the stocks mentioned. Jason Hall owns shares of Tile Shop Holdings and Walt Disney. Timothy Green owns shares of Hanesbrands. The Motley Fool owns shares of and recommends Walt Disney. The Motley Fool recommends Tile Shop Holdings. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, Dexcom's stock was clobbered last week after the FDA approved Abbott Laboratories 's (NYSE: ABT) FreeStyle Libre Flash Glucose Monitoring System. Rigel's lead candidate missed the mark in arthritis, but ITP is a different disease caused by the unwarranted destruction of the platelets that allow blood to clot properly. Dexcom is a leading provider of continuous glucose monitoring system that allows people with diabetes to track their blood sugar levels in real time. | However, Dexcom's stock was clobbered last week after the FDA approved Abbott Laboratories 's (NYSE: ABT) FreeStyle Libre Flash Glucose Monitoring System. We asked a team of investors to weigh in, and they picked Rigel Pharmaceuticals (NASDAQ: RIGL) , Hanesbrands (NYSE: HBI) , Walt Disney (NYSE: DIS) , Tile Shop Holdings (NASDAQ: TTS) , and Dexcom (NASDAQ: DXCM) . An overlooked biotech gem Cory Renauer (Rigel Pharmaceuticals): My stock pick this month has been under pressure thanks to a couple of issues, but I don't think either will stop this biotech from advancing its first drug from clinical trials to pharmacy shelves early next year. | However, Dexcom's stock was clobbered last week after the FDA approved Abbott Laboratories 's (NYSE: ABT) FreeStyle Libre Flash Glucose Monitoring System. We asked a team of investors to weigh in, and they picked Rigel Pharmaceuticals (NASDAQ: RIGL) , Hanesbrands (NYSE: HBI) , Walt Disney (NYSE: DIS) , Tile Shop Holdings (NASDAQ: TTS) , and Dexcom (NASDAQ: DXCM) . Yet Walt Disney's shares have taken a tumble in recent months, and they now trade at less than 18 times trailing earnings and less than 16 times anticipated forward earnings. | However, Dexcom's stock was clobbered last week after the FDA approved Abbott Laboratories 's (NYSE: ABT) FreeStyle Libre Flash Glucose Monitoring System. Hanesbrands depended on Wal-Mart and Target for about 50% of its annual innerwear sales in 2016, so the fact that both of those retailers are reporting comparable sales increases is notable. Walt Disney is on the list -- but there are nine others you may be overlooking. |
33488.0 | 2017-10-03 00:00:00 UTC | Analysts Act on Health Care Stocks | ABT | https://www.nasdaq.com/articles/analysts-act-health-care-stocks-2017-10-03 | nan | nan | Analysts have taken action on some health care stocks.
Among the health care companies that saw their stocks re-rated by investment banking and financial services companies are AbbVie ( ABBV ) and two mid-caps, bluebird bio ( BLUE ) and Alnylam Pharmaceuticals ( ALNY ).
The first stock of this short list of re-rated health care companies is AbbVie. According to thefly.com, LEERINK Partners LLC - the health care specialized investment bank - upgraded shares of AbbVie from Market Perform to Outperform.
The U.S. global health care company that was originated in 2013 as Abbott Laboratories ' ( ABT ) spinoff and headquartered in Lake Bluff, Illinois, is trading at $90.39 per share, a few below its 52-week high of $90.95 per share. The health care stock is uptrending and has gained a hefty 44.35% year to date.
Despite this solid accretion in the market value of AbbVie, Leerink analyst Geoffrey Porges, still sees in the long run more positive development in the share price of the health care stock "as the company's late-stage pipeline comes to fruition," reports The Fly. Why? Because as the company will gradually complete the projects it is advancing, explained Porges, analysts will increase their estimates on AbbVie with positive impact on the market value.
Concerning expectations on AbbVie's sales and revenue for the next two years, analysts foresee that the company will close the full fiscal 2017 with a 14.5% increase year over year in the EPS to $5.52 and a 18.5% increase year over year in the EPS for full fiscal 2018 to $6.54. Both estimates on the company's earnings are backed on revenue that for the two fiscal years in question are projected to come in at $27.91 billion (up 9.20% year over year) and at $30.74 billion (up 10.20% year over year).
For the next five years, analysts see a 14.16% annual average increase in AbbVie's sales.
Leerink also increased by 19.1% its target price on shares of AbbVie from $89 to $106 per share. This raise dragged the average target price up to $87.82 per share of AbbVie. This is a mean of a total of 17 estimates of analysts who were surveyed on AbbVie's target price and range between a low of $60 per share and a high of $107 per share.
AbbVie has a recommendation rating of 2.4 out of 5.
AbbVie distributes an annual dividend of $2.56 - through quarterly payments of 64 cents - to its shareholders for a dividend yield of 2.88% versus a current Standard & Poor's 500 dividend yield of 1.90%.
GuruFocus gives AbbVie a financial strength rating of 5 out of 10 and a profitability and growth rating of 7 out of 10.
AbbVie currently has a market capitalization of $144.09 billion, a price-book (P/B) ratio of 23.94, a price-sales (P/S) ratio of 5.47 and a price-earnings (P/E) ratio of 22.21. The forward P/E ratio is 13.46.
The second health care stock of this list is bluebird bio, a clinical-stage biotechnology company that is engaged in transformative gene therapies' development for serious genetic diseases such as hereditary neurological disorders, intermedia and major beta-thalassemia, severe anaemias and cancer types such as relapsed/refractory multiple myeloma and certain human papilloma virus related cancer.
Bluebird bio has been downgraded by Morgan Stanley to Underweight from Equal-Weight, reports StreetInsider.com.
The biotech stock has an average target price of $117.33 per share, which represents a 6.5% downside from the current share price of $125.45 that with a total volume of 45.59 million shares outstanding leads to a market capitalization of $5.72 billion.
The average target price is a mean of 15 estimates on bluebird bio's target price. These estimates range between a low of $39 per share and a high of $158 per share.
Bluebird bio has a recommendation rating of 2.3 out of 5.
Bluebird is currently trading at $125.45 per share, with a market capitalization of $5.72 billion, a P/B ratio of 4.77 and a P/S ratio of 190.97.
GuruFocus gives bluebird a financial strength rating of 6 out of 10, and a profitability and growth rating of 1 out of a total of 10.
The last health care stock on this list is Alnylam Pharmaceuticals, a biopharmaceutical company that is engaged in the development and commercialization of RNA interference-based new therapeutics for the treatment of genetic disorders, cardio-metabolic diseases and infectious diseases of the liver.
The biopharmaceutical company has been upgraded by Goldman Sachs to a rating of Buy from the previous rating of Neutral.
As reported by StreetInsider.com, Goldman Sachs analyst Terrance Flynn "raises Patisiran peak sales from $1.8 billion to $2.9 billion and believes the stock is only pricing in about have [sic] of the total estimate revenues."
Patisiran is a medication used as treatment for patients affected with familial amyloidotic polyneuropathy, a rare progressive sensual-motor and autonomous system neuropathy, which onset starts in the adult age. Common complications of this rare disease are weight loss and heart involvement. Ocular and renal problems can also occur.
Alnylam Pharmaceuticals is trading at $122.31 per share, with a market capitalization of $11.22 billion, a P/B ratio of 9.99 and a P/S ratio of 160.29.
For full fiscal years of 2017 and 2018, analysts forecast a 66.70% and 59% year-over-year increase to $78.6 million and to $124.97 million in the company's revenue, but a worsening is expected in the bottom line of Alnylam Pharmaceuticals' income statement for full fiscal years of 2017 and 2018 to a loss of $5.2 and $5.3 per share.
The average target price - after Goldman Sachs' 162.9% raise from $62 to $163 per share - is $117.06 per share, and the recommendation rating is 2.2 out of 5.
GuruFocus gives Alnylam Pharmaceuticals a financial strength rating of 6 out of 10 and a profitability and growth rating of only 1 out of 10.
Disclosure: I have no positions in any stock mentioned in this article.
Warning! GuruFocus has detected 3 Warning Sign with AMZN. Click here to check it out.
AMZN 15-Year Financial Data
The intrinsic value of AMZN
Peter Lynch Chart of AMZN
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The U.S. global health care company that was originated in 2013 as Abbott Laboratories ' ( ABT ) spinoff and headquartered in Lake Bluff, Illinois, is trading at $90.39 per share, a few below its 52-week high of $90.95 per share. Despite this solid accretion in the market value of AbbVie, Leerink analyst Geoffrey Porges, still sees in the long run more positive development in the share price of the health care stock "as the company's late-stage pipeline comes to fruition," reports The Fly. Because as the company will gradually complete the projects it is advancing, explained Porges, analysts will increase their estimates on AbbVie with positive impact on the market value. | The U.S. global health care company that was originated in 2013 as Abbott Laboratories ' ( ABT ) spinoff and headquartered in Lake Bluff, Illinois, is trading at $90.39 per share, a few below its 52-week high of $90.95 per share. Among the health care companies that saw their stocks re-rated by investment banking and financial services companies are AbbVie ( ABBV ) and two mid-caps, bluebird bio ( BLUE ) and Alnylam Pharmaceuticals ( ALNY ). Concerning expectations on AbbVie's sales and revenue for the next two years, analysts foresee that the company will close the full fiscal 2017 with a 14.5% increase year over year in the EPS to $5.52 and a 18.5% increase year over year in the EPS for full fiscal 2018 to $6.54. | The U.S. global health care company that was originated in 2013 as Abbott Laboratories ' ( ABT ) spinoff and headquartered in Lake Bluff, Illinois, is trading at $90.39 per share, a few below its 52-week high of $90.95 per share. Despite this solid accretion in the market value of AbbVie, Leerink analyst Geoffrey Porges, still sees in the long run more positive development in the share price of the health care stock "as the company's late-stage pipeline comes to fruition," reports The Fly. Concerning expectations on AbbVie's sales and revenue for the next two years, analysts foresee that the company will close the full fiscal 2017 with a 14.5% increase year over year in the EPS to $5.52 and a 18.5% increase year over year in the EPS for full fiscal 2018 to $6.54. | The U.S. global health care company that was originated in 2013 as Abbott Laboratories ' ( ABT ) spinoff and headquartered in Lake Bluff, Illinois, is trading at $90.39 per share, a few below its 52-week high of $90.95 per share. For the next five years, analysts see a 14.16% annual average increase in AbbVie's sales. Leerink also increased by 19.1% its target price on shares of AbbVie from $89 to $106 per share. |
33489.0 | 2017-10-03 00:00:00 UTC | Health Care Sector Update for 10/03/2017: JNJ, PFE, ABT, MRK, AMGN, DMPI, RDHL, RIGL | ABT | https://www.nasdaq.com/articles/health-care-sector-update-10032017-jnj-pfe-abt-mrk-amgn-dmpi-rdhl-rigl-2017-10-03 | nan | nan | Top Health Care Stocks:
JNJ: +0.4%
PFE: +0.03%
ABT: flat
MRK: +0.2%
AMGN: flat
Health care shares were mostly higher in pre-market trade Tuesday.
In sector news, DelMar Pharmaceuticals ( DMPI ) rose nearly 16% after the company said Tuesday it will present data that demonstrate how its lead asset VAL-083 targets the DNA of cancer cells differently than platinum-based chemotherapeutic agents or PARP Inhibitors. The company said the differences in mechanistic action positions VAL-083 as a potential new therapeutic option in the treatment of ovarian cancer.
In other sector news,
(+) RIGL (+9.8%) Fostamatinib meets pre-specified primary endpoint in study
(-) RDHL (-5.4%) Phase 2 study of Bekinda meets primary endpoint.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat AMGN: flat Health care shares were mostly higher in pre-market trade Tuesday. In sector news, DelMar Pharmaceuticals ( DMPI ) rose nearly 16% after the company said Tuesday it will present data that demonstrate how its lead asset VAL-083 targets the DNA of cancer cells differently than platinum-based chemotherapeutic agents or PARP Inhibitors. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: flat In other sector news, (+) RIGL (+9.8%) Fostamatinib meets pre-specified primary endpoint in study (-) RDHL (-5.4%) Phase 2 study of Bekinda meets primary endpoint. | ABT: flat AMGN: flat Health care shares were mostly higher in pre-market trade Tuesday. In sector news, DelMar Pharmaceuticals ( DMPI ) rose nearly 16% after the company said Tuesday it will present data that demonstrate how its lead asset VAL-083 targets the DNA of cancer cells differently than platinum-based chemotherapeutic agents or PARP Inhibitors. | ABT: flat AMGN: flat Health care shares were mostly higher in pre-market trade Tuesday. In sector news, DelMar Pharmaceuticals ( DMPI ) rose nearly 16% after the company said Tuesday it will present data that demonstrate how its lead asset VAL-083 targets the DNA of cancer cells differently than platinum-based chemotherapeutic agents or PARP Inhibitors. |
33490.0 | 2017-10-02 00:00:00 UTC | Abbott Gets FDA Nod for FreeStyle Libre, Boosts Diabetes Arm | ABT | https://www.nasdaq.com/articles/abbott-gets-fda-nod-for-freestyle-libre-boosts-diabetes-arm-2017-10-02 | nan | nan | AbbottABT recently announced the receipt of FDA approval for the FreeStyle Libre Flash glucose monitoring system in the United States.
The approval is likely to widen this Illinois-based medical device major's customer base in diabetes management. The company aims at making the product commercially available to 30 million people with diabetes in the United States by the end of 2017. This flagship product will be available at major retail pharmacies for end users on a prescription basis.
Meanwhile, Abbott has been steadily progressing with the development of its diabetics segment. Recently, the company announced the receipt of national reimbursement for FreeStyle Libre in the U.K., marking another milestone for the company. Notably, the FreeStyle Libre system is partially or fully covered in 17 countries, including France, Germany and Japan.
Moreover, the company recently announced receipt of Health Canada License for FreeStyle Libre Flash Glucose Monitoring System. This will drive growth in the Diabetes Care sales segment, which saw revenue growth of 18.7% in second-quarter 2017 on continued consumer acceptance of FreeStyle Libre internationally. We believe the latest FDA nod will boost the company's performance in the domestic arena as well.
We expect Freestyle Libre to contribute to Abbott's top line as along with the U.K., Japanese and Canadian developments, the French Health Ministry has approved national reimbursement for the device.
Per a report by Mordor Intelligence, theglobal marketfor diabetes care devices is projected to reach a value of $30.25 billion by 2021, at a CAGR of 5.93%. Given the bullish market sentiments, we believe the recent regulatory approvals for FreeStyle Libre have come at an opportune moment.
However, the diabetes market is dominated by many well-established players, Johnson & Johnson JNJ being the most prominent one. In this space, Johnson & Johnson also has a tie-up with U.S.-based Animas Corporation for the development of insulin delivery systems.
Share Price Performance
Abbott has been gaining investor confidence on consistently positive results. Over the last three months, Abbott's share price has outperformed the broader industry . The stock has gained 10.1%, in contrast to the broader industry's decline of 0.7%. The company has also outperformed the 3.6% gain of the S&P 500 market over the same time frame.
Zacks Rank & Key Picks
Abbott carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks in the medical sector are Orthofix International N.V. OFIX and Owens & Minor, Inc. OMI . Orthofix International and Owens & Minor sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Orthofix International has a long-term expected earnings growth rate of 11.8%. The stock has rallied roughly 3% over the last three months.
Owens & Minor has a long-term expected earnings growth rate of 5%. The stock has gained 4.4% in the last month.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Orthofix International N.V. (OFIX): Free Stock Analysis Report
Owens & Minor, Inc. (OMI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottABT recently announced the receipt of FDA approval for the FreeStyle Libre Flash glucose monitoring system in the United States. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Orthofix International N.V. (OFIX): Free Stock Analysis Report Owens & Minor, Inc. (OMI): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, the company recently announced receipt of Health Canada License for FreeStyle Libre Flash Glucose Monitoring System. | AbbottABT recently announced the receipt of FDA approval for the FreeStyle Libre Flash glucose monitoring system in the United States. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Orthofix International N.V. (OFIX): Free Stock Analysis Report Owens & Minor, Inc. (OMI): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, the company recently announced receipt of Health Canada License for FreeStyle Libre Flash Glucose Monitoring System. | AbbottABT recently announced the receipt of FDA approval for the FreeStyle Libre Flash glucose monitoring system in the United States. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Orthofix International N.V. (OFIX): Free Stock Analysis Report Owens & Minor, Inc. (OMI): Free Stock Analysis Report To read this article on Zacks.com click here. Recently, the company announced the receipt of national reimbursement for FreeStyle Libre in the U.K., marking another milestone for the company. | AbbottABT recently announced the receipt of FDA approval for the FreeStyle Libre Flash glucose monitoring system in the United States. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Orthofix International N.V. (OFIX): Free Stock Analysis Report Owens & Minor, Inc. (OMI): Free Stock Analysis Report To read this article on Zacks.com click here. Over the last three months, Abbott's share price has outperformed the broader industry . |
33491.0 | 2017-10-02 00:00:00 UTC | Why MannKind Corporation Popped Today | ABT | https://www.nasdaq.com/articles/why-mannkind-corporation-popped-today-2017-10-02 | nan | nan | What happened
Shares of MannKind Corporation (NASDAQ: MNKD) , a commercial-stage biopharma focused on inhaled insulin, rose as much as 13% in afternoon trading on Monday. Shareholders can largely thank two positive developments for the jump.
So what
First, MannKind announced that the FDA has OK'd an update to Afrezza's prescribing information. Here's a quick review of the labeling update:
MannKind will now be able to include study data that shows the time-action profile by dosage strength. The company will be able to show that the 4 and 12 unit cartridges of Afrezza have a first measurable effect after 12 minutes, peak after 35 to 45 minutes, and then returns to baseline after approximately 1.5 to 3 hours.
The new labeling will provide clarity on the "Starting" and "Adjusting" mealtime dose.
The new labeling will include updates on pregnancy and lactation that conform to current FDA label guidance.
Here's what MannKind's CEO Michael Castagna had to say about this labeling change on a special investor call:
Second, the company also announced that it was able to exchange 1.3 million shares of its common stock for all of the outstanding Series A and Series B stock purchase warrants that were issued in May 2016. CFO Steven Binder said this move will allow the company to access the full $50 million of its at-the-market facility. That's welcome news since the Series A and Series B warrants had previously limited the company's access to the facility to just $10 million. In Binder's words, this change provides "us with greater options for recapitalizing the company."
Given the two positive news items, it is easy to understand why traders are cheering on Monday.
Now what
Castagna had a few other upbeat tidbits to share with investors on the special conference call, including:
Sales of Afrezza have recently stabilized at over 400 prescriptions a week.
Castanga believes that the recent approval of Abbott Laboratories (NYSE: ABT) new Libre product will expand the market for Afrezza.
The first pediatric patient was dosed in a study last Friday.
The company is about to file for regulatory approval in Brazil, with more international deals in the works.
Novo Nordisk (NYSE: NVO) recently won FDA approval for its new ultra-rapid-acting insulin Fiasp, which Castanga believes will help the company get the word out about the risks of hypoglycemia associated with other mealtime insulins.
Given all of the good news, you might be asking why MannKind's stock isn't up more. The most likely answer is that shareholders know even more dilution is on the way. MannKind ended June with only $48 million on its books, which isn't much when compared to last quarter's loss of $35 million. With the warrant restrictions out of the way and the stock price up, MannKind is likely to act quickly on issuing stock to shore up its balance sheet.
While MannKind's turnaround continues to impress, I have a hard time getting excited about this growth story since a lot more dilution is coming. For that reason, I'm content to root for MannKind's turnaround from the sidelines.
10 stocks we like better than MannKind Corporation
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and MannKind Corporation wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Castanga believes that the recent approval of Abbott Laboratories (NYSE: ABT) new Libre product will expand the market for Afrezza. What happened Shares of MannKind Corporation (NASDAQ: MNKD) , a commercial-stage biopharma focused on inhaled insulin, rose as much as 13% in afternoon trading on Monday. Here's a quick review of the labeling update: MannKind will now be able to include study data that shows the time-action profile by dosage strength. | Castanga believes that the recent approval of Abbott Laboratories (NYSE: ABT) new Libre product will expand the market for Afrezza. Here's what MannKind's CEO Michael Castagna had to say about this labeling change on a special investor call: Second, the company also announced that it was able to exchange 1.3 million shares of its common stock for all of the outstanding Series A and Series B stock purchase warrants that were issued in May 2016. Novo Nordisk (NYSE: NVO) recently won FDA approval for its new ultra-rapid-acting insulin Fiasp, which Castanga believes will help the company get the word out about the risks of hypoglycemia associated with other mealtime insulins. | Castanga believes that the recent approval of Abbott Laboratories (NYSE: ABT) new Libre product will expand the market for Afrezza. Here's what MannKind's CEO Michael Castagna had to say about this labeling change on a special investor call: Second, the company also announced that it was able to exchange 1.3 million shares of its common stock for all of the outstanding Series A and Series B stock purchase warrants that were issued in May 2016. With the warrant restrictions out of the way and the stock price up, MannKind is likely to act quickly on issuing stock to shore up its balance sheet. | Castanga believes that the recent approval of Abbott Laboratories (NYSE: ABT) new Libre product will expand the market for Afrezza. Here's what MannKind's CEO Michael Castagna had to say about this labeling change on a special investor call: Second, the company also announced that it was able to exchange 1.3 million shares of its common stock for all of the outstanding Series A and Series B stock purchase warrants that were issued in May 2016. Novo Nordisk (NYSE: NVO) recently won FDA approval for its new ultra-rapid-acting insulin Fiasp, which Castanga believes will help the company get the word out about the risks of hypoglycemia associated with other mealtime insulins. |
33492.0 | 2017-10-02 00:00:00 UTC | Abbott to Gain from Alere's Takeover Due for Oct 3 Closure | ABT | https://www.nasdaq.com/articles/abbott-to-gain-from-aleres-takeover-due-for-oct-3-closure-2017-10-02 | nan | nan | Investors keen on the consolidation of Abbott LabsABT with Alere may expect that much-awaited good news to arrive soon. Per Abbott's latest update, with all the necessary regulatory clearances getting fulfilled for the closure, the company finally plans to complete the hugely contentious acquisition of Alere, Inc., on Oct 3, 2017.
Notably, after a year's rollercoaster ride to overcome the regulatory hurdles, both Abbott and Alere had progressed with the merger process based on certain amended terms of the original agreement.
Per the amended agreement clauses (announced earlier in April), Abbott has agreed to pay $51 per common share to acquire Alere, a reduction from the earlier deal of $56 per common share in cash upon the transaction's conclusion. This results in an expected, new equity value of approximately $5.3 billion, lower than the originally estimated equity value of almost $5.8 billion.
Our Take
Abbott has stated that with the successful wrap up of this transaction, its total diagnostics sales should be $7 billion. The company also anticipates to emerge a lead player in the $7 billion point-of-care diagnostic space within the broader $50 billion in-vitro diagnostics market with this takeover. The combined entity is expected to generate approximately $2.5 billion in point of care testing sales worldwide.
The buyout would also enable the company to gain an access to new channels and geographies, including entries into fast growing outlets, such as doctors' offices, clinics, pharmacies and at-home testing. More to that, Alere's complementary portfolio of diagnostic products, comprising tests for infections such as HIV, tuberculosis, malaria and dengue will be added to Abbott's portfolio. Significantly, Alere develops simple, rapid tests, including Alere i - the molecular test for flu and strep - to deliver reports in less than 15 minutes.
Hence, the shared business will offer several options of tests in a broad array, for instance, infectious disease, molecular, cardiometabolic and toxicology testings. Also, this union would definitely expand Abbott Labs' platforms to include benchtop and rapid strep tests. Although Alere would hitherto generate over half its total sales from the United States alone, the company has a growing presence in key international markets with potential to strengthen Abbott's footprint ahead in these territories.
Price Performance
Over the past three months, Abbott's share price has outperformed the broader industry it belongs to. The stock has gained 9.5% versus the industry's loss of 0.7%.
Zacks Rank and Other Key Picks
Abbott currently carries a Zacks Rank #3 (Hold). Some better-ranked medical stocks are IDEXX Laboratories, Inc. IDXX , Luminex Corp. LMNX and Masimo Corp. MASI , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
IDEXX Laboratories has a positive earnings surprise of 9.3% over the last four quarters. The stock has roughly surged 37.5% over the last year.
Luminex Corp. has a long-term expected earnings growth rate of 16%. The stock has gained around 22.2% over the last month.
Masimo has an expected long-term adjusted earnings growth of almost 14%. The stock has rallied nearly 29% year to date.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Luminex Corporation (LMNX): Free Stock Analysis Report
Masimo Corporation (MASI): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors keen on the consolidation of Abbott LabsABT with Alere may expect that much-awaited good news to arrive soon. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, after a year's rollercoaster ride to overcome the regulatory hurdles, both Abbott and Alere had progressed with the merger process based on certain amended terms of the original agreement. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. Investors keen on the consolidation of Abbott LabsABT with Alere may expect that much-awaited good news to arrive soon. Some better-ranked medical stocks are IDEXX Laboratories, Inc. IDXX , Luminex Corp. LMNX and Masimo Corp. MASI , each carrying a Zacks Rank #2 (Buy). | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. Investors keen on the consolidation of Abbott LabsABT with Alere may expect that much-awaited good news to arrive soon. Significantly, Alere develops simple, rapid tests, including Alere i - the molecular test for flu and strep - to deliver reports in less than 15 minutes. | Investors keen on the consolidation of Abbott LabsABT with Alere may expect that much-awaited good news to arrive soon. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. Significantly, Alere develops simple, rapid tests, including Alere i - the molecular test for flu and strep - to deliver reports in less than 15 minutes. |
33493.0 | 2017-09-29 00:00:00 UTC | Abbott's Ellipse ICD Receives FDA Approval for MRI Scans | ABT | https://www.nasdaq.com/articles/abbotts-ellipse-icd-receives-fda-approval-for-mri-scans-2017-09-29 | nan | nan | Abbott'sABT Ellipse implantable cardioverter defibrillator (ICD) recently gained FDA approval for magnetic resonance (MR) conditional labeling. This should solidify the company's footprint in the Rhythm Management space.
Post-approval, patients implanted with an Ellipse device and Durata or Optisure leads will be able to undergo MRI scans. Moreover, Ellipse will now be available to patients suffering from severely high heart rhythms and in need of an ICD along with a MRI scan. Thus, we believe that this latest regulatory approval will expand the company's customer base and drive its top line.
Moreover, Ellipse is embedded with features known as Abbott's TailoredTherapy and is capable of directly, securely and wirelessly forwarding all therapy and related data to a patient's physician through the Merlin.net Patient Care Network.
Continuing with its efforts to expand the MR-conditional labeling enabled devices, the company received FDA approval for MR-conditional labeling for Assurity MRI pacemaker and Tendril MRI pacing lead. Also, the company has received certain prior MR-conditional labeling approvals in Europe.
Meanwhile, Abbott had applied for FDA approval of MRI-conditional labeling for its Quadra Assura Cardiac Resynchronization Therapy Defibrillator (CRT-D) products and Quartet family of left ventricular leads.
Interestingly, the company witnessed softness in its Rhythm Management segment majorly due to tough competition in the MRI-conditional category of products. The market is dominated by some well-established players like Medtronic plc MDT , Boston Scientific Corporation BSX and Edwards Lifesciences Corporation EW , among others.
Abbott's strategy to gain traction in the Rhythm Management sub-segment seems to be aligned with data provided by Allied Market Research . Per the report, the global Cardiac Monitoring and Cardiac Rhythm Management market is expected to see a CAGR of 7.6% from 2016 to 2022 to reach a value of $32,216 million.
We believe that unhealthy lifestyle and a rise in ageing population will continue to result in high incidence of cardiovascular diseases. This is further supported by data provided by GBI Research . Per the report, the global cardiovascular diseases market will see a CAGR of 4.1% by 2019, and within this space, the U.S. market is expected to witness the highest momentum at a CAGR of 4.7%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott'sABT Ellipse implantable cardioverter defibrillator (ICD) recently gained FDA approval for magnetic resonance (MR) conditional labeling. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, Abbott had applied for FDA approval of MRI-conditional labeling for its Quadra Assura Cardiac Resynchronization Therapy Defibrillator (CRT-D) products and Quartet family of left ventricular leads. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott'sABT Ellipse implantable cardioverter defibrillator (ICD) recently gained FDA approval for magnetic resonance (MR) conditional labeling. Continuing with its efforts to expand the MR-conditional labeling enabled devices, the company received FDA approval for MR-conditional labeling for Assurity MRI pacemaker and Tendril MRI pacing lead. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott'sABT Ellipse implantable cardioverter defibrillator (ICD) recently gained FDA approval for magnetic resonance (MR) conditional labeling. Continuing with its efforts to expand the MR-conditional labeling enabled devices, the company received FDA approval for MR-conditional labeling for Assurity MRI pacemaker and Tendril MRI pacing lead. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott'sABT Ellipse implantable cardioverter defibrillator (ICD) recently gained FDA approval for magnetic resonance (MR) conditional labeling. Continuing with its efforts to expand the MR-conditional labeling enabled devices, the company received FDA approval for MR-conditional labeling for Assurity MRI pacemaker and Tendril MRI pacing lead. |
33494.0 | 2017-09-28 00:00:00 UTC | Why DexCom Stock Is Getting Crushed Today | ABT | https://www.nasdaq.com/articles/why-dexcom-stock-getting-crushed-today-2017-09-28 | nan | nan | What happened
Shares of medical device company and diabetes specialist DexCom Inc. (NASDAQ: DXCM) slipped sharply Thursday morning, declining by more than 36% as of 11:50 a.m. EDT. This tumble stemmed from the FDA's approval of Abbott Laboratories' (NYSE: ABT) FreeStyle Libre Flash Glucose Monitoring System, which is the first continuous glucose monitoring device to not require a finger-stick blood sample for calibration. Patients using DexCom's G5 Mobile device, on the other hand, need to perform up to two finger-sticks per day for the purposes of calibration. Abbott's shares were up by more than 4% on the back of this positive regulatory development.
So what
DexCom's stock has skyrocketed in the last few years because of its dominant position in the rapidly growing glucose-monitoring market. In fact, sales of its G5 mobile CGM were forecast to grow by another 25% to 30% this year after the Centers for Medicare and Medicaid Services ruled that the device was indeed " therapeutic ," and could therefore be covered under Medicare Part B. With the entry of Abbott's more user-friendly device, though, DexCom's blistering levels of growth may start to taper off.
Now what
Can Abbott's newly approved CGM device truly disrupt the market and steal a significant chunk of the market share away from DexCom? Based on the performance of DexCom's shares Thursday, the overwhelming sentiment among investors appears to be "yes," and I happen to agree with the market's initial assessment.
Unfortunately, DexCom is about a year away from bringing a similar no-calibration (and hence, no finger-stick) device to market, and that lag could spell disaster for the CGM specialist. A first-mover advantage, after all, should translate into a formidable economic moat against follow-on devices -- putting DexCom in a bad position. So while it might be tempting to grab some shares in the wake of this dramatic decline, I'd caution against it for the time being.
10 stocks we like better than DexCom
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This tumble stemmed from the FDA's approval of Abbott Laboratories' (NYSE: ABT) FreeStyle Libre Flash Glucose Monitoring System, which is the first continuous glucose monitoring device to not require a finger-stick blood sample for calibration. What happened Shares of medical device company and diabetes specialist DexCom Inc. (NASDAQ: DXCM) slipped sharply Thursday morning, declining by more than 36% as of 11:50 a.m. EDT. Based on the performance of DexCom's shares Thursday, the overwhelming sentiment among investors appears to be "yes," and I happen to agree with the market's initial assessment. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. This tumble stemmed from the FDA's approval of Abbott Laboratories' (NYSE: ABT) FreeStyle Libre Flash Glucose Monitoring System, which is the first continuous glucose monitoring device to not require a finger-stick blood sample for calibration. What happened Shares of medical device company and diabetes specialist DexCom Inc. (NASDAQ: DXCM) slipped sharply Thursday morning, declining by more than 36% as of 11:50 a.m. EDT. | This tumble stemmed from the FDA's approval of Abbott Laboratories' (NYSE: ABT) FreeStyle Libre Flash Glucose Monitoring System, which is the first continuous glucose monitoring device to not require a finger-stick blood sample for calibration. So what DexCom's stock has skyrocketed in the last few years because of its dominant position in the rapidly growing glucose-monitoring market. Now what Can Abbott's newly approved CGM device truly disrupt the market and steal a significant chunk of the market share away from DexCom? | This tumble stemmed from the FDA's approval of Abbott Laboratories' (NYSE: ABT) FreeStyle Libre Flash Glucose Monitoring System, which is the first continuous glucose monitoring device to not require a finger-stick blood sample for calibration. So what DexCom's stock has skyrocketed in the last few years because of its dominant position in the rapidly growing glucose-monitoring market. Now what Can Abbott's newly approved CGM device truly disrupt the market and steal a significant chunk of the market share away from DexCom? |
33495.0 | 2017-09-28 00:00:00 UTC | IWD, WMT, SLB, ABT: Large Inflows Detected at ETF | ABT | https://www.nasdaq.com/articles/iwd-wmt-slb-abt-large-inflows-detected-etf-2017-09-28 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $265.9 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 309,400,000 to 311,650,000). Among the largest underlying components of IWD, in trading today Wal-Mart Stores, Inc. (Symbol: WMT) is off about 1%, Schlumberger Ltd (Symbol: SLB) is off about 0.5%, and Abbott Laboratories (Symbol: ABT) is higher by about 4.6%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average:
Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $118.10. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWD, in trading today Wal-Mart Stores, Inc. (Symbol: WMT) is off about 1%, Schlumberger Ltd (Symbol: SLB) is off about 0.5%, and Abbott Laboratories (Symbol: ABT) is higher by about 4.6%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $118.10. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWD, in trading today Wal-Mart Stores, Inc. (Symbol: WMT) is off about 1%, Schlumberger Ltd (Symbol: SLB) is off about 0.5%, and Abbott Laboratories (Symbol: ABT) is higher by about 4.6%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $118.10. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWD, in trading today Wal-Mart Stores, Inc. (Symbol: WMT) is off about 1%, Schlumberger Ltd (Symbol: SLB) is off about 0.5%, and Abbott Laboratories (Symbol: ABT) is higher by about 4.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $265.9 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 309,400,000 to 311,650,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $118.10. | Among the largest underlying components of IWD, in trading today Wal-Mart Stores, Inc. (Symbol: WMT) is off about 1%, Schlumberger Ltd (Symbol: SLB) is off about 0.5%, and Abbott Laboratories (Symbol: ABT) is higher by about 4.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $265.9 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 309,400,000 to 311,650,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $118.10. |
33496.0 | 2017-09-28 00:00:00 UTC | 3 High-Yield Stocks With Virtual Monopolies | ABT | https://www.nasdaq.com/articles/3-high-yield-stocks-virtual-monopolies-2017-09-28 | nan | nan | In the United States, monopolies technically aren't supposed to exist, thanks to the Sherman Antitrust Act of 1890. However, there are a handful of U.S.-based companies that do, in fact, own a disproportionate share of their respective markets and therefore sport unusually rich free cash flows. And fortunately, some of these titans of industry have also chosen to use their strong free cash flows to reward loyal shareholders with a top-notch dividend yield.
Armed with this insight, we asked three of our Motley Fool investors which high-yield stocks with virtual monopolies in their primary markets they think are worth buying right now. They recommended AbbVie (NYSE: ABBV) , AB-InBev (NYSE: BUD) , and Enterprise Products Partners, LP (NYSE: EPD) . Read on to find out why. | However, there are a handful of U.S.-based companies that do, in fact, own a disproportionate share of their respective markets and therefore sport unusually rich free cash flows. And fortunately, some of these titans of industry have also chosen to use their strong free cash flows to reward loyal shareholders with a top-notch dividend yield. Armed with this insight, we asked three of our Motley Fool investors which high-yield stocks with virtual monopolies in their primary markets they think are worth buying right now. | However, there are a handful of U.S.-based companies that do, in fact, own a disproportionate share of their respective markets and therefore sport unusually rich free cash flows. And fortunately, some of these titans of industry have also chosen to use their strong free cash flows to reward loyal shareholders with a top-notch dividend yield. They recommended AbbVie (NYSE: ABBV) , AB-InBev (NYSE: BUD) , and Enterprise Products Partners, LP (NYSE: EPD) . | However, there are a handful of U.S.-based companies that do, in fact, own a disproportionate share of their respective markets and therefore sport unusually rich free cash flows. And fortunately, some of these titans of industry have also chosen to use their strong free cash flows to reward loyal shareholders with a top-notch dividend yield. Armed with this insight, we asked three of our Motley Fool investors which high-yield stocks with virtual monopolies in their primary markets they think are worth buying right now. | In the United States, monopolies technically aren't supposed to exist, thanks to the Sherman Antitrust Act of 1890. However, there are a handful of U.S.-based companies that do, in fact, own a disproportionate share of their respective markets and therefore sport unusually rich free cash flows. And fortunately, some of these titans of industry have also chosen to use their strong free cash flows to reward loyal shareholders with a top-notch dividend yield. |
33497.0 | 2017-09-28 00:00:00 UTC | Morning Movers: Endo Slumps, Hain Jumps, Philip Morris Rises | ABT | https://www.nasdaq.com/articles/morning-movers-endo-slumps-hain-jumps-philip-morris-rises-2017-09-28 | nan | nan | Stocks look set for a lower open today as Trump's tax plan continues to dominate the news.
Getty Images
S&P 500 futures have declined 0.2%, while Dow Jones Industrial Average futures have fallen 0.2%. Nasdaq Composite futures have dropped 0.4%.
Accenture (ACN) has fallen 1.6% to $134.50 after its earnings and sales topped analyst forecasts.
Archer Daniels Midland (ADM) has dropped 2.9% to $41.80 after getting cut to Neutral from Buy at Citigroup.
BlackBerry (BBRY) has climbed 7.8% to $9.95 after its earnings topped second-quarter forecasts.
DexCom (DXCM) has plunged 27% to $49.50 after Abbott Laboratories (ABT) announced that it had received FDA approval for a sugar-monitoring system for diabetics that doesn't involve a finger prick, a potential hit to one of DexCom's big businesses. Abbott has gained 3.8% to $54.15.
Endo International (ENDP) has dropped 2.7% to $8.80 after Goldman Sachs started it as a Sell.
Hain Celestial Group (HAIN) has jumped 8.8% to $44 after reaching an agreement with Engaged Capitalto reconstitute its board, and agreed to explore strategic alternatives.
McDonald's (MCD) has advanced 0.9% to $155.51 after getting upgraded to Buy from Neutral at Longbow.
McCormick (MKC) has risen 2.7% to $99.01 after beating earnings forecasts and offering above-consensus full-year guidance.
Mallinckrodt (MNK) has gained 3.4% to $36.60 after getting started at Buy at Buy at Goldman Sachs.
Philip Morris International (PM) has risen 1.2% to $113 after Goldman Sachs added the tobacco company to its Conviction Buy list.
Pier 1 Imports (PIR) has tumbled 9.8% to $4.06 after beating earnings forecasts but offering below-consensus guidance.
Sherwin-Williams (SHW) has declined 1.4% to $345.02 after cutting its third-quarter earnings guidance due to the recent hurricanes.
Thor Industries (THO) has gained 3.9% to $124.65 after beating earnings forecasts.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | DexCom (DXCM) has plunged 27% to $49.50 after Abbott Laboratories (ABT) announced that it had received FDA approval for a sugar-monitoring system for diabetics that doesn't involve a finger prick, a potential hit to one of DexCom's big businesses. Stocks look set for a lower open today as Trump's tax plan continues to dominate the news. Philip Morris International (PM) has risen 1.2% to $113 after Goldman Sachs added the tobacco company to its Conviction Buy list. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. DexCom (DXCM) has plunged 27% to $49.50 after Abbott Laboratories (ABT) announced that it had received FDA approval for a sugar-monitoring system for diabetics that doesn't involve a finger prick, a potential hit to one of DexCom's big businesses. Pier 1 Imports (PIR) has tumbled 9.8% to $4.06 after beating earnings forecasts but offering below-consensus guidance. | DexCom (DXCM) has plunged 27% to $49.50 after Abbott Laboratories (ABT) announced that it had received FDA approval for a sugar-monitoring system for diabetics that doesn't involve a finger prick, a potential hit to one of DexCom's big businesses. McCormick (MKC) has risen 2.7% to $99.01 after beating earnings forecasts and offering above-consensus full-year guidance. Mallinckrodt (MNK) has gained 3.4% to $36.60 after getting started at Buy at Buy at Goldman Sachs. | DexCom (DXCM) has plunged 27% to $49.50 after Abbott Laboratories (ABT) announced that it had received FDA approval for a sugar-monitoring system for diabetics that doesn't involve a finger prick, a potential hit to one of DexCom's big businesses. Nasdaq Composite futures have dropped 0.4%. Mallinckrodt (MNK) has gained 3.4% to $36.60 after getting started at Buy at Buy at Goldman Sachs. |
33498.0 | 2017-09-27 00:00:00 UTC | Abiomed's Latest Regulatory Progress Boosts Impella Line | ABT | https://www.nasdaq.com/articles/abiomeds-latest-regulatory-progress-boosts-impella-line-2017-09-27 | nan | nan | Abiomed Inc. 's ABMD flagship Impella product line shines bright on the receipt of pre-market approval from the FDA for its Impella RP heart pump. Notably, Impella RP is the only FDA-cleared percutaneous temporary ventricular support device available in the market.
The Impella RP System has been exclusively formulated to provide temporary right ventricular support to patients with acute right heart failure or decompensation. Its important to note that, the device does not involve any sort of surgical procedure for insertion. In fact, Impella RP provides more than four liters of blood per minute to provide hemodynamic support to patients.
Per management, the latest regulatory go ahead eradicates the risks associated with Right Ventricular Failure (RVF). These risks include increased mortality, longer lengths of stay in the intensive care unit and end-organ dysfunction.
We believe that robust demand for Impella products will continue to drive Abiomed's top line over the long term. Notably, Impella line has other FDA-approved products like Impella 2.5, Impella CP and Impella 5.0. This business line is exclusively designed to treat patients in cardiogenic shock or undergoing elective and urgent percutaneous coronary interventions (PCI). Evidently, Impella heart pump's global revenues grew a strong 30% in the last quarter.
Bottom Line
Lately, management at Abiomed has made significant investments in training and data collection procedures from Impella platform. The Impella line has been gaining prominence in the international ventricular-assist devices markets as well. The company's continued progress in countries like Germany and Japan, leveraging on the Impella line, is worth a mention.
Data from Research And Markets suggests that the ventricular-assist devicesglobal marketis set to reach a worth of $2.8 billion by 2023. Meanwhile, the company faces stiff competition from organizations developing permanent heart assist products like Teleflex Inc. TFX , Abbott Laboratories ABT and Fresenius Medical Care FMS .
4 Stocks to Watch after the Massive Equifax Hack
Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?
Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor's Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.
Get the new Investing Guide now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Teleflex Incorporated (TFX): Free Stock Analysis Report
Fresenius Medical Care Corporation (FMS): Free Stock Analysis Report
ABIOMED, Inc. (ABMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, the company faces stiff competition from organizations developing permanent heart assist products like Teleflex Inc. TFX , Abbott Laboratories ABT and Fresenius Medical Care FMS . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report Fresenius Medical Care Corporation (FMS): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report To read this article on Zacks.com click here. The Impella RP System has been exclusively formulated to provide temporary right ventricular support to patients with acute right heart failure or decompensation. | Meanwhile, the company faces stiff competition from organizations developing permanent heart assist products like Teleflex Inc. TFX , Abbott Laboratories ABT and Fresenius Medical Care FMS . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report Fresenius Medical Care Corporation (FMS): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report Fresenius Medical Care Corporation (FMS): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, the company faces stiff competition from organizations developing permanent heart assist products like Teleflex Inc. TFX , Abbott Laboratories ABT and Fresenius Medical Care FMS . Abiomed Inc. 's ABMD flagship Impella product line shines bright on the receipt of pre-market approval from the FDA for its Impella RP heart pump. | Meanwhile, the company faces stiff competition from organizations developing permanent heart assist products like Teleflex Inc. TFX , Abbott Laboratories ABT and Fresenius Medical Care FMS . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report Fresenius Medical Care Corporation (FMS): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report To read this article on Zacks.com click here. The Impella RP System has been exclusively formulated to provide temporary right ventricular support to patients with acute right heart failure or decompensation. |
33499.0 | 2017-09-26 00:00:00 UTC | FDA Chief Gottlieb Addresses Opioids, Cancer, New Therapies | ABT | https://www.nasdaq.com/articles/fda-chief-gottlieb-addresses-opioids-cancer-new-therapies-2017-09-26 | nan | nan | In his first run with the Food and Drug Administration, gene and cell therapy were early-stage, theoretical concepts, FDA Commissioner Scott Gottlieb said Tuesday.
[ibd-display-video id=2322032 width=50 float=left autostart=true]But last month, the FDA approved its first cellular therapy, a drug called Kymriah from Novartis ( NVS ) to treat a form of acute lymphoblastic leukemia in patients age 25 and younger. Kite Pharma ( KITE ), soon to be acquired by Gilead Sciences ( GILD ), is expected to grab a similar approval in November.
In 2005, gene/cell therapy and drugs that biologically copy an existing product - known as biosimilars - didn't exist, Gottlieb told the MedTech Conference in San Jose, Calif.
"Now we have products we're reviewing and approving," he said.
Gottlieb is nearly five months into his stint as FDA commissioner. He was among the first appointments by President Donald Trump and took office in May. He first served as an FDA deputy commissioner in 2005-07.
Gottlieb's background has him uniquely prepared to head up what is now a much bigger FDA, said Scott Whitaker, Chief Executive of AdvaMed, the world's largest medical technology association. Gottlieb was diagnosed with a type of lymphoma when he was younger.
"It was the kind of tumor only a hypochondriac doctor would have found on himself," Gottlieb told the audience at the San Jose McEnery Convention Center. As a doctor, Gottlieb researched the type of treatment he wanted, knowing he had a very good chance of survival.
IBD'S TAKE:Medtech stocks have been riding out drug-pricing fears that have hurt the pharma and biotech sectors, analysts say. Head to the Industry Snapshot for a closer look at winners and losers in the political discourse.
He acknowledged not every patient fits into that bucket.
"I was a very different patient from the patient who is told, 'You have a 20% chance of survival,'" he said. "They're looking for something experimental; something that might not be approved yet. There's a lot of different cancer patients."
Part of his challenge, Gottlieb says, is ensuring the FDA has policies that help all patients.
"It's difficult to simultaneously serve both types of patients because by serving one patient you could potentially impact another patient," he said.
Today, the FDA has its hands in a number of areas. Gottlieb says most people would be surprised to find he spends most of his time working on the tobacco side. What won't surprise the public, though, is that the FDA is working closely on ameliorating the opioid crisis.
Last month, Trump declared the opioid crisis a national emergency. To cope, companies like Boston Scientific ( BSX ), Abbott Laboratories ( ABT ) and Medtronic (MDT) are working on therapies called neuromodulation, which use electricity to conceal pain from the brain.
Gottlieb notes medical products could step in as alternatives to addictive opioids. A medical device "could deliver localized therapy or a patch to treat localized pain vs. drugs that have a systemic approach and are very addictive," he said.
The FDA is also working on a framework for quicker review and certification of software programs. Rather than go through the longer products review, these software programs can be reviewed with less information.
Apple (APPL), FitBit (FIT), Johnson & Johnson (JNJ), Pear Therapeutics, Phosphorus, Roche (RHHBY), Samsung, Tidepool and Verily will be involved in the pilot program which seeks to identify the information companies will need to provide for the quicker review process, Gottlieb said.
"We need to modernize our regulatory framework so that it matches the kind of innovation we're being asked to evaluate, and foster beneficial technology while ensuring that consumers have access to high-quality, safe and effective digital health devices," he said.
RELATED:
This Biotech Craters 70% On Late-Stage Alzheimer's Drug Failure
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | To cope, companies like Boston Scientific ( BSX ), Abbott Laboratories ( ABT ) and Medtronic (MDT) are working on therapies called neuromodulation, which use electricity to conceal pain from the brain. [ibd-display-video id=2322032 width=50 float=left autostart=true]But last month, the FDA approved its first cellular therapy, a drug called Kymriah from Novartis ( NVS ) to treat a form of acute lymphoblastic leukemia in patients age 25 and younger. "We need to modernize our regulatory framework so that it matches the kind of innovation we're being asked to evaluate, and foster beneficial technology while ensuring that consumers have access to high-quality, safe and effective digital health devices," he said. | To cope, companies like Boston Scientific ( BSX ), Abbott Laboratories ( ABT ) and Medtronic (MDT) are working on therapies called neuromodulation, which use electricity to conceal pain from the brain. In 2005, gene/cell therapy and drugs that biologically copy an existing product - known as biosimilars - didn't exist, Gottlieb told the MedTech Conference in San Jose, Calif. "Now we have products we're reviewing and approving," he said. Apple (APPL), FitBit (FIT), Johnson & Johnson (JNJ), Pear Therapeutics, Phosphorus, Roche (RHHBY), Samsung, Tidepool and Verily will be involved in the pilot program which seeks to identify the information companies will need to provide for the quicker review process, Gottlieb said. | To cope, companies like Boston Scientific ( BSX ), Abbott Laboratories ( ABT ) and Medtronic (MDT) are working on therapies called neuromodulation, which use electricity to conceal pain from the brain. [ibd-display-video id=2322032 width=50 float=left autostart=true]But last month, the FDA approved its first cellular therapy, a drug called Kymriah from Novartis ( NVS ) to treat a form of acute lymphoblastic leukemia in patients age 25 and younger. In 2005, gene/cell therapy and drugs that biologically copy an existing product - known as biosimilars - didn't exist, Gottlieb told the MedTech Conference in San Jose, Calif. "Now we have products we're reviewing and approving," he said. | To cope, companies like Boston Scientific ( BSX ), Abbott Laboratories ( ABT ) and Medtronic (MDT) are working on therapies called neuromodulation, which use electricity to conceal pain from the brain. "I was a very different patient from the patient who is told, 'You have a 20% chance of survival,'" he said. "It's difficult to simultaneously serve both types of patients because by serving one patient you could potentially impact another patient," he said. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.